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Small molecules have provided means to combat many diseases caused by 
pathogens. In the last six decades, advances in the structural and biological understanding 
of nucleic acid functions have led to rational drug design programs in order to solve 
current therapeutic challenges.  
The work described in this dissertation addresses discovery of aminoglycosides as 
novel binders to G-quadruplex nucleic acids. Understanding of effect of linker length on 
the B-DNA binding of a series of Hoechst 33258 derivatives have been provided. Novel 
Hoechst 33258 based monobenzimidazoles have been synthesized and their biological 
properties have been compared with the bisbenzimidazoles. The bisbenzimidazoles have 
been designed to be useful towards click chemistry applications. These clickable Hoechst 
33258 derivatives were then used to prepare neomycin-Hoechst 33258 conjugates with 
varied linker spacing between them. The binding studies of these novel neomycin-
Hoechst 33258 conjugates show intercalative binding of bisbenzimidazole moiety of the 
ligand to an RNA duplex. Finally, the novel neomycin-Hoechst 33258 conjugates have 
been screened against G-quadruplex forming promoter sequences and biophysical 
characterization to its binding has been provided. 
Overall, these studies have led to synthesis of novel small molecules that bind to 
various nucleic acids and their new binding modes have been discovered. The studies 
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MOLECULAR RECOGNITION OF NUCLEIC ACIDS:  
PROMISE OF SMALL MOLECULES 
Introduction 
The scientific developments in the last century have put us on a platform where a 
systematic and logical plan could be laid out and executed in curing us of the harmful 
effects of unwanted microorganisms. One way of countering the harmful effects of 
microorganisms has been the use of medicinally important plants. There is ample historic 
evidence of herbal use by humans (Neanderthals) 60000 years ago.
1
 In many parts of 
world, diseases were cured by invoking supernatural powers (and this practice still exists 
today). Such practices have existed for centuries primarily because of the lack of 
understanding of how biological processes occur and how their functions are modulated 
to obtain desired effects.  
The scientific findings of the last century are considered recent when considered 
next to the documented history of organized life. Thanks to advances in all walks of 
science, we are able to target the undesired functions of many dreaded diseases (which 
were fatal previously) and therefore have a healthier life. In the field of chemistry, the 
advances in the areas of synthetic organic chemistry, development of sophisticated 
analytical tools, and aid of computational chemistry have made the understanding of 
biological processes easier than ever.  This chapter focuses on the discovery of a few 
small molecules such as penicillin and their impact on drug development. The structure 
of nucleic acids is also discussed.  
2 
 
Discovery of DNA structure, genetic code and beginning of nucleic acid recognition. 
DNA was first discovered by Mesisher in 1869, though he called it nuclein.
2
 Despite not 
being able to obtain high purity DNA in his initial experiments in Hope-Seyller’s 
laboratory, he demonstrated that this novel substance was rich in phosphorous (and hence 
not similar to proteins).
2
 A couple of decades later, Altmann successfully obtained a pure 
“nuclein” and termed it nucleic acids. Later work by Levene established the presence of 
the ribose/deoxyribose phophodiester connectivity and the presence of either of the four 
bases adenine, guanine, cytosine or thymine in nucleic acids.
2
 A state of dormancy 
continued in the initial twentieth century towards nucleic acid research. This was largely 
attributed to Levene’s proposal of “tetranucleotide theory,” which led many of the 
researchers to disbelieve in the hereditary connection of nucleic acids, which instead led 
much of the efforts towards focusing on proteins.
2
 It was not until the discovery by 
Oswald T. Avery, Colin MacLeod and Maclyn McCarthy in 1944 that a new interest in 
the understanding of nucleic acids arose.
2
 
They identified nucleic acids as the genetic carriers of living organisms. This 
coincided with Chargaff’s discovery that nucleic acids were composed of purine and 
pyrimidine bases, and individually the ratio of purines or pyrimidines equaled close to 
one.
3
This decade of the mid twentieth century was historical in many ways. The end of 
World War II, the emergence of small molecules (natural) to treat fatal diseases, 





Table 1.1 Chronology of discoveries in the development of nucleic acids as 
substances of profound interest. 
 
Invention Ineventor/s Year 
 





Discovery of nucleotides Levene 1910 
DNA as a genetic material Oswald 1944 
Base composition of nucleic 
acids 
Chargaff 1949 
DNA double helix Watson and Crick 1953 
DNA triple helix Rich 1957 
DNA:RNA hybrids Rich 1958 
DNA tetraplex Davies 1962 
Genetic Code Khorana, Nirenberg 1968 
 
 
understand the  biological functions of nucleic acids earmarked the beginning a new era. 
Soon after the publication of the initial model of DNA by Linus Pauling,
4
 
 and aided by the famous “picture 51” taken by Rosalind Franklin, Watson and Crick 
proposed the structure of a double helical DNA in 1953
5
.  The model proposed by 
Watson and Crick stimulated an intense interest in the study of nucleic acids so that 
within a decade, a multitude of other manners in which nucleic acids could associate was 
unearthed (Table 1.1).  Finally, the seminal work of Khorana and Nirenberg presented 
the world the “genetic code” that held answers to many questions in molecular genetics. 
These discoveries firmly established nucleic acids as materials of immense interest. 
4 
 
Discovery of Penicillin and Stretptomycin, the first antibiotics in the antimicrobial world. 
For many centuries it was (and still is in some areas) widely accepted that diseases are 
caused because of supernatural elements. Therefore, to get rid of diseases, rituals were 
performed to appease those unhappy “superpowers” to cure many endemics/epidemics. 
However, herbs have been in use in early civilizations such as Indus Valley civilization.
6
 
Now, with the advent of science, it has been demonstrated that ingredients of such herbal 
plants are actually small organic molecules.
6
 Some of these herbs, which are now 
established to be injurious to health, were used as medicines for some time. One famous 
documented example has been the use of tobacco leaves in hookah as medicine by 
Emperor Akbar in the early seventeenth century
7
 when it was first brought in India. 
In 1928, a small molecule that exhibited antibiotic properties was discovered. The 
molecule was named Penicillin by Alexander Fleming since it was discovered in the 
mould of the fungus Penicillium. Penicillin (Figure 1.1) was effective against gram 
positive bacteria and helped treat the sexually transmitted disease syphilis and infections 
caused by staphylococci and streptococci. The discovery of Penicillin and its antibacterial 
properties showed for the first time that small molecules can be used to alter the functions 
of  bacteria in a way that cures diseases. This discovery, along with almost concurrent 
development of sulfa drugs, pioneered efforts in the direction of small molecule based 
agents that could inhibit harmful functions of bacteria. The discovery of penicillin 


































Penicillin G Streptomycin  
Figure 1.1 Chemical structures of Penicillin G and Streptomycin. 
 
science, Europe, was deeply engulfed in war, and these events may have contributed 
towards the slow progress in the discovery of small molecules. The year 1944 proved to 
be a landmark year as it witnessed the discovery of another small molecule, Streptomycin 
(Figure 1.1), in the laboratory of Selman Waksman at Rutgers College, New Jersey.
8
 
 The impact of Streptomycin was more profound than the discovery of Penicillin since 




 Within a few years of its use, it saved thousands of lives from tuberculosis. For 






The discovery of streptomycin, and other molecules of the same family called 
aminoglycosides, initiated the first organized efforts towards the use of small molecules 
to cure diseases. The success of aminoglycoside antibiotics, despite their soon obvious 
toxic effects, showed for the first time, hope in targeting life threatening diseases (such as 
tuberculosis) by gram negative bacteria. The discovery of different types of nucleic acid 
structures in the next two decades, and the isolation of proteins and determination of their 
functions, gave a solid foundation of knowledge to fight diseases by developing novel 
drugs.  Drug discovery soon took a new turn when DNA and RNA specific binders were 
discovered, and their modes of binding were understood.  This led to classification of 
drugs that bind in a similar fashion.  
Modes of Nucleic Acid Binding. Nucleic acid binders can be divided in three broad 
categories: major groove binders, intercalators and minor groove binders. This 
classification applies to their binding to a certain type of DNA. For example, a DNA 
minor groove binder may or may not bind to RNA, or it may bind to RNA in a different 
mode. The difference in binding is inherent to subtle, but significant, changes in the 
structural features of DNA and RNA. Three of the four natural bases found in nucleic 
acids are the same in both DNA and RNA. The chemical structures of the four natural 
bases found in nucleic acids are shown in Figure 1.2a, of which two (thymine and 
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Figure 1.2. (a) Chemical structures of the four natural bases found in nucleic acids (b) 





to the purine class. Each nucleotide is composed of a base, the ribose sugar and 
phosphates at the 3’ and 5’ ends (Figure 1.2a). The differences in DNA and RNA can be 
marked   in their constituent bases as well as in the sugar components.  In RNA, the 2’  
position of the sugar ring remains hydroxylated while in DNA it remains in the deoxy 
form (Figure 1.2b). The difference in the structure of thymine and uracil bases is also 
apparent in Figure 1.2b.   
The methyl group in thymine present on the pyrimidine ring is replaced by a 
hydrogen atom in uracil. These structural differences in the base and sugar composition 
bring about a lot of changes in their structure, shape and hydration patterns.  Another 
interesting difference between the  DNA and RNA is in the puckering of the sugars, 
(Figure 1.3) as well as in the orientation of the bases (syn/anti) around the sugar to which 
the bases are attached (When bases orient toward the sugar it is termed syn while the 
opposite orientation is termed anti). Overall these changes lead to different variations in 
the nucleic acid structures. In DNA alone, these changes are responsible for the presence 
of different types of structural forms. A summary of such differences are presented in 
Table 1.2. The striking differences in A and B-form of DNA is evident in the sugar 
pucker and their groove widths. In A-from DNA, the major groove in narrow but has a 
wide/shallow narrow groove. It also contains the sugar in C3’ endo puckered form. In 
contrast, the narrow groove of B-DNA is much narrower and gets even narrower in 
DNAs with contiguous AT stretches where the width of the narrow groove dips to ~2.8 Å 





 In cotrast to the A and B-form DNA, Z-DNA is right handed and contains features of 
both A and B-DNA.
10
 The perception about DNA grooves has continuously changed 
since the discovery of multi-stranded DNA structures such as G-quadruplexes
11
 which 
uses eight hydrogen bonds to form a tetrad (Figure 1.4). Nearly two decades of structural 
work have provided useful insights into the DNA architecture. G-quadruplex structures 
have been found to possess many diverse structures.  For example, G-quadruplex DNAs 
can form by one, two or four strands.
12
 In a parallel tetramolecular quadruplexe d(TG4T), 
the features of nucleotides at each base resemble that of the B-DNA (C2’ endo sugar 














Figure 1.3. Changes in the sugar pucker of the ribose ring. 
 
However, in fold-back structures (quadruplexes in particular) unusual loop connectivities 
give rise to extremely wide grooves in addition to narrow and medium grooves.
13
 
 Fold back structures of antiparallel DNA structures formed by the telomeric DNA 
(Telomeres are the single strand overhang at the very end of chromosomal DNA) of 
Oxytricha nova and human telomeres have shown the presence of all types of grooves 





Table 1.2.  A table showing the differences in the A, B and Z-form DNA 
(Adapted from  Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New 
York: W H Freeman and Co.; 2002 and Saenger, W. Principles of Nucleic Acid 
Structure. In Cantor, C. R., Ed.; Springer-Verlag: New York, 1984). 
 
 
A-form  B-form  Z-form  
 







Base pairs/turn  11  10.4  12  
Pitch per turn of 
helix 
25.3 Å  35.4 Å  45.6 Å  
Glycosyl bond anti  anti  
Alternating  
anti and syn  




Narrow and very 
deep 




Very broad and 
shallow 
Narrow and quite 
deep 




The width of wide grooves goes up to ~ 18 Å, far exceeding the groove widths found in 
B-DNA structures. The bases can have all anti or a mix of syn and anti orientations.
14
 On 
the other hand, RNA structures have been more complex. Apart from the helical duplex 
regions, they have been known to form bulges, knots and hairpin structures. 
More recently, four stranded RNA quadruplexes have also been reported, and 
have been shown to have significant biological implications.
15
 Duplex RNA has A-form 
nucleic structure and its major groove is narrow.
10
  A number of ligands have been 
developed to target these grooves in nucleic acids. Most of this targeting has been 











































































































































Figure 1.4.  A figure showing the hydrogen bonding patterns observed in (a) duplex (b) 
triplex and (c) quadruplex DNA structures.  
12 
 
recognition of B-DNA minor groove or A-RNA major groove. Ligands that solely target 
B-DNA major groove or RNA minor groove are virtually nonexistent.
16 
A recent report 
has identified an aminoglycoside derivative capable of interacting in the B-DNA major 
groove.
16 
 Figure 1.5 shows an illustration showing the three established modes in which 
nucleic acids interact with the small molecules. 
 
 
Figure 1.5.  A figure showing the major groove binding (red), minor groove binding 
(blue) and intercalation (black) processes. 
 
In the following chapters, advances that have been made towards the development 
of both DNA and RNA nucleic acid binders are presented.  The work presented address 
some key discoveries made in the recognition of DNA minor groove and RNA major 
groove, as well as the recognition of novel forms of higher order DNA structures. A new 
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AMINOGLYCOSIDE BINDING TO G-QUADRUPLEX NUCLEIC ACIDS 
Introduction-I 
In this chapter, the discovery of aminoglycosides as G-quadruplex DNA binding 
agents is discussed. The chapter is presented in two sections:   Parallel and antiparallel 
quadruplex binding by aminoglycosides.  The binding studies presented in this chapter 
describe the binding of three  structurally well known DNA quadruplexes. 
Aminoglycoside Binding to Antiparallel G-Quadruplexes.  Telomerase is a nucleoprotein 
capable of reverse transcription of telomeric DNA, which exists as single stranded 
overhangs at the ends of chromosome. The emergence of G-quadruplexes as potential 
telomerase inhibitors shows considerable promise for combating cancer. 
1-3
 The 
biological relevance of such structures lies in the propensity of many telomeric and 
promoter sequences to form G-quadruplexes under physiological conditions.
4
 Increased 
expression of telomerase, a ribonucleoprotein, has been suggested to be one of the main 
reasons for the immortality of cancer cells. 
5-8
 The telomerase induced immortality to 
cancer cells stems from its ability to act as a reverse transcriptase, elongating curtailed 
single stranded telomeric ends.
9
 However, to be active, telomerase requires chromosomal 
ends to be single stranded. Therefore, ligands that are capable of keeping these ends in 
non-single stranded forms, such as G-quadruplexes are attractive for cancer treatment.
1
 







































































































































Figure 2.1. (a) Diagram of a G-tetrad showing the cyclic array of guanine bases 
connected by eight hydrogen bonds in Hoogsteen fashion. The cavity in the middle of the 
G-tetrad is usually occupied by a monovalent or divalent cation represented by the black 
circle (b) representative structures of two broad classes of G-quadruplexes based upon 
number of strands involved in their formation. (c) a figure showing the differences in 




date, the number of ligands that bind to G-quadruplexes with high affinity is limited. This 
necessitates the search for new compounds to advance G-quadruplex based drug design. 




The planar arrangement of the guanine bases gives rise to the formation of a G-





 The G-quadruplex forming nucleic acid structures are broadly classified as 
“parallel” or “antiparallel” depending upon the orientation of strands. The G-quadruplex 
forming nucleic acids utilize one or more strands for their formation (Figure 2.1b). 
Parallel DNA quadruplexes have all strands pointing in the same direction whereas 
antiparallel quadruplexes  have at least one strand in the opposing direction than other 
strands.  There are many variants to G-quadruplex structures which are often dictated by 
loops and the nature of stabilizing metal cations. The four guanines that form a G-tetrad 
are connected by eight Hoogsteen bonds (Figure 2.1a). Hoogsteen hydrogen bonds have 
purine bases in the syn configuration paired to pyrimidine bases which have bases in the 
anti configuration (Figure 2.1c). In contrast, Watson-Crick hydrogen bonded base pairs 
have both purine and pyrimidine bases in anti configuration.  
To date, several types of ligands have been reported to bind to different types of 
G-quadruplexes. Most of these ligands have a common feature of possessing a planar  








, oxazole containing macrocyclic compounds 
18
, 
cationic corrole derivatives 
19
, steroid derivatives 
20
, and berberine derivatives 
21
 to name 
18 
 
a few.  Classical duplex minor groove binders such as distamycin 
22
 and Hoechst 33258
23
 
have also been shown to interact with G-quadruplex structures. Interestingly, the majority 
of the ligands that bind to G-quadruplexes have been proposed to have stacking 
interactions between G-tetrads or simply binding at the ends.  Ligands that selectively 
recognize G-quadruplex grooves are few even though quadruplex groove recognition is 
likely to provide much more quadruplex selective ligands.
24
 The development of ligands 
that can possibly recognize G-quadruplex through non-stacking mechanisms are essential 
for complementing existing approaches for recognition of G-quadruplexes. 
In recent years, numerous targets of aminoglycosides have been uncovered.  
These include group I Introns, the Rev response element, element of HIV-1 virus, 
hammerhead ribozymes 
25-27
, and well as single stranded nucleic acids (Poly A). 
28
 We 
have expanded this list to include triple helical nucleic acids comprised of DNA, RNA or  
 



























































Figure 2.2. Structure of the ligands used in the study. 
hybrid structures
29-32
  and , more broadly,  nucleic acid structures that adopt the A-form 
conformation. 
33-36
 We have also shown that when combined with a suitable DNA minor 
19 
 
groove binder, neomycin can even be compelled to bind in the B-DNA major groove.
37, 38
 
This establishes neomycin’s versatility as a groove binder.  We therefore explored the 
possibility of aminoglycoside groove recognition of G-quadruplexes.  The flexible nature 
of aminoglycosides makes them better candidates for groove recognition when compared 
to other more rigid DNA groove binders such as distamycin.  Besides, quadruplex 
grooves vary greatly depending upon the structural forms (Figure 2.1b) they belong to. 
For example, a tetramolecular parallel quadruplex e.g. d(TG4T)4 has all identical, 
medium sized grooves while an antiparallel quadruplex can have grooves of all sizes: 
wide, medium or narrow.  Neomycin was of interest to study its binding to narrow G-
quadruplexes since it prefers to bind grooves adopting an A-form like conformation. 
As a part of our exploration of groove recognition of nucleic acids, we report here 
that aside from its traditional targets like RNA, there is a considerable affinity of 
neomycin for G-quadruplex DNA structures. Our studies showed a marked preference of 
aminoglycosides to the well characterized Oxytricha nova telomeric sequence which is 
known to adopt an antiparallel G-quadruplex structure containing a diagonal loop.
39
 We 
have used isothermal calorimetry (ITC), circular dichroism (CD), ultraviolet (UV) 
spectroscopy, fluorescence spectroscopy, nuclear magnetic resonance (NMR) 
spectroscopy and computational modeling to characterize the binding of aminoglycosides 
to various G-quadruplexes.  This part of the chapter aims at describing the interaction of 
neomycin and related aminoglycosides (Figure 2.2) to antiparallel G-quadruplexes that 
belong to antiparallel family of G-quadruplexes formed by Oxytricha nova and human 
telomeric sequences.   
20 
 
Materials and Methods-I 
Nucleic Acid Samples. All DNA oligonucleotides were purchased from IDT (Coraville, 
IA). The concentration of the DNA solutions were determined by measuring UV 
absorbance at 85 

C for the quadruplex forming samples, while all other samples were 
measured at room temperature. G-quadruplex structures were formed by heating the stock 
nucleotide solution in cacodylate buffer solution containing varying amounts of either 
sodium or potassium salts to 95 

C for 25 minutes and cooling back to room temperature. 
The nucleic acid samples were then left to incubate at 4 

C for 2-7 days. The 12-mer 
duplex (5'-dA12-x-dT12-3') was synthesized on Expedite Nucleic Acid Synthesis System 
(8909) using standard phosphoramidite chemistry.
40
 Hexaethyleneglycol was used as a 
spacer (denoted by –x– in the oligomeric DNA sequence). The oligomers were purified 
on an anion exchange HPLC column (Water Gen-Pak FAX, 4.6100 mm) with a 
Tris·HCl buffer system. Buffer A: 25 mM Tris·HCl, 1 mM EDTA, and 10 % (v/v) 
MeCN; Buffer B: Buffer A + 1 M NaCl. Conditions: 2-60 % buffer B over buffer A 
during 0-16 min at a flow rate of 0.75 mL/min.  All commercially obtained nucleic acids 
were used without further purification. The G-quadruplex (parallel/antiparallel) formation 
was checked by CD spectroscopy by looking at the CD intensity maximum (260/295 
nm). 
Chemicals. Aminoglycosides used in the study were purchased from MP Biomedicals 




Circular Dichroism (CD) Experiments.  CD experiments were performed at 20 

C on a 
Jasco J-810 spectropolarimeter with a thermo-electrically controlled cell holder. The CD 
spectra were recorded as an average of 3-5 scans. For CD titrations, a concentrated 
solution of the ligand was serially added to the nucleic acid sample and allowed to 
equilibrate for 5 min before a scan was taken. The resulting scan was plotted for CD 
signal change with respect to wavelength. Data processing was done using Kaleidagraph 
3.5 software.  
Isothermal Titration Calorimetry (ITC) Experiments. ITC titrations were performed at 
20.0 

C on a MicroCal VP-ITC (MicroCal, Inc.; Northampton, MA). In most cases, small 
aliquots (5-10 L) of ligand solution were injected (thirty injections) from a rotating 
syringe with a stirring speed of 260 revolutions per minute into an isothermal sample 
chamber containing 1.42 mL of the quadruplex solution at 30/60 M strand 
concentration. Each experiment was followed by a control experiment under the same 
conditions using buffer (cacodylate buffer having sodium or potassium salt as required in 
the experiment) solution instead of the quadruplex. The enthalpy of the ligand interaction 
with buffer was subtracted. The area under each heat burst curve was integrated and the 
resulting data points were fitted using the Origin (version 5.0) software. 
 Fluorescence Intercalator Displacement (FID) Assay. Fluorescence experiments were 
performed on Photon Technology International instrument (Lawrenceville, NJ) and on a 
TECAN Genois 96 well plate reader. All experiments were performed in a temperature 
range of 20-22 

C.  The experiments were performed in a 3-mL quartz cell using 10 mM 
sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl buffer at pH 7.0. For experiments 
22 
 
performed in 96 well plates, a total volume of 200 L was used. The DNA solutions were 
prepared at 0.25 M per quadruplex and mixed with thiazole orange (TO) at a 
concentration of 0.50 M. The ligand was serially added to the DNA/TO solution 
followed by a 4 minute equilibration time before the fluorescence emission was recorded. 
The TO excitation was performed at 501 nm and the emission was recorded from 510-
650 nm.   
UV Spectroscopy. All UV spectra were obtained on a 12 cell holder Cary 1E UV-Vis 
spectrophotometer equipped with a temperature controller. Quartz cells of 1 cm path 
length were used for all experiments. The thermal denaturation of the G-quadruplex was 
monitored at 260, 235 and 295 nm wavelengths. The DNA samples were heated in the 
temperature range 20.0-98.0 

C at the heating rate of 0.2 

C /minute. The resulting 
temperature-absorbance profiles were plotted using Kaleidagraph 3.5 software. For Tm 
determination, first derivative analysis was used. 
1
H NMR Titration. All NMR experiments were performed on a Bruker Avance (500 
MHz) spectrophotometer equipped with z-gradients and temperature control (Department 
of Chemistry, Clemson University NMR facility). The DNA concentration used in 
1
H 
NMR titrations was 0.5 mM per strand. 2D NOESY experiments were performed at 2 
mM per strand a concentration (250 L total volume). All experiments were performed in 
a Shimegi microvolume NMR tube matched with D2O and collected at room temperature 
(~ 22 

C) or at 5 

C. All NMR samples contained 10 mM sodium phosphate, 0.5 mM 
EDTA and 100 mM NaCl buffer at pH 7.0.  The G-quadruplex samples were prepared in 
either 90 % H2O + 10% D2O or 100 % D2O solution. For 1D water suppression, a pulse 
23 
 
sequence with pre-saturation of HOD signal was used. For 
1
H NMR experiments, a total 
of 512 scans were collected. The data was visualized with Bruker X-win Plot 3.5 
software. For 2D NOESY experiments mixing times of 150, 200 and 250 ms were used 
in which acquisition delay was 1.29s. A total of 64 scans were collected. For NOESY 
experiments phase sensitive water suppression was utilized as described by Sklenar 
41
. 
Data was subsequently 2D imported into SPARKY
42
 for visualization and resonance 
assignment. DNA proton resonances were assigned based on NOE patterns and 
previously published chemical shifts.
43, 44
  
Molecular Modeling. All dockings were performed as blind dockings (blind-docking 
refers to the use of a grid box which is large enough to encompass any possible ligand-
receptor complex) using Autodock Vina 1.0.
45
 AutoDock Vina was chosen because of (a) 
its ability to take advantage of multiple core processors as well as its much more efficient 
search of the potential energy surface and (b) its high accuracy with ligands possessing 
more than 20 rotatable bonds when compared to Autodock 4.2. Autodock Vina docking 
was performed using the default exhaustiveness value of eight for all molecules except 
for neomycin and paromomycin which were docked with an exhaustiveness value of 50.  
All other parameters were used as defaults.  All rotatable bonds within the ligand were 
allowed to rotate freely and the receptor was considered rigid.  The Protein Data Bank 
files (PDB ID 156D and 143 D)
46, 47
 were used as the DNA quadruplex receptors for all 
dockings.  All ligand structures were created using Discovery Studio® Visualizer 2.5 and  
then brought to their energetically minimized structures by the Vega ZZ program 
48
 





 was used to convert the ligand and receptor molecules to the required file formats 
for AutoDock Vina docking. Validation that AutoDock Vina has the ability to identify 
the binding site and correctly score the receptor-ligand interactions was confirmed by its 
ability to accurately predict the differences among experimental binding constants for a 
series of aminoglycosides analyzed in this investigation.  Further confidence is gained 
from AutoDock Vina’s ability to produce dockings consistent with other available 
experimental data such as salt dependence.  Additionally, AutoDock Vina was used to 
confirm docking of neomycin to triplex DNA which showed docking of the ligand in the 
Watson-Hoogsteen groove as reported.
50
 
Results and Discussion-I 
Selection of Aminoglycosides as G-quadruplex Binding Ligands. A recent study by 
Jarstfer and coworkers suggested aminoglycosides as a new class of small molecules for 
telomerase inhibition.
51
 In addition, our initial findings suggested that aminoglycosides 
(neomycin specifically) apart from their preference for RNA targets, bind to various 
DNA structures. Remarkable stabilization of triple helices of DNA, RNA and hybrid 
structures prompted us to probe the common feature that makes neomycin bind such 
novel targets.  Our studies suggested that aminoglycosides prefer to bind nucleic acid 
structures that adopt A-form
36
 which are known for the narrowness of their major groove. 
Since G-quadruplex grooves can adopt varying sizes (narrow/medium/wide), which is 
dictated by the conformation of the base (syn/anti) participating in the G-tetrad 
formation, we have investigated if neomycin can possibly fit in the quadruplex grooves. 
Since neomycin lacks a group that can be detected by spectrophotometric techniques such 
25 
 
as UV absorption or fluorescence spectroscopy, we have previously performed studies 
with ligands where a fluorescent probe (pyrene, acridine) conjugated to neomycin was 
used to find neomycin’s preference for nucleic acid structures using competition dialysis 
experiments. The results indicated that apart from its preference for binding to RNA, 
there is considerable binding of aminoglycoside to G-quadruplex structures as well, 
particularly antiparallel structure.
36
 Interesting binding properties were found with 
different types of antiparallel structures. Herein, we present a structurally well 
characterized Oxytricha nova telomeric sequence, which is known to adopt an antiparallel 
G-quadruplex structure. The choice of Oxytricha nova quadruplex was made since this 
quadruplex possesses three distinct types of grooves that quadruplex structures have been 
known to adopt. 
ITC Titration of Neomycin into G-Quadruplex and Determination of Binding Parameters 
of Interaction. ITC has been one of the most sought after techniques for studying the 
interaction of biological molecules with ligands in recent years. ITC allows us to extract 
various thermodynamic parameters from a single experiment.
52-54
 We determined binding 
of Oxytricha nova antiparallel quadruplex d(GGGGTTTTGGGG)2 with two 
aminoglycosides, neomycin and paromomycin using ITC. The affinities of the other 
aminoglycosides were too weak to obtain accurate thermodynamic data using ITC. ITC 
titrations with neomycin and paromomycin were performed in cacodylate buffers 





Figure 2.3. ITC profiles for the titration of Oxytricha nova antiparallel quadruplex 
d(GGGGTTTTGGGG)2 with neomycin  at 20 

C (a) 10 mM sodium cacodylate, 0.5 mM 
EDTA and 30 mM NaCl at   pH 7.0 (b) 10 mM sodium cacodylate, 0.5 mM EDTA and 
100 mM NaCl at  pH 7.0 (c) 10 mM sodium cacodylate, 0.5 mM EDTA and 30 mM KCl 
at pH 7.0.    The heat burst curve (top panel in the figures) is the result of 10 L injection 
of a concentrated ligand solution into the DNA solution. The data points (lower panels of 
the figure) reflect the corrected injection heats, which were obtained after subtracting the 
dilution heats obtained from separate control experiments in which ligand was titrated 
with buffer only. The injectant on the Y-axis of the lower panel of graphs is the ligand 
used in that titration.  The red line represents the calculated fits of the data using one 





appendix I Figure S1). The binding constants (Ka) obtained from ITC titrations are 
shown in Table 2.1.   In the presence of both sodium and potassium salts, with increasing 
salt concentrations, a slight decrease in the association constant was observed. In the 
presence of potassium ions, the association constant for the interaction decreased as the 
salt concentration increased from 30 to 90 mM. A similar effect in the association 
constant of neomycin to the quadruplex was observed in the presence of sodium ions as 
well. An almost four fold decrease occurred as the sodium salt concentration was varied 
from 30 to 100 mM. However, under similar salt conditions (30 mM), neomycin had a 










In order to determine the number of ion pairs formed during the binding, a plot of 
association constants versus salt concentrations was constructed and is shown in Figure 
2.5.
55, 56
 The slope of this log plot reveals the formation of at least one ion pair (see 
appendix I for calculation). This is in contrast to our findings for triple helical DNA as 
well as previous work on binding of neomycin class antibiotics to the A-site rRNA 
construct where formation of three ion pairs was found. 
57
  The formation of one ion pair 
thus suggests that binding occurs with lesser electrostatic interaction than what has been 
observed for the recognition of nucleic acid pockets in the aforementioned nucleic acids.  
The ITC titrations reveal close to a 1:1 binding stoichiometry (ligand to 
quadruplex) for both neomycin and paromomycin. The binding stoichiometry obtained 






Figure 2.4. ITC profiles for the titration of Oxytricha nova antiparallel quadruplex 
d(GGGGTTTTGGGG)2 with neomycin or Paromomycin  at 20 

C. (a) Neomycin in 
buffer 10 mM sodium cacodylate, 0.5 mM EDTA, and 60 mM KCl, at pH 7.0. (b) 
Neomycin in buffer 10 mM sodium cacodylate, 0.5 mM EDTA, and 90 mM KCl at pH 
7.0. (c) Paromomycin in buffer 10 mM sodium cacodylate, 0.5 mM EDTA, and 60 mM 
KCl at pH 7.0.   The heat burst curves (top panel in the figures) is the result of 10 L 
injection of a concentrated ligand solution into the DNA solution in buffer conditions as 
described earlier. The data points (lower panel in the figures) reflect the corrected 
injection heats, which were obtained by subtracting the dilution heats obtained from 
separate control experiments in which ligand was titrated with buffer only. The injectant 
on the Y-axis of the lower panel of graphs is the ligand used in that titration. The red line 
represents the calculated fits of the data using one binding site model. The data fitting 
was carried out using Origin 5.0 software. 
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grooves. The solution structure of this quadruplex has revealed that two strands associate 
in an antiparallel fashion where thymine loops are diagonally connected.
39
 The bases 
around each tetrad are associated in a syn-syn-anti-anti fashion giving rise to a wide, two 
medium sized and a narrow groove.
44, 58
 One way of classifying DNA grooves is looking 
 
Table 2.1. Association constants obtained using ITC titration of Oxytricha nova 
quadruplex d(GGGGTTTTGGGG)2 with neomycin and paromomycin under different 




















 Neomycin 30 0.97 + 0.08 3.79 + 0.22 
Na
+
 Neomycin 100 0.89 + 0.01 1.03 + 0.50 
K
+
 Neomycin 30 1.34 + 0.02 2.76 + 0.21 
K
+
 Neomycin 60 0.89 + 0.02 1.42 + 0.10 
K
+
 Neomycin 90 0.77 + 0.04 1.15 + 0.08 
K
+
 Paromomycin 60 1.34 + 0.03 0.87 + 0.04 
K
+
 Paromomycin 90 1.07 + 0.05 0.45 + 0.01 
. 
at the interphosphate distance between the two strands. DNA grooves that have 
interphosphate distances upto ~ 6 Å can be termed narrow.  Medium grooves have typical 
width of ~12 Å while wide grooves have widths of ~15 Å (and above). The DNA wide 
grooves are typically found in DNA quadruplexes. We investigated the shape 
complementarity of neomycin and paromomycin to the different grooves of quadruplex. 
Previous studies have shown that neomycin doesn’t stabilize B-DNA owing to wide B-  
30 
 


















Figure 2.5. Salt dependence study of neomycin binding to Oxytricha nova quadruplex 
d(GGGGTTTTGGGG)2 in  10 mM sodium cacodylate, 0.5 mM EDTA at pH 7.0 (T = 20 
C) at varying salt concentrations (30, 60 and 90 mM KCl respectively). The 
experimental data was fit with linear regression and the solid line reflects the resulting 
curve fit. 
 
DNA major groove, 
38
 however the wide groove of Oxytricha nova quadruplex grooves is 
much shallower than a B-form DNA major groove. Additionally, and perhaps more  
importantly, there are two medium sized grooves; a binding stoichiometry of two ligand 
molecules per quadruplex would be expected if binding were to occur to these grooves. 
Recognition of neomycin is thus likely in the narrow or wide groove present.  The 
paromomycin binding also shows 1:1 binding stoichiometry which is suggestive of its 
31 
 
binding to the same place as neomycin since the two aminoglycosides are structurally 
very similar, with neomycin possessing an extra amino group (Figure 2.2).   A weaker 
binding of paromomycin is similar to observations previously reported, where neomycin 
shows a much higher increase in nucleic acid affinity than paromomycin.
25, 29
  
Fluorescence Intercalator Displacement Experiments Suggest Neomycin as the Best 
Binder. Fluorescence interclator displacement assay (FID) developed by Boger
59
  allows 
the study of non fluorescent molecules binding to DNA. This assay has been extended to 
study the ligand binding to G-quadruplexes as well.
60,61
  
We chose thiazole orange (TO) as our fluorescent probe. Thiazole orange is a more 
suitable probe than ethidium bromide allowing for determination of high affinity sites as 
well as its non sequence specificity.
61
  Additionally, the fluorescence emission 
enhancement upon binding to DNA has been observed to be many fold higher for 
thiazole orange than ethidium bromide. Recently the ability of a ligand binding to a G-
quadruplex has been expressed in terms of 
G4
DC50 values. These values are representative 
of the concentration of a ligand required to displace 50 % of the probe bound to the G-
quadruplex target in the displacement assays. The 
G4
DC50 values are obtained by titrating 
an intercalator-nucleic acid complex (thiazole orange–quadruplex DNA in the present 
case) with the ligand of interest until all the bound intercalator is displaced from the DNA 
binding sites. This is reflected by no further change in the fluorescence emission of the 
intercalator probe which experiences continuous drop in the fluorescence until all bound 
intercalator is displaced from the nucleic acid. Once all the bound intercalator is 
displaced, a plot is created which looks at the changes in % fluorescence change (where 
32 
 
initial fluorescence emission of thiazole orange is considered as 0 % displaced while the 
fluorescence emission after all the intercalator is displaced is considered as 100 %) with 
respect to the amount of the ligand of interest added. The resulting plot is then fitted with 
a dose response curve to obtain 
G4
DC50 values.  To ascertain the ratio of fluorescent probe 
bound to DNA, we performed direct fluorescence titration where thiazole orange was 
titrated with concentrated quadruplex DNA solution. The titration revealed that thiazole 
orange binds to DNA in 2:1 stoichiometric ratio (Figure 2.6a-b). In Figure 2.6b 
abbreviation  rdq has been used to express the ratio of DNA to quadruplex. In this 
titration, a concentrated DNA solution is added into a known amount of the thiazole 
orange solution.  The increase in the fluorescence emission of thiazole orange is observed 
until all the binding sites are occupied on the DNA. The saturation of the DNA binding 
sites is reflected by no further increase in the fluorescence emission of thiazole orange. 
The response of fluorescence emission of thizaole orange with respect to the amount of 
DNA added can then be plotted to obtain the binding stoichiometry of the interaction.    A 
DNA solution containing two equivalents of thiazole orange was first titrated with 
appropriate ligand solution displacing the bound thiazole orange. As increasing amounts 
of ligand was added, the fluorescence intensity continued to decrease suggesting 
displacement of bound thiazole orange Figure 2.6c. To see if the fluorescence quenching 
was, indeed, an outcome of aminoglycoside binding, control experiments were run. 
Titration of thiazole orange with neomycin did not cause any significant drop in the 




Figure 2.6. (a) Fluorescence titration of thiazole orange with Oxytricha nova quadruplex. 
The thiazole orange solution was titrated with a concentrated DNA solution (b) The 
binding stoichiometry plot of thiazole orange with quadruplex DNA (c) A representative 
FID displacement titration showing the displacement of fluores cent probe with the 
addition of concentrated aminoglycoside (neomycin) from the bound quadruplex DNA 
(d) A graph showing the displacement of thiazole orange from quadruplex DNA using 
different aminoglycosides.  All experiments were performed in buffer 10 mM sodium 






bound thiazole orange (see appendix I Figure S2).  Even after addition of a large amount 
of polyamine, extremely poor thiazole orange displacement resulted. These findings 
indicate that fluorescence quenching of the probe, thiazole orange, is not the outcome of 
non specific interactions.  Among the aminoglycosides studied, neomycin clearly showed 
the least amount of ligand required to displace 50% of fluorescent probe. The order of G-
quadruplex preference for four aminoglycosides studied was found to be neomycin > 
paromomycin > ribostamycin > neamine Table 2.2, Figure 2.6d. The 
G4
DC50 value 
obtained for this experiment showed clear preference of neomycin for Oxytricha nova 
quadruplex (at least four fold higher) than its affinity to duplex B-DNA.  The other 
aminoglycosides showed even higher DC50 values (DC50 is the concentration of ligand 
required to displace 50 % of the bound intercalator probe from a target nucleic acid in a 
FID assay) for duplexes. For quadruplex, the neomycin DC50 (16.6 M) is almost two 
fold lower than paromomycin (29.1 M) and approximately 4.5 fold lower than 
ribostamycin DC50 (68 M). A much larger difference is seen with aminoglycoside 
binding to the DNA triplex, with neomycin preference DC50 (13 M) almost 15- fold less 
than paromomycin DC50 (157 M), and about 35-fold lower than ribostamycin DC50 (459 
M) as observed for the 5'-dA12-x-dT12- x-dT12-3' triplex. 
62
  While the relative affinities 
of the ligands to the same target can be compared using this method, one should be 
cautious in comparing ligand binding to different targets, as slight differences in affinities 
of thiazole orange to duplex DNA, triplex DNA and quadruplex DNA can complicate the 
analysis.  A closer look at the relative affinities of aminoglycosides reveal the same 
general trend where neomycin was found to have least DC50 value.  The finding 
35 
 
presented here correlates very well with the ability of aminoglycosides in telomerase 
inhibition where neomycin was identified as best of all aminoglycosides studied.
51
 The 
results presented in Table 2.2 show an increasing DC50 value with decreasing number of 
amino groups on aminoglycoside suggesting that number of amino groups (which can be 
protonated and exist in the charged form during DNA binding) present on them plays a 
role in their affinity to the quadruplex. Of the ligands studied, neomycin contains the 
maximum number amino groups (six) followed by paromomycin (five). Both 
ribostamycin and neamine have four amino groups (Figure 2.2).    
The salt dependence studies performed with Oxytricha nova quadruplex using 
neomycin as ligand displayed little variations in the binding affinity of neomycin. Given 
that salt dependence studies indicate less charge interactions between neomycin and the 
Oxytricha nova quadruplex  ( as reflected by the formation of one ion pair formation for 
quadruplex DNA as opposed to three ion pairs for triplex DNA), shape complementarity 
driven binding seems more likely for Oxytricha nova quadruplex. This is in contrast to 
the triplex groove recognition by aminoglycosides where both charge/potential 
complementarities play a significant role in binding. 
The difference between neomycin and paromomycin is one –NH2 group. The 
binding studies indicate that the structural difference (amino group) between neomycin 
and paromomycin leads to a two-fold increase in neomycin binding to the quadruplex and 
a fifteen fold increase in neomycin binding to the triplex.  Additionally, as seen with the 
salt dependence studies, very little dependence on salt is seen with aminoglycoside 
binding to quadruplex (one ion-pair) as opposed to three ion pairs seen with neomycin  
36 
 
Table 2.2. The table of DC50 values obtained from studies on 













Paromomycin 29.1±5.0 328.1±64.2 
Ribostamycin 68.1±16.0 1037.9±193.0 
Neamine 79.0±24.0 520.7±244.4 
 
 
bound to a DNA triplex. One can infer that shape complementarity (as opposed to 
potential complementarity) plays a larger role in aminoglycoside based recognition of the 
quadruplex grooves, when compared to their binding to the DNA triplex grooves. 
CD Spectroscopy. We performed CD titrations to find out ligand induced changes in the 
CD signal to observe any conformation change accompanying the ligand binding. The 
CD titration of the Oxytricha nova quadruplex, 5’-GGGGTTTTGGGG-3’ was carried in 
the presence of aminoglycosides (Figure 2.7). The maxima of the CD signals in all 
experiments performed were observed at ~295 nm while the minima are at ~260 nm. This 
is consistent with the antiparallel structure of the G-quadruplex.
63
 However, binding of 
neomycin induces small CD changes Figure 2.7a in the DNA absorption region even 
after addition of large amount of ligand (more than three equivalents). A similar CD 
pattern was also observed for paromomycin, Figure 2.7b. These CD results suggest that 







































Figure 2.7.  CD titration of (GGGGTTTTGGGG) 2  quadruplex with (a) neomycin and 
(b) paromomycin  in buffer 10 mM Sodium Cacodylate and 100 mM NaCl at pH 7.0. 
Small aliquots of ligand were serially added to the DNA (15/10 M/str) solution at 20 

C. 
During the titration, the DNA solution was magnetically stirred with the added ligand for 
five minutes followed by another five minutes of equilibration time. The CD signal 
represents an average of three scans. 
 
UV Thermal Denaturation Studies. UV thermal denaturation experiments were performed 
to find any ligand induced thermal stabilization. The Oxytricha nova quadruplex meltedat 
55.7 

C in cacodylate buffer containing 100 mM sodium salt. Quadruplex was 
thermallydenatured with aminoglycosides.  At 1:1 ligand to quadruplex ratio, the thermal 
denaturation profiles showed ~1-2 

C stabilization in the presence of neomycin (Figure 
2.8, appendix I Figure S3). Similar affinities with DNA triplex lead to >10 

























Figure 2.8.  UV thermal denaturation profiles of Oxytricha nova quadruplex 
d(GGGGTTTTGGGG)2 in the presence of various ligands. The oligonucleotide 
concentration was 10 M/strand and the ligands were added to achieve 1:1 quadruplex/ 
ligand ratio. The buffer used in the experiment was 10 mM sodium cacoldylate, 0.5 mM 
EDTA and 100 mM NaCl at pH 7.0. The nucleic acid samples were heated at the rate of 
0.2 

C /min. The thermal denaturation temperatures were determined by the first 
derivative analysis. 
 
triplex denaturation temperatures. We probed these somewhat surprising thermal 
denaturation profiles by studying the binding of neomycin at increased temperatures 
using ITC.  In potassium buffer, a general decreasing trend in the association constant 
was observed as temperature was raised.  Almost four fold decrease in the association 






Table 2.3   Thermodynamic parameters of melting of d(GGGGTTTTGGGG)2 G-
quadruplex in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 
7.0. [DNA] = 5 M/strand. Please see appendix I for additional details for calculation of 
thermodynamic parameters. 






None -133.36 -380.55 -8.49 
Neomycin(1:1) -134.20 -382.7 -8.62 
 
 
 (appendix I, Figure S4, Table S1). In the sodium buffer, when we performed the ITC 
experiment at 50 

C, weak and broad heat burst curves were obtained. The resulting 
enthalpy profile could not be fitted.  Because of these limitations, the association constant 
close to melting temperatures could not be determined. The ITC titrations at different 
temperatures in potassium buffer suggest a weakened binding at temperatures close to the 
melting point of the DNA.  Additionally, we also probed the thermal denaturation profile 





 The thermodynamic data was obtained at 1:1 quadruplex to 
ligand ratio. The neomycin binding was found to be enthalpically favored (as compared 
to DNA melting alone) by -0.84 Kcal.mol
-1 
(Table 2.3), whereas the Gibbs free energy 
for the quadruplex dissociation was favored by -0.13 Kcal.mol
-1
 at 55 

C.  This small 
favorable dissociation of the quadruplex again shows that binding of neomycin is weak/ 
negligible at temperatures close to the melting temperatures of the quadruplex. It should, 
however,  be borne in mind that ligand association to a nucleic acid leading to thermal 
stabilization  of the nucleic acid  doesn’t always represent a tight affinity, as the final 
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state of the entire binding process is determined by the overall effect of enthalpic and 
entropic contributions.Another interesting aspect of neomycin binding to the quadruplex 
is the sharpness of thermal denaturation profile as compared to the melting of DNA alone 
(consistent with multiple trials). A sharper transition is indicative of a strongly 
temperature dependent affinity constant 
64
 which is in accordance with our findings from 
ITC measurements. 
NMR Studies with Paromomycin and Neomycin.  The solution structure of the Oxytricha 
nova is well established having been solved in the presence of both sodium and 
potassium ions. Both the sodium and potassium forms of the structure have same overall 
fold with slight local variations in the T4 loop.
43, 44
 To investigate the binding of 
neomycin and paromomycin to quadruplex DNA, the DNA sample was prepared in 
similar conditions as employed  in other biophysical experiments. The chemical shifts for 





H NMR titration was initially performed with 
increasing amounts of neomycin. However, even at low ligand concentration (0.5 molar 
equivalent of ligand to DNA) considerable precipitation was seen. We, therefore, carried 
out 
1
H NMR titration with structurally similar ligand paromomycin. ITC experiments 
with paromomycin indicated a slightly lower binding to our G-quadruplex DNA target 
yet demonstrated the same stoichiometry as neomycin. Given its nearly identical structure 






H NMR titration of Oxytricha nova quadruplex DNA with paromomycin. 
Increasing amounts of the ligand were serially added to the DNA solution as indicated on 
each spectrum. The DNA solution was prepared in 10 mM sodium phosphate, 0.5 mM 




binding as what would be expected with neomycin. No precipitation was seen with 
paromomycin titration into the DNA up to 1.0 molar equivalent of the ligand. The 
addition of the paromomycin to the DNA caused both shifts in individual resonance 
positions as well as broadening of the chemical shifts in both imino and aromatic regions 




Figure 2.10.  A bar graph plot showing the changes in the proton resonance of (a) imino 
protons (b) aromatic protons of Oxytricha nova  G-quadruplex  after 
1
H NMR titration 
with paromomycin at 1:1 DNA to ligand ratio.  
 
Several proton resonances demonstrated shifts in both imino and aromatic regions of 
proton spectra as shown in Figure 2.9.  The chemical shift of both imino and aromatic 
protons of G2 showed the greatest change (Figure 2.10). The other major shifts were 
observed for G3, G4 and G10 proton resonances.  The G10 imino proton signal was 
broadened as well. Interestingly thymine bases that make the loop in Oxytricha nova 
DNA structure showed little effect on them upon paromomycin titration. Titrations with 
neomycin also showed similar shifts until precipitation was seen (appendix I Figure S5). 
However, the broadening of the imino resonances was more prominent in comparison to 
paromomycin. While a comprehensive analysis is needed to completely characterize the 
structure of the complex, these initial results clearly demonstrate the binding of 
paromomycin to DNA in a single stable conformation. Looking at the groove structures 
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of the four grooves of the quadruplex, the wide groove  is comprised of bases (G1-G4 )-
(G4-G1) while the two medium grooves are comprised of bases (G1-G4) –(G9-G12) (G4-
G1)-(G12-G9) and the minor groove involves (G9-G12)-(G12-G9) bases. Most of the 
changes in the chemical shifts of imino and aromatic protons are centered on G1-G4 
bases which comprise the wide groove of the quadruplex, suggesting that the drug 
binding likely occurs in the wide groove of the G-quadruplex.  
Docking Studies. There has been an increasing interest in using docking methods which 
allow rapid selection of promising candidates from drug libraries.
24, 66
 AutoDock, initially 
designed to study protein interactions, has been used to study small molecule nucleic acid 
interactions revealing accurate reproducibility of crystal structures for both groove 
binders and intercalators bound to nucleic acids.
67
 Few laboratories have also benefited 
from the use of AutoDock for probing small molecule interactions with the G-
quadruplex.
24, 68, 69
 We have performed docking studies using recently introduced 
AutoDock Vina. According to the molecular modeling performed in this study, neomycin 
shows marked preference for the wide groove of the Oxytricha nova quadruplex as 
compared to the two medium sized grooves and the narrow groove (Table 2.4, Figure 
2.11). When bound to the quadruplex, neomycin can adopt four different conformations 
that are identical in energy due to the symmetry of the G-quadruplex’s wide groove.  
These conformations all share the following characteristics (a) all rings are essentially 
parallel to the groove floor except for ring I (b) in each conformation there exists either 
one close electrostatic interaction (< 3.5 Ǻ), consistent with the experimentally 




Figure 2.11. Computer generated models showing two different views of neomycin (red) 
bound to four different grooves of Oxytricha nova (a) neomycin docked in the wide 
groove (b) neomycin docked in the narrow groove (c-d) neomycin docked in the two 
medium grooves. 
 
Table 2.4.  Binding energy obtained from docking of neomycin and paromomycin in the 
different grooves of the quadruplex DNA studied. 
 










Neomycin Medium(1) -5.4 
Neomycin Medium (2) -5.4 
Neomycin Wide -7.2 






Figure 2.12. Computer generated model showing the four docked poses of neomycin to 
quadruplex where (a-d) represent the four poses of equal energy available to neomycin.  




contacts (< 4.5 Ǻ) (c) each low energy conformation resides in the wide groove (d) every 
conformation has approximately the same energy (-7.2 kcal·mol
-1
) according to the 
AutoDock Vina scoring function. The poses for neomycin have been divided into four 
archetypes (Figure 2.12).  Within these archetypes there is a great deal of flexibility 
favoring increased electrostatics, van der Walls or hydrogen bonding interactions.  We 
also carried out similar docking studies with paromomycin. As expected, due to the 
structural similarity (Figure 2.2) between paromomycin and neomycin, the observed low 
energy binding pocket is also the wide groove of the quadruplex (Figure 2.13a-c). In 
comparison to neomycin binding to the quadruplex, it is energetically disfavored by 0.2 
kcal·mol
-1
 (Table 2.4) corroborating the findings from our calorimetric studies.  The 
absence of one amine group, as compared to neomycin leads to two low energy 





Figure 2.13. Computer generated models showing paromomycin bound to Oxytricha 
nova G-quadruplex.  (a) and (b) demonstrate the two poses available to paromomycin in 
the wide groove (c) a computer generated model showing neomycin (blue) and 
paromomycin (green) viewed together in the wide groove. Ion pairing interaction of 
neomycin to phosphate backbone is shown by the solid black line. 
 
Neomycin’s unfavorable interaction in the narrow groove of the quadruplex likely 
stems from the extreme narrowness of the groove (end to end distance < 4.5 Ǻ). Few 
reports of G-quadruplex groove binding ligands have been reported.
24
 It has been 
suggested that the G-quadruplex groove recognition is expected to give a higher degree 
of selectivity over the other DNA structures, yet few groove binders have been 
identified.
24
 Polyamides such as distamycin have been shown to bind as two sets of 
stacked dimers in two of the four identical grooves of d(TGGGGT)4 parallel quadruplex 
with much lower affinities than the duplex. Aminoglycoside based shape 
complementarity to the G-qaudruplex possibly in the wide groove thus opens up new 
avenues for selective groove recognition of the quadruplexes.  
47 
 
We also carried out docking studies of neomycin binding to another antiparallel 
quadruplex formed by the 22mer DNA sequence (5’-
AGGGTTAGGGTTAGGGTTAGGG-3’) mimicking the human telomeric end. Like 
Oxytricha nova quadruplex, the G-quadruplex formed by human telomere  also has four 
grooves (narrow, medium and wide) as revealed by its solution NMR structure.
47
  ITC 
experiments with the human telomeric G-quadruplex using neomycin revealed a 1:1 
binding stoichiometry which is same as observed with the Oxytricha Nova quadruplex 
(Figure 2.14a, appendix I, Table S2). The docking studies showed that similar to 
Oxytricha Nova, the most favorable binding pose had neomycin in the middle of the wide 
groove (Figure 2.14b). 
This result also suggests that binding of neomycin is probable in the wide groove 
of the G-quadruplex DNA DNA structures (as opposed to medium/ narrow grooves). To 
compare the dependence of ligand binding to nucleic acid groove widths, AutoDock 
analysis of groove binding of neomycin to different nucleic acids was also carried. The 
results from this analysis are presented in Figure 2.15. A linear correlation between 
groove width and neomycin binding was seen. There is a decrease in binding affinity 
with increasing groove width indicating that neomycin binding to different DNA 
structures is clearly groove width dependent. As grooves get wider (from A-site RNA to 
quadruplex DNA), decrease in the shape complementarity of ligand-nucleic acid leads to 







Figure 2.14.  (a) ITC titration of neomycin into human telomeric G-quadruplex DNA in 
buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0 (T = 20 

C) (b) computer model of neomycin binding in the wide groove of 22 mer DNA 
sequence d-(AGGGTTAGGGTTAGGGTTAGGG) mimicking the human telomeric end. 














































Figure 2.15.  A graph showing the binding affinity of neomycin to different nucleic acids 
with respect to their groove widths (please see appendix I for PDB ID of nucleic acids 
used in the study, Table S3). 
  
Binding of Neomycin to Oxytricha  Nova  Telomeric DNA at Low pH 
pH 5.5.  The formation of the antiparallel quadruplex was checked using CD 
spectroscopy.  As seen in Figure 2.16a, a positive band at 295 nm and a negative band at 
260 nm were observed, which are characteristic CD signatures of antiparallel G-
quadruplex structures. To investigate any binding induced changes, CD titration 
experiments were carried out.  The DNA solution was serially titrated with a concentrated 




































































Figure 2.16.  CD titration of Oxytricha nova quadruplex (10 M/strand) with neomycin.  
A concentrated solution of neomycin was added to the DNA solution followed by five 
minute equilibration.  The ratio of DNA to ligand is depicted on each graph.  The CD 
scans are an average of two scans. The titrations were conducted in buffer 10 mM sodium 
cacodylate, 0.5 mM EDTA and 100 mM NaCl at (a) pH 5.5 (b) pH 6.8 
 
small changes in the CD signal at 295 nm or 260 nm were observed. These results 
indicate that the quadruplex is conformationally rigid and neomycin binding does not 
perturb the quadruplex structure significantly. To further test the binding, UV thermal 
denaturation experiments were carried out. The quadruplex melted at 55.9 

C in the 
absence of ligand.  At 1:1 ligand to quadruplex the DNA melted at 56.3 

C. ITC 
experiments were also performed.  However, the enthalpy of ligand-quadruplex 
interaction was very small at this pH which could not be fitted to get an association 




pH 6.8.  Similar to observations at pH 5.5, the CD showed the formation of quadruplex 
(Figure 2.16b). The CD titration with neomycin did not result in significant binding 
induced changes. This suggested that the protonated state of the amines on neomycin did 
not significantly contribute to the binding induced changes in the CD spectrum. There 
was also a small thermal stabilization upon ligand binding at 1:1 ligand to quadruplex 
ratio.  The ITC experiments were carried to get the binding affinities (appendix I, Figure 
S6b). The ITC derived binding stoichiometry showed approximately one ligand binding 




.   
Binding of Neomycin to Human Telomeric DNA at Low pH. 
pH 5.5.  Human telomeric DNA contains a hexamer repeat unit (d-5’TTAGGG). A 
22mer oligonucleotide model sequence d(AGGGTTAGGGTTAGGGTTAGGG) has 
been shown to adopt an antiparallel structure in solution. CD experiments were 
conducted to check the formation of the quadruplex.  The CD spectrum showed a positive 
peak at 295 nm and a negative peak at 260 nm which are consistent with the antiparallel 
structure of the quadruplex (Figure 2.17a). To characterize the binding induced structural 
changes, CD titration experiments were conducted. Neomycin was serially added to the 
quadruplex solution and the resulting spectrum was recorded. Even after large addition of 
neomycin to the quadruplex, very small changes in the CD intensity were observed at 295 
nm.  The CD result indicates that similar to Oxytricha nova, human telomeric quadruplex 
undergoes very small structural changes upon ligand binding and the overall antiparallel 
fold of the quadruplex is preserved. The UV thermal denaturation studies showed a small 
stabilization of the human telomeric quadruplex.  ITC experiments were conducted to 
52 
 
find the binding affinities. Similar to the Oxytricha nova small enthalpy of interaction the 



























































Figure 2.17.  CD titration of human telomeric quadruplex (10 M/strand) with 
neomycin.  A concentrated solution of neomycin was added to the DNA solution 
followed by five minute equilibration.  The ratio of DNA to ligand is depicted on each 
graph.  The CD scans are an average of two scans. The titrations were conducted in 10 
mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at (a) pH 5.5 (b) pH 6.8. 
 
pH 6.8.  As seen from the CD spectrum, the antiparallel structure was confirmed by the 
positive band at 295 nm. The addition of neomycin resulted in minimal changes in the 
CD intensity at 295 nm (Figure 2.17).  Similar to the results at pH 5.5, UV thermal 
denaturation experiments also showed small thermal stabilization.  ITC derived binding 
constants were obtained using a one site binding model (appendix I, Figure S7b). The 
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results obtained show that neomycin binds to the human telomeric DNA with 1:1 ligand 






Aminoglycoside Binding to Parallel Quadruplexes. Over the last two decades, the ability 
of guanine rich nucleic acids to form four stranded structures and inhibit the functions of 
telomerase 
70
 have generated immense interest in their biological functions. Since the 
structural elucidations of tetramolecular, bimolecular and unimolecular quadruplexes in 
early 1990s, significant attention has been paid to develop small molecules
71
 that 
selectively recognize G-quadruplex nucleic acids with high specificity and affinity.
72
 A 
number of small molecules, most of which have extended planar aromatic rings, have 
been reported to bind to G-quadruplexes, with the majority having micromolar 
affinities.
73
 Most of these ligands primarily recognize G-quadruplexes through terminal 
stacking interactions between the -ring systems of the ligand and the planar tetrad 
formed by a cyclic array of four guanosines.
74
 But as it is becoming increasingly clear, 
groove recognition presents an enticing approach for selective recognition of quadruplex 
structures.
74
 Recently ligands that contain both rigid (planar aromatic) and flexible units 
(polyamines) in one molecule have been reported to bind G-quadruplexes.
75, 76
 The 
flexible polyamine units have been suggested to interact with the G-quadruplex grooves
77
 
and facilitate better binding. Despite recent advances in the G-quadruplex groove 
recognition, 
24, 78
 it still remains a vastly unexplored area. We have recently reported the 
binding of aminoglycosides to DNA-quadruplexes and our preliminary investigations 





In this section, we present high affinity binding of a non planar and an all 
carbohydrate ligand neomycin to a parallel G-quadruplex formed by the Tetrahymena 
telomere. To the best of our knowledge, this is the first report of such high affinity 
binding of a completely non-planar ligand to a G-quadruplex. Our studies indicate the 
molecular recognition of a dimeric form of the quadruplex. A number of recent reports 
have indicated such dimer/multimer formation by G-quadruplexes.
80, 81
 G-quadruplex 
nucleic acids are highly polymorphic DNA structures that associate and orient in a 
number of different ways giving rise to a variety of loop connectivity, groove width and 
shapes. The quadruplexes often result in the formation of all possible types of grooves 
(small, medium and wide). Unlike A, B or Z-DNA, G-quadruplexes lack generality that 
define their features. However, their structural diversity (especially differing shapes of 
grooves and loops) makes them attractive targets to be studied by aminoglycoside ligands 
(Figure 2.2) whose binding (particularly neomycin) has been shown to occur in bulges
82
 
and in the narrow major groove
83
 of A-form nucleic acids.
84
 To study aminoglycoside 
binding to parallel quadruplexes, we chose to study the parallel quadruplex formed by 
Tetrahymena telomere. This quadruplex was chosen due to the reported A-form features 
at the junction of the quadruplex dimer observed in the crystal structure.
85
 
Since the discovery of streptomycin in 1944, the research on aminoglycoside-
biomacromolecule interactions has established them as a versatile nucleic acid binder.
83
 
Buoyed with their desirable effects as clinical antibiotics, aminoglycosides have been 
unearthed to possess very unique ability of being shape selective nucleic acid binding 
agents.
83, 84
 The antibiotic effect of aminoglycosides stems from their ability to induce 
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infidelity in the codon-anticodon recognition by binding to the A-site of the 16S 
ribosomal subunit. Many new nucleic acid targets for aminoglycosides have been 
indentified
35, 86





transcriptional activator region from HIV,
89, 90
 5’- UTR of thymidylate synthase
91
 and  
RNA aptamers from in vitro selection.
92
 Apart from these RNA targets, aminoglycosides 
have been shown to possess remarkable DNA binding properties.
93, 94
 Nearly a decade of 
research in our laboratory has indentified aminoglycosides (more specifically neomycin) 
as a nucleic acid binder which recognizes A-form nucleic acids with higher affinities than 
B-form nucleic acids.
83
 Covalent attachment of other nucleic acid binders 





 and hybrid 
34
 structures with high affinities that are comparable to the 
affinities of protein-nucleic acid interactions. More recently, we have identified the 
nucleic acid binding of aminoglycosides to four stranded nucleic acids (G-quadruplexes 
and i-motifs).
79,83
 The conjugation of neomycin to a G-quadruplex binder 
perylenediimide has resulted in the higher specificity of the conjugate towards the 
binding to a unimolecular antiparallel G-quadruplex formed by a four repeat human 
telomeric sequence.
76
 In this report, extend our studies to aminoglycoside binding to 
parallel quadruplexes to understand and contrast their binding to antiparallel 
quadruplexes using calorimetric and spectroscopic techniques. 
Materials and Methods-II 
All DNA oligonucleotides were purchased from either IDT (Coraville, IA) or 
MWG Operon (Huntsville, AL) in standard desalted form and were used without further 
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purification. A-site rRNA 5’-r(GGC GUC ACA CCU UCG GGU GAA GUC GCC) was 
purchased from Dharmacon (Lafayette, CO). The concentration of the nucleic acid 
solutions was determined spectrophotometrically at 90 

C using extinction coefficients 
provided by the supplier. Quadruplexes were formed by heating the stock nucleotide 




) to 95 

C for 25 min and cooling back to 
room temperature followed by incubation for several (4-12) weeks at 4 

C. The 
quadruplex formation was checked by Circular Dichroism (CD) and 
1
H NMR 
spectroscopy.  All aminoglycosides were purchased from MP Biomedical (Solon, OH) 
and used without further purification. The NMR experiments were performed on a 
Bruker (500 MHz) spectrometer.   The NMR data was processed using XWinPlot 3.5 
software. 
Fluorescencent Intercalator Displacement (FID) Experiments.  Fluorescence experiments 
were performed on TECAN Genois fluorometer (Männedorf, 
Switzerland) equipped with a 96 well plate reader. All experiments were performed at 
room temperature (21-23 

C).  The experiments were performed in the 96 well plates in 
triplicates. The DNA solution was prepared at 1 M/quadruplex in 10 mM sodium 
cacodylate, 0.5 mM EDTA, 30 mM NaCl at pH 7.0 or 10 mM sodium cacodylate, 0.5 
mM EDTA, 60 mM KCl at pH 7.0. The DNA solution was mixed with thiazole orange 
(TO) at a concentration of 2 M. The ligand was added to the DNA/TO complex solution 
at 1:1 ratio followed by five minute equilibration time before the fluorescence emission 
was recorded. The change in the fluorescence was plotted as - 
% fluorescence change = (F/IF) × 100 
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Where, F = Change in fluorescence upon ligand addition and IF = Initial fluorescence of 
the DNA/TO complex. 
Isothermal Titration Calorimetry (ITC) Experiments. ITC titrations were performed at the 
appropriate temperature (as indicated on each graph) on a MicroCal VP-ITC (MicroCal, 
Inc.; Northampton, MA) calorimeter. Small aliquots of ligand solution, typically 5-10 L 
of  a 300 M ligand), were injected from a rotating syringe at a stirring speed of 260 rpm 
into an isothermal sample chamber containing 1.42 mL of the quadruplex solution at 60 
M/strand concentration. Each experiment was followed by a control experiment under 
the same conditions using in which the ligand solution was titrated into the buffer. The 
enthalpy of ligand-buffer interaction was subtracted from ligand-quadruplex titration 
experiment to give corrected enthalpy of interaction for each injection. The area under 
each heat burst curve was integrated manually and the resulting binding isotherms were 
fitted using the Origin (version 7.0) software using one or two binding site model 
provided in the software for ITC data fitting. 
Ultra Violet (UV) Thermal Denaturation Experiments. All UV spectra were obtained on a 
12 cell holder Cary 1E UV-Vis spectrophotometer equipped with a temperature 
controller. Quartz cuvettes with 1 cm path length were used for all the experiments. 
Spectrophotometer stability and wavelength alignment were checked prior to initiation of 
each thermal denaturation experiment.   For all experiments, the samples were prepared 
by diluting a stock sample. The melting of DNA quadruplex with and without the ligand 
was carried at a heating rate of 0.2 °C / min.   Samples were brought back to 20 °C after 
the experiment.   All UV thermal denaturation experiments were monitored at 260 and 
58 
 
295 nm.   The thermal denaturation temperature (Tm) was obtained by drawing baselines 
on the pre and post thermal denaturation regions as described by Mergny.
64
 Data points 
were recorded every 1.0 °C. The DNA concentration was 1 M/quadruplex. The 
ligand:DNA ratio was 1:1 for experiments carried out in the presence of ligands.  
Circular Dichroism (CD) Experiments. CD experiments were performed at 20 

C using a 
Jasco J-810 spectropolarimeter with a thermo-electrically controlled cell holder. The CD 
spectra were recorded as an average of two scans. For CD titration, small aliquots of 
concentrated ligand solution (1 mM ) was serially added to the nucleic acid sample (65 
M/strand) in buffer 10 mM sodium cacodylate, 0.5 mM EDTA, 60 mM KCl at pH 7.0 
and allowed to equilibrate for five minute before a scan was taken. The resulting scans 
were plotted for CD signal change with respect to wavelength at varying ratio of 
ligand:quadruplex. Data processing was done using Kaleidagraph 3.5 software.  
Results and Discussion-II 
 
Fluorescent Intercalator Displacement (FID) Assay. To ascertain aminoglycoside 
preference for the parallel quadruplex, we used FID assay.
100
 FID experiment allows 
rapid screening of nucleic acid binding agents in a simple assay, in which, a large number 
of nucleic acid binders can be indentified for their structure /sequence specificity.
100, 101
 
This assay, developed by Boger,
100
 relies on the fluorescence emission response of an 
intercalator ligand (usually thiazole orange or ethidium bromide) upon small molecule 
binding. The intercalator is mixed with a nucleic acid in an appropriate ratio (which can 
be determined from a titration experiment), which results in a large increase in the 













































































































Figure 2.18. FID plot showing the change in the fluorescence emission upon ligand 
binding in a d(TG4T)–Thiazole Orange (TO) complex.  [DNA] = 1 M/quadruplex, [TO] 
= 2 M, [Ligand] = 1 M. The experiments were performed in (a) buffer 10 mM sodium 
cacodylate, 0.5 mM EDTA and 30 mM NaCl at pH 7.0 (b) buffer 10 mM sodium 
cacodylate, 0.5 mM EDTA and 60 mM KCl at pH 7.0.  Each entry represents an average 
of three experiments. 
 
intercalator can then be displaced by the addition of the ligand of interest. Thus for a 
particular nucleic acid sequence, various ligands can be screened to obtain a rank of their 
binding abilities that nucleic acid.  The fluorescence emission changes corresponding to 
the ligand addition can also be utilized to obtain sequence specificity which can be 
determined from the addition of a ligand to various nucleic acids differing in their 
sequence patterns. It can also be utilized to construct a binding isotherm which can be 





have applied this technique previously and have been able to identify duplex, triplex and 
quadruplex nucleic acid binders.
83, 102, 103
  
In a similar strategy as shown by Boger, Monchaud and coworkers have shown 
that this assay can also be utilized to identify G-quadruplex binders.
61
  In this assay, the 
quadruplex-thiazole orange (TO) complex was added with different aminoglycosides. 
The displacement of TO from quadruplex by ligand results in a decrease in fluorescence 
emission of TO. The nucleic acid binding strength of the ligand directly correlates to the 
change in the fluorescence such that a higher affinity is generally reflected by a higher 
change in the fluorescence emission.  The resulting change in the fluorescence was 
plotted to determine the best aminosugar quadruplex binder.  Our results showed 
neomycin to be best displacer of TO suggesting it to have the highest affinity among 
aminoglycosides studied (Figure 2.18). As seen in Figures 2.18a-b, percentage of 
fluorescence change in the presence of sodium and potassium ions gave the same trend of 
TO displacement.  
Interaction of Neomycin with d(TG4T) and d(UG4T) Quadruplexes at pH 7.0. Advances 
in the development of sophisticated microcalorimeters in the last couple of decades have 
made possible the study of a large number of small molecule-biomacromolecule 
interactions. Isothermal calorimetery (ITC) has greatly assisted in the understanding of 
thermodynamics of many biomacromolecular reactions.
104,105
 ITC allows determination 
of several parameters such as binding stoichiometry, association constant, binding 
enthalpy and entropy from a single experiment.
105
 This is done by the fitting the binding 
isotherm of the reaction under investigation using appropriate non linear least square 
61 
 
fitting models (the binding isotherms presented in this study were fitted using one or two 
binding site models that came with ITC software package Origin 7.0. The nonlinear 
regression analysis of the binding isotherms is an iterative process which helps in 
reducing the errors). A number of small molecule-G-quadruplex interactions have been 












Figure 2.19 shows the ITC profiles of neomycin being titrated into d(TG4T) 
quadruplex. The titration of d(TG4T) with neomycin under three different salt 
concentrations (30-90 mM)  is shown  in Figures 2.19a-c. The binding isotherms under 
different salt concentrations showed two binding events during the titration. The first 
binding reaction saturated at neomycin to quadruplex ratio of ~ 0.5 (i.e. one neomycin 
molecule per two quadruplex monomer units) with association constants                        




 (Table 2.5a). The second binding event showed ~ 1.5-2.0:1 





. The stoichiometry the ligand-quadruplex association was also corroborated by other 
experiments (CD, FID) of as discussed in the later sections (see appendix I, Figure S8). It 
is interesting to note the “non-wholeness” of stoichiometry values of the binding 
interaction and their interpretation is discussed later in this section. The results clearly 
show the dependence of the association constant for both first and second binding events 
on the potassium salt concentration as it changes from 30-90 mM.  The binding affinity 
decreases nearly fivefold as the potassium concentration increases from 30 mM to 90 





Figure 2.19. ITC titration profile of the neomycin (300 M) titration into d(TG4T) 
quadruplex (60 M per strand). The titrations were performed in 10 mM sodium 
cacodylate, 0.5 mM EDTA at pH 7.0 under different salt concentrations at T = 20 

C. (a) 
30 mM KCl (b) 60 mM KCl (c) 90 mM KCl.  Each heat burst curve is an outcome of 5 or 
7 L injection of a concentrated ligand (neomycin 300 M) into quadruplex (60 M per 
strand). The enthalpy of neomycin-d(TG4T) interaction was corrected  for contribution 
from neomycin-buffer interaction by running separate experiments in which neomycin 








nearly tenfold. This shows that there is clearly a role of electrostatics in the binding for 
both first and second binding events. Under all salt concentrations binding reactions were 
exothermic (Table 2.5b). However, the enthalpy of neomycin-quadruplex interaction 
became less exothermic with increasing salt concentrations (Table 2.5b). 
The first binding event in the d(TG4T)-neomycin interaction is of particular 
interest due to its high affinity and the “non-wholeness” of the  binding stoichiometry 
obtained from these titrations. The crystal structure of d(TG4T) has shown the formation 
of a dimeric quadruplex in a head to head (5’-5’) fashion
85
 under different salt 
conditions.
110-112
 The binding stoichiometry of ~0.5 neomycin per quadruplex or in other 
words one neomycin molecule per quadruplex dimer can be plausible if neomycin can 
induce such dimerization in solution. To the best of our knowledge, of the few solution 
NMR studies that have been conducted on d(TG4T) quadruplex,  none of them have 
identified the dimer formation in solution (though the conditions employed in their 
studies were different than what we have utilized in the present study).  However, several 




 forms have shown the 
formation of quadruplex dimer by d(TG4T) under different conditions. Recently, an 
analogous sequence d(UG4T) has also been suggested to exist as a dimer in solution using 
NMR diffusion experiments.
114
 Therefore, we performed the ITC titration of d(UG4T) 
quadruplex with neomycin (Figures 2.20a-c) under the same salt conditions used for 





Table 2.5a. ITC derived binding stoichiometry and association constant for the d(TG4T)-    
neomycin interaction under varying salt concentrations.
a 
 











30 mM KCl 
 
0.46 + 0.01 
 
2.33 + 1.09 
 
1.84 + 0.01 
 
11.70 + 1.45 
60 mM KCl 0.45 + 0.01 2.10 + 0.80 1.63 + 0.01 8.90 +  0.60  




Table 2.5b. Thermodynamic parameters obtained after fitting the binding isotherms of 
neomycin -d(TG4T) interaction using two binding site model.
b 
 
Salt H1(Kcal/mol) S1(Kcal/mol/K) H2(Kcal/mol) S2(Kcal/mol/K) 
 
 
30 mM KCl 
 




-9.1 + 0.10 
 
-2.78 
60 mM KCl -3.78 + 0.15 25.12 -8.40 + 0.10 -1.45 
90 mm KCl -0.43 + 0.01 33.70 -5.41 + 0.01  9.13 
 
a 
 N1 and N2 denote  binding stoichiometry of first and second binding events 
respectively. Ka1 and Ka2 represent the association constant for first and second binding 
events respectively.  
b
 H1 and H2 denote the enthalpy of interaction for first and 
second binding events respectively whereas S1 and S2 denote the entropy of 
interaction for first and second binding events respectively. 
 
 
only one binding event which saturated at a quadruplex to ligand ratio of ~ 2.0 neomycin 
molecules per quadruplex (Table 2.6). The association constant for the binding reactions 




. Analogous to d(TG4T), the association 
constants were impacted by the change in salt concentrations clearly showing the 
electrostatic nature of  the binding. This binding constant was reflective of the second 





Figure 2.20. ITC titration profiles of neomycin-d(UG4T) quadruplex interaction in (a) 30 
mM KCl (b) 60 mM KCl and (c) 90 mM KCl containing 10 mM sodium cacodylate and 
0.5 mM EDTA at pH 7.0. Each heat burst curve is an outcome of 10 L injection of 300 
M neomycin into d(UG4T) (60 M/str). The enthalpy of neomycin-d(UG4T) interaction 
was corrected  for contribution from neomycin-buffer interaction by running separate 





binding isotherm as well as similarity of the association constants.  As shown in Table 
2.6, the increase in the potassium salt concentration from 30-90 mM resulted in nearly 
twentyfold decrease in the association constant of the neomycin-d(UG4T). In addition to 
this, similar to neomycin-d(TG4T) interaction, the enthalpy of interaction becomes 




Table 2.6. ITC derived binding stoichiometry and association constants for the d(UG4T)-    
neomycin interaction. 
 




) H (Kcal/mol) S (Kcal/mol/K) 
 
 
30 mM KCl 
 
2.06 + 0.01 
 
11.80 + 0.18 
 
-12.69 + 0.07 
 
-10.93 
60 mM KCl 1.88 + 0.01 1.23 + 0.05 -10.54 + 0.06 -10.08 
90 mM KCl 2.01 + 0.02 0.60 + 0.06 -7.52 + 0.01 0.79 
 
 
from these studies we infer that both neomycin-d(TG4T) and neomycin-d(UG4T) binding 
are driven by electrostatic interactions at pH 7.0. Because all 
amino groups on neomycin are not prorogated at pH 7.0 there is a strong likelihood of 
binding induced protonation of amines during neomycin-quadruplex interaction as 
aminoglycosides have previously been known to undergo such protonation.
115
  
Additionally, the binding stoichiometry obtained from the first binding site is 
suggestive of recognition of a quadruplex dimer in solution (in our hands we have been 
able to consistently observe this two binding site nature of interaction in multiple repeat 
attempts). We discuss both of these outcomes separately in the following sections. First 
we describe the role of pH on the binding.  
Interaction of Neomycin with TGT and UGT Quadruplexes at pH 5.5. Aminoglycosides 
have differing number of amino groups that can be protonated during the binding process 
(Figure 2.2). A well known example is the binding of aminoglycosides to a mimic 
sequence of its natural target the bacterial A-site.
115
 However at pH 5.5, the binding of 
aminoglycosides such as neomycin, paromomycin and lividomycin have been found to be 
independent of drug protonation.
115
   Therefore, we performed our experiments at pH 5.5 
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to obtain the thermodynamic parameters that are free of such ligand protonation effects 
that arise due to the nucleic acid binding.  The ITC profiles of neomycin titration into 
d(TG4T) is shown in Figure 2.21. As shown in Figures 2.21a-c, all titrations showed a 
similar ITC profiles which indicated one binding event during the interaction. These 
binding profiles are in complete contrast to their profiles at pH 7.0 which showed two 
binding events during the titration at all three salt concentrations studied. These 
interactions are suggestive of completely different recognition events at pH 5.5 and 7.0.  
While the binding at pH 7.0 is indicative of the recognition of quadruplex dimer in 
solution, at pH 5.5, the binding stoichiometry obtained from the titrations suggest one 
ligand molecule per quadruplex (Table 2.7) which could arise from the recognition of the 
monomeric quadruplex species in solution . In addition to this, the dependence of the 
association constants on the salt concentration is negligible as the binding affinities are 
similar in magnitude at all three salt conditions (Table 2.7). The binding enthalpy 
changes associated with neomycin-d(TG4T) interaction  (Figure 2.21) show much 
smaller changes (~0.5 Kcal/mol) at pH 5.5 which is also in complete contrast to the same 
at pH 7.0 (~3.7 Kcal/mol). These results indicate the absence of electrostatic dominance 
on the ligand-nucleic acid interaction.  We then performed ITC experiments of neomycin 
interaction with d(UG4T) at pH 5.5. The ITC profiles of neomycin-d(UG4T) interaction 
are shown in Figure 2.22. Unlike neomycin-d(TG4T) interaction at  pH 5.5, neomycin-






Figure 2.21. ITC titration profile of the neomycin (300 M) titration into d(TG4T) 
quadruplex (60 M/quadruplex). The titrations were performed in (a) 30 mM KCl (b) 60 
mM KCl and (c) 90 mM KCl containing 10 mM sodium cacodylate and 0.5 mM EDTA 
at pH 5.5. Each heat burst curve is an outcome of 7 L injection of a concentrated 
neomycin (300 M) solution into the quadruplex. The enthalpy of neomycin-d(TG4T) 
interaction was corrected  for contribution from neomycin-buffer interaction by running 
separate experiments in which neomycin was titrated into buffer only.  All experiments 
were run at 20 

C. 
pH 7.0 (Figure 2.20). The binding stoichiometry observed in these titrations was ~2.0 
molecules/quadruplex as observed at pH 7.0. However, similar to neomycin-d(TG4T) 
interaction at  pH 5.5, neomycin-d(UG4T) interaction showed very small (negligible) 
dependence of salt concentration on the association constants determined for the 
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interaction. This again shows that electrostatic effects play little role in the neomycin-
d(UG4T) interaction at pH 5.5.  Finally, the difference in the magnitude of enthalpy  
 
Table 2.7. ITC derived binding stoichiometry and association constants for the d(TG4T)-    
neomycin interaction at pH 5.5. 
 




) H (Kcal/mol) S (Kcal/mol/K) 
 
 
30 mM KCl 
 
1.08 + 0.01 
 
2.67 + 0.31 
 
-2.26 + 0.03 
 
21.68 
60 mM KCl 0.91 + 0.01 2.26 + 0.20 -2.29 + 0.03 21.24 
90 mM KCl 1.14 + 0.01 2.95 + 0.31 -1.78 + 0.02 23.51 
 
 
change at various salt concentrations is much smaller (~0.5 Kcal/mol) as compared to the 
same at pH 7.0 (~5.0 Kcal/mol). Thus the difference in the enthalpy of interactions at 
various salt concentrations is similar in magnitude as found with neomycin-d(TG4T) 
interaction at pH 5.5 (~0.5 Kcal/mol). These results show that both d(TG4T) and d(UG4T) 
show lack of electrostatic dominance of  neomycin  binding at pH 5.5. The studies with 
d(TG4T) at 5.5 indicates the recognition of monomeric species by neomycin in solution in 
contrast to the recognition of dimeric species in solution at pH 7.0.  We have previously 
shown that neomycin prefers to bind to nucleic acids that have A-form characteristics 
84
 
and even induces structures that are known to have A-form conformation upon 
binding.
116
 Our results clearly show that at pH 7.0, the simple substitution of a thymine 





Figure 2.22. ITC titration profiles of d(UG4T) quadruplex with neomycin in (a) 30 mM 
KCl and (b) 60 mM KCl and (c) 90 mM KCl buffer containing 10 mM sodium 
cacodylate and 0.5 mM EDTA at pH 5.5 . Each heat burst curve is an outcome of 10 L 
injection of 300 M neomycin into d(UG4T) (60 M/str). The enthalpy of neomycin-
d(UG4T) interaction was corrected  for contribution from neomycin-buffer interaction by 
running separate experiments in which neomycin was titrated into buffer only. All 




may have originated from the small but significant changes at the interface of quadruplex 
dimers in the two structures. 
While the structures of both d(TG4T) and d(UG4T) quadruplexes show stacking of 
the monomer quadruplexes in a head to head (5’-5’) fashion leading to the dimer 
formation, there are significant differences at the dimeric interface . 
114, 117
 The G2 bases 
71 
 
at the interface have been shown to have A-form features
117
 with four narrow regions at 
the interface of monomers. 
 
Table 2.8. ITC derived binding stoichiometry and association constants for the d(UG4T)-    
neomycin interaction at pH 5.5. 
 




) H (Kcal/mol) S (Kcal/mol/K) 
 
 
30 mM KCl 
 
2.07 + 0.01 
 
1.22 + 0.19 
 
-3.84 + 0.03 
 
19.19 
60 mM KCl 2.21 + 0.01 1.71 + 0.24 -3.74 + 0.03 20.33 
90 mM KCl 2.02 + 0.01 1.09 + 0.10 -3.43 + 0.02 20.49 
 
 
However, in d(UG4T), the 5’- uracil bases form a U-tetrad retaining B-DNA like 
features at all nucleotides of the quadruplex.
114
 The small pockets formed by the A-form 
thymines in d(TG4T) are thus likely binding sites for the first binding interaction in 
d(TG4T). Over the years, we have identified that there is clearly a greater liking of 
neomycin towards A-form nucleic acid structures using competition dialysis
84
 and other 
experiments.
83
  The association constant obtained for neomycin-nucleic acid interactions 
have shown a higher affinity of neomycin towards A-form nucleic acids.
83
 Thus, the A-
form thymines at the interface may create a favorable binding pocket for neomycin 
(Figure 2.23). The second binding event which shows binding stoichiometry in the range 
of 1.5-2.0 ligands per quadruplex (or 3-4 ligand per dimeric quadruplex) may be 




Figure 2.23. A figure showing the changes at the interface regions of (a) (dUG4T) and (b) 
d(TG4T). The models have been adapted from references 114 and 85 respectively.  
 
site as well as quadruplex grooves. The lack of such A-form junction interface is likely 
the root of completely different binding profile of d(UG4T) in which binding most likely 
takes place through interaction in the grooves as neomycin does not contain any feature 
(usually a flat molecular surface capable of making end stacking interactions) that would 
facilitate its stacking at the terminal G-tetrads.   These studies were followed by testing 
possibility of dimeric quadruplex recognition at pH 7.0 by studying neomycin-
quadruplex interaction to those quadruplexes which are incapable of forming dimers.    
Interaction of Neomycin with Quadruplexes Incapable of Forming Quadruplex Dimers. 
To test the hypothesis of neomycin binding to the interface of monomer quadruplexes 





Figure 2.24. ITC titration profile of neomycin (300 M) being titrated into (a) 
d(T2G4T2) and (b) d(T3G4T3).  The concentration of DNA quadruplex in each experiment 
was 60 M/strand. The titration was performed in buffer 10 mM sodium cacodylate, 0.5 
mM EDTA and 60 mM KCl at pH 7.0. Each heat burst curve is an outcome of 10 L 
injection of 300 M neomycin into the indicated quadruplex. The enthalpy of neomycin-
quadruplex interaction was corrected  for contribution from neomycin-buffer interaction 
by running separate experiments in which neomycin was titrated into buffer only. All 







parallel quadruplexes that do not form dimeric structures. It has been shown that 
additional thymine bases at the termini of G-tetrads disfavors the dimer formation.
81
 
Thus, we studied neomycin binding to d(T2G4T2),  d(T3G3T3) and d(T4G4T4) 
quadruplexes. In contrast to d(TG4T),  the binding isotherm in these extended thymine 
quadruplexes  showed  a single binding reaction as shown in Figure 2.24 (also see 
appendix I, Figure S9). The binding isotherm of the neomycin-d(T2G4T2) interaction was 
fitted using one binding site model which revealed 1:1 binding of the ligand to the 




) affinities.   We could not fit 
the binding isotherms obtained for neomycin-d(T3G4T3) and neomycin-d(T4G4T4) 
interactions but they do show one binding event  in contrast to the two binding sites 
observed with d(TG4T). 
The d(UG4T) and d(T2G4T2) ITC titrations with neomycin suggest that lack of the 
A-form region (that results when d (TG4T) forms a dimer) in both of these quadruplex 
structures (either because of the formation of U-tetrad or disfavored dimer formation due 
to extended thymines at the 5’ end) lead to the loss of first binding event found in the 
neomycin-d(TG4T) ITC titrations at pH 7.0. These observations, together, suggest that 
the unique A-form narrow region found exclusively at the d(TG4T) interface of two 
monomeric units,  is the probable binding site of the first binding event in the d(TG4T) – 




Recent studies by the Plavec laboratory have identified the formation of d(UG4T) 
dimer in solution (in the presence of 10 mM K
+





 Under the same conditions, d(TG4T) quadruplex showed the formation of 
a less bulky species. However, dimer-monomer equilibrium of G-quadruplexes has been 





mM-90 mM KCl used in our study as opposed to 10 mM K
+
 used by Plavec 
laboratory
114
). We further performed 
1
H NMR titration experiments to look into the 
d(TG4T)-neomycin interaction. However, even at low ligand:quadruplex ratio, complex 
precipitation was observed leading to complications in the analysis of this binding 
interaction by NMR (appendix I, Figures S10-S11). 
  The dimer formation by d(TG4T) in the ligand bound form has also been observed 
previously. Neidle laboratory has shown the recognition of the dimeric form of d(TG4T) 
quadruplex by daunamycin
113
 using X-Ray crystallography where the aromatic moiety of 
the molecule was “sandwiched” at the dimer interface while the aminosugar 
(glucosamine) part protrudes towards the groove.
74,113
 We have previously reported 
neomycin binding to quadruplexes formed by Oxytricha nova and human telomeres in the  
wide groove of these quadruplexes as suggested by modeling studies
79
 and 2D NMR 
experiments (unpublished results).  Additionally, non-planar molecules such as neomycin 
lack the  interactions necessary for stacking interactions. Taken together, we propose 
that the second binding event of neomycin is in the additional grooves of d(TG4T) 
quadruplex. B-DNA minor groove binder Distamycin A has been shown to bind to the 
d(TG4T) grooves in a stacked manner with much lower  affinities
107
 in comparison to the 
first binding event in our case at pH 7.0,  but comparable to the affinities observed for our 
second binding event during the ITC titration experiments. 
76 
 
Effect of Temperature on Binding. The effect of temperature on binding by neomycin to 
d(TG4T) was also evaluated using ITC (Figure 2.25). Our studies indicate that up-to 40 

C, the binding isotherm retains the same profile as observed at 20 

C. The binding 
constants obtained for both the first and second binding events did not indicate any 
appreciable change (Table 2.9). However, we saw loss of binding at elevated  
 
 
Figure 2.25. ITC titration profile of neomycin (300 M) being titrated into the indicated 
d (TG4T) quadruplexes (60 M/strand). The titration was performed in buffer 10 mM 
sodium cacodylate, 0.5 mM EDTA and 30 mM KCl at pH 7.0. Each heat burst curve is an 
outcome of 10 L injection of 300 M neomycin into the quadruplex. The enthalpy of 
neomycin-d(TG4T) interaction was corrected  for contribution from neomycin-buffer 
interaction by running separate experiments in which neomycin was titrated into buffer 







C and 55 

C) as indicated by very weak signals obtained during 
titration of d(TG4T) with neomycin (appendix I, Figure S12).  This indicates that 
temperature dependent binding of neomycin to d(TG4T). It is interesting to note here that 
d(TG4T) quadruplex does not unfold  into individual strands until 76 

C at 60 mM KCl 
concentration as indicated by thermal denaturation experiments.   Therefore, it is likely 
that temperature induced shape or entropic changes (either the changes in the salt patterns 
or hydration) drive to such binding loss. We have also seen such temperature dependent 
















30 mM KCl 
 
0.44 + 0.01  
 
(1.75 + 0.75) 
 
1.70 + 0.01  
 
(1.90 + 0.24)  
 
 
Importance of Ring I in the Binding. The 2-deoxystreptamine (2-DOS) moiety of 
neomycin class antibiotics has been found to play important role in aminoglycoside-
nucleic acid interaction.
119
  We have previously seen the change in the single functional 
group (from amino to hydroxyl) on ring I of neomycin leads to profound effect in the 
binding to triplex DNA.
94
 Paromomycin, which is structurally very similar to neomycin 
(differing only in one functional group on ring I, see Figure 2.2) was thus tried to 
evaluate its binding to both d(TG4T) and d(UG4T). In stark contrast to the neomycin 





 Figure 2.26. ITC titration profile of paromomycin (300 M) being titrated into (a) 
d(TG4T) (60 M/str) and (b) d(UG4T)  (60 M/str). The titration was performed in buffer 
10 mM sodium cacodylate, 0.5 mM EDTA and 60 mM KCl at pH 7.0. Each heat burst 
curve is an outcome of 10 L injection of 300 M neomycin into the indicated 
quadruplex. The enthalpy of neomycin-quadruplex interaction was corrected for 
contribution from neomycin-buffer interaction by running separate experiments in which 




enthaply of interaction and the resulting binding isotherm could not be fitted (Figure 
2.26a). Such ITC binding isotherms are typically reflective of very weak binding 
interaction. On the other hand, titration of paromomycin to d(UG4T) resulted in the 
binding (Figure 2.26b) whose stoichiometry was similar (~2.0 molecules per 
quadruplex) to the binding observed with neomycin but the binding affinity was an order 
of magnitude lesser . These results show that ring I of neomycin plays a key role in the 
79 
 
binding of these two quadruplexes. While in the former case, binding could not be 
evaluated due to low enthalpy of interaction, the latter shows a weaker binding 
highlighting the importance of ring I in the quadruplex recognition.   
Circular Dichroism Studies.  Circular dichroism has been used to study ligand-nucleic 
acid interactions and can be used to obtain information related to the binding induced 




Figure 2.27. (a) CD titration   d(TG4T) with neomycin . The experiment was  performed 
in 10 mM sodium cacodylate, 0.5 mM EDTA and 60 mM KCl at pH 7.0 ( T = 20 

C).  
The d(TG4T) quadruplex (65 M/strand) was titrated with concentrated neomycin 
solution (1 mM). Each addition was followed by mixing of the ligand-quadruplex 
complex solution with a magnetic stirrer followed by ten minute equilibration. Each 
spectrum is an average of five scans. (b)  A plot showing the binding stoichiometry of 




 interaction. The binding of neomycin was thus probed using circular dichroism 
spectroscopy (Figure 2.27). As depicted in Figure 2.27, in the absence of ligand, the 
quadruplex showed a positive CD peak at 260 nm and a minimum at 240 nm suggesting 
the presence of the parallel form of the quadruplex (The presence of antiparallel 
quadruplex or hybrid quadruplexes is characterized by the maximum at 295 nm and 280 
nm respectively). As increasing amount of neomycin was added, the positive peak at 260 
nm continuously diminished in intensity suggesting complex formation between the 
ligand and the quadruplex. These changes in the CD spectra are dissimilar to the CD 
titration profile of neomycin binding to an antiparallel quadruplex derived from 
Oxytricha nova quadruplex in which addition of neomycin caused negligible changes in 
the CD signal.
79
 The titration shows that overall parallel structure of the d(TG4T) 
quadruplex is retained during the titration. Addition of more ligand to the DNA solution 
resulted in the turbidity of the ligand-quadruplex complex solution. We utilized the 
changes in intensity during the CD titration in obtaining the binding stoichiometry of the 
interaction. As shown in Figure 2.27b, the binding stoichiometry was ~0.5 molecules per 
quadruplex corroborating the results obtained from ITC studies for the first binding event 
during neomycin-d(TG4T) interaction. The binding stoichiometry was also supported by 
FID experiments which showed two binding site behavior of the interaction where the 
ligand to quadruplex ratio for the first and second binding events was similar to those 
obtained with ITC experiments (appendix I, Figure S8). Such detection of two binding 
site behavior was found to be concentration dependent as at low concentrations of 
quadruplex (2 M/str) we could detect only the second binding event of neomycin-
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d(TG4T) interaction determined by ITC which showed ~2:1 ligand:quadruplex ratio (data 
not shown). The lack of detection of the first binding event at low quadruplex 
concentration is also indicative of the concentration dependent formation of the dimeric 
quadruplex species in solution.  
UV Thermal Denaturation Studies. The ligand binding was also evaluated using UV 
thermal denaturation experiments. The quadruplex melted at   61.9 

C in the absence of 
ligand at 1:1 ligand:quadruplex ratio. The thermal denaturation temperatures are listed in 
 
Table 2.10. UV thermal denaturation of TGT quadruplex in the absence and presence of 














Neomycin 64.9 3.0 
Paromomycin 64.1 2.2 
Neamine 63.5 1.6 
Ribostamycin 63.5 1.6 
Neomycin (8 eq) 65.8 3.9 
  
 
(appendix I, Figure S13). The quadruplex was then mixed with various aminoglycosides  
Table 2.10. Neomycin, as expected, afforded the highest thermal stabilization of the 
ligands studied although changes in the melting temperature observed were small. 
The small thermal stabilization by neomycin, which despite binding with the high 
affinity to d(TG4T) at pH 7.0, could be the outcome of temperature dependent binding by 
the ligand as seen with ITC (discussed before). The high affinity binding event in 
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neomycin binding to d(TG4T), which our studies suggest,  likely involves a quadruplex 
dimer during the recognition process , may not  be observable by changes in the UV 
absorbance as large changes in the absorbance during the melting process  are observed 
when bases of an ordered nucleic acid are destacked as a result of the heating. Since 
heating may cause dissociation of dimer to monomer species which might not reflect in 
the sharp absorbance changes as observed preciously, the observation of thermal 
stabilization may not be observed by UV. The thermal stabilizations reflected by 
neomycin may thus be reflective of the second binding event which has much lower 
binding affinitythan the first site. 
Comparison of Binding to A-site RNA and Groove Width Dependence. Neomycin’s 
binding to its natural target, the A-site rRNA was also evaluated. The ITC profile of 
neomycin binding to A-site rRNA is shown in Figure 2.28. The association constant 
determined from this titration reveals a nearly two fold higher affinity for the quadruplex 
as compared to the A-site rRNA under identical solution conditions (appendix I, Table 
S4). The quadruplex A-form interface shown here is an even better fit for the 
aminoglycoside than the rRNA bulge targeted by Streptomyces in killing bacteria!
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Stacked quadruplex monomeric units leading to dimer/multimer formation has 
been noticed for several parallel quadruplexes in recent years.
80, 121-123
 The dimers can 
form by the stacking or interlocking of terminal G-tetrads of the monomeric units, using 
either 5’-5’, 3’-3’, or 5’-3’ ends.
81
 The growing number of reports of the quadruplex 




Figure 2.28   ITC profile of neomycin binding to the A-site rRNA in buffer 10 mM 
sodium cacodylate, 0.5 mM EDTA and 60 mM KCl at pH 7.0 (T = 20 

C)    
 
understanding of the structural and biological details of the dimer interface regions is still 
growing, a recent report has shown DNAzyme activity of multimeric quadruplexes.
124
  
Summary and Conclusions 
The recent advances in the G-quadruplex recognition by small molecules have 
prompted us to explore the groove binding nature of aminoglycosides. From our studies, 
the following conclusions can be drawn: 
 (1) Neomycin binds Oxytricha Nova quadruplex with 1:1 binding stoichiometry. The 
direct ITC titration of the Oxytricha Nova quadruplex DNA revealed that neomycin binds 




 in the presence of both sodium and potassium 




(2) The salt dependence studies in the presence of both sodium and potassium ions 
showed the same trend.  A decrease in the association constants with an increase in the 
salt concentrations was observed. This indicates that the binding interaction of neomycin 
to the quadruplex is moderately driven by electrostatic interactions.  The binding 
stoichiometry of 1: 1 is indicative of a single unique site for neomycin complexation.   
(3) FID assays were conducted with the Oxytricha Nova quadruplex. The binding of 
fluorescent probe indicated a 2:1 ratio of ligand to quadruplex binding. The 
G4
DC50 
values obtained from FID titrations show that neomycin is best in displacing the 
fluorescent probe bound to quadruplex. The other aminoglycosides were much worse in 
displacing the fluorescent probe bound to these quadruplexes. Neomycin binds 
approximately five fold better than ribostamycin.   
(4) The binding of neomycin does not perturb the structure of the quadruplex. The CD 
experiments showed that binding of either neomycin or any other aminoglycoside brings 
negligible change in the CD signal.  
(5)  The binding of ligands is accompanied by small thermal stabilization under the 
conditions, we have used. UV melting studies show that complexation of any of the 
ligands studied, result in small increase in the melting temperature of the quadruplex 
DNA due to decreased binding at temperatures near the melting point of the DNA.  
(6) 
1
H NMR titration of the quadruplex DNA with paromomycin suggests ligand binding 
in the wide groove.  
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(7) A molecular model generated using AutoDock Vina corroborates the experimental 
results suggesting that neomycin binds to the wide quadruplex groove with one amino 
group forming an ion pair with quadruplex phosphate negative charge. 
(8) Neomycin binds to the parallel quadruplex formed by tetrahymena telomeric 
sequence with higher affinity than Oxytricha nova and human telomeric G-quadruplex. 
These affinities obtained for neomycin-d(TG4T) are one of highest affinities ever 
reported for the binding of a completely non-planar ligand to a G-quadruplex target. 
(9) Our results indicate the recognition of the dimeric form of the parallel quadruplex. 
Our studies also suggest that neomycin binds to a dimeric form of a parallel quadruplex 
formed by the Tetrahymena telomere with high affinity at pH 7.0. The high affinity 
binding is affected by changes in temperature, pH and slight variations in the ligand 
structure.  The studies indicate a shape selective binding where the high affinity binding 
is supposed to occur in the A-form regions of the quadruplex dimer.   
To the best of our knowledge, this is the highest affinity reported for a completely 
non-planar molecule binding to a quadruplex and holds promise in the development of 
quadruplex targeted  therapeutics. Antibiotics, such as aminoglycosides, production has 
been long believed to provide a useful way by Streptomyces to fight off other bacteria for 
nutrients in the soil.   It is thus understandable that aminoglycosides show the highest 
affinity for eubacterial rRNA and decades of in vitro experiments have not been able to 
identify natural aminosugar targets that surpass these affinities.  Aminoglycosides, 
however, have also been known to inhibit Tetrahymena growth and the mechanisms of 
growth inhibition have been shown to vary considerably from the established prokaryotic 
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mechanism of increased translational errors.
28
  While most Tetrahymena are aquatic 
species, moist soil Tetrahymena have been reported.
29
 In addition to opening up new 
approaches for selective recognition of quadruplexes, our finding lends support to the 
possibility that aminoglycoside production by Streptomyces may have evolved to fight off 




1. Mergny, J. L.; Helene, C. G-quadruplex DNA: a target for drug design. Nature 
Medicine (New York) 1998, 4, 1366-1367.  
2. Neidle S.; Read M. A. G-quadruplexes as therapeutic targets. Biopolymers 2000, 56, 
195-208.  
3. Riou, J. F.; Gomez, D.; Morjani, H.; Trentesaux, C. Quadruplex ligand recognition: 
Biological aspects. In Neidle Stephen, Balasubramanian Shankar, Eds.; The Royal 
Society of Chemistry: Cambridge, UK, 2006; pp 154-179.  
4. Oganesian, L.; Bryan, T. M. Physiological relevance of telomeric G-quadruplex 
formation: a potential drug target. Bioessays 2007, 29, 155-165.  
5. Camarena, F. S.; Serral, G. C.; Santalo, F. S. Telomerase and telomere dynamics in 
ageing and cancer: current status and future directions. Clin.Transl.Oncol. 2007, 9, 145-
154.  
6. Helder, M. N.; Wisman, G. B. A.; Van der , Z. Telomerase and telomeres: from basic 
biology to cancer treatment. Cancer Invest. 2002, 20, 82-101.  
7. Kelland, L. R. Telomerase: biology and phase I trials. Lancet Oncol. 2001, 2, 95-102.  
8. Kelland, L. Targeting the Limitless Replicative Potential of Cancer: The 
Telomerase/Telomere Pathway. Clin. Cancer Res. 2007, 13, 4960-4963.  
9. Autexier, C.; Lue, N. F. The Structure and Function of Telomerase Reverse 
Transcriptase. Annu. Rev. Biochem. 2006, 75, 493-517.  
10. Burge, S.; Parkinson, G. N.; Hazel, P.; Todd, A. K.; Neidle, S. Quadruplex DNA: 
sequence, topology and structure. Nucleic Acids Res. 2006, 34, 5402-5415.  
11. Hud, N. V.; Plavec, J. The role of cations in determining quadruplex structure and 
stability. In Quadruplex Nucleic Acids; Neidle Stephen, Balasubramanian Shankar, Eds.; 
The Royal Society of Chemistry: Cambridge, UK, 2006; pp 100-130.  
12. Ping Wang, L.R., Hanping He, Feng Liang, Xiang Zhou, Zheng Tan, A Phenol 
Quaternary Ammonium Porphyrin as a Potent Telomerase Inhibitor by Selective 




13. Seenisamy, J.; Bashyam, S.; Gokhale, V.; Vankayalapati, H.; Sun, D.; Siddiqui-Jain, 
A.; Streiner, N.; Shin-ya, K.; White, E.; Wilson, W. D.; Hurley, L. H. Design and 
Synthesis of an Expanded Porphyrin That Has Selectivity for the c-MYC G-Quadruplex 
Structure. J. Am. Chem. Soc. 2005, 127, 2944-2959.  
14. Wei, C.; Jia, G.; Yuan, J.; Feng, Z.; Li, C. A Spectroscopic Study on the Interactions 
of Porphyrin with G-Quadruplex DNAs. Biochemistry (N. Y. ) 2006, 45, 6681-6691.  
15. Hounsou, C.; Guittat, L.; Monchaud, D.; Jourdan, M.; Saettel, N.; Mergny, J. L.; 
Teulade-Fichou, M. P. G-quadruplex recognition by quinacridines: a SAR, NMR, and 
biological study. ChemMedChem 2007, 2, 655-666.  
16. Zagotto, G.; Sissi, C.; Moro, S.; Ben, D. D.; Parkinson, G. N.; Fox, K. R.; Neidle, S.; 
Palumbo, M. Amide bond direction modulates G-quadruplex recognition and telomerase 
inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives. Bioorg. Med. Chem. 
2008, 16, 354-361.  
17. Waller, Z. A. E.; Shirude, P. S.; Rodriguez, R.; Balasubramanian, S. Triarylpyridines: 
a versatile small molecule scaffold for G-quadruplex recognition. Chemical 
Communications (Cambridge, United Kingdom) 2008, 1467-1469.  
18. Jantos, K.; Rodriguez, R.; Ladame, S.; Shirude, P. S.; Balasubramanian, S. Oxazole-
Based Peptide Macrocycles: A New Class of G-Quadruplex Binding Ligands. J. Am. 
Chem. Soc. 2006, 128, 13662-13663.  
19. Fu, B.; Huang, J.; Ren, L.; Weng, X.; Zhou, Y.; Du, Y.; Wu, X.; Zhou, X.; Yang, G. 
Cationic corrole derivatives: a new family of G-quadruplex inducing and stabilizing 
ligands. Chemical Communications 2007, 3264-3266.  
20. Brassart, B.; Gomez, D.; Cian, A. D.; Paterski, R.; Montagnac, A.; Qui, K. H.; 
Temime-Smaali, N.; Trentesaux, C.; Mergny, J. L.; Gueritte, F.; Riou, J. F. A new steroid 
derivative stabilizes G-quadruplexes and induces telomere uncapping in human tumor 
cells. Mol. Pharmacol. 2007, 72, 631-640.  
21. Franceschin, M.; Rossetti, L.; D'Ambrosio, A.; Schirripa, S.; Bianco, A.; Ortaggi, G.; 
Savino, M.; Schultes, C.; Neidle, S. Natural and synthetic G-quadruplex interactive 
berberine derivatives. Bioorg. Med. Chem. Lett. 2006, 16, 1707-1711.  
22. Cocco, M. J.; Hanakahi, L. A.; Huber, M. D.; Maizels, N. Specific interactions of 
distamycin with G-quadruplex DNA. Nucl. Acids Res. 2003, 31, 2944-2951.  
23. Maiti, S.; Chaudhury, N. K.; Chowdhury, S. Hoechst 33258 binds to G-quadruplex in 





24. Cosconati, S.; Marinelli, L.; Trotta, R.; Virno, A.; Mayol, L.; Novellino, E.; Olson, A. 
J.; Randazzo, A. Tandem Application of Virtual Screening and NMR Experiments in the 
Discovery of Brand New DNA Quadruplex Groove Binders. J. Am. Chem. Soc. 2009, 
131, 16336-16337.  
25. Arya, D. P. Aminoglycoside-nucleic acid interactions: the case for neomycin. Top. 
Curr. Chem. 2005, 253, 149-178.  
26. Willis, B.; Arya, D. P. Major groove recognition of DNA by carbohydrates. Curr. 
Org. Chem. 2006, 10, 663-673.  
27. Willis, B.; Arya, D. P. An expanding view of aminoglycoside-nucleic acid 
recognition. Adv. Carbohydr. Chem. Biochem. 2006, 60, 251-302.  
28. Xi, H.; Gray, D.; Kumar, S.; Arya, D. P. Molecular recognition of single-stranded 
RNA: Neomycin binding to poly(A). FEBS Lett. 2009, 583, 2269-2275.  
29. Arya, D. P.; Coffee, R. L.,Jr.; Willis, B.; Abramovitch, A. I. Aminoglycoside-Nucleic 
Acid Interactions: Remarkable Stabilization of DNA and RNA Triple Helices by 
Neomycin. J. Am. Chem. Soc. 2001, 123, 5385-5395.  
30. Arya, D. P.; Xue, L.; Tennant, P. Combining the best in triplex recognition: synthesis 
and nucleic acid binding of a BQQ-neomycin conjugate. J. Am. Chem. Soc. 2003, 125, 
8070-8071.  
31. Xue, L.; Charles, I.; Arya, D. P. Pyrene-neomycin conjugate: dual recognition of a 
DNA triple helix. Chem. Commun. 2002, 1, 70-71.  
32. Arya, D. P.; Coffee, R. L.,Jr.; Charles, I. Neomycin-induced hybrid triplex formation. 
J. Am. Chem. Soc. 2001, 123, 11093-11094.  
33. Shaw, N. N.; Arya, D. P. Recognition of the unique structure of DNA:RNA hybrids. 
Biochimie 2008, 90, 1026-1039.  
34. Shaw, N. N.; Xi, H.; Arya, D. P. Molecular recognition of a DNA:RNA hybrid: sub-
nanomolar binding by a neomycin-methidium conjugate. Bioorg. Med. Chem. Lett. 2008, 
18, 4142-4145.  
35. Arya, D. P.; Shaw, N.; Xi, H. Novel targets for aminoglycosides. In Aminoglycoside 
Antibiotics: From chemical biology to drug discovery; Arya, D. P., Ed.; Wiley: New 




36. Arya, D. P.; Xue, L.; Willis, B. Aminoglycoside (neomycin) preference is for A-form 
nucleic acids, not just RNA: results from a competition dialysis study. J. Am. Chem. Soc. 
2003, 125, 10148-10149.  
37. Willis, B.; Arya, D. P. Recognition of B-DNA by Neomycin-Hoechst 33258 
Conjugates. Biochemistry 2006, 45, 10217-10232.  
38. Arya, D. P.; Willis, B. Reaching into the major groove of B-DNA: synthesis and 
nucleic acid binding of a neomycin-hoechst 33258 conjugate. J. Am. Chem. Soc. 2003, 
125, 12398-12399.  
39. Smith, F. W.; Feigon J. Quadruplex structure of Oxytricha telomeric DNA 
oligonucleotides. Nature 1992, 356, 164-168.  
40. Beaucage, S. L.; Iyer, R. P. Advances in the synthesis of oligonucleotides by the 
phosphoramidite approach. Tetrahedron 1992, 48, 2223-2311.  
41. Piotto, M.; Saudek, V.; Sklenar, V. Gradient-tailored excitation for single-quantum 
NMR spectroscopy of aqueous solutions. J. Biomol. NMR 1992, 2, 661-665.  
42. Goddard T. D.; Kneller D. G. SPARKY 3,University of California, San Francisco. , .  
43. Smith, F. W.; Feigon, J. Strand orientation in the DNA quadruplex formed from the 
Oxytricha telomere repeat oligonucleotide d(G4T4G4) in solution. Biochemistry (N. Y. ) 
1993, 32, 8682-8692.  
44. Schultze, P.; Hud, N.; Smith, F.; Feigon, J. The effect of sodium, potassium and 
ammonium ions on the conformation of the dimeric quadruplex formed by the Oxytricha 
nova telomere repeat oligonucleotide d(G(4)T(4)G(4)). Nucl. Acids Res. 1999, 27, 3018-
3028.  
45. Trott, O.; Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking 
with a new scoring function, efficient optimization, and multithreading. J. Comput. 
Chem. 2010, 31, 455-461.  
46. Schultze, P.; Smith, F. W.; Feigon, J. Refined solution structure of the dimeric 
quadruplex formed from the Oxytricha telomeric oligonucleotide d(GGGGTTTTGGGG). 
Structure 1994, 2, 221-233.  
47. Wang, Y.; Patel, D. J. Solution structure of the human telomeric repeat 




48. Pedretti, A.; Villa, L.; Vistoli, G. VEGA-an open platform to develop chemo-bio-
informatics applications, using plug-in architecture and script programming. J. Comput. 
Aided Mol. Des. 2004, 18, 167-173.  
49. Sanner, M. F. Python: a programming language for software integration and 
development. J. Mol. Graph. Model. 1999, 17, 57-61.  
50. Arya, D. P.; Micovic, L.; Charles, I.; Coffee, R. L.,Jr.; Willis, B.; Xue, L. Neomycin 
Binding to Watson-Hoogsteen (W-H) DNA Triplex Groove: A Model. J. Am. Chem. Soc. 
2003, 125, 3733-3744.  
51. Dominick, P. K.; Keppler, B. R.; Legassie, J. D.; Moon, I. K.; Jarstfer, M. B. Nucleic 
acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg. Med. Chem. 
Lett. 2004, 14, 3467-3471.  
52. Buurma, N. J.; Haq, I. Advances in the analysis of isothermal titration calorimetry 
data for ligand-DNA interactions. Methods (Oxford, United Kingdom) 2007, 42, 162-172.  
53. Haq, I.; Jenkins, T. C.; Chowdhry, B. Z.; Ren, J.; Chaires, J. B. Parsing free energies 
of drug-DNA interactions. Meth. Enzymol. 2000, 323, 373-405.  
54. Haq, I.; Trent, J. O.; Chowdhry, B. Z.; Jenkins, T. C. Intercalative G-Tetraplex 
Stabilization of Telomeric DNA by a Cationic Porphyrin. J. Am. Chem. Soc. 1999, 121, 
1768-1779.  
55. Record, M. T. J.; Anderson, C. F.; Lohman, T. M. Thermodynamic Analysis of Ion 
Effects on the Binding and Conformational Equilibria of Proteins and Nucleic Acids: The 
Roles of Ion Association or Release, Screening, and Ion Effects on Water Activity. Q. 
Rev. Biophys. 1978, 2, 103-178.  
56. Jin, E.; Katritch, V.; Olson, W. K.; Kharatisvili, M.; Abagyan, R.; Pilch, D. S. 
Aminoglycoside binding in the major groove of duplex RNA: the thermodynamic and 
electrostatic forces that govern recognition. J. Mol. Biol. 2000, 298, 95-110.  
57. Kaul, M.; Pilch, D. S. Thermodynamics of aminoglycoside-rRNA recognition: the 
binding of neomycin-class aminoglycosides to the A site of 16S rRNA. Biochemistry 
2002, 41, 7695-7706.  
58. Haider, S.; Parkinson, G. N.; Neidle, S. Crystal Structure of the Potassium Form of an 
Oxytricha nova G-quadruplex. J. Mol. Biol. 2002, 320, 189-200.  
59. Tse, W. C.; Boger, D. L. A Fluorescent Intercalator Displacement Assay for 




60. Allain, C.; Monchaud, D.; Teulade-Fichou, M. P. FRET Templated by G-Quadruplex 
DNA: A Specific Ternary Interaction Using an Original Pair of Donor/Acceptor Partners. 
J. Am. Chem. Soc. 2006, 128, 11890-11893.  
61. Monchaud, D.; Allain, C.; Teulade-Fichou, M. Development of a fluorescent 
intercalator displacement assay (G4-FID) for establishing quadruplex-DNA affinity and 
selectivity of putative ligands. Bioorg. Med. Chem. Lett. 2006, 16, 4842-4845.  
62. Xi, H.; Kumar, S.; Dosen-Micovic, L.; Arya, D. P. Calorimetric and spectroscopic 
studies of aminoglycoside binding to AT-rich DNA triple helices. Biochimie 2010, 92, 
514-529.  
63. Balagurumoorthy, P.; Brahmachari, S. K.; Mohanty, D.; Bansal, M.; Sasisekharan, V. 
Hairpin and parallel quartet structures for telomeric sequences. Nucleic Acids Res. 1992, 
20, 4061-4067.  
64. Mergny, J. L.; Lacroix, L. Analysis of thermal melting curves. Oligonucleotides 
2003, 13, 515-537.  
65. Bishop, G. R.; Ren, J.; Polander, B. C.; Jeanfreau, B. D.; Trent, J. O.; Chaires, J. B. 
Energetic basis of molecular recognition in a DNA aptamer. Biophys. Chem. 2007, 126, 
165-175.  
66. Warui, D. M.; Baranger, A. M. Identification of Specific Small Molecule Ligands for 
Stem Loop 3 Ribonucleic Acid of the Packaging Signal Î¨ of Human Immunodeficiency 
Virus-1. J. Med. Chem. 2009, 52, 5462-5473.  
67. Holt, P. A.; Chaires, J. B.; Trent, J. O. Molecular Docking of Intercalators and 
Groove-Binders to Nucleic Acids Using Autodock and Surflex. Journal of Chemical 
Information and Modeling 2008, 48, 1602-1615.  
68. Ma, Y.; Ou, T.; Hou, J.; Lu, Y.; Tan, J.; Gu, L.; Huang, Z. 9-N-Substituted berberine 
derivatives: Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. 
Bioorg. Med. Chem. 2008, 16, 7582-7591.  
69. Tan, J.; Ou, T.; Hou, J.; Lu, Y.; Huang, S.; Luo, H.; Wu, J.; Huang, Z.; Wong, K.; 
Gu, L. Isaindigotone Derivatives: A New Class of Highly Selective Ligands for 
Telomeric G-Quadruplex DNA. J. Med. Chem. 2009, 52, 2825-2835.  
70. Zahler, A. M.; Williamson, J. R.; Cech, T. R.; Prescott, D. M. Inhibition of 
telomerase by G-quartet DNA structures. Nature 1991, 350, 718-720.  
71. Monchaud, D.; Teulade Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. 




72. Dixon, I. M.; Lopez, F.; Tejera, A. M.; EstÃ¨ve, J.; Blasco, M. A.; Pratviel, G.; 
Meunier, B. A G-Quadruplex Ligand with 10000-Fold Selectivity over Duplex DNA. J. 
Am. Chem. Soc. 2007, 129, 1502-1503.  
73. Pagano, B.; Mattia, C. A.; Giancola, C. Applications of isothermal titration 
calorimetry in biophysical studies of G-quadruplexes. Int. J. Mol. Sci. 2009, 10, 2935-
2957.  
74. Stephen, N. Design Principles for Quadruplex-binding Small Molecules. In 
Therapeutic Applications of Quadruplex Nucleic Acids; Academic Press: Boston, 2012; 
pp 151-174.  
75. Rossetti, L.; Franceschin, M.; Schirripa, S.; Bianco, A.; Ortaggi, G.; Savino, M. 
Selective interactions of perylene derivatives having different side chains with inter- and 
intramolecular G-quadruplex DNA structures. A correlation with telomerase inhibition. 
Bioorg. Med. Chem. Lett. 2005, 15, 413-420.  
76. Xue, L.; Ranjan, N.; Arya, D. P. Synthesis and Spectroscopic Studies of the 
Aminoglycoside (Neomycin)âˆ’Perylene Conjugate Binding to Human Telomeric DNA. 
Biochemistry 2011, 50, 2838-2849.  
77. Micheli, E.; Lombardo, C. M.; D’Ambrosio, D.; Franceschin, M.; Neidle, S.; Savino, 
M. Selective G-quadruplex ligands: The significant role of side chain charge density in a 
series of perylene derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 3903-3908.  
78. Cosconati, S.; Marinelli, L.; Trotta, R.; Virno, A.; De Tito, S.; Romagnoli, R.; 
Pagano, B.; Limongelli, V.; Giancola, C.; Baraldi, P. G.; Mayol, L.; Novellino, E.; 
Randazzo, A. Structural and Conformational Requisites in DNA Quadruplex Groove 
Binding: Another Piece to the Puzzle. J. Am. Chem. Soc. 2010, 132, 6425-6433.  
79. Ranjan, N.; Andreasen, K. F.; Kumar, S.; Hyde-Volpe, D.; Arya, D. P. 
Aminoglycoside Binding to Oxytricha nova Telomeric DNA. Biochemistry 2010, 49, 
9891-9903.  
80. Smargiasso, N.; Rosu, F.; Hsia, W.; Colson, P.; Baker, E. S.; Bowers, M. T.; De, P., 
Edwin; Gabelica, V. G-Quadruplex DNA Assemblies: Loop Length, Cation Identity, and 
Multimer Formation. J. Am. Chem. Soc. 2008, 130, 10208-10216.  
81. Mukundan, V. T.; Do, N. Q.; Phan, A. T. HIV-1 integrase inhibitor T30177 forms a 
stacked dimeric G-quadruplex structure containing bulges. Nucleic Acids Research 2011, 




82. Fourmy, D.; Recht, M. I.; Blanchard, S. C.; Puglisi, J. D. Structure of the A site of 
Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. 
Science 1996, 274, 1367-1371.  
83. Xi, H.; Davis, E.; Ranjan, N.; Xue, L.; Hyde-Volpe, D.; Arya, D. P. Thermodynamics 
of nucleic Acid "shape readout" by an aminosugar. Biochemistry 2011, 50, 9088-9113.  
84. Arya, D. P.; Xue, L.; Willis, B. Aminoglycoside (neomycin) preference is for A-form 
nucleic acids, not just RNA: results from a competition dialysis study. J. Am. Chem. Soc. 
2003, 125, 10148-10149.  
85. Laughlan, G.; Murchie, A. I.; Norman, D. G.; Moore, M. H.; Moody, P. C.; Lilley, D. 
M.; Luisi, B. The high-resolution crystal structure of a parallel-stranded guanine 
tetraplex. Science 1994, 265, 520-524.  
86. Arya, D. P. Aminoglycoside-Nucleic Acid Interactions: The Case for Neomycin. Top. 
Curr. Chem. 2005, 253, 149-178.  
87. von Ahsen, U.; Noller, H. F. Footprinting the sites of interaction of antibiotics with 
catalytic group I intron RNA. Science 1993, 260, 1500-1503.  
88. Stage, T. K.; Hertel, K. J.; Uhlenbeck, O. C. Inhibition of the hammerhead ribozyme 
by neomycin. RNA 1995, 1, 95-101.  
89. Zapp, M. L.; Stern, S.; Green, M. R. Small molecules that selectively block RNA-
binding of HIV-1 REV protein inhibit REV function and viral production. Cell 1993, 74, 
969-978.  
90. Elson-Schwab, L.; Tor, Y. In In Targeting HIV-1 RNA with aminoglycoside 
antibiotics and their derivatives. Section Title: Pharmacology; 2007; pp 267-287, 2 
plates.  
91. Tok, J. B.; Cho, J.; Rando, R. R. Aminoglycoside antibiotics are able to specifically 
bind the 5'-untranslated region of thymidylate synthase messenger RNA. Biochemistry 
(N. Y. ) 1999, 38, 199-206.  
92. Hamasaki, K.; Killian, J.; Cho, J.; Rando, R. R. Minimal RNA constructs that 
specifically bind aminoglycoside antibiotics with high affinities. Biochemistry (N. Y. ) 
1998, 37, 656-663.  
93. Arya, D. P.; Coffee, R. L.,Jr. DNA Triple Helix Stabilization by Aminoglycoside 




94. Arya, D. P.; Coffee, R. L., Jr.; Willis, B.; Abramovitch, A. I. Aminoglycoside-
Nucleic Acid Interactions: Remarkable Stabilization of DNA and RNA Triple Helices by 
Neomycin. J. Am. Chem. Soc. 2001, 123, 5385-5395.  
95. Kumar, S.; Xue, L.; Arya, D. P. Neomycin-Neomycin Dimer: An All-Carbohydrate 
Scaffold with High Affinity for AT-Rich DNA Duplexes. J. Am. Chem. Soc. 2011, 133, 
7361-7375.  
96. Arya, D. P.; Coffee, R. L.; Xue, L. From triplex to B-form duplex stabilization: 
reversal of target selectivity by aminoglycoside dimers. Bioorg. Med. Chem. Lett. 2004, 
14, 4643-4646.  
97. Willis, B.; Arya, D. P. Recognition of B-DNA by neomycin-Hoechst 33258 
conjugates. Biochemistry (N. Y. ) 2006, 45, 10217-10232.  
98. Willis, B.; Arya, D. P. Triple recognition of B-DNA. Bioorg. Med. Chem. Lett. 2009, 
19, 4974-4979.  
99. Xue, L.; Xi, H.; Kumar, S.; Gray, D.; Davis, E.; Hamilton, P.; Skriba, M.; Arya, D. P. 
Probing the Recognition Surface of a DNA Triplex: Binding Studies with Intercalator 
Neomycin Conjugates. Biochemistry 2010, 49, 5540-5552.  
100. Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C.; Hedrick, M. P. A Simple, 
High-Resolution Method for Establishing DNA Binding Affinity and Sequence 
Selectivity. J. Am. Chem. Soc. 2001, 123, 5878-5891.  
101. Boger, D. L.; Fink, B. E.; Hedrick, M. P. Total Synthesis of Distamycin A and 2640 
Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, 
Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen 
for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity. 
J. Am. Chem. Soc. 2000, 122, 6382-6394.  
102. Xi, H.; Kumar, S.; Dosen-Micovic, L.; Arya, D. P. Calorimetric and spectroscopic 
studies of aminoglycoside binding to AT-rich DNA triple helices. Biochimie 2010, 92, 
514-529.  
103. Kumar, S.; Xue, L.; Arya, D. P. Neomycin-Neomycin Dimer: An All-Carbohydrate 
Scaffold with High Affinity for AT-Rich DNA Duplexes. J. Am. Chem. Soc. 2011, 133, 
7361-7375.  
104. Haq, I.; Chowdhry, B. Z.; Jenkins, T. C. Calorimetric techniques in the study of 




105. Haq, I. Biocalorimetry: Application of Calorimetry in the Biological Sciences. John 
Wiley and sons, Chichester 1998, 41-61.  
106. Haq, I.; Trent, J. O.; Chowdhry, B. Z.; Jenkins, T. C. Intercalative G-Tetraplex 
Stabilization of Telomeric DNA by a Cationic Porphyrin. J. Am. Chem. Soc. 1999, 121, 
1768-1779.  
107. Martino, L.; Virno, A.; Pagano, B.; Virgilio, A.; Di Micco, S.; Galeone, A.; 
Giancola, C.; Bifulco, G.; Mayol, L.; Randazzo, A. Structural and Thermodynamic 
Studies of the Interaction of Distamycin A with the Parallel Quadruplex Structure 
[d(TGGGGT)]4. J. Am. Chem. Soc. 2007, 129, 16048-16056.  
108. White, E. W.; Tanious, F.; Ismail, M. A.; Reszka, A. P.; Neidle, S.; Boykin, D. W.; 
Wilson, W. D. Structure-specific recognition of quadruplex DNA by organic cations: 
Influence of shape, substituents and charge. Biophys. Chem. 2007, 126, 140-153.  
109. Hudson, J. S.; Brooks, S. C.; Graves, D. E. Interactions of Actinomycin D with 
Human Telomeric G-Quadruplex DNA. Biochemistry (N. Y. ) 2009, 48, 4440-4447.  
110. Creze, C.; Rinaldi, B.; Haser, R.; Bouvet, P.; Gouet, P. Structure of a d(TGGGGT) 
quadruplex crystallized in the presence of Li+ ions. Acta Crystallographica Section D 
2007, 63, 682-688.  
111. Lee, M. P. H.; Parkinson, G. N.; Hazel, P.; Neidle, S. Observation of the 
Coexistence of Sodium and Calcium Ions in a DNA G-Quadruplex Ion Channel. J. Am. 
Chem. Soc. 2007, 129, 10106-10107.  
112. Cáceres, C.; Wright, G.; Gouyette, C.; Parkinson, G.; Subirana, J. A. A thymine 
tetrad in d(TGGGGT) quadruplexes stabilized with Tl+/Na+ ions. Nucleic Acids 
Research 2004, 32, 1097-1102.  
113. Clark, G. R.; Pytel, P. D.; Squire, C. J.; Neidle, S. Structure of the First Parallel 
DNA Quadruplex-Drug Complex. J. Am. Chem. Soc. 2003, 125, 4066-4067.  
114. Sket, P.; Plavec, J. Tetramolecular DNA Quadruplexes in Solution: Insights into 
Structural Diversity and Cation Movement. J. Am. Chem. Soc. 2010, 132, 12724-12732.  
115. Kaul, M.; Barbieri, C. M.; Kerrigan, J. E.; Pilch, D. S. Coupling of drug protonation 
to the specific binding of aminoglycosides to the A site of 16S rRNA: elucidation of the 
number of drug amino groups involved and their identities. J. Mol. Biol. 2003, 326, 1373-
1387.  
116. Arya, D. P.; Coffee, R. L., Jr.; Charles, I. Neomycin-Induced Hybrid Triplex 




117. Aboul-ela, F.; Murchie, A. I. H.; Norman, D. G.; Lilley, D. M. J. Solution structure 
of a parallel-stranded tetraplex formed by d(TG4 T) in the presence of sodium ions by 
nuclear magnetic resonance spectroscopy. J. Mol. Biol. 1994, 243, 458-471.  
118. Trajkovski, M.; Webba da Silva, M.; Plavec, J. Unique structural features of 
interconverting monomeric and dimeric G-quadruplexes adopted by a sequence from 
intron of N-myc gene. J. Am. Chem. Soc. (Just Accepted doi: 10. 1021/ja208483v) 2012, .  
119. Fourmy, D.; Recht, M. I.; Puglisi, J. D. Binding of Neomycin-class Aminoglycoside 
Antibiotics to the A-site of 16 S rRNA. J. Mol. Biol. 1998, 277, 347-362.  
120. Waksman, S. A.; Lechevalier, H. A. Neomycin, a New Antibiotic Active against 
Streptomycin-Resistant bacteria, Including Tuberculosis Organisms. J. Antibiot. 1949, 
109, 305-309.  
121. Krishnan-Ghosh, Y.; Liu, D.; Balasubramanian, S. Formation of an Interlocked 
Quadruplex Dimer by d(GGGT). J. Am. Chem. Soc. 2004, 126, 11009-11016.  
122. Phan, A. T.; Kuryavyi, V.; Ma, J.; Faure, A.; Andréola, M.; Patel, D. J. An 
interlocked dimeric parallel-stranded DNA quadruplex: A potent inhibitor of HIV-1 
integrase. Proc. Natl. Acad. Science U. S. A. 2005, 102, 634-639.  
123. Sakuma, N.; Ozawa, M.; Kawano, S.; Mita, H.; Hemmi, H.; Yamamoto, Y. 
Thermodynamics of dimerization of parallel quadruplex DNAs through the end-to-end 
stacking of 3'-terminal G-quartets. Nucleic Acids Symp. Ser. 2007, 245-246.  
124. Stefan, L.; Denat, F.; Monchaud, D. Deciphering the DNAzyme Activity of 
Multimeric Quadruplexes: Insights into Their Actual Role in the Telomerase Activity 



















ROLE OF LINKER LENGTH AND COMPOSITION ON  
HOECHST 33258 BINDING TO B-DNA 
Introduction 
 
Nucleic acid-protein interactions are some of the key cellular events that allow for 
the smooth functioning of processes such as replication, transcription and translation. 
Progress in the structural elucidation of both nucleic acids and proteins has led to an 
understanding of the key roles played by the individual proteins during the cell cycle. 
Development in the structural understanding of both the large 
1
 and small 
2
 subunits of 
the ribosome and the effect of small molecule binding 
3
 have demonstrated the power of 
these ligands in regulating cellular functions and serve therapeutic purposes. A deeper 
understanding of nucleic acid-ligand interaction is required for the design of small 
molecules to target nucleic acids as changes in the functional groups or introduction of 
bulky groups on these ligands often leads to profound effects on their binding. Moreover, 
some of these molecules may bind by different modes to DNA/RNA with differing 
affinities. Thus, a variety of information coming from structural, thermodynamic and 
structure activity relationship (SAR) studies is required to develop ligands of therapeutic 
interest and increase the efficacy of established drugs. 
Research on DNA-minor groove binders such as distamycin and netropsin 
(Figure 3.1) greatly assisted in understanding DNA-small molecule interactions and led 
to the development of polyamides for sequence specific DNA targeting.
4
 The studies 




revealed that crescent shaped heterocyclic molecules (Figure 3.1) match the minor 
groove pitch. These molecules also engage in a variety of molecular interactions within 
the groove such as hydrogen bonding, electrostatic interactions and van der Walls forces 
that result in the tight affinity binding. , Hoechst 33258, a synthetic bisbenzimidazolehas 
been extensively studied due to its high affinity binding to AT-rich DNA and its excellent 
fluorescent properties that allow spectroscopic investigation in vivo.
5
 Since the structural 
studies of the Hoechst 33258-B-DNA complex 
6,7
 in the late 1980s, its binding to B-DNA 
has been probed by a variety of spectroscopic techniques 
8-10
 which have established it as 
a high affinity B-DNA minor groove binding agent. In contrast to its high affinity binding 
to AT-rich DNA, the binding of Hoechst 33258 to GC rich DNA has been found much 
weaker (about two orders of magnitude lower). Moreover unlike the minor groove 
binding in the case of B-DNA, Hoechst 33258 has been proposed to bind in an 
intercalative way 
11
 to GC rich DNA likely to avoid steric clash with protruding amino 






































Hoechst 33258  





Binding of Hoechst 33258 to RNA has received less attention due to poorer 
binding as compared to DNA. The fluorescence emission enhancement of Hoechst 33258 
in the presence of RNA has also found to be extremely weak. In recent years, a few 
biologically important RNA regions have been studied for Hoechst 33258 binding. The 
binding of Hoechst 33258 to Trans Activating Region (TAR) RNA has been shown to 
occur in an intercalative way.
12
  The antibacterial activity of Hoechst 33258 has also been 
evaluated 
13
 and its binding to group I self splicing introns
14
 (introns are nucleotides that  
are removed during the RNA splicing process) has been reported. The presence of 
sterically bulky groups has been shown to greatly diminish the DNA binding abilities.
15
  
Since reports on the synthesis of triplex forming oligonucleotides (TFO)- Hoechst 33258 
conjugates by McLaughlin and coworkers
16
, a number of studies have been initiated to 
develop Hoechst 33258 based conjugates to achieve desired nucleic acid recognition at 
multiple sites. These have included imidazole-pyrrole based polyamide-Hoechst 33258 
conjugates
17-21
, Hoechst 33258-porphyrin derivatives,
22
 Hoechst 33258-neomycin 
conjugates
23-26
, Hoechst33258-oligonucleotide conjugates as well as triple recognition 
agents.
25
 We have previously shown that by covalently conjugating neomycin to Hoechst 
33258, an aminosugar neomycin can be “coerced” to bind in the major groove of B-
DNA.
23
  These studies were followed by the investigation on the effect of linker length 
between the neomycin and Hoechst 33258 units.
24
 These studies show that linker length 
between the two units does play a role in the binding of the conjugate where a 22 atom 
linker showed about four fold decrease in the association constant, relative to a 12 atom 
linker, to a B-DNA duplex.
24




of magnitude lower than Hoechst 33258.
24
 However, whether this diminished binding of 
the neomycin-Hoechst 33258 conjugate was an outcome of neomycin’s inability to reach 
the major groove of B-DNA, or due to the weakened binding of Hoechst 33258 in the 














































































Figure 3.2. Chemical structure of the ligands used in this study. 
 
In order to answer these questions, we probed the effect of linker size on the 
Hoechst 33258 binding to B-DNA. A small library of Hoechst 33258 derivatives that 




linkers vary in their length as well as their oxygen content (monooxygen, bisoxygen and 
polyoxygen). Their binding to B-DNA was investigated using UV thermal denaturation, 
fluorescent intercalator displacement (FID) assay, circular dichroism (CD), UV-vis 
absorption, fluorescence spectroscopy and isothermal calorimetry (ITC). Described 
below is the characterization of binding of novel Hoechst 33258 derivatives with B-
DNA. 
Materials and Methods 
General Methods.   Unless otherwise specified, chemicals were purchased from Aldrich 
(St. Louis, MO) or Fisher Scientific (Pittsburgh, PA) and used without further 
purification. Di-tert-butyl dicarbonate (Boc anhydride) was purchased from Advanced 
Chem Tech (Louisville, KY).   All solvents were purchased from VWR (West Chester, 
PA). Silica gel (32-65 M mesh size) was purchased from Sorbtech (Atlanta, Georgia). 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker Model Avance (300 / 500 
MHz) Spectrometer. Chemical shift is given in ppm.  The chemical shifts are referenced 




C NMR).  
MS (MALDI-TOF) spectra were collected using a Bruker Microflex mass spectrometer.   
UV spectra were collected on a Varian (Walnut Creek CA) Cary 100 Bio UV-Vis 
spectrophotometer equipped with a thermoelectrically controlled 12-cell holder. 
Fluorescence Intercalator Displacement (FID) experiments were performed on Cary 
Photonics fluorimeter equipped with a 96 well plate reader. 
Nucleic Acids. Nucleic acids were purchased from Eurofins MWG Operon (Huntsville, 




using the extinction coefficient provided by the supplier. Nucleic acid solutions were 
prepared in buffer 10 mM sodium cacodylate, 0.1 mM EDTA and 100 mM NaCl at pH 
7.0 (to make 1 mM/strand stock solution of the nucleic acid). The nucleic acid solutions 
were prepared by heating them at 95 

C for 15 minutes and then slowly allowing it cool 
back to room temperature. After two days of incubation, the duplex formation was 
checked by UV thermal denaturation experiments. The stock solution was stored at 4 

C 
and diluted to desired concentrations (the actual concentration used in each experiment is 
mentioned in the legend of each figure) as required. 
Ultra Violet (UV) Thermal Denaturation Experiments.    All UV experiments were 
performed on a Cary 1E UV-Vis spectrophotometer (12 cell holder) equipped with a 
temperature controller. Quartz cells with 1 cm path length were used for all the 
experiments. Spectrophotometer stability and wavelength alignment were checked prior 
to initiation of each melting point experiment. The melting of DNA with and without the 
ligand was performed at a heating rate of 0.2 °C/min.   Samples were brought back to 20 
°C after the experiment.   All UV melting experiments were monitored at 260 nm.   For 
the Tm determinations, first derivatives were used. Data points were recorded every 1.0 
°C.  The DNA concentration used was 1 M /duplex while the ligand concentration was 
10 mM. All ligand solutions were prepared in dimethyl sulfoxide (DMSO) as 
concentrated solution and were diluted as desired.  
Fluorescencent Intercalator Displacement (FID) Experiments.  Fluorescence experiments 
were performed on Cary Photonics fluorometer (Walnut Creek, CA) equipped with a 96 






The experiments were performed in the 96 well plates as triplicates. The DNA solution 
was prepared at 1 M / duplex in buffer 10 mM sodium cacodylate, 0.1 mM EDTA, 100 
mM NaCl at pH 7.0 and mixed with thiazole orange (TO) at a concentration of 6 M. 
The ligand was added to the DNA / TO complex solution at 1:1 ratio. It was followed by 
a 5 minute equilibration time before the fluorescence emission was recorded. The TO 
excitation was performed at 501 nm and the emission was recorded at 534 nm.  The 
change in the fluorescence was plotted as - 
% fluorescence change (% F) = (F/IF) × 100 
where, F = Change in fluorescence upon ligand addition and IF = Initial fluorescence of 
the DNA- TO complex 
Fluorescence Emission Experiments.  Fluorescence emission experiments were 
performed in a 3.0 mL quartz cuvette on a Photon Technology International instrument 
(Lawrenceville, NJ). The fluorescence emission spectrum of the ligand solution (100 nM) 
was recorded in the absence of DNA in buffer 10 mM sodium cacodylate, 0.5 mM EDTA 
and 100 mM NaCl at pH 7.0. This was followed by the addition of the DNA duplex 
solution (so that the ratio of ligand:DNA was 1:1).  After 5 minute equilibration, the 
emission spectrum was recorded. All experiments were performed at 20 

C. 
Isothermal Titration Calorimetry (ITC).  All ITC measurements were performed on a 
MicroCal VP-ITC (MicroCal, Inc., Northampton, MA) instrument. The DNA 
concentration was 10 M/duplex.  In every titration, a 10 µL aliquot of ligand solution 
was injected into a sample cell containing 1.42 mL of nucleic acid solution. The injection 




duration of each injection was 20s. For each titration, a control experiment was 
performed by titrating the ligand into buffer. The resulting data was processed using 
Origin 5.0. Integrating the area under each heat burst curve yielded the enthalpy upon 
ligand injection. The corresponding enthalpy of dilution was subtracted to obtain the 
actual enthalpy changes associated with the ligand-nucleic acid binding. 
Differential Scanning Calorimetry (DSC).  The nucleic acid melting temperature and 
enthalpy changes were obtained using a MicroCal VP-DSC (MicroCal, Inc., 
Northampton, MA).  The DNA concentration was 50 M/duplex. The scan rate was 1 
ºC/min, and the operating temperature range was 5- 110 ºC.  After each DSC experiment, 
a corresponding control experiment was conducted with only buffer in the sample cell.  
The corrected DSC profile was obtained by subtracting the control data from the sample 
data.  The enthalpy of melting of the duplex DNA was calculated by integrating the area 
under the heat capacity curves using Origin version 5.0. 
Synthesis. Synthesis of DPA 151 is presented here. For synthesis of DPA152-DPA 159, 
see appendix II. 
 
Synthesis of 4-(prop-2-ynyloxy)benzaldehyde. To a solution of p-hydroxybenzaldehyde 
(2.00 g, 16.3 mmol) in dry dichloromethane (30.0 mL) and 1, 4 dioxane (5.00 mL), 
triphenyl phosphine (6.30 g, 24.2 mmol) and propargyl alcohol (0.91 g, 16.3 mmol) were 
dissolved under argon and the solution was ice cooled. To this, diisopropyl 
azodicarboxylate (DIAD) (4.80 mL, 24.2 mmol) was added dropwise over a period of 15 
min at 0 

C.  The contents were initially stirred at 0 

C for 30 min and then allowed to 




monitored using thin layer chromatography (TLC) on silica gel. The volatiles were 
removed under reduced pressure and the gummy residue was redissolved in ethyl acetate-
hexane (60.0 mL, 1:1 v/v) mixture and allowed to stand overnight in the refrigerator. The 
precipitated solid was vacuum filtered and the filtrate was concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel 
(hexanes-ethyl acetate, 100:0-70:30) to afford the desired compound as a white solid (1.3 
g, 50 %): Rf  =  0.42 (hexanes: ethyl acetate 7:3 v/v) ; mp 80-81 

C; IR (neat, cm
-1
) 3419, 
2112, 1654, 1437, 1184, 1017; 
 1
H NMR (500 MHz, CDCl3) δ 9.91(s, 1H), 7.87 (dd, J1 = 
8.82 Hz, J2 = 1.94 Hz, 2H), 7.10 (dd, J1 = 8.74 Hz, J2 = 1.70 Hz, 2H), 4.77 (d, J = 2.36 
Hz, 2H, -OCH2CCH), 2.60 (t, J = 2.43 Hz, 1H, -OCH2CCH); 
13
C NMR (125 MHz, 
CDCl3)  190.7, 162.3, 131.8, 130.6, 115.1, 77.8, 76.3, 55.9.N-methoxy-N-methyl-2-(4-
(prop-2-ynyloxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide (DPA 151-b). To a 
solution of  N- Methoxy, N-methyl 3, 4 dinitrobenzamide (0.90 g, 3.52 mmol) in ethanol 
(20.0 mL), 150 mg of Pd-C (10%) was added. Hydrogenation for 5h at the atmospheric 
pressure afforded corresponding diamine. The diamine was used immediately after 
filtration of the catalyst without purification. 4-(prop-2-ynyloxy)benzaldehyde (0.62 g, 
3.87 mmol) and sodium metabisulfite (0.37 g, 1.93 mmol ) in water ( 1.00 mL) were 
added into the diamine and the reaction mixture was refluxed overnight. The volatiles 
were evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol (0-10 % methanol in 
dichloromethane) as eluent to afford the desired product as a pale yellow solid (0.55 g, 83 
%): Rf = 0.53 (dichloromethane : methanol 9:1, v/v); mp 245-246 







2974, 2929, 2124, 1617, 1486, 1318, 1233, 1025, 837, 735;  
1
H NMR (500 MHz, DMSO-
d6) δ 13.1 (s, 1H), 8.15 (d, J = 8.5 Hz, 2H),  7.91-7.79 (m, 1H),  7.67 (d, J = 8.50 Hz, 1H, 
7.55 (d, J = 8.00 Hz, two sets of doublets, 1H), 7.50-7.46 (m, 1H), 7.18 (dd, J1 = 2.50 Hz, 
J2 = 9.00 Hz, 2H), 4.92 (d, J = 2.53 Hz, 2H, , -OCH2CCH), 4.36 (d, J = 2.12 Hz, 1H, ¸-
OCH2CCH),  3.58 (s, 3H), 3.35 (s, 3H);   
13
C NMR (125 MHz, DMSO-d6) δ 170.1, 
169.9,  159.4,  159.3, 153.6, 153.1, 145.9, 137.0, 128.6, 123.1, 119.0, 115.8, 111.0, 




2-(4-(prop-2-ynyloxy)phenyl)-1H-benzo[d]imidazole-6-carbaldehyde (DPA 151-c). To a 
solution of N-methoxy-N-methyl-2-(4-(prop-2-ynyloxy)phenyl)-1H-benzo[d]imidazole-
6-carboxamide (0.30 g, 0.89 mmol) in tetrahydrofuran (THF)-ether (40 mL, 3:1 v/v), 
lithium aluminum hydride (0.13 g, 3.57 mmol) was added in small portions at -70 

C 
under argon and then the stirring was continued for 6h at 0 

C.  Thin layer 
chromatography on silica gel was used to monitor the progress of the reaction. The 
reaction mixture was quenched by the addition of saturated ammonium chloride solution 
(50 mL). The precipitated grey solid was filtered off. The filtrate was extracted with ethyl 
acetate (3 × 50 mL). Organic layers were combined and then dried over sodium sulfate. 
Volatiles were removed under reduced pressure. The crude product was purified by 
column chromatography on silica gel using hexanes: ethyl acetate (1:1-2:1 v/v) to yield 
the desired compound as a light yellow solid (0.18 g, 73%): Rf   =  0.76 (in ethyl acetate) ; 
mp >255 

C (dec); IR (neat, cm
-1
) 3278, 2919, 2842, 2120, 1669, 1611, 1495, 1290, 
1020; 
1




Hz, 2H), 8.10 (br, 1H), 7.77 (br, 1H) 7.68 (br, 1H) 7.20 (d, J = 9.0 Hz, 2H), 4.92 (d, J = 
2.66 Hz, 2H, , -OCH2CCH), 3.65 (t, J = 2.28 Hz, 1H, ¸-OCH2CCH); 
13
C NMR ( 125 
MHz, DMSO-d6)  193.0,  159.6, 155.4, 154.1, 149.0, 144.2, 135.5, 131.5, 129.0, 123.4, 
,119.3, 115.8, 114.2, 112.2, 79.4, 60.2, 56.1;  MS (MALDI-TOF) m/z calcd for 
C17H12N2O2 [M]
+ 




bibenzo[d]imidazole (DPA 151). To a solution of 5-(4-methylpiperazin-1-yl)-2-
nitroaniline (0.06 g, 0.27 mmol) in ethanol (8.0 mL), 10 % Pd-C (40.0 mg) was added 
and then it was hydrogenated for 6h at the atmospheric pressure. TLC on silica gel 
showed complete reduction of the starting material. After filtering the catalyst over a bed 
of celite, 2-(4-(prop-2-ynyloxy)phenyl)-3H-benzoimidazole-5-carbaldehyde  (0.08 g, 
0.31 mmol) and a solution of Na2S2O5 (30.0 mg, 0.16 mmol) in water (0.2 mL) was added 
and the mixture was refluxed for 14h . The starting diamine was consumed completely. 
The reaction mixture was allowed to come to the room temperature. The volatiles were 
evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol as eluent  (0-18% 
methanol in dichloromethane) to afford the desired product as yellow solid (85 mg, 65 
%): Rf = 0.23 (ethyl acetate-methanol 8:2 v/v); mp 252-256 

C; IR (neat, cm
-1
) 3235, 
2919, 2849, 1672, 1614, 1495, 1441, 1367, 1279, 1248, 1171, 1024, 831, 738; 
  1
H NMR 
(300 MHz, methanol-d4)  8.25 (br, 1H), 8.06 (d, J = 8.84 Hz, 2H), 7.95 (dd, J1 = 9.97 
Hz, J2 =1.30 Hz, 1H), 7.69 (d, J = 8.32 Hz, 1H),7.51 (d, J = 8.77 Hz, 1H), 7.15 ( 3H), 




1H), 2.72 (t, J = 4.64 Hz, 4Hz),  2.42 (s, 3H) (some protons peaks are masked with the 
solvent peaks) ;  
13
C NMR (75 MHz, DMSO-d6)  159.1, 153.2, 152.1, 145.3, 144.5, 
138.6, 136.4, 135.7, 128.6, 123.5, 122.0, 120.7, 119.1, 116.5, 115.7, 111.9, 97.6, 79.4, 
79.0, 56.0, 55.3, 50.7 50.2, 46.2; MS (MALDI-TOF) m/z calcd. for C28H26N6O [M]
+ 
 
462.22, found 462.24. 
Results and Discussion 
Design and Synthesis of Aliphatic Derivatives of Hoechst 33258.  A number of studies 
have been carried out on Hoechst 33258 derivatives to achieve dual/multiple recognition 
of nucleic acids. Alkyne derivatized Hoechst 33258 derivatives were initially prepared 
for the incorporation of boron cages for radiation therapy.
27
 McLaughlin and coworkers 
prepared an oligonucleotide-Hoechst 33258 conjugate tethered with a hexaethylene 
glycol linker
28
 for effective stabilization of the triple helix. Porphyrin-Hoechst 33258 
conjugate,
22
 as well as oligonucleotide-Hoechst 33258 conjugate, (using a thiol 
maleimide coupling) has also been reported.
29
 A small library of Hoechst 33258 
derivatives terminating with alkyl groups has been reported for the transcriptional control 
in human melanoma cells.
30
 We have previously reported the synthesis of neomycin-
Hoechst 33258 conjugates for the dual/multiple recognition of nucleic acids.
23, 24
 During 
our studies with the neomycin-Hoechst 33258 conjugates to target DNA, we observed 


















































































-(CH2CH2O)6OCH2- DPA 159  
 
Scheme 3.1.  Reagent and conditions (i) PPh3, DIAD, dioxane, dichloromethane, rt, 
overnight, 30-90 %,  (ii) Pd-C, H2 (atmospheric), ethanol, rt, 5h, qaunt  (iii) DPA 151-
159a, ethanol, Na2S2O5, H2O, reflux, 12-14 h, 27-85 % (for two steps),  (iv) THF- ether, 
LAH , -78 

C to r.t., 6-12 h, 42-91 %, (v) DPA 151-159c,  ethanol, Na2S2O5, H2O,  






larger (22 atoms as opposed to 12 atoms) linker was used to separate the neomycin and 
Hoechst 33258 units.  We initially hypothesized this to be the outcome of a larger  
flexibility allowed by a longer linker to the neomycin binding to B-DNA. However, we 
also questioned the role of linkers on the binding to B-DNA. To have an understanding of 
effect of the linker length on the B-DNA binding, a small library of Hoechst 33258 
derivatives was synthesized. The derivatization of Hoechst 33258 was carried on the 
phenolic end of the molecule using aliphatic linkers of variable length. These derivatives 
can be broadly categorized in three categories as those containing monooxygen, 
bisoxygen or polyoxygen atoms (Figure 3.2).  
The ligands were synthesized using a similar chemistry as reported earlier.
31, 32
 As 
shown in Scheme 3.1, a divergent strategy was used to construct these Hoechst 33258 
derivatives.  To introduce the linkers, we carried out Mitsunobu reactions of 4-hydroxy 
benzaldehyde with aliphatic alcohols that terminated in an alkyne functionality (the 
aliphatic alcohols were obtained either commercially or prepared in one step from 
corresponding diols
33
). This afforded 4-substituted benzaldehydes (DPA 151-159a) that 
was coupled with 3, 4-diamino-N-methoxy-N-methylbenzamide in the presence of an 
oxidant to yield corresponding benzimidazoles (DPA 151-159b) derivatives. These 
benzimidazoles (DPA 151-159b) that contained Wienreb amide functionalities were 
easily reduced to corresponding aldehydes (DPA 151-159c) using lithium aluminum 
hydride reduction. Coupling of these aldehydes (DPA 151-159c) with 4-(4-
methylpiperazin-1-yl) benzene-1, 2-diamine, in the presence of an oxidant resulted in the 




rather inert functional group alkyne makes these molecules useful for click chemistry 
applications.  
UV Thermal Denaturation Experiments. The UV thermal denaturation experiments of the 
synthesized ligands were carried out with two DNA duplexes. A 60 mer B-DNA duplex 
that was prepared by mixing equimolar amounts of a 60 mer homoadenine with a 60 mer 
homothymine while a shorter self complementary dodecamer oligonucleotide whose 
binding is well established 
34,35
 to Hoechst 33258 was also used. The results obtained 
from these experiments are shown in Figure 3.3 and Table 3.1. 
The thermal denaturation experiments for both DNA duplexes with the ligands 
DPA 151-DPA 159 show very interesting thermal stabilization trend with respect to the 
length of the alkyl linker of Hoechst 332258 derivatives DPA 151-DPA 159. As depicted 
in Figure 3.3a, in the absence of ligand, the duplex dA60.dT60 exhibited a sharp 
hyperchroism at 62.5 

C indicating the dissociation of the duplex into single strands. The 
thermal denaturation of dA60.dT60 was then performed in the presence of DPA 151 (10 
M). At this concentration the DNA was saturated with ligand as lower concentration (2 
M) of ligand resulted in the biphasic thermal denaturation profiles. In the presence of 
DPA 151, a 23.9 

C thermal stabilization was seen. The thermal stabilization afforded by 
DPA 151 was similar to the thermal stabilization afforded by Hoechst 33258 (24.6 

C). 
This thermal stabilization was found to be clearly dependent on the length and 
composition of the linker. As depicted in Figure 3.3b, the thermal stabilization afforded 
by all newly synthesized ligands are shown in a bar graph plot and categorized in the 


































































































































































































































Figure 3.3. (a) A representative UV thermal denaturation plot of dA60.dT60 duplex in the 
absence and presence of ligand (DPA 151). (b) A bar graph plot showing the increase in 
the thermal denaturation temperature of duplex dA60.d60 in the presence of different  
ligands. (c) A representative UV thermal denaturation plot of d(CGCAAATTTGCG)2 
duplex in the absence and presence of ligand (DPA 151). (d) A bar graph plot showing 
the increase in the thermal denaturation temperature of duplex d(CGCAAATTTGCG)2 in  
the presence of different ligands.   The DNA duplexes (1 M/duplex for dA60.d60   and 2 
M/duplex for d(CGCAAATTTGCG)2) were mixed with various ligands (10 M each 









C (at a rate of 0.2 

C/min) in buffer 10 mM sodium cacodylate, 0.1 mM 
EDTA, 100 mM NaCl at pH 7.0.  
 
red bars represent ligands having two oxygen atoms and the blue bar represents the ligand 
having polyoxygen atoms on their linker arm. For the monooxygen linker derivatives, as 
the linker length increased from three atoms to six, nearly 2 

C difference in the thermal 
stabilization was observed (23.9 

C thermal stabilization for DPA 151 and 21.9 

C 
thermal stabilization for DPA 152 respectively) for dA60.dT60 duplex. 
 A much larger decrease in the thermal stabilization was obtained with DPA 153, 
which contains 11 atoms on its linker arm. The thermal stabilization afforded by DPA 
153 was 8.0 

C. The large decrease in the thermal stabilization clearly showed the role of 
linker length in the binding of Hoechst 33258 derivatives to the B-DNA duplex 
dA60.dT60. For the bisoxygen linkers (DPA 154-DPA 158) similar dependence on the 
linker length to the thermal stabilization of the B-DNA duplex dA60.dT60 was also 
observed. For DPA 154 (which has eight atoms on its linker) 23.4 

C increase in the 
thermal melting temperature was observed. The thermal stabilization of DPA 154 to the 
B-DNA duplex was similar to the thermal stabilizations obtained with DPA 151 and DPA 
152. For DPA 155 (which has ten atoms on its linker), the thermal stabilization to the 
DNA duplex dA60.dT60 decreased to 17.8 

C, which was nearly 6 

C lower than the 
thermal stabilization obtained with DPA 151, DPA 152 or DPA 154. This was 




length, such a significant drop in the thermal stabilization was seen. An increase of two 
more carbon atoms on the length of the linker (DPA 156, a total spacing of 12 atoms on 




Table 3.1. A table showing the thermal denaturation temperature of the ligand-DNA 
complexes studied with the two B-DNA duplexes (For thermal denaturation profiles 



























DPA 151 3 85.4 23.9 66.1 8.3 
DPA 152 6 83.4 21.9 66.5 8.7 
DPA 153 11 70.5 8.0 59.2 1.4 
DPA 154 8 85.9 23.4 66.8 9.0 
DPA 155 10 80.3 17.8 66.1 8.3 
DPA 156 12 74.3 11.8 62.6 4.8 
DPA 158 14 64.6 1.9 58.5 0.7 
DPA 157 16 63.7 1.2 58.1 0.3 
DPA 159 21 74.7 12.2 59.5 1.7 
 
 
thermal stabilization of the B-DNA duplex dA60.dT60
. 
 As the linker length further 
increased in the same series for DPA 158 and DPA 157 (14 and 16 atoms long linkers 
respectively), the thermal stabilization became really small (< 2 

C). The results obtained 
from the bisoxygen containing linkers of Hoechst 33258 derivatives again showed that 
there is clearly a relation between the length of linker of the Hoechst 33258 derivatives 
and their DNA binding.  We then tested another ligand (which was longest in terms of 
linker length of all the ligands studied) DPA 159 whose linker arm was made from 




Table 3.2. A table showing the experimentally determined distribution 
coefficients of the newly synthesized ligands against octanol-buffer (10 mM 
sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0) system. 
 
Name Linker length UV
max











DPA 152 6 348 0.41 
DPA 154 8 348 0.92 
DPA 155 10 348 1.00 
DPA 153 11 348 1.62 
DPA 156 12 348 2.29 
DPA 158 14 348 2.20 
DPA 157 16 348 2.47 
DPA 159 21 348 2.50 
 
 
thermal stabilization as compared with other longer linkers (DPA 158 and DPA 157) was 
seen in this case. The thermal stabilization obtained with DPA 159 was 12.2 

C, which 
was similar to thermal stabilization obtained with DPA 156 (a twelve atom spaced 
linker). This observation suggested that it is not just length but also the composition of 
the linker that plays a role in the binding to the B-DNA duplex.  
The thermal denaturation experiments were also conducted with a dodecamer 
oligonucleotide d(CGCAAATTTGCG)2 which is well known for Hoechst 33258 binding 
to its AT-rich region.
34,35
 The DNA duplex formation was checked using both UV- 
thermal denaturation and differential scanning calorimetry (DSC) experiments (see 
appendix II Figure S3).  Figure 3.3c shows a representative thermal melting profile of 




leads to 8.3 

C increase in the thermal stability of the DNA and also results in a thermal 
melting profile which suggests cooperative binding. Figure 3.3d, shows the increase in 
the melting temperature of the novel ligands as a bar graph plot. This bar graph plot is 
nearly a replica of Figure 3.3b validating the trend observed with the B-DNA duplex 
dA60. dT60.  
These results lead to a few important conclusions (i) the thermal stability afforded 
by the novel ligands is clearly dependent on the linker length of Hoechst 33258 
derivatives (DPA 151-DPA 159) (ii) linkers having up to 8 atoms, provide nearly similar 
thermal stabilization. The thermal stabilization starts to decrease as the linker length 
increases beyond eight atoms. Hoechst 33258 derivatives with longer linkers (14 and 16 
atoms) lead to very poor thermal stabilization (iii) a reversal in the thermal stability of the 
B-DNA provided by longer linkers was seen with a linker that contained polyoxygen 
atoms. 
What could possibly be hindering the interaction of bisbenzimidazoles, which 
have longer length, with the B-DNA?  We observed that increasing the length of the 
linker arm caused these molecules to be increasingly hydrophobic as determined from 
their distribution coefficient in buffer-octanol mixtures (Table 3.2). However, in polar 
media, as used in our experiments, these long alkyl chain linkers are highly prone to 
experience hydrophobic effect which could possibly lead to micelle type structures.
36
 It 
could also lead to the formation of “collapsed alkyl  bulk”  on the phenolic end of these 
Hoechst 33258 derivatives. This could likely prevent the bisbenzimidazoles to enter the 




Hoechst 33258 derivatives that carry bulky groups on the phenolic ring of Hoechst 33258 
have been reported in an effort to develop RNA selective ligands due to the inability of 
these sterically hindered derivatives to bind AT-rich DNA duplexes.
37
 
Credence to the hypothesis of hydrophobic effect driven diminished binding of 
Hoechst 33258 derivatives with long linkers to B-DNA duplex is further provided by 
enhanced thermal stabilization of DPA 159. DPA 159, despite having the longest linker, 
is able to have appreciable thermal stabilization in comparison to other similar derivatives 
(such as DPA 158 and DPA 157).   The difference between DPA 159 and DPA 158 or 
DPA 157 is the presence of more oxygen atoms (five extra oxygen atoms in DPA 159 as 
compared to DPA 158 or DPA 157). Hydrophobic effect works primarily by breaking the 
hydrogen bonding network in the polar media. In the case of DPA 158 or DPA 157, a 
much greater hydrophobic effect would be expected since the larger number of oxygen 
atoms present in DPA 159 would enable it to have more hydrogen bonding contacts in 
the aqueous media thus lessening the hydrophobic effect. This lessened hydrophobic 
effect in DPA 159 would, in turn, better opportunities for the bisbenzimidazole unit to 
interact in the minor groove of B-DNA. The possibility that the stacking of aromatic units 
of bisbenzimidazole causes the weakened binding of ligands having longer linkers does 
not seem probable because of the lack of biphasic transition in the thermal denaturation 
profiles. Hoechst 33258 has been known to stack in solution in the presence of DNA. 
However such complexes result in biphasic transitions in which one arises from the 




to the dissociation of the duplex DNA.
38
 The absence of such biphasic transitions in our 
studies suggests the absence of such stacking interactions.  
Fluorescence Intercalator Displacement (FID) Assay.  FID assay has been developed to 
screen sequence specific DNA binding agents,
39
 which can also be utilized to obtain 
DNA binding affinities of the ligands.
40
 It has also been utilized for the identification of 
triple helix DNA binders
41
 as well quadruplex DNA binders.
42
 We have previously used 




 and quadruplex binders.
45,46
This assay relies on 
changes in the fluorescence emission experienced by a DNA-intercalator (usually 
ethidium bromide or thiazole orange) complex upon ligand binding. DNA intercalators 
such as ethidium bromide or thiazole orange have very poor fluorescence emission in the 
absence of DNA. However, when bound to DNA, fluorescence emission increases 
multifold, which can be used to study the DNA binding of ligands. For FID experiments, 
nucleic acid affinity of ligands can be determined either by obtaining the DC50 values 
(DC50 value refers to concentration of ligand required to displace 50 % of the bound 
intercalator). Alternately, multiple ligands can be screened to gauge their DNA binding 
affinities by adding ligands (at a fixed ligand-nucleic acid ratio) to the DNA-intercalator 
complex solution. The resulting fluorescence change is then plotted to rank the affinities 
of those ligands. 
In the present study, we used ethidium bromide (EtBr) as our intercalating agent. 
The DNA-EtBr complex was added with the ligands DPA 151-DPA 159 in 1:1 duplex: 





































































Figure 3.4. A bar graph plot showing percent change in fluorescence emission of 
ethidium bromide upon ligand binding. The DNA d(CGCAAATTTGCG)2 duplex          
(1 M/duplex) was mixed with ethidium bromide (EtBr) (6 M) . The DNA-EtBr 
complex was added with the ligands at 1:1 ligand:DNA duplex ratio. The experiment was 
performed in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 
7.0 at room temperature (21-23 

C). Each entry represents an average of three 
experiments. 
 
DNA binding affinities of these ligands. The percent fluorescence change (% F) is the 
percent change in the fluorescence emission of ethidium bromide upon binding of 
aparticular ligand in the present study (for mathematical equation that details the 
determination of percent fluorescence emission change, please see materials and methods 




afforded by the ligands followed the same trend as observed with UV thermal 
denaturation experiments where a general decrease in the DNA binding affinity with the 
increasing linker length of the Hoechst 33258 derivatives was observed. The results 
obtained from this assay reaffirmed the findings of the UV thermal denaturation 
experiments. 
Circular Dichroism (CD) Studies. In order to investigate if the ligands with long linkers 
were able to form complexes with the DNA, we performed CD studies. Circular 
dichroism studies help in obtaining crucial details regarding the ligand-nucleic acid 
interaction. A number of studies have been conducted previously detailing Hoechst 
33258-DNA interactions.
47
 The binding of Hoechst 33258 in the DNA minor groove 
results in a positive induced CD indicating the ligand-DNA interaction. A large positive 
induced CD typically results from the binding chromophores in the DNA groove. 
To identify the complex formation, we chose DPA 151, DPA 157 and DPA 159 to 
observe the changes in the chromophore absorption region of the CD spectrum. We chose 
DPA 151 and DPA 157 as they represented the best and worst binders while DPA 159 
had an improved binding amongst all ligands that contained long linkers. As a control, we 
also performed the experiments with Hoechst 33258.  
As depicted in Figure 3.5, the binding of different ligands to dodecamer DNA 
d(CGCAAATTTGCG)2 is shown . Figure 3.5a shows the interaction of Hoechst 33258 
to the DNA duplex. At 1:1 ligand-DNA ratio, an induced positive CD signal at 352 nm 
results as a consequence of DNA binding by Hoechst 33258.  DPA 151 also showed a 










































































Figure 3.5.   Circular dichroism studies of DNA duplex d(CGCAAATTTGCG)2 with 
various ligands as indicated on each graph. The duplex DNA sample (10 M/duplex) was 
mixed with the ligands (10 M) and equilibrated for five minutes before the CD scan was 
taken. Each spectrum is an average of three scans. All experiments were conducted in 
buffer 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl at pH 7.0 at 20 

C. In 
each graph, the CD spectrum of DNA in the absence of DNA is shown in black while the 
same in the presence of ligand is shown in blue. 
 
153 and 157 showed no induced CD spectrum between 300-400 nm and their CD spectra 
was identical and superimposable to CD spectrum of the DNA in the absence of ligand.  
However for DPA 159, we observed the positive induced CD spectrum similar in 




These CD studies provide some insight into the ligand-DNA complexation of the 
newly synthesized ligands. First of all, DPA 151 binds in a similar manner to Hoechst 
33258 leading to an induced CD signal of similar magnitude. The absence of induced CD 
in the 300-400 nm for DPA 153 and DPA 157 indicate that the bisbenzimidazole moiety 
of these molecules is unable to reach the minor groove of B-DNA (as evident by the lack 
of induced CD). The presence of positive induced CD in the case of DPA 159, which was 
of nearly equal magnitude as obtained with Hoechst 33258, shows that it also interacts in 
a similar way as Hoechst 33258.  
These results also support our initial hypothesis of hydrophobic effect based 
binding of these molecules. As discussed earlier, the presence of large alkyl groups on the 
linkers of DPA 153 and DPA 157 make them more prone to undergo hydrophobic effect 
leading to the inaccessibility   of the minor groove of B-DNA. The restoration of minor 
groove binding in the case of DPA 159 also supports this hypothesis, as the presence of 
multiple oxygen atoms in its linker is likely to allow lesser hydrophobic effect because of 
the ability of oxygen atoms to engage in hydrogen bonding. 
UV-Vis Absorption Studies. The binding of DPA 151, DPA 153, DPA 157 and DPA 159 
were also evaluated using UV-Vis absorption spectroscopy. The changes in the 
absorbance of Hoechst 33258 upon DNA binding has been previously reported by several 
other laboratories.
8, 9, 38, 47, 48
 In our studies we studied the binding of the above mentioned 





















































































Figure 3.6.   UV-Vis absorption studies of DNA duplex d(CGCAAATTTGCG)2 with 
various ligands as indicated on each graph. The DNA sample (5 M/duplex) was mixed 
with the ligands (5 M) and equilibrated for five minutes before a scan was taken. All 
experiments were performed in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 
100 mM NaCl at pH 7.0 (T = 20 

C). In each graph, the UV spectrum of DNA duplex in 
the absence of ligand is shown in black while the same in the presence of ligand is shown 
in blue. Isobestic points are indicated by arrows on each plot.  
 
As shown in Figure 3.6, upon binding, the absorption maximum of the Hoechst 
33258 spectrum underwent a red shift by 15 nm and was accompanied by a slight 
hyperchroism. However, two clear isobestic points (at 300 nm and 344 nm) were 




similar spectrum where the absorption maximum was red shifted by 16 nm. Again, we 
observed two isobestic points at 301 nm and 343 nm suggesting the complex formation 
between the DNA duplex and DPA 151. However, the binding of DPA 153 and DPA 157 
to DNA duplex resulted in much lower red shifts (~ 8 nm each). The two ligands, also, 
did not show the presence of any isobestic points indicating lack of binding. However, 
DPA 159 resulted in the red shift of the maximum absorption by 17 nm. The presence of 
isobestic points at 301 nm and 345 nm was also observed. All of these findings 
corroborated the results obtained with the UV thermal denaturation and CD studies which 
also showed the decreased binding of DPA 153 and DPA 157 to the DNA duplex. 
Fluorescence Emission Studies of DPA 151, DPA 153 and DPA 159.  Hoechst 33258 and 
related ligands have been known for excellent fluorescence emission properties when 
bound to a B-DNA duplex even at very low concentrations (1 ng/mL).
5
 This unique 
highly fluorescent nature of Hoechst 33258 and similar compounds made them ideal for 
nuclear staining. The fluorescence emission enhancement of these compounds result from 
reduced loss of energy to the bulk solvent when bound in the minor groove of B-DNA. 
We, therefore, conducted fluorescence emission studies of DPA 151-159 with the 
Dickerson duplex DNA sequence d(CGCAAATTTGCG)2. The results from these studies 
are depicted in Figure 3.7. In each graph, the fluorescence emission spectrum of ligand 
in the absence of DNA duplex is shown in the black while the blue lines represent the 
fluorescence emission profile of each ligand in the presence of DNA duplex. Both 


































































































Figure 3.7. Fluorescence emission spectrum of various ligands in the absence and 
presence of DNA duplex d(CGCAAATTTGCG)2 as indicated on the graph. The 
experiment was conducted at 100 nM/ligand concentrations and appropriate amount of 
the DNA duplex was added to achieve 1:1 DNA-ligand ratio. The experiments were  
conducted in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 
7.0 (T = 20 

C). Each entry in the spectrum represents an average of two scans. 
 
with DNA duplex (~49 fold increase). However, both DPA 153 and DPA 157 display 
very poor enhancement in the fluorescence emission when bound to DNA duplex (~ 2 
fold in both cases). In the case of DPA 159, however, the enhancement in the 
fluorescence emission is restored back to be nearly similar magnitude as found with 




binding is missing/weakened in the cases DPA 153 and DPA 157. Restoration of 
fluorescent enhancement for DPA 159 is in accord with the results discussed in the 
previous sections and is indicative of the hydrophobic effect clearly playing a role since 
the presence of multiple oxygen atoms on the linker is likely to reduce such effect. 
Testing the Role of Hydrophobic Effect.  The DNA binding studies discussed so far 
unequivocally suggest the role of hydrophobic effect in the ligand binding. To test this, 
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Figure 3.8. (a) Circular dichroism studies of DNA duplex d(CGCAAATTTGCG)2 with 
DPA DPA 151, 153 and DPA 157 as indicated on each graph. The DNA sample (10 M / 
duplex) was mixed with the ligands (10 M) and equilibrated for five minutes before a 
scan was taken. Each spectrum is an average of three scans. All experiments were 
conducted in 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl buffer at pH 
7.0 mixed with 1,4 dioxane (20 % v/v) at 20 

C. In each graph, the CD spectrum of DNA 




Figure 3.8 (continued) 
the presence of DNA as indicated on the graph. The experiment was conducted at 100 
nM/duplex DNA concentration and appropriate amounts of the ligands were added to 
achieve 1:1 DNA / ligand ratio. The experiments were conducted in buffer 10 mM  
sodium cacodylate, 0.5 mM EDTA and  100 mM NaCl at pH 7.0 mixed with 1,4 dioxane 




dioxane (20 % v/v). The reduction in the solvent polarity will lead to a decrease in the 
hydrophobic effect, which, in turn, would better the minor groove binding of the ligands 
DPA 153 and DPA 157. 
 As shown in Figure 3.8a, both DPA 153 and DPA 157 show an induced CD 
signal in the bisbenzimidazole absorption region, which is in contrast to their CD 
spectrum shown in Figure 3.4, where we did not observe any induced CD. This shows 
that increasing the non-polar character of the solvent does lead to minor groove binding 
of these ligands, which could be an outcome of loss/reduction of hydrophobic effect. In 
the case of DPA 153, the magnitude of induced CD was slightly lower than DPA 151, 
while the same for DPA 157 was much lower. These results indicate that even though 
increasing the solvent polarity leads to decrease in the hydrophobic effect, it is not fully 
undone. We further tested these results using the fluorescence emission experiments. The 
fluorescence emission spectrum for each ligand is shown in Figure 3.8b. Both DPA 153 
and DPA 157 showed improved fluorescence emission in the presence of 20 % (v/v) 1,4 




Table 3.3. Fluorescence emission properties of various ligands in the absence and 
presence of 1, 4 dioxane (reduced hydrophobic effect).  
 











DPA 151 0 % 457 49.78 
DPA 153 0 % 457 2.04 
DPA 157 0 % 457 1.60 
DPA 159 0 % 457 58.98 
DPA 151 20 % 456 24.99 
DPA 153 20 % 454 7.24 
DPA 157 20 % 456 3.12 
 
 
the absence of 1,4 dioxane, the ratio of increase in the fluorescence emission for both 
Hoechst 33258 and DPA 151 is nearly 24 fold higher than  DPA 153 or 157. However the  
same in the presence of 1,4 dioxane is ~ 3 and ~8 for DPA 153 and DPA 157 respectively 
(Table 3.3). These studies clearly show that reducing the polar character of the solvent 
results in enhanced fluorescence emission of DPA 153 and DPA 157, which arises likely 
from the reduced hydrophobic effect experienced by the alkyl termini of these novel 
Hoechst 33258 derivatives. 
Restoration of the Binding of Bisbenzimidazole Moiety of DPA 157.  We have previously 
reported that conjugation of neomycin with Hoechst 33258 results in a dual binding 
ligand that leads to larger thermal stabilization of Poly[d(A).d(T)] than any of their 
individual units. The conjugate also results in higher binding affinity to Poly[d(A).d(T)] 








































Figure 3.9. Circular dichroism studies of DNA duplex d(CGCAAATTTGCG)2 with (a) 
DPA 172 and (b) the comparison of induced CD of Hoechst 33258, DPA 151, DPA 153, 
DPA 157, DPA 159 and DPA 172 as indicated on each graph. The DNA sample (10 M / 
duplex) was mixed with the ligands (10 M) and equilibrated for five minutes before the 
scan was taken. Each spectrum is an average of three scans. All experiments were 
conducted in 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl buffer at pH 




neomycin-Hoechst 33258 conjugate where the binding of neomycin was suggested to 
occur in the major groove.
24
  
We, therefore, thought of synthesizing a ligand in which the neomycin was 
conjugated to DPA 157. The attachment of neomycin makes the molecule become 
hydrophilic. Also, the presence of neomycin will supposedly impact the hydrophobicity 





A neomycin conjugate DPA 172, was thus prepared (synthesis of DPA 172 is 
reported in Chapter 5) and its binding to B-DNA was tested. As seen in Figure 3.9, upon 
complex formation, we observed the positive induced CD at 352 nm which suggests the 
complexation of the bisbenzimidazole unit.  However, the magnitude of the positive 
induced CD was nearly half of the same obtained with Hoechst 33258 alone. This 
observation suggests that the ligand still experiences some hydrophobic effect yet is not 
sufficient enough to completely block the entry of the bisbenzimidazole unit into the 
minor groove of the DNA. 
Calorimetric Insights into DNA Binding. To understand the enthalpy changes associated 
with DNA-ligand complexation, we performed excess site ITC titrations
49
 at various 
temperatures (appendix II, Figure S4). The resulting enthalpy values are given in Table 
3.4.  For DPA 151, we obtained a positive enthalpy of interaction at temperatures 20 ºC,  
25 ºC, while a negative enthalpy of interaction at 30 ºC was observed. This resulted in a 
negative heat capacity value of -134 cal/mol/K for the DNA-ligand interaction. However, 
for both DPA 157 and DPA 159 we observed negative enthalpy of interaction at all 
studied temperatures as well as negative heat capacity values of –117 cal/mol/K and -382 
cal/mol/K respectively (Figure 3.10). The differing heat capacity values of the three 
ligands studied can be attributed to the overall effect of ligands on the displacement of  
water molecules from the bulk solvent and the  DNA minor groove, as binding of 
Hoechst 33258 is known to alter the hydration patterns of the minor groove.
50
 For DPA 











































































Figure 3.10.  Heat capacity plots of (a) DPA 151 (b) DPA 157 and (c) DPA 159 in buffer 
10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. 
 
experimentally determined heat capacity change for Hoechst 33258 interaction with 
d(CGCAAATTTGCG)2 duplex under similar comditions.
10
 The differences in the heat 
capacity values obtained with DPA 159 to that reported in the literature could originate 
from changes in the structure of the two ligands (DPA 159 having a much larger alkyl 
chain tail) which may contribute to bulk water displacement as well differences in the 
experimental conditions (different buffer and higher salt in study done by Chaires and 
coworkers
10
). For DPA 157, the heat capacity change was less negative and could largely 
be contributed by hydrophobic effect exerted by the long alkyl linker, as it does not enter 
the minor groove of DNA duplex. Alkyl groups have also previously been known to 
contribute to negative enthalpy in systems that are prone to micelle formation.
51
  






Table 3.4 A table showing the heat of enthalpy of DPA 151, DPA 153 and DPA 159’s 
interaction with d(CGCAAATTTGCG)2. 
 
















1.15 + 0.30 
  
0.62 + 0.01 
 
-0.19 + 0.10 
DPA 157 -0.68 + 0.04 -1.28 + 0.04 -1.85 + 0.03 
DPA 159 -3.50 + 0.10 -4.83 + 0.13 -7.30 + 0.10 
 
 
was nearly two and half times lower than the experientially determined negative heat 
capacity values of Hoechst 33258 interaction with d(CGCAAATTTGCG)2 duplex. 
Besides the changes in the experimental conditions, the binding stoichiometry obtained 
for DPA 151 binding was found different than the same obtained with Hoechst 33258. 
Hoechst 33258 binds to d(CGCAAATTTGCG)2 duplex with a 1:1 ligand: duplex binding 
stoichiometry, while DPA 151 binds to the same duplex in 2:1 ligand:duplex ratio as 
determined by the Job plot analysis. This “anomalous” binding stoichiometry has 
previously been described by Bruice and coworkers with a Hoechst 332258 related ligand 
Hoechst 33377.
52
 Hoechst 33377 differs from Hoechst 33258 just by a phenyl ring on the 
phenolic end, is able to self stack by  - stacking of terminal phenyl ring on Hoechst 
33377 and the central benzimidazoles  in a side by side binding manner. Due to presence 

























Figure 3.11. A Job plot of DPA 151 binding to d(CGCAAATTTGCG)2 duplex showing 
2:1 binding stoichiometry. The experiment was done in buffer 10 mM sodium cacodylate, 




interaction between the terminal alkyne and the benzene rings of central benzimidazoles 
drive the 2:1 binding in this case (Figure 3.11). 
Summary and Conclusions 
The studies presented here highlight the importance of the linker length and the 
composition on the DNA binding ability of derivatives of a well-established DNA minor 
groove binder Hoechst 33258. Since the development of Hoechst 33258 as a molecular 
tool to study DNA minor groove interactions, growing literature reports have indicated 




binding ligands with enhanced nucleic acid binding can be obtained. However, the role of 
linker length was not thoroughly investigated.  We have recently observed that the nature 
of atoms, rings and flexibility on the linker between the two covalently attached nucleic 
acid binding ligands does have a role in the binding
53, 54
  and the nucleic acid selectivity. 
This study also delineates the “good” and “bad” on the linkers of Hoechst 33258 
derivatives which will help in the future design of Hoechst 33258 based ligands. The 
disfavored binding of linkers with longer aliphatic groups indicate the efforts initiated to 
have increased lipophilicity in a ligand may help a ligand in better permeability but not 
necessarily better binding. This study thus, will aid significantly in the development of 
Hoechst 33258 based derivatives. 
Appendix II.  All UV thermal denaturation profiles, ITC titration plots, synthesis details 
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EVALUATION OF NUCLEIC ACID BINDING AND BIOLOGICAL ACTICITY OF 
HOECHST 33258 RELATED MONO AND BISBENZIMIDAZOLES 
Introduction 
Hoechst 33258 is a bisbenzimidazole compound that has been a subject of intense 
study for over three decades due to its binding to a variety of nucleic acid structures.
1-5
 Its 
high affinity binding to AT- rich double stranded DNA and excellent fluorescence 
properties,
1
 when bound to a nucleic acid, have established it as a molecular probe to 
study many biological processes. A number of studies have been done to understand 
Hoechst 33258 binding to nucleic acids. The binding of Hoechst 33258 to the B-DNA is 
driven by its shape complementarity to the minor groove of DNA and is mediated by a 




Crystallographic studies have shown that the binding of Hoechst 33258 occurs in 
the minor groove of a B-DNA dodecamer duplex d(CGCGAATTCGCG).
6
 The 
bisbenzimidazole moiety covers the four central A/T bases while the piperazine part of 
the molecule interacts with the G/C base pair. The flat face of Hoechst 33258 lies nearly 
parallel to the adjacent benzimidazole ring. These observations were further validated by 


















































































































































Hoechst 33258 based bisbenzimidazole derivatives
 
 




using solution NMR studies, which showed at least four A/T base pairs are covered 
during the binding.
3
 Equilibrium binding studies using spectroscopic methods showed 







The ability of Hoechst 33258 to bind selectively in the minor groove of the DNA 
in a sequence specific manner to A/T base pairs propelled further studies to investigate 
effects of its binding to DNA-protein interactions as these interactions hold the key to the 
faithful DNA replication. In fact, A/T rich regions, such as those found in eukaryotes and 
known as TATA box, are crucial for recruiting proteins (which are known as TATA 
binding proteins (TBP)) which leads to the further recruiting of regulatory proteins before 
the formation of transcription initiation complex.  Studies have indicated that Hoechst 
33258 inhibits the DNA-TBP complex
10
 formation and is therefore an important tool to 
study nucleic acid recognition with an ultimate goal of developing chemotherapeutic 
agents.  
In order to achieve better recognition of DNA with enhanced coverage of A/T 
sequences, terbenzimidazoles have been developed.
11-13
 Some of these have shown better 
binding to DNA and more enhanced cytotoxicity than bisbenzimidazoles.
11
 Their binding 
has been impacted by the nature of substituents on the phenyl rings where electron 
donating functional groups showed more increase in the thermal denaturation temperature 
of DNA than those with electron withdrawing groups.
14
 These benzimidazoles also 
display poisoning of the nuclear enzyme DNA topoisomerase I, which is considered as a 




directly related to their ability to penetrate into the cell irrespective of their DNA 
topoisomerase I poisoning effects.  
A variety of benzimidazoles that display a widespread range of biological activity 
has been resported Halogenated monobenzimidazoles have shown antimycobacterial 
activity better than isoniazid.
15
 Similarly, triazolyl derivatized monobenzimidazoles have 
displayed antimicrobial properties.
16
 In comparison to abundant literature reports on the 
biological properties of monobenzimidazoles, studies on the antimicrobial properties of 
bisbenzimidazoles
17
 (particularly those derived from Hoechst 33258) are less.  In this 
report we present the synthesis, nucleic acid binding, and antimicrobial activity, as well 
as topoisomerase I activity of Hoechst 33258 based novel mono and bisbenzimidazoles    
(Figure 4.1). A range of functional variations has been exercised to achieve varied 
hydrophobicity/hydrophilicity as they control cellular permeability. The results obtained 
shed light on the relationship of DNA binding ability of these ligands with their 
antimicrobial activity as well as the effects of altered hydrophobicity on topoisomerase I 
inhibition.  
Materials and Methods 
General Methods. Unless otherwise specified, chemicals were purchased from Aldrich 
(St. Louis, MO) or Fisher Scientific (Pittsburgh, PA) and used without further 
purification. Di-tert-butyl dicarbonate (Boc anhydride) was purchased from Advanced 
ChemTech (Louisville, KY). All solvents were purchased from VWR (West Chester, 
PA). Silica gel (32-65 M mesh size) was purchased from Sorbtech (Atlanta, Georgia). 
1
H NMR and 
13









C NMR).  MS (MALDI-TOF) spectra were collected using a Bruker 
Microflex mass spectrometer. Ultra Violet (UV) spectra were collected on a Varian 
(Walnut Creek CA) Cary 100 Bio UV-Vis spectrophotometer equipped with a 
thermoelectrically controlled 12-cell holder.   FID experiments were performed on Cary 
Eclipse fluorometer equipped with a 96 well plate reader. 
Nucleic Acids. Nucleic acids were purchased from The Midland Certified Reagent 
Company, Inc. (Midland, Texas) and Eurofins MWG Operon (Huntsville, AL). The 
nucleic acids were used without further purification. The nucleic acid concentration was 
determined using the extinction coefficients provided by the supplier. Nucleic acid 
solutions were prepared in buffer 10 mM sodium cacodylate, 0.1 mM EDTA and 100 
mM NaCl at pH 7.0. The nucleic acid solutions were prepared by heating at 95 

C for 15 
minutes and then slowly allowing it to cool back to room temperature. After two days of 
incubation, the duplex formation was checked by UV thermal denaturation experiments. 
The stock solution was stored at 4 

C and diluted to desired concentrations as required. 
Ultra Violet (UV) Thermal Denaturation Experiments.    All UV spectra were obtained 
on a 12 cell holder Cary 1E UV-Vis spectrophotometer equipped with temperature 
controller. Quartz cells with 1cm path length were used for all the experiments. 
Spectrophotometer stability and wavelength alignment were checked prior to initiation of 
each thermal denaturation experiment.   For all experiments, the samples were prepared 
by diluting a stock sample. The melting of DNA with and without the ligand was carried 




experiment.   All UV melting experiments were monitored at 260 nm.   For the Tm 
determinations, derivatives were used.   Data points were recorded every 1.0 °C.  The 
DNA concentration was 1 M /duplex while the ligand concentration was 10 M. All 
ligand solutions were prepared in dimethyl sulfoxide (DMSO) as concentrated stock 
solution and diluted to desired concentrations in buffer.  
Fluorescencent Intercalator Displacement (FID) Experiments.  Fluorescence experiments 
were performed on a Cary Eclipse fluorometer (Walnut Creek, CA) equipped with a 96 
well plate reader. All experiments were performed at room temperature (21-23 

C).  The 
experiments were performed in the 96 well plates as triplicates. The DNA solution was 
prepared at 1 M / duplex in 10 mM sodium cacodylate, 0.1 mM EDTA and 100 mM 
NaCl at pH 7.0 and mixed with thiazole orange (TO) at a concentration of 6 M. The 
ligand was added to the DNA / TO complex solution at 1:1 ratio and followed by a five 
minute equilibration time before the fluorescence spectrum was recorded. The TO 
fluorescence excitation was performed at 501 nm and the fluorescence emission was 
recorded at 534 nm.  The change in the fluorescence was plotted as - 
% fluorescence change = (F/IF) × 100 
where, F = Change in fluorescence upon ligand addition and IF = Initial fluorescence of 
the DNA- TO complex 
 Minimum Inhibitory Concentration (MIC) Determination. Bacteria used in this study 
were Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Escherichia 
coli K12, Staphylococcus aureus ATCC 33591, Pseudomonas aeruginosa ATCC 27853, 




dilution method following Clinical and Laboratory Standards Institute guidelines.
44
 
Briefly, Mueller-Hinton broth (Difco Laboratories, Becton Dickinson) was inoculated 
with each organism and incubated at 37 °C with shaking to establish logarithmic growth.  
Following incubation, each culture was pelleted by centrifugation (3,500 x g for 5 min) 
and resuspended in 0.85% sterile saline solution to an optical density at 625 nm of 0.1.  
Samples were tested in triplicate using 96-well microplates (Corning Costar Corp. 
Cambridge, MA), yielding final bacterial concentrations of 5 x 10
5
 CFU/ml, and 
incubated for 24 h at 37 °C.  Following incubation, optical densities of each well were 
determined with a µQuant microplate spectrophotometer (BioTek Instruments, Inc., 
Winooski, VT) at 625 nm.  The MIC was defined as the lowest concentration needed to 
completely inhibit growth as compared to no treatment controls. 
Topoisomerase I Inhibition Assay. The E. coli DNA topoisomerase I inhibition assay was 
used to determine the activities of the newly synthesized compounds against E. coli 
topoisomerase I. The reaction mixture (30 l) contained 20 mM Tris-HCl pH 7.9, 50 mM 
potassium acetate, 10 mM magnesium acetate, 1 mM DTT, 1 µg/mL BSA, 150 ng 
supercoiled plasmid pBAD-GFPuv, 6 nM of E. coli topoisomerase I, and one of the drugs 
at a specified concentration that ranges from 0.5 to 45 µM. All components were 
assembled on ice and incubated for 15 min at 37 °C. After the incubation, the reactions 
were terminated by extraction with an equal volume of phenol. The topological state of 
the DNA samples was analyzed with 1% agarose gel electrophoresis in 1×TAE buffer, 
pH 7.8. Following electrophoresis, the agarose gel was stained with Ethidium Bromide, 




determined using KODAK 1D Image Analysis Software. The percentage of (-) 
supercoiled DNA was calculated from a comparison of the intensity of the (-) supercoiled 
band with the total intensity of all DNA topoisomers. The IC50 was calculated as the 
amount of the drug for which 50% of the DNA was still in a (-) supercoiled state. 
Synthesis of DPA 101. To a solution of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.47 g, 
2.00 mmol) in ethanol-ethyl acetate (2:1 v/v) mixture (20.0 mL), 10 % Pd-C (0.20 g) was 
added and the mixture was hydrogenated for 4h at the atmospheric pressure which 
afforded corresponding diamine. Catalyst was filtered off.  To the diamine, 4-(prop-2-
ynyloxy) benzaldehyde (0.32 g, 2.00 mmol) and sodium metabisulfite (0.36 g, 1.80 
mmol) in water (0.50 mL) was added, and the mixture was refluxed overnight. The 
volatiles were removed under reduced pressure. The crude mixture was purified on a 
silica gel column using dichloromethane-methanol (0-15 % methanol in 
dichloromethane) as eluent to afford the desired compound as pale yellow solid  (0.44 g, 
65 %):
 
Rf = 0.51 (dichloromethane-methanol 8:2 v/v); mp 150-155 

C; IR (neat) cm
-1  
3280 (alkyne C-H stretch), 2928, 2800, 2110 (alkyne C-C stretch), 1606, 1436, 1229, 
1173, 1018, 841;  
1
H NMR (500 MHz, methanol-d4)  7.99 (d, J = 8.87 Hz, 2H), 7.48 (d, 
J = 8.81 Hz, 1H), 7.13-7.11 (m, 3H), 7.02 (dd, J1 = 8.89 Hz, J2 = 2.24 Hz, 1H), 4.80 (d, J 
= 2.33 Hz, 2H), 3.22 (t, J = 4.57 Hz, 4H), 3.02 (t, J = 2.49 Hz, 1H), 2.72 (t, J = 4.99 Hz, 
4H), 2.41 (s, 3H) (The imino proton of the molecule was not detected due to solvent 
exchange with the NMR solvent); 
13
C NMR (125 MHz, methanol-d4)  157.6, 149.9, 
146.4,137.1, 133.6, 126.0, 121.3, 113.4, 113.3, 99.3, 76.4, 74.2, 53.7, 53.0, 48.6, 46.9, 






Synthesis of DPA 102. To a solution of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.40 g, 
1.69 mmol) in ethanol-ethyl acetate (2:1 v/v) mixture (15.0 mL), 10 % Pd-C (0.20 g) was 
added and the mixture was hydrogenated for 4h at the  atmospheric pressure which 
afforded corresponding diamine. Catalyst was filtered off.  To this diamine, 4-(2-
azidoethoxy)benzaldehyde (0.41 g, 2.16 mmol) and sodium metabisulfite (0.32 g, 1.69 
mmol) in water (0.50 mL) was added.  The contents were refluxed overnight. The 
volatiles were removed under reduced pressure. The crude mixture was purified on a 
silica gel column using dichloromethane-methanol (0-15 % methanol in 
dichloromethane) as eluent to afford the desired compound as off white solid  (0.53 g, 82 
%): Rf = 0.53  (dichloromethane-methanol 8:2 v/v); mp  > 250 

C (dec); IR (neat) cm
-1
 
2937, 2798, 2103 (azide N-N str), 1585, 1437, 1282, 959; 
1
H NMR (500 MHz, methanol-
d4)  8.02 (d, J = 8.88 Hz, 2H), 7.50 (d, J = 8.77 Hz, 1H), 7.14-7.11 (m, 3H), 7.06 (dd, J1 
= 8.88 Hz, J2 = 2.06 Hz, 1H), 4.26 (t, J = 4.76 Hz, 2H), 3.65 (t, J = 4.87 Hz, 2H), 3.25 (t, 
J = 4.55 Hz, 4H), 2.72 (t, J = 4.65 Hz, 4H),  2.42 (s, 3H) (The imino proton of the 
molecule was not detected due to solvent exchange with the NMR solvent); 
13
C NMR 
(125 MHz, methanol-d4)  158.5, 150.0, 146.6, 139.5, 134.3, 132.1, 126.2, 119.4, 113.4, 
113.2, 97.7, 65.6, 53.2, 48.8, 48.4, 43.1; MS (MALDI-TOF) m/z calcd for C20H23N7O 
377.19, found 377.07 [M]
+
. 
Synthesis of  DPA 851. To a solution of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.50 g, 
2.12 mmol) in ethanol-ethyl acetate (2:1 v/v) mixture (20.0 mL), Pd-C (150 mg) was 
added and the mixture was hydrogenated for 4h at the atmospheric pressure, which 




benzaldehyde (0.32 g, 2.12 mmol) and an aqueous solution of Na2S2O5 (0.40 g, 2.12 
mmol) were added, and the mixture was refluxed overnight. The mixture was brought to 
room temperature and volatiles were removed under reduced pressure. The crude product 
was purified by column chromatography on silica gel using dichloromethane-methanol 
(0-15 % methanol in dichloromethane) as eluent to afford the desired product as off white 
solid (0.34 g, 47 %): Rf  =  0.55 (dichloromethane-methanol 8:2 v/v); mp 165-170 

C;  IR 
(neat) cm
-1
  3423 (N-H wagging), 2970 (aromatic C-H stretch), 1629, 1449, 1245, 1171, 
1036;  
1
H NMR (500 MHz, acetone-d6) 9.89 (s, 1H), 8.13 (dd, J1 = 8.8 Hz, J2 = 2.8 Hz, 
2H), 7.44 (d, J = 8.6 Hz, 1H), 7.04-7.02 (3H), 6.95 (dd, J1 =  2.3Hz, J2 = 8.8 Hz, 1H), 
4.12 (q, 2H), 3.15 (t, J = 4.89 Hz, 4H), 2.57 (t, J = 5.0 Hz, 4H), 2.31 (s, 3H), 1.39  (t, J = 
6.94 Hz, 3H  );  
13
C NMR ( 75 MHz, DMSO-d6)  160.0, 151.0, 148.0, 130.8, 128.1, 
123.3, 115.1, 114.0, 63.7, 55.2, 50.3, 46.0, 15.0; MS (MALDI-TOF) m/z calcd. for 
C20H24N2O 
 
336.43, found 336.57 [M]
+
. 
Synthesis of  DPA 852. To a solution of 5-chloro 2-nitroaniline (0.52 g, 3.01 mmol) in a 
mixture of ethanol-ethyl acetate (20.0 mL), Pd-C (0.20 g) was added. The mixture was 
hydrogenated for 5h at atmospheric pressure, which afforded the dehalogenated diamine 
product. Catalyst was filtered off. To this, 4-hydroxybenzaldehyde (0.37 g, 3.01 mmol) 
was added followed by addition of sodium metabisulfite (0.57 g, 3.01 mmol). The 
mixture was refluxed overnight. Volatiles were removed under reduced pressure. The 
crude product was purified on a silica gel column using dichloromethane-methanol (0-15 
% methanol in dichloromethane) as eluent to afford the desired compound a beige solid 
(0.54 g, 84 %): Rf = 0.80  (dichloromethane-methanol 8:2 v/v) ; mp >260 







 3366, 3194, 1604, 1510, 1457, 1384, 1277, 1171, 844;  
1
H NMR (500 MHz, DMSO-
d6)  10.9 (s, 1H), 8.32 (d, J = 8.2 Hz, 2H), 7.78 (q, 2H), 7.49 (q, 2H), 7.09 (d,  J = 8.8 
Hz, 2H); 
13
C NMR (75 MHz, DMSO-d6) )  162.5, 149.3, 133.0, 130.5, 125.4, 116.8, 




Synthesis of DPA 854.  To a solution of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.11 g, 
0.46 mmol) in ethanol-ethyl acetate (2:1 v/v) mixture (10.0 mL), 10 % Pd-C (0.06 g) was 
added and the mixture was hydrogenated for 4h at atmospheric pressure, which afforded 
corresponding diamine. Catalyst was filtered off.  To this, 4-(6-(prop-2-
ynyloxy)hexyloxy) benzaldehyde (0.12 g, 0.46 mmol) and an aqueous solution of 
Na2S2O5 (0.09 g, 0.48 mmol) were added, and the mixture was refluxed overnight. The 
mixture was brought to room temperature, and volatiles were removed under reduced 
pressure. The crude product was purified by column chromatography on silica gel using 
dichloromethane-methanol (0-15 % methanol in dichloromethane) as eluent afforded the 
desired product as yellow solid (0.14 g, 67 %): Rf = 0.66 (dichloromethane-methanol 8:2 
v/v); mp 262 

C;  IR (neat) cm
-1 
3435, 2937, 2851, 2123, 1735, 1608, 1457, 1241, 1004, 
836; 
1
H NMR (500 MHz, methanol-d4) 7.99 (d, J = 8.83 Hz, 2H), 7.50 (d, J = 8.72 Hz, 
1H),  7.15 (d, J = 1.78 Hz, 1H), 7.09-7.05 (m, 3H), 4. 16 (d, J = 2.32 Hz, 2H),  4.08 (t, J 
= 6.41 Hz, 2H), 3.56 (t, J = 6.58 Hz, 2H), 3.29 (t, J = 4.45 Hz, 4H), 2.87 (t, J = 4.09 Hz, 
4H),  2.84 (t, J = 2.14 Hz, 1H), 2.53 (s, 3H), 1.86-1.82 (m, 2H), 1.68-1.62 (m, 2H), 1.58-






Synthesis of  DPA 855.  To a solution of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.50 
g, 2.12 mmol) in a mixture of ethanol-ethyl acetate (20.0 mL, 2:1 v/v), Pd-C (0.10 g) was 
added and the mixture was hydrogenated for 4h at atmospheric pressure, which afforded 
corresponding diamine.  Catalyst was filtered off, and the diamine solution was added 
with tert-butyl 3-(4-formylphenoxy)propylcarbamate (0.59 g, 2.12 mmol). To this 
mixture, an aqueous solution of Na2S2O5 (0.40 g, 2.12 mmol in 1.50 mL water) was 
added, and the mixture was refluxed for 6h. The reaction mixture was brought to room 
temperature and the volatiles were removed under reduced pressure. The crude mixture 
was purified on a silica gel column using  dichloromethane-methanol (0-15 % methanol 
in dichloromethane) as eluent to afford the desired compound as dark red solid (0.62 g, 
63 %): Rf = 0.54 (dichloromethane-methanol 8:2 v/v); mp 210-220 

C; IR (neat) cm
-1
 
2973, 2928, 1678, 1449, 1232, 1175; 
1
H NMR (500 MHz, DMSO-d6)  12.4 (br, 1H), 
8.05 (d,  J = 8.5Hz , 2H), 7.42 (br, 1H), 7.07 (d, J = 8.8 Hz,  2H), 6.96-6.91 (m,  2H), 
4.05 (t, J = 6.15 Hz, 2H), 3.13 (m, 6H), 2.51 (s, 3H), 1.86  (m, 2H), 1.42 (s, 9H) (some  
proton signals are  masked by the NMR solvent peak); 
13
C NMR (125 MHz, methanol-
d4)  162.5, 160.1, 156.1, 131.7, 128.0,  123.6, 115.2, 114.6, 77.9, 65.9, 61.8, 55.2, 50.3, 
47.6, 46.2, 37.4, 29.6, 28.7, 23.2, 15.6; MS (MALDI-TOF) m/z calcd. for C26H35N5O3 
465.58, found 465.43 [M]
+
.   
Synthesis of DPA 856. To a solution of methyl 3-amino-5-(4-methylpiperazin-1-yl)-2-
nitrobenzoate (0.21 g, 0.71 mmol) in a mixture of ethanol-ethyl acetate (15.0 mL, 2:1 
v/v),  10 % Pd-C (0.06 g) was added and the mixture was hydrogenated for 6h at room 




diamine solution was added with 4-hydroxy benzaldehyde (0.09 g, 0.71 mmol). To this 
mixture an aqueous solution of Na2S2O5 (0.13 g, 0.71 mmol in 0.80 mL H2O) was added 
and the mixture was refluxed for 6h. The reaction mixture was brought to room 
temperature and the volatiles were removed under reduced pressure.  The crude mixture 
was purified by column chromatography on silica gel using dichloromethane-methanol 
(0-15 % methanol in dichloromethane) as eluent to afford the desired compound as 
yellow solid (0.13 g, 47 %): Rf = 0.50 (dichloromethane-methanol 8:2 v/v); mp 260-262 

C;   IR (neat) cm
-1
 3460, 2945, 2830, 1715, 1608, 1494, 1273, 1208;  
1
H NMR (300 
MHz, DMSO-d6) 9.98 (s, br, 1H), 8.10 (d, J = 8.20 Hz, 2H), 7.49-7.45 (2H), 6.90 (d, J 
= 8.7 Hz, 2H), 3.97 (s, 3H), 3.23 (s, br, 4H), 2.77 (s, br, 4H), 2.42 (s, 3H);
 13
C NMR (75 
MHz, DMSO-d6)   166.2, 159.8, 154.2, 147.1, 146.5, 129.6, 129.2, 121.1, 116.3, 114.4, 
114.4, 113.7, 111.3, 55.0, 52.5, 50.1, 45.9; MS (MALDI-TOF) m/z calcd. for C20H22N4O3 
366.16, found 366.54 [M]
+
.   
Synthesis of DPA 857. A solution of methyl 2-(4-hydroxyphenyl)-6-(4-methylpiperazin-
1-yl)-1H-benzimidazole-4-carboxylate (55.00 mg, 0.15mmol) in 1N NaOH (3.00 mL) 
was heated at 80 

C for 1h. The mixture was then cooled to room temperature and 
neutralized with 1N HCl.  Volatiles were removed, and the crude mixture was purified on 
a short path silica gel column to give the desired product as yellow solid (30 mg, 58 %): 
Rf = 0.08 ( dichloromethane-methanol 8:2 v/v); mp > 260 

C; IR (neat) cm
-1
 3362, 2830, 
2720, 1723, 1641, 1608, 1494, 1290, 1179, 967;  
1
H NMR (300 MHz, D2O)  7.48 (d, J = 




3.60-3.57 (br, 2H), 3.10 (br, 4H), 2.90 (s, 3H);  MS (MALDI-TOF) m/z calcd. for 
C19H20N4O3 352.38, found 353.54 [M+H]
+
.    
 Synthesis of DPA 858. To a solution of tert-butyl 3-(4-(6-(4-methylpiperazin-1-yl)-1H-
benzimidazol-2-yl) phenoxy) propylcarbamate (0.12 g, 0.25 mmol) in dichloromethane 
(3.00 mL), trifluoroacetic acid (0.50 mL) was added and the mixture was stirred at room 
temperature for 2h. The volatiles were removed under reduced pressure. The desired 
compound was obtained in quantitative yield as moist dark red solid: Rf = 0.03 
(dichloromethane-methanol 8:2 v/v); IR (neat) cm
-1
 3403, 3047, 2953, 1687, 1507, 1266, 
1209, 1131, 841, 718;  
1
H NMR (300 MHz, D2O) 7.74 (d, J = 8.7 Hz,  2H), 7.47 (d, J = 
8.1 Hz, 1H), 7.15-7.02 (m, 4H), 4.06 (t, J = 5.50 Hz, 2H), 3.73 (d, J = 11.8 Hz,  2H), 3.55 
(d, J = 11.2 Hz,  2H), 3.14-3.04 (m, 6H), 2.86 (s, 3H), 2.07 (m, 2H); MS (MALDI-TOF) 
m/z calcd. for C21H27N5O 365.22, found 365.54 [M+H]
+
.     
Synthesis of DPA 103 and DPA 105. To a solution of DPA 101 (0.10 g, 0.29 mmol) in a 
mixture of methanol-water (3.00 mL, 2:1 v/v), appropriate diazide
45
 (30 fold excess) was 
added, followed by the addition of a freshly prepared copper catalyst {copper sulfate 
(0.007 g, 0.043 mmol), sodium ascorbate (0.020 g, 0.100 mmol) in water 1.0 mL}. The 
mixture was stirred overnight at room temperature. Volatiles were removed under 
reduced pressure. The crude product was purified by column chromatography using 
dichloromethane-methanol (0-15 % methanol in dichloromethane) as eluent to afford the 
desired compounds as pale yellow powder. 
DPA 103.  (90 mg, 68 %); Rf = 0.40 (dichloromethane-methanol 8:2 v/v); mp 125-135 

C; IR (neat) cm
-1
 2099, 1617, 1454, 1229, 1184, 1004;  
1




d4) 8.18 (s, 1H), 8.01 (d, J = 8.78 Hz, 2H), 7.50 (d, J = 8.62 Hz, 1H), 7.19 (d, J = 8.86 
Hz, 1H), 7.14 (d, J = 1.72 Hz, 1H), 7.05 (dd, J1 = 8.61 Hz, J2 = 1.89 Hz, 1H), 5.29 (s, br, 
2H), 4.62 (t, J = 5.68 Hz, 2H),   3.85 (t, J = 5.40 Hz, 2H), 3.26 (t, J = 4.29 Hz, 4H),   2.78 
(t, J = 4.48 Hz, 4H), 2.46 (s, 3H); 
13
C NMR (75 MHz, methanol-d4) 159.8, 151.5, 
148.0, 143.5, 127.7, 124.6, 122.8, 115.0, 61.0, 54.6, 50.3, 50.1, 49.3, 44.4; MS (MALDI-
TOF) m/z calcd for C23H26N10O 458. 22, found 458.15 [M]
+
. 
DPA 105. (45 mg, 30 %); Rf = 0.45 (dichloromethane-methanol 8:2 v/v); mp 92-93 

C;   
IR (neat) cm
-1
 2935, 2849, 2092, 1613, 1451, 1255, 1180, 999; 
1
H NMR (500 MHz, 
methanol-d4)    8.11 (s, 1H), 8.02 (d, J = 8.39 Hz, 2H), 7.51 (d, J = 8.64 Hz, 1H), 7.18 
(d, J = 8.39 Hz, 2H), 7.15 (s, br, 1H), 7.06 (dd, J1 = 8.88 Hz, J2 = 1.97 Hz, 1H), 5.27 (s, 
br, 2H), 4.43 (t, J = 6.91 Hz, 2H), 3.29-3.23 (m, 6H), 2.89 (br, 4H), 2.55 (s, 3H), 1.96-
1.90 (m, 2H), 1.58-1.52 (m, 2H), 1.44-1.38 (m, 2H), 1.35-1.29 (m, 2H); MS (MALDI-
TOF) m/z calcd for C27H34N10O 514.29, found  514.17 [M]
+
. 
Synthesis of DPA 108. To a solution of 2-(4-(2-azidoethoxy)phenyl)-6-(4-
methylpiperazin-1-yl)-1H-benzo[d]imidazole (0.08 g, 0.21 mmol) in a mixture of 
methanol-water (3.00 mL, 2:1 v/v), CuSO4 (0.007 g, 0.043  mmol) and sodium ascorbate 
(0.020 g, 0.100 mmol) were added. To this, 1,4 diethynylbenzene  (57 fold excess) was 
added and the reaction mixture was stirred at room temperature for 24h. Volatiles were 
removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel using dichloromethane-methanol (0-15 % methanol in 
dichloromethane) as eluent. The desired compound was obtained as pale yellow powder 
(0.06 g, 57 %); Rf = 0.48 (dichloromethane-methanol 8:2 v/v); mp 198-200 







 2937, 2798, 2103, 1585, 1437, 1282, 959; 
1
H NMR (500 MHz, methanol-d4)  8.47 
(s, 1H), 7.96 (d, J = 8.60 Hz, 2H), 7.83 (d, J = 8.25 Hz, 2H), 7.53 (d, J = 8.42 Hz, 2H), 
7.487 (d, J = 8.78 Hz, 1H), 7.10-7.02 (m, 4H), 4.89 (t, J = 4.91 Hz , 2H), 4.53 (t, J = 4.91 
Hz, 2H), 3.58 (s, 1H), 3.22 (t, J = 4.27 Hz, 4H) ,  2.72 (t, J = 4.38 Hz, 4H), 2.42 (s, 3H)   
(Imino proton was not observed because of exchange with the NMR solvent); 
13
C NMR 
(75 MHz, methanol-d4)  159.6, 151.5, 148.1, 146.6, 140.1, 132.1, 130.6, 127.7, 125.2, 
123.0, 122.1, 122.0, 114.9, 114.7,101.1, 82.2, 66.2, 54.6, 50.2, 49.6, 44.5 (some carbons 
were not observed likely because of the aggregating nature of the molecule); MS 
(MALDI-TOF) m/z calcd for C30H29N7O  503.24, found 504.23 [M]
+
. 
Synthesis of DPA 112. To a solution of 2-(4-(2-azidoethoxy)phenyl)-6-(4-
methylpiperazin-1-yl)-1H-benzo[d]imidazole (0.08 g, 0.21 mmol) in a mixture of 
methanol-water(3.00 mL, 2:1 v/v), CuSO4 (0.007 g, 0.043  mmol) and sodium ascorbate 
(0.020 mg, 0.100 mmol) were added. To this solution, 1,9 decadiyne (1.61 g, 12.0 mmol) 
was added and the reaction mixture was stirred at room temperature for 24h. Volatiles 
were removed under reduced pressure. The crude product was purified by column 
chromatography using dichloromethane-methanol (0-15 % methanol in dichloromethane) 
as eluent. The desired compound was obtained as pale yellow powder (0.09 g, 79 %): Rf 
= 0.32 (dichloromethane-methanol 8: 2 v/v); mp 85-86 

C;   IR (neat) cm
-1
 2931, 2852, 
2114, 1636, 1606, 1451, 1289, 1248, 1173, 1052, 965;  
1
H NMR (500 MHz, methanol-d4) 
7.97-7.95 (d, J = 8.70 Hz, 2H), 7.81 (s, 1H), 7.48 (d, J = 8.70 Hz, 1H), 7.11 (d, J = 1.34 
Hz, 1H),   7.04-7.01 (m, 3H), 4.78 (t, J = 4.68 Hz, 2H), 4.45 (t, J = 4.68 Hz, 2H), 3.21 (t, 




(m, 2H), 1.67-1.61 (m, 2H), 1.48-1.28 (m, 8H); 
13
C NMR (125 MHz, methanol-d4) d 
159.7, 151.4, 148.1, 147.8, 127.7, 123.0, 122.5, 114.9, 114.7, 83.6, 68.1, 66.3, 54.2, 50.3, 
49.4, 44.6, 29.0, 28.1, 28.0, 24.7, 17.5;  MS (MALDI-TOF) m/z calcd for C30H37N7O 
511.30, found 511.40. 
Synthesis of DPA 151-DPA 157.  Complete synthetic details of these compounds are 
given in appendix II. 
Results and Discussion 
Synthesis of Novel Mono and Bisbenzimidazoles. To achieve the synthesis of the desired 
compounds, three different strategies were employed. For the synthesis of 
monobenzimidazoles that bear no triazolyl functionalities on them (DPA 101, DPA 102, 
DPA 851, DPA 852, DPA 854, DPA 855 and DPA 856), the desired compounds were 
obtained via condensation of an ortho diamine with an appropriate aldehyde (Scheme 
4.1) in the presence of an oxidant (sodium metabisulfite).
18
 The use of sodium 
metabisulfate avoids the use of harsh chemicals, such as concentrated acids or 
nitrobenzene, to achieve the synthesis of similar compounds.  Compound DPA 857 was 
synthesized by the basic hydrolysis of DPA 856, while DPA 858 was obtained by the 
removal of the Boc protecting group of DPA 855 using trifluoroacetic acid (Scheme 4.2). 
To achieve the synthesis of triazolyl derivatized monobenzimidazoles, we exploited the 
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Scheme 4.1.  (i) Pd-C, H2, ethanol, rt, 5h, quant.  (ii) Na2S2O5, H2O, ethanol, reflux, 












































Scheme 4.2.   Reagent and conditions (i) 1N NaOH (aq), 80 

C, 58 % (ii) Trifluoroacetic 






















































Scheme 4.3. Reagent and conditions (i) ethanol, sodium ascorbate, CuSO4, rt, 24h, 30-68 
% (ii) 1, 4 diethynyl benzene, ethanol, sodium ascorbate, CuSO4, rt, 24h, 57 %  (iii) 1,9 





and DPA 102 (an azide). Alkynes and azides are key components for the copper 
catalyzed 1, 3 dipolar cylcoaddition, which results in the regioselective formation of 1,4 
substituted 1,2,3 triazoles. 
19, 20
 DPA 101 was reacted with excess bisazides to afford 
triazolyl bearing monobenzimidazoles that terminate with an azide end. Similarly, DPA 
102 was reacted with excess bisalkynes to yield triazolyl bearing monobenzimidazoles  
that terminate with an alkyne end (Scheme 4.3). The preparation of bisbenzimidazoles 
(DPA 151-DPA157) has been discussed in Chapter 3.  
UV Thermal Denaturation Studies. To further evaluate the DNA binding abilities of these 
ligands, we performed thermal denaturation studies with a DNA duplex dA60.dT60. The 
duplex dA60.dT60 was prepared by mixing a 60 mer homopurine strand (dA60) with a 60 
mer homopyrimidine strand (dT60) in an equimolar ratio. The formation of the duplex 
was confirmed by the sharp melting transition at 62.5 

C in the presence of 100 mM NaCl 
salt. The ligands (10 M) were mixed with the DNA (1 M / duplex) and annealed. The 
results obtained from the thermal denaturation studies are depicted as a bar graph plot 
shown in Figure 4.2 (Table 4.1) (for complete melting profiles and melting temperatures 














































































































































































Figure 4.2. A bar graph plot showing the increase in the temperature of thermal 
denaturation of duplex dA60.d60 in the presence of different ligands.  The DNA duplex (1 





C ( at a rate of 0.2 

C / min) in buffer 10 mM sodium cacodylate, 0.1 
mM EDTA, 100 mM NaCl at pH 7.0. The increase in the thermal denaturation of 
monobenzmimidazoles is shown by black bars, triazolyl benzimidazoles by blue bars and 
bisbenzimidazoles by orange bars. A representative thermal denaturation profile of DPA 





Table 4.1.  A table showing the thermal denaturation temperatures of 
duplex DNA (dA60.dT60) in the presence of all studied ligands (10 M 
each) in buffer 10 mM sodium cacodylate, 0.1 mM EDTA and 100 mM 
NaCl at pH 7.0. 









Hoechst 33258 87.1 24.6 
Hoechst 33242 86.6 24.1 
DPA 101 65.1 2.6 
DPA 102 64.4 1.9 
DPA 851 64.2 1.7 
DPA 852 62.5 0.0 
DPA 854 63.9 1.4 
DPA 855 63.5 1.0 
DPA 856 62.5 0.0 
DPA 857 62.5 0.0 
DPA 858 65.8 3.3 
DPA 103 63.7 1.2 
DPA 105 63.0 0.5 
DPA 108 64.4 1.9 
DPA 112 63.0 0.5 
DPA 151 85.4 22.9 
DPA 152 83.4 20.9 
DPA 153 70.5 8.0 
DPA 154 85.9 23.4 
DPA 157 63.7 1.2 
 
 
The stabilization in the thermal melting temperature of monobenzimidazoles, triazolyl 
monobenzimidazoles, and bisbenzimidazoles are shown in black, blue, and orange bars  
respectively. All monobenzimidazoles ligands showed up to 3 

C increase in the thermal 
stabilization of dA60.dT60 duplex. Similar thermal stabilization was also found with the 




much smaller in comparison to most of the bisbenzimidazoles which showed up to ~ 25 

C increase in the thermal denaturation temperature of dA60.dT60 duplex. Of seven 
bisbenzimidazoles studied, five of them (Hoechst 33258, Hoechst 33242, DPA 151, DPA 
152, DPA 154) displayed thermal stabilization greater than 20 

C. However two of them, 
DPA153 and DPA 157, showed much lower thermal stabilization (8.0 

C and 1.2 

C  
respectively). The thermal stabilization afforded by DPA 157 is comparable to the 
thermal stabilization obtained with monobenzimidazoles and triazolyl 
monobenzimidazoles. This indicates the role of linker length in the DNA binding of  
bisbenzimidazoles, which is being investigated further in our laboratory. These results 
show that monobenzimidazoles are weaker DNA binders than bisbenzimidazoles. Wilson 
and coworkers have previously shown that Hoechst 33258 like ligands that have two 
benzimidazoles units (but lack the piperazine part) afford similar thermal stabilizations 
when bound in the minor groove of B-DNA.
21
 However, Hoechst 33258 derived 
monobenzimidazoles, which terminate with a guanidinium group or an imidazole (in 
place of piperazine), produce much higher thermalstabilization in comparison to same 
terminating with a piperazine. 
21
 This suggests that a key feature of the Hoechst 33258 
like DNA binding agents is the presence of a bisbenzimidazole moiety, and the DNA 
binding may be helped by the presence of the piperazine moiety, but is certainly not a 
driving factor.  
Fluorescent Intercalator Displacement (FID) Experiments. FID is an efficient and rapid 
technique to identify the structure and sequence specificity of ligands towards a nucleic 
acid.
22
 Developed by Boger,
23

















































































































































Ligands Studied  
 
Figure 4.3. FID plot showing the change in the fluorescence emission upon ligand 
binding in a DNA d(CGCAAATTTGCG)2-thiazole orange (TO) complex.  [DNA] = 1 
M, [TO] = 6 M, [Ligand] = 1 M. All experiments were performed in buffer 10 mM 
sodium cacodylate, 0.1 mM EDTA and 100 mM NaCl at pH 7.0.  Thiazole orange was  
excited at 501 nm and the emission was recorded at 534 nm. Each entry represents an 
average of three experiments. 
 
bound intercalator probe upon the addition of the ligand of the interest. It has been shown 
that both the sequence selectivity as well the affinity of the ligand molecule towards 
certain nucleic acids can be obtained reliably. We have previously shown that by using  
this technique, qualitative affinity of ligands towards certain nucleic acids can be reliably 
obtained,
24, 25
 as supported by other spectroscopic / calorimetric techniques.
26-28
 In a 




choice, (usually ethidium bromide or thiazole orange) which is followed by the 
fluorescence excitation of intercalator at the appropriate wavelength. The resulting 
fluorescence emission spectrum is recorded.  This is followed by the addition of the 
ligand of interest at the desired ratio. The resulting emission spectrum is recorded and the 
change is plotted. The rank obtained provides us with the relative affinity of the ligands 
towards that particular nucleic acid target. 
In our experiments, we chose a dodecamer DNA duplex d(CGCAAATTTGCG)2 
as our nucleic acid to be probed for relative affinity of the synthesized ligands towards 
this DNA duplex. The choice of this DNA duplex was made because the binding of 
bisbenzimidazoles to this sequence is well established.
29, 309
 The nucleic acid solution was 
mixed with thiazole orange and the DNA - TO complex fluorescence emission spectrum 
was recorded. The ligands were added at 1:1 ratio and the fluorescence emission 
spectrum was recorded again. The change in fluorescence emission was plotted to obtain 
the relative affinity of these ligands towards the DNA duplex. As shown in Figure 4.3, 
the bisbenzimidazoles showed better displacement of the bound TO than 
monobenzimidazoles or triazolyl derivatized benzimidazoles. Additionally, 
bisbenzimidazoles with shorter alkyl linkers showed better displacement of the 
intercalator probe than the same with longer alkyl linkers, and were almost similar to 
displacement shown by monobenzimidazoles or triazolyl benzimidazoles. These results 
suggest that a bisbenzimidazole moiety is required for an effective binding to DNA 
duplex, and that variations at the phenolic end of the bisbenzimidazoles may also impact 




Antibacterial Effect of the Studied Ligands Shows Correlation with DNA Binding Ability 
(Experiments were performed in the laboratory of Prof. Xiuping Xiang, Clemson 
University). Compounds belonging to the bisbenzimidazole class of ligands have shown 
profound antibacterial effect against a variety of strains, which include methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus 
Faecalis.
31, 32
 Hoechst 33258 has been shown to have antimicrobial activity against 
Pneumocystis carinii f. sp. muris, Candida albicans and Candida dubliniensis.
17
 Hoechst 
33258 has also been shown to inhibit self splicing of group I introns.
33
 Binding of 
Hoechst 33258 and related compounds to RNAs has also been reported.
34
 Thus, from the 
point of entry into the cellular membrane, Hoechst 33258 comes across a variety of 
targets until it enters into the nucleus. Despite significant research in this area, there is not 
much consensus over its mechanism of cytotoxic effects. Therefore, we evaluated the 
antibacterial effect of these novel Hoechst 33258 based mono and bisbenzimidazole 
ligands against both gram positive and gram negative strains, as listed in Table 4.2. In 
cases where a sharp inflection in the bacterial growth was not observed, the MIC is given 
as a range of values.  Nearly all monobenzimidazoles (including the triazolyl derivatives)  
displayed similar MIC values (16-32 g/mL) against Staphylococcus aureus ATCC 
29213 and Staphylococcus aureus  ATCC 33591.However, bisbenzimidazoles (Hoechst 
33258, Hoechst 33342, DPA 151, DPA 152, and DPA 154) showed much lower MIC 
values against the same strains (2-4 g/ mL).  Two of the bisbenzimidazoles, DPA 153 
and DPA 157, showed relatively higher MIC values (16 g / mL and 16-32 g / mL 




Table 4.2. Minimal Inhibitory Concentrations (MIC) of the studied ligands against 




























2-4 2-4 8-16 16 8 
16-32 
DPA 101 ≥ 32 16-32 16 16 16 16-32 
DPA 102 ≥ 32 16-32 16 16 16 16-32 
DPA 103 16-32 16-32 16 16 16 16-32 
DPA 105 16-32 16 16 16 16 16-32 
DPA 108 16-32 16 16 16 16 16-32 
DPA 112 16-32 16-32 16 16 16 16-32 
DPA 151 2-4 2-4 8 16 8 16-32 
DPA 152 2-4 2-4 8-16 16 8-16 4 
DPA 153 16 16 16 16 8-16 16-32 
DPA 154 2-4 2-4 8-16 16 8-16 8 
DPA 157 16-32 16-32 16 16 16 16-32 
DPA 851 16-32 16-32 16 16 16 16 
DPA 852 16-32 16-32 16 16 16 16 
DPA 854 16-32 16-32 16 16 16 16-32 
DPA 855 16-32 16-32 16 16 16 16-32 
DPA 856 16-32 16-32 16 16 16 16-32 
DPA 857 >32 >32 >32 >32 >32 >32 
DPA 858 >32 >32 >32 >32 >32 >32 
          
 
  As described in the aforementioned sections, these two ligands also showed poor DNA 
binding ability, as evident from FID and thermal denaturation experiments. These two 
ligands have a common feature in their chemical structure, which is the presence of long 
alkyl linker. The presence of the long aliphatic group at the terminal renders the molecule 




cellular membrane. Therefore, these results demonstrate that antibacterial activity of 
ligands against Staphylococcus aureus arise from their DNA binding abilities.  
We also tested these ligands against the gram negative bacterial strains of 
Escherichia Coli ATCC 25922 and Escherichia Coli K12. The MIC values were 8-16 g 
/ mL for most of the ligands. These values are similar to the MIC values obtained from -
lactamase antibiotics, such as carbenicillin and cephalothin, against Escherichia Coli 
ATCC 25922.
35
 However, aminoglycosides display much better antibacterial activity 
against the same.
35
 In contrast to the trend obtained with Staphylococcus aureus (which 
showed better antibacterial activities of bisbenzimidazoles than monobenzimidazoles), 
we did not observe any distinct differentiation between the MIC values obtained for 
mono and bisbenzimidazoles. These results suggest that antibacterial effect in gram 
negative bacteria is not elicited by their DNA binding abilities, and is likely mediated by 
some other cellular binding events. This may include RNA binding, as recent studies 
have indicated Hoechst 33258 binding to RNA targets. The MIC values obtained against 
another gram negative strain Pseudomonas aeruginosa ATCC 27853 showed similar 
MIC values, (16 g/mL) as observed with Escherichia Coli ATCC 25922 and 
Escherichia Coli K12 for majority of the ligands tested. The MIC values  again did not  
showany distinction between monobenzimidazoles and bisbenzimidazole classes of 
ligands. These results further corroborated the lack of distinction between 
monobenzimidazoles and bisbenzimidazoles, as obtained with Escherichia Coli ATCC 
25922.  Hence, we believe that these ligands inhibit the growth of the gram negative 




To ascertain the selectivity of these ligands between the gram positive and gram 
negative bacteria, we tested another gram positive strain from vancomycin resistant 
Enterococcus faecalis ATCC 29212. Similar to our observations with Staphylococcus 
aureus, we obtained lower MIC values obtained with certain bisbenzimidazoles (DPA 
152, DPA 154) which were clearly much lower than other bisbenzimidazoles and 
monobenzimidazoles tested. These bisbenzimidazoles have similar DNA affinities as 
those obtained with Hoechst 33258 and Hoechst 33342. The higher MIC values obtained 
with Hoechst 33258 and Hoechst 33342 may likely be explained because of their poor 
cellular uptake in comparison to better DPA 152 and DPA 154, which can have better 
cellular permeability due to the alkyl chains present at their phenolic ends. We have 
obtained a correlation between the DNA binding ability and the length of the alkyl linker, 
which clearly shows that beyond a certain length of linker, the bisbenzimidazole starts 
losing its binding to B-DNA (as discussed in chapter 3). Overall, these results show that 
bisbenzimidazoles bind better to gram positive bacteria than gram negative bacteria and 
their inhibitory effects are related to their DNA binding strength in gram positive strains. 
Topoisomerase I Inhibition Assay (Experiments were performed in the laboratory of Prof. 
Fenfei Leng, Florida International University). Enzymes, such as topoisomerase I and 
gyrase, are potential targets of antibacterial compounds.
36, 37
 In this study, we tested the 
inhibitory effects of the newly synthesized compounds against these two enzymes. 
Although these new compounds were not found to greatly inhibit the activities of DNA 








































































Figure 4.4. A bar graph plot showing the results obtained from the topoisomerase I 
inhibition assay. Each data point represents an average of three experiments. 
 
activity of E. coli DNA topoisomerase I (Figure 4.4). Bisbenzimidazoles are well known 
to inhibit the activity of the nuclear enzyme topoisomerase I, as well as to act as 
helicase.
38
 Terbenzimidazoles have also been shown to poison topoisomerase I activity, 
and it is believed to be an outcome of established binding of these ligands in the minor 
groove of the DNA.
39, 40
 However, DNA binding is not a sole criterion for effective 
topoisomerase inhibition since a DNA non binder camptothecin
41
 is a well known DNA 
topoisomerase I poison.
42
 The effective antibacterial activity of bisbenzimidazoles 






Figure 4.5. Inhibitory activity of DPA 151 against E. coli DNA topoisomerase I. (A) The 
inhibition effects of DPA 151 against E. coli ENA topoisomerase I. The E. coli DNA 
topoisomerase I inhibition assays were performed as described under Materials and 
Methods. The plasmid DNA molecules were isolated and subjected to 1% agarose gel 
electrophoresis in the absence of chloroquine. Lanes 1 to 11 contain 0, 1.0, 1.5, 2.0, 3.0, 
4.0, 5.0 6.0, 7.0, 8.0, 10 µM of DPA151 respectively. (B) The quantification analysis of 
the inhibitory activities of DPA 151 against E. coli DNA topoisomerase I. The values of 
IC50 were obtained from these analyses. Standard deviation was obtained from three 
independent determinations. (scDNA = Super coiled DNA). 
 
The results obtained are displayed in Figure 4.4 and Figure 4.5 (Please see Appendix III 
Figures S15-S17 for additional images). In this assay, the relaxation of supercoiled 
plasmid pBAD-GFPuv was observed in the presence of various ligands (Figure 4.5a). 
The supercoiled DNA was mixed with E.Coli topoisomerase I and a specific 
concentration of the test ligand in an appropriate buffer (see Materials and Methods for 




of concentrations can be prepared and run simultaneously on a gel to observe the effect of 
the ligands on the relaxation of supercoiled DNA. The amount of remaining supercoiled  
DNA (after the assay was performed) was quantified using KODAK 1D image analysis 
software. The IC50 was calculated, as the concentration of the ligand at which 50 % of 
DNA was still in the supercoiled state. This can be done by quantifying the amount of 
supercoiled DNA remaining at each concentration of the test ligand under study and 
plotting them with respect to the concentration of the test ligand. The sigmoidal pattern 
generated can then be fit to obtain IC50 values (Figure 4.5b). All bisbenzimidazole 
molecules showed much better poisoning (requiring < 7 M ligand) of the topoisomerase 
I than Hoechst 33258 or Hoechst 33342 (Figure 4.4). This could be an outcome of better 
membrane permeability of these novel ligands.  
The DNA topoisomerase I inhibition also appeared to be unrelated to the DNA binding 
affinity of these ligands. For example, the thermal stabilization afforded by DPA 157 was 
only ~ 2 

C, while the same for DPA 151 was ~ 24 

C, but both show nearly similar 
concentrations required to inhibit DNA topoisomerase I. It may, therefore, be concluded 
that a more lipophilic bisbenzimidazole would likely be more effective in the poisoning 
of DNA topoisomerase I. 
Summary and Conclusions 
  Benzimidazoles derived from Hoechst 33258 are an important class of molecules 
that are effective against wide range of biological targets.  After being established as an 
AT-rich DNA minor groove binder, there has been an increasing interest in determining 




location of binding of these ligands may help answer long standing questions related to 
its biological activity as it is becoming increasingly clearer that DNA is not its sole target.  
   We have previously shown that by taking advantage of its high affinity to B-
DNA, these molecules can be used as molecular “anchors” where weakly binding 
aminoglycosides can be placed in the major groove.
43
 Moreover, these molecules can 
easily carry charged molecules such as aminoglycosides in the cell nucleus (unpublished 
results).  Therefore, compounds of this class are of immense value towards the molecular 
recognition of nucleic acids. In this study, we have demonstrated that Hoechst 33258 like 
monobenzimidazoles are much weaker DNA binding agents than their bisbenzimidazole 
counterparts, as revealed from their FID and UV thermal denaturation experiments. 
Bisbenzimidazoles displayed superior antibacterial inhibition of gram positive bacteria 
than monobenzimidazoles, and their antibacterial effect to gram negative bacteria seemed 
to be unrelated to their DNA binding strength. The DNA topoisomerase I poisoning 
strength of bisbenzimidazoles were unrelated to their DNA binding strength, and were 
likely to be driven by their increased lipophilicity. These studies reveal the requirement 
of a bisbenzimidazole unit for effective DNA of Hoechst 33258 like molecules. 
Additionally, the presence of an alkyne end at the terminal of these bisbenzimidazole 
may be useful in click chemistry based bioconjugation reactions of these 
bisbenzimidazoles. 
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INTERCALATIVE BINDING OF BISBENZIMIDAZOLE UNIT OF HOECHST 33258 
DERIVATIVES IN RNA DUPLEX 
Introduction 
The study of small molecule binding to nucleic acid targets has been one of the 
most important areas in the development of novel drugs. Recognition of DNA or RNA 
targets by small molecule has led to the discovery of many clinically useful compounds.
1
 
Understanding the mode and mechanism of a ligand binding to a nucleic acid is thus 
important for the development of more potent drugs (and also for the understanding of 
many undesired effects). Noncovalent binding of small molecules to nucleic acids 
primarily occurs in three locations: the major groove, the minor groove and between the 
base pairs (intercalation). However some natural products that contain more than one 
moiety capable of nucleic acid binding can bind dually ((Figure 5.1).
2
 Taking guidance 
from nature, molecules can be engineered for multiple recognition of nucleic acids.
3
 
However, binding of these small molecules is highly dependent on the nucleic acid 
shape/structure/composition. For example, Hoechst 33258 (Figure 5.1) is known to bind 
to AT– rich duplex DNA sequences in the minor groove while the same has been 
proposed to bind to GC-rich DNA sequences via intercalation.
4
 Similarly another small 
molecule berenil (Figure 5.1) is known to bind to DNA sequences via the minor groove 





































Figure 5.1. Structures of compounds that interact with the nucleic acids at more than one 
sites/ways. 
 
Thus study of the ligand binding to various types of nucleic acids is important in finding 
the features that dictate the mode the binding. 
Hoechst 33258 is a bisbenzimidazole that is well established for its binding to 
AT-rich DNA duplexes.
6
 Structural studies have shown that it binds snugly in the minor 
groove of DNA using a variety of molecular forces.
7-10
 This sequence specific binding 
has been determined to have nanomolar affinities using spectroscopic techniques.
6, 11
 
Calorimetric insights into the binding of Hoechst 33258 to a B-DNA dodecamer have 
shown that the binding of Hoechst 33258 leads to negative heat capacity change
11
 and 
alternation in the hydration pattern of the DNA duplex
12
 has been suggested to play a key 
role in the binding. A number of different approaches have been initiated in an effort to 
increase the DNA binding of Hoechst 33258 and enhance cellular permeability. These 
have included hetero atom substitutions in the bisbenzimidazole core,
13




various functional groups on the aromatic rings of the benzimidazoles,
14
 extension of 
benzimidazoles to terbenzimidazoles
15
 and alkyl chain substitutions at the phenolic end.
16
 
A key feature of Hoechst 33258/Hoechst 33342 has been its easy cellular entry and 
nuclear localization. 
Efforts on the synthesis of Hoechst 33258 based small molecule nucleic acid 
binding agents have been centered on the discovery of more potent DNA binders. The 










 as well as triple recognition agents
3, 23
. These 
conjugates have resulted in dual/multiple recognition of the DNA duplex leading to 
recognition of higher number of base pairs and enhanced affinity.
23
 The apparent lack of 
interest to target RNA structures using Hoechst 33258 has been inherent to its weak 
binding to regular RNA duplex structures as reflected by poor thermal stabilization and 
very small fluorescence emission enhancement upon binding to RNA. However, RNA is 
structurally quite diverse in comparison to DNA and can adopt many unusual structures 
in the form of loops, bulges, and knots that lead to the creation of binding sites that are 
targeted by a specific class of compounds. One such example has been the binding of 




Hoechst 33258 has also been reported to bind to some RNA structures of 
biological relevance. Binding studies to a model sequence representing the trans 










































































Figure 5.2. Chemical structures of the ligands used in the study. 
 
Hoechst 33258 binds in the bulged regions of the TAR leading to enhanced thermal 
stabilization of the native duplex.
25
 Unlike the minor groove binding in DNA duplexes, 
Hoechst 33258 binds to the TAR RNA in an intercalative mode where the chromophore 
was found to be oriented nearly perpendicular to the helical axis.
26
 Binding of Hoechst 
33258 to Watson-Crick paired A-form and Hoogsteen paired H
L
-form of the RNA duplex 
poly(CG) has been found to bring conformational changes.
27




looked at the antibacterial properties of Hoechst 33258 and related compounds.
28
 
Therefore, the study of Hoechst 33258 and its derivatives binding to RNA is important to 
understand the desired and undesired effects of ligand binding in the cell. 
Towards this end we decided to synthesize novel neomycin-Hoechst 33258 
conjugates (Figure 5.2) to look into the RNA binding. Previous studies in our laboratory 
have shown that by conjugating Hoechst 33258 to neomycin, B-DNA duplex can be 
targeted in a dual binding mode simultaneously through the major and minor groove 
binding.
29
 It is interesting to note here that neomycin binding to B-DNA duplex is 
moderate,    (Ka ~10
5
    M
-1
) and the dual binding is anchored, in part, by the high affinity 
binding of Hoechst 33258 in the minor groove of the DNA duplex.  This dual binding is 
reflected by remarkable increase in the thermal stabilization of the DNA duplex as well 
as enhanced binding affinity.
22, 30
 This dual binding has, however, been dependent on the 
length of the linker joining the two binding moieties.
30
  
We, therefore, hypothesized if the reverse could be true where neomycin (whose 
high affinity binding to RNA structures is well established)
31
 can be used as an anchor to 
direct the RNA binding of Hoechst 33258. In this report, we present the binding of novel 
neomycin-Hoechst 33258 conjugates to RNA duplex. To look into the linker length 
effects to the RNA binding, a series of compounds were tested.  
In this series, the length of the linker was varied from 4 to 22 atoms. Following 






Materials and Methods 
General Methods.  Di-tert-butyl dicarbonate (Boc anhydride) was purchased from 
Advanced ChemTech (Louisville, KY).  Neomycin was purchased from MP Biomedicals 
(Solon, OH). All other chemicals were purchased from Aldrich (St. Louis, MO) or Acros 
Organics (Pittsburgh, PA) and used without further purification.  All solvents were 
purchased from VWR (West Chester, PA).   Silica gel (32-65 M mesh size) was 
purchased from Sorbtech (Atlanta, GA).   
1
H NMR and 
13
C NMR spectra were recorded 
on a Bruker Avance (300/500 MHz) Spectrometer. Chemical shifts are given in ppm and 




C NMR). MS (MALDI-TOF) spectra 
were collected using a Bruker Microflex mass spectrometer. Ultra Violet (UV) spectra 
were collected on a Varian (Walnut Creek CA) Cary 100 Bio UV-Vis spectrophotometer 
equipped with a thermoelectrically controlled 12-cell holder.   FID experiments were 
performed on Tecan Genois (Austria) fluorimeter equipped with a 96 well plate reader. 
Nucleic Acids. Poly (rA.rU) was purchased from The Midland Certified Reagent 
Company, Inc. (Midland, Texas). The dodecamer RNA oligonucleotide 
r(CGCAAAUUUGCG) was purchased from IDT (Coraville, IA) and used without further 
purification . The nucleic acid concentrations were determined using the extinction 
coefficients provided by the supplier. Nucleic acid solutions were prepared in buffer 10 
mM sodium cacodylate, 0.1 mM EDTA and 100 mM NaCl at pH 7.0. The nucleic acid 
solutions were prepared by heating them at 95 

C for 15 minutes and then slowly 




formation was checked by UV thermal denaturation experiments. The stock solution was 
stored at 4 

C and diluted to desired concentrations as required. 
Fluorescencent Intercalator Displacement (FID) Experiments.  Fluorescence experiments 
were performed on Tecan Genois (Austria) instrument equipped with a 96 well plate 
reader. All experiments were performed at room temperature (21-23 

C).  The 
experiments were performed in the 96 well plates as triplicates. The RNA solution was 
prepared at 1 M/duplex in buffer 10 mM sodium cacodylate, 0.1 mM EDTA, and 100 
mM NaCl at pH 7.0. The nucleic acid solution was then mixed with thiazole orange (TO) 
at a concentration of 2 M. The ligand was added to the RNA / TO complex solution at 
1:1 ratio and followed by a five minute equilibration time before the fluorescence 
spectrum was recorded. The change in the fluorescence was plotted as - 
% fluorescence change = (F/IF) × 100 
where, F = Change in fluorescence upon ligand addition and IF = Initial fluorescence of 
the DNA- TO complex 
Circular Dichroism (CD) Spectroscopy. CD experiments were performed in a 3.0 mL 
quartz cell on a Jasco J-810 spectropolarimeter equipped with a thermo-electrically 
controlled cell holder. The experiments were performed at 40 M/bp RNA concentration 
in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. The 
ligands were prepared as concentrated (1-3 mM) stock solutions and added to RNA 
duplex solution serially in small aliquots and equilibrated for five minutes before the CD 
scan was taken. Each CD spectrum is an average of three scans. All experiments were 






Linear Dichrosim (LD) Experiments. LD spectra were measured on a Jasco J-810 
spectropolarimeter equipped with the linear dichroism accessory. Orientation of the 
ligand/nucleic acid samples was achieved in a microcouette flow cell with an outer 
rotating cylinder. The experimental path length was 0.3 cm.  The experimental data 
obtained was   normalized to a 1 cm path length.  The RNA solution (1 mM/bp) was 
rotated at a speed of 3000 rpm for five minutes before the scan was taken. Each scan 
represents an average of three readings. To obtain the LD spectrum in the presence of 
ligands, the RNA solution (1 mM/bp) was mixed with the ligands at nucleic acid/ligand 
ratio 10. The angle of ligand orientation was calculated using methods described in the 
literature.
32-34
 All experiments were performed at room temperature (21-23 

C) in buffer 
10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. 
UV-vis Absorption Studies. UV-vis absorption studies were performed on a Cary 1 UV-
vis spectropolarimeter (Walnut creek, CA). The ligand sample (5 M) was scanned 
between the 500-200 nm wavelength for absorption. To this, RNA sample was added to 
achieve 1:1 ligand to RNA duplex ratio and absorption was recorded. The data was 
recorded every 1 nm. The experiments were performed in buffer in buffer 10 mM sodium 
cacodylate, 0.5 mM EDTA, 100 mM NaCl at pH 7.0 at room temperature (21-23 

C). 
Ultra violet (UV) Thermal Denaturation Experiments.    All UV spectra were obtained on 
a 12 cell holder Cary 1E UV-Vis spectrophotometer equipped with temperature 
controller. Quartz cells with 1 cm path length were used for all the experiments. 
Spectrophotometer stability and wavelength alignment were checked prior to initiation of 




diluting the stock sample. The melting of RNA in the absence and presence of the ligand 
was carried at a heating rate of 0.2 °C / min.   Samples were brought back to 20 °C after 
the experiment.   All UV melting experiments were monitored at 260 nm.   For the Tm 
determinations, derivatives were used.   Data points were recorded every 1.0 °C.  The 
RNA concentration was 15 M/base pair while the ligand concentration was varied.  
FID Titration Experiments. FID titration experiment was conducted on a Photon 
Tecchnology International (Lawrenceville, NJ) instrument equipped with the temperature 
controller. The RNA solution (0.25 M/duplex) was added with thizaole orange (1.5 M) 
solution. The RNA- thizaole orange complex was excited at 501 nm and the emission 
spectrum was recorded between 510-750 nm. Ligand was added successively in small 
aliquots until no more changes in the fluorescence emission spectrum were observed. The 
resulting emission profile was then plotted to obtain binding stoichiometry and analyzed 




Results and Discussion. 
 Design and Synthesis of Ligands. Covalent linking of Hoechst 33258 to other binding 
moieties have relied primarily on the coupling of a Hoechst 33258 derivative  containing  





 resulting in the formation of amide or thiourea linkages. We, however, 
thought of derivatizing Hoechst 33258 with varying length of the linker in such a way 
that they terminated with an alkyne.  Having alkyne at the terminal of these Hoechst 
33258 derivatives makes those useful for click chemistry applications.
36,37




terminated Hoechst 33258 derivatives could be potentially useful in template directed 
click chemistry reaction in vivo. The synthesis of a series of alkyne terminated Hoechst 
33258 derivatives DPA 151-DPA 159 has been described previously (Chapter 3). 
Coupling of DPA 151-DPA159 to Boc protected neomycin azide (prepared in three steps 
from neomycin sulfate)
22
 resulted in the synthesis of Boc protected neomycin-Hoechst 
33258 conjugates with poor yields in most cases (~20 % as determined from the recovery 
of neomycin azide from the reaction mixture after column purification). However the 
purification of Boc protected neomycin-Hoechst 33258 using traditional purification 
methods such as column chromatography from alkyne terminated Hoechst 33258 was 
extremely tedious due to highly polar nature of the starting material alkyne and the Boc 
protected neomycin-Hoechst 33258 conjugates. In contrast, an analogous ligand DPA 
101 (see chapter 4 for chemical structure) undergoes facile click chemistry reaction with 
Boc protected neomycin azide (80-85 % isolated yield). The differences in the reactivity 
of bisbenzimidazoles (DPA 151-DPA 159) and monobenzimidazoles (DPA 101) may 
likely be the outcome of differences in coordination of copper (I) to mono and 
bisbenzimidazoles as well as autocatalytic properties of the monobenzimidazoles towards 
click chemistry reactions.
38
 We countered the click chemistry reactivity as well as 
purification problems by simple derivatization of the bisbenzimidazoles (DPA 151-DPA 
159) to their diBoc derivatives. Introduction of the diBoc functionality on the 
bisbenzimidazoles results in two apparent advantages. These bisbenzimidazoles become 





















































chemistry reactions give better yields (75-80 % isolated yields) and their purification 
becomes much easier using column chromatography. As shown in Scheme 5.1, the 
bisbenzimidazoles were treated with sodium hydride in dry THF to deprotonate the imino 
protons of the bisbenzimidazoles. (Boc)2O was then introduced to the reaction mixture in 
slight excess and the reaction mixture was stirred at room temperature for 6-12h . This 










































































Scheme 5.2. Reagents and conditions (a) CuSO4, sodium ascorbate , H2O,   C2H5OH, rt, 






compositions as determined by NMR and MALDI-TOF (see appendix IV) but travel with 
different retention factors as indicated by the thin layer chromatography experiments. 
These two products could possibly be the rotamers where the Boc groups just flip their 
orientations but are oriented in trans fashion. The possibility of the two Boc groups 
oriented in a cis fashion is highly unlikely because of the steric bulk created by the two 
Boc groups. We then utilized the faster moving rotamer of all diBoc derivatives of DPA 
151-DPA 159 for click chemistry applications. The diBoc Hoechst 33258 derivatives 
were then reacted with Boc protected neomycin azide using CuSO4 and sodium ascorbate 
to generate Cu (I) in situ in water-ethanol mixture as the reaction solvent. This resulted in 
the formation of Boc protected neomycin-Hoechst 33258 conjugates. The Boc proetected 
neomycin-Hoechst conjugates were then deprotected in the presence of strong acid 
(trifluoroacetic acid) to yield the desired conjugates DPA 165-DPA 173 (Scheme 5.2). 
Fluoroscence Intercalator Displacement (FID) Experiments. FID assay was developed 
nearly a decade ago in Boger laboratory
35
 in an attempt to rapidly screen nucleic acid 
binders. This assay also allows determination of association constants in an indirect way 
which yields association constant values in close agreement with other rigorous and 
independent methods.
39
  FID assay utilizes a simple principle in which the fluorescence 
changes in the emission spectrum of an intercalator bound to a nucleic acid is monitored 
with respect to the interaction of a ligand under investigation.  
The changes in the fluorescence emission properties of the nucleic acid bound 
intercalator can then be utilized to obtain sequence selectivity, binding stoichiometry, or 









Figure 5.3.  A plot showing the screening of conjugates DPA 165-173 with RNA duplex 
r(CGCAAAUUUGCG)2 using the FID assay. The RNA concentration was 1 M/duplex 
while ethidium bromide concentration was 6 M. The experiments were performed in 








In our studies, we used ethidium bromide (EtBr) as the intercalator. EtBr was 
mixed with a dodecamer RNA duplex followed by addition of various ligands at 1:1 
duplex:ligand ratio. We chose the RNA duplex r(CGCAAAUUUGCG)2  as its DNA 
equivalent d(CGCAAATTTGCG)2 is well established for Hoechst 33258 binding. The 




change with respect to the linker lengths as indicated on the X-axis of each bar in Figure 
5.3. The changes afforded in the fluorescence emission provide means to differentiate the 
ligands of higher affinity from weaker binders. These results, however, are by no means a 
quantitative analysis of the binding, yet they help in detecting the higher affinity binding 
ligands. As shown in Figure 5.3, nearly all conjugates showed improved displacement of 
the intercalator probe (EtBr in our case) in comparison to neomycin or Hoechst 33258 
showing that these conjugates result in a better binder when conjugated together vis a vis 
their binding to the same duplex target independently. These conjugates have been 
further sub classified according to the nature of the linkers present on each conjugate. 
The conjugates shown in the black represent linkers that have only one oxygen atom on 
them and the ones shown in blue have two oxygen atoms on them, while the one shown 
in orange has seven oxygen atoms on them. The differing content of oxygen atoms on the 
linkers alters the hydrophobic effect experienced by these linkers, as determined by our 
previous study (Chapter 3). One trend that has emerged from this displacement assay is 
that increasing the length (higher than ten atoms) of the linker leads to decreased change 
in fluorescence. However, as stated earlier, such changes in the fluorescence do not shed 
much light on the quantitative nature of the binding as fluorescence quenching can also 
be impacted by other factors. We picked some of the best displacers in each series of 
ligand for further analysis. 
Circular Dichroism Experiments. Circular dichroism (CD) has been utilized to study 





































































































































































Figure 5.4.  CD titration of Poly r(A).r(U) with (a) Hoechst 33258 (b) neomycin (c)  
DPA 166 in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 
7.0 (T = 25 

C).  A concentrated solution of ligand solution was added serially to a 
solution of Poly r(A).r(U) (40 M/ bp) after five minute  equilibration time.  Each 
measurement represents an average of two scans. The plots (d-f) show the binding site 
Hoechst 33258, neomycin and DPA 166 respectively. rbd is the ratio of RNA base pairs 
per drug molecule 
 
such as nucleic acids have characteristic CD signatures which can be used to analyze the 
conformational changes associated with the binding reaction and can be used to obtain 
binding stoichiometry as well as binding constants. For example, the maximum CD 




acids are characterized by their maximum absorption around 260 nm. In opposition, 
antiparallel DNA quadruplex displays their absorption maximum at 295 nm.  In addition 
to this, as a consequence of nucleic acid binding, chirality can be induced in small 
molecules, which results in an induced CD in the chromophore absorption region of the 
ligand. DNA minor groove binders result in positive induced CD while intercalators 
result in negative or small induced CD (close to zero values) changes.
32
 
Therefore, we used CD titrations experiments to allow us to determine the binding 
site size (as denoted by rbd which is an abbreviation for ratio of base pairs of RNA per 
drug molecule) of some of the best binders, as well as to have some insight into the 
nature of the binding. Figures 5.4a-c shows the CD titration profiles of neomycin, 
Hoechst 33258 and DPA 166 respectively, while Figures 5.4d-f shows the binding 
stoichiometry determined from these titrations. As shown in Figure 5.4a, in the absence 
of ligand, CD spectrum shows the maximum absorption at 263 nm which reflects the 
typical A-form structure of the poly (rA.rU) RNA duplex. However, as increasing 
amount of the ligand (Hoechst 33258) is added, the intensity of the absorption decreases 
at 263 nm while it shows induced CD in 320-380 nm region. As stated earlier, these 
induced CD changes indicate the interaction of the ligand with the host RNA duplex.The 
changes in CD response upon binding of a ligand (Hoechst 33258, neomycin and DPA 
166 in the present study) can be used to obtain binding site size. This can be obtained by 
plotting the changes in the CD signal with respect to the amount of ligand added. The 
inflection point/s in the plot (Figures 5.4d-f) reveals the binding site size which has been 




Hoechst 33258 binding to Poly r(A).r(U) duplex shows that it covers five base pairs 
during the binding reaction. This is in contrast to their binding site size for polymeric B-
DNA duplex which has been shown to have a binding site size of ~10 base pairs.
30
  
However the induced CD shows changes in both negative (332 nm) and positive (371 
nm) direction. This bidirectional induced CD is very similar to changes brought about by 
carbocyanine dyes which were proposed to bind in a mixed groove binding/stacking 
fashion.
44
 We therefore believe that Hoechst 33258 binds in a similar mixed groove 
binding/intercalation mode leading to the excitonic nature of the induced CD. The 
changes in the CD signal at Hoechst 33258 to DNA and RNA also suggest difference in 
the binding modes to these nucleic acids. We then performed CD titration experiment of 
poly (rA.rU) with neomycin (Figure 5.4c). Binding of neomycin led to diminished CD 
intensity at 266 nm. The changes in the CD intensity at this wavelength allowed us to 
determine the binding site size of the neomycin interaction. As shown in Figure 5.4d, the 
plot of CD intensity change at 266 nm with the RNA:ligand ratio shows an inflection 
point at ~8 base pairs. This binding site size is same for neomycin as determined by us 
previously, while under similar conditions.
31
  
Following this, we performed CD titration of poly (rA.rU) with DPA 166.  The 
CD titration draws immediate attention as reflected by the changes in the CD intensity at 
266 nm and 339 nm. As shown in Figure 5.4e, the changes in the CD signal are much 
pronounced at 266 nm than the same induced by either neomycin or Hoechst 33258 
alone.  Furthermore, the induced CD at 339 nm is unidirectional and negative. This is 




bound to the same RNA duplex. Strong negative induced CD signals are typically seen 
when ligands bind in the intercalating fashion. The more pronounced changes by the 
conjugate DPA 166 show that neomycin and Hoechst 33258, when bound together, cause 
more structural changes, and also change the binding of the Hoechst 33258 binding from 
a possible mixed groove binding-intercalation mode to an exclusive intercalative mode 
(whose analysis is discussed in the next section). This shows that molecules bind in 
synergy with each other. In DPA 166 binding, the changed mode of Hoechst 33258 
binding could arise of some of the possible changes in the RNA duplex structure. As 
discussed earlier, Hoechst 33258 binding to the poly rA.rU duplex by itself is very weak 
while neomycin binds to the same duplex with high affinity. It has been previously 
shown that TATA binding proteins opens the minor groove of DNA.
45, 46
 Therefore, it is 
quite reasonable to suggest the more dominant partner of the conjugate DPA 166, 
neomycin, and leads to opening of the minor groove by binding in the major groove of 
the RNA duplex thereby making intercalation facile for Hoechst 33258 moiety of the 
conjugate. Clearly the conjugate results in better binding than the individual binding 
units, as suggested by the FID assay discussed in the previous section. 
Linear Dichroism (LD) Experiments.  To ascertain the binding mode of Hoechst 33258 
moiety of the conjugate, we performed LD experiments. LD has been previously utilized 
to determine the binding mode of many established and novel ligands.
47-51
 One of the 
drawbacks of LD had been the need of large amounts of nucleic acid and ligand samples. 
However these problems have been circumvented with the development of microvolume 
couette flow LD.
52
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Figure 5.5. LD spectrum of poly rA.rU in the absence (black line) and presence of DPA 
166 (purple line). The RNA duplex (1mM/bp) was mixed with DPA 166 at rbd 10 before 
the scan was taken for the RNA-ligand complex. The experiments were performed in 
buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0 at room 
temperature. Each spectrum is an average of three scans. 
 
chromophore with respect to the helical axis of the RNA duplex.  Figure 5.5 shows a 
representative LD spectrum of the poly (rA.rU) duplex in the absence and presence of 
DPA 166. The LD spectrum of RNA duplex shows negative absorption at 260 nm which 
is reflective of the nearly perpendicular orientation of RNA base pairs with respect to the 
helical axis. In the presence of DPA 166, changes at both 260 nm and 337 nm are worthy 
of note. As seen in Figure 5.5, the absorption at 260 nm becomes more negative upon 
ligand binding which is reflective of the intercalative binding which leads to lengthening 
of the helix as has been observed with classic DNA intercalators, such as ethidium 
bromide.
52




centered at 348 nm. The negative induced LD is observed with intercalating ligands.  We 
also performed the LD experiments with other conjugates used in this study. Similar to 
DPA 166, all other conjugates showed negative induced LD in the chromophore 
absorption region indicating the similarity of the binding mode of all these conjugates 
(see appendix IV, Figure S1). We then used the induced LD values to calculate the angle 
at which Hoechst 33258 is bound to the RNA duplex with respect to the helical axis as 
described by Norden.
51




Figure 5.6. (a) A pictorial representation of Hoechst 33258 intercalation into RNA 
duplex. Hoechst 33258 moiety has been shown in red while linker and neomycin have 
been shown in black and blue respectively (b) Pictorial representation of enhanced 
intercalation of Hoechst 33258 with increasing linker length of the conjugates. As shown 
in the picture, with the increase in the linker length (4-22 atoms) between neomycin and 







 The angles shown in Table 5.1 show that Hoechst 33258 binds in the intercalative 
fashion for all conjugates nearly matching with angles at which RNA base pairs are 




 for  DPA 173.   The effect of varying the linker length can 
be easily observed in Table 5.1. Increasing the linker spacing from 4 (DPA 165) to 21 
(DPA 173) results in enhancement of intercalation by the Hoechst 33258 moiety of the 
conjugate (Figure 5.6). The enhancement in the extent of intercalation could likely arise 
from the flexibility allowed by the conjugates having the longer linkers to the binding of 
Hoechst 33258 moiety. 
 
Table 5.1.  A table listing the angles of the bound Hoechst 33258 moiety of the 
neomycin-Hoechst 33258 conjugates DPA 165-DPA 173 when bound to the poly (rA.rU) 
duplex. 
 









DPA 166 7 65.6 
DPA 168 9 65.7 
DPA 169 11 65.0 
DPA 167 12 70.7 
DPA 170 13 66.8 
DPA 171 15 67.1 
DPA 172 17 69.5 
DPA 173 22 73.9 







UV Thermal Denaturation Experiments. UV thermal denaturation experiments were 
performed to observe the thermal stabilizations afforded by these conjugates to the poly 
(rA.rU) duplex. As shown in Figure 5.7, in the absence of ligand, poly rA.rU melts at 
58.1 

 C as reflected by the sharp hyperchroism displayed by the RNA bases as a result of 
melting of the duplex. In the presence of Hoechst 33258, only a 0.4 

C thermal 
stabilization was seen while neomycin afforded 10.9 

C thermal stabilization. In the 
presence of both neomycin and Hoechst 33258 together, at their saturating rbd, the thermal 
stabilization was 10.6 

C suggesting thermal stabilization solely coming from the 
neomycin binding to the RNA duplex due to the close similarity in the numerical value of 
the thermal stabilization afforded by neomycin. However, conjugate DPA 169, at its 
saturating rbd, shows 19.0 

C thermal stabilization. This large thermal stability afforded 
by the conjugate DPA 169 shows the effect of conjugation playing a role in the RNA 
binding as free neomycin and Hoechst 33258 showed much poorer thermal stabilization. 
These results suggest that conjugation, in fact, restricts the free movement of the Hoechst 
moiety practically forcing it to bind to the RNA duplex. The thermal stabilization of the 
conjugate DPA 169 is nearly 10.0 

C higher than the thermal stabilization afforded by 
neomycin alone (Table 5.2). This shows that a good part of the thermal stabilization 
comes from the Hoechst 33258 binding to the RNA duplex which binds synergistically 






























































































Figure 5.7. UV thermal denaturation profiles of various ligands (a) only RNA (b) 
Hoechst 33258 (c) neomycin and (d) DPA 169 as indicated on each graph. The 
concentration of RNA duplex used in each experiment was 15 M/bp.  The rbd for 
Hoechst 33258, neomycin and DPA 169 to RNA duplex were 5, 8 and 5 respectively. All 
experiments were carried in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 









Table 5.2. A table showing the RNA denaturation temperatures obtained by UV-thermal 
denaturation experiments.  
 














Hoechst 33258 5 58.5 0.4 
Neomycin 8 68.9 10.8 
Neomycin+Hoechst 
33258 
8 and 5 respectively 68.6 10.5 
DPA 169 5 78.1 19.0 
  
 
UV-Vis Experiments. Changes in the absorption spectrum of ligand upon nucleic acid 
binding have long been studied to understand ligand-nucleic acid interactions. In the 
present study we have used the changes in the absorbance spectrum of DPA 169 upon 
binding to RNA duplex poly (rA.rU) and compared it to the binding of the Hoechst 
33258 to the same RNA duplex (Figure 5.8). The superior binding of the conjugate DPA 
169 is reflected by the greater red shift (10 nm) of the absorption maximum of the 
Hoechst 33258 moiety of the conjugate as compared to the Hoechst 33258 alone (1 nm). 
The binding of the conjugate DPA 169 also results in larger hypochromic shift in the 
absorption maximum as compared to Hoechst 33258 alone. The optical properties are 
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Figure 5.8.  UV-Vis absorption profile of (a) Poly (rA. rU)-Hoechst 33258 complex and 
(b)  Poly(rA. rU)-DPA 169 complex. The concentration of the RNA duplex was             
15 M/bp while the concentration of Hoechst 33258 or DPA 169 was 3 M in each 
experiment. The experiments were performed at room temperature in buffer 10 mM 
sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. 
 
Table 5.3. A table showing the optical properties of Hoechst 33258 and DPA 169 upon poly 
(rA.rU) binding. 
 
























Fluorescence Emission Properties. Fluorescence emission properties of Hoechst 33258 
have previously been used extensively to study their interaction with nucleic acids. 
Binding of Hoechst 33258 to AT rich B-DNA results in a very large increase in the 
fluorescence emission due reduced vibrational energy loss in the protected environment 
of the minor groove. But the lack of such binding in the case of RNA duplex results in 
practically no increase in the fluorescence emission.  We therefore compared the 












































Figure 5.9. Fluorescence emission spectrum of 12 mer DNA duplex 
d(CGCAAATTTGCG), hybrid duplex d(CGCAAATTTGCG)-HEG-
r(CGCAAAUUUGCG) and RNA duplex  r(CGCAAAUUUGCG) in the presence of (a) 
Hoechst 33258 and (b) DPA 169 at 1:1 ligand:duplex ratio in buffer  10 mM sodium 
cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. Concentration of the ligands 




containing the optimal sequence for the Hoechst 33258 binding and its corresponding 
hybrid and RNA duplexes (Figure 5.9). As shown in Table 5.4, both Hoechst 33258 and 
DPA 169 show ~48 fold increase in the fluorescence emission when bound to the 
oligomeric self complementary  DNA duplex d(CGCAAATTTGCG). Binding of 
Hoechst 33258 and DPA 169 to the hybrid duplex d(CGCAAATTTGCG)-X-
r(CGCAAAUUUGCG) where  –X–  is the hexaethylene glycol spacer also resulted in  
 
Table 5.4.  A table showing the change in the fluorescence emission properties of 
Hoechst 33258 and DPA 169 in the presence of a 12 mer oligonucleotide duplex 




Fluorescence increase (fold) at 456 nm 
Fluorescence increase 
(fold) at 456 nm 
Fluorescence increase 








DNA-RNA hybrid 40.39 38.22 
RNA duplex 1.04 2.30 
 
 
similar increase in the fluorescence emission ( ~40 and ~38 fold increase in the 
fluorescence emission respectively). However, the binding of DPA 169 to the RNA 
duplex results in a 2.20 fold higher increase in the fluorescence emission of the conjugate 
than Hoechst 33258 alone. These studies show that the conjugation leads to the better 
fluorescence emission of the Hoechst 33258 moiety to RNA duplex because reduction of 




Determination of Association Constant to RNA Duplex Binding. To determine the 
association constant for the conjugate binding, we performed FID experiment as this 
assay allows the determination of the association constant in an indirect way as described 
by Boger.
35
  This indirect method was chosen over the direct fluorescence titration 
because despite the enhanced fluorescence emission of the conjugate in the presence of 
RNA duplex, the fluorescence emission was poor enough to have smooth emission 
profiles without much noise in the signal. 
As shown in Figure 5.10a, the addition of increasing amounts of DPA 166 led to 
the displacement of the bound intercalator (thiazole orange), leading to the diminished 
emission. The addition of DPA 166 in small aliquots was continued until no more 
changes in the fluorescence emission of the intercalator were observed. The changes in 
the fluorescence emission were then plotted against the ligand-RNA duplex ratio to 
obtain binding stoichiometry (Figure 5.10b). The plot in Figure 5.10b shows an 
inflection at approximately 1.2 suggesting the 1:1 binding stoichiometry of the DPA 166 
to RNA duplex. The changes in the fluorescence emission were then plotted to obtain 



















































































































































Figure 5.10.  FID titration of RNA dodecamer r(GCGAAAUUUCGC)2 with DPA 166. 
[RNA = 0.25 M/duplex], [TO] = 1.5 M. Thiazole orange was excited at 504 nm and 
the emission scans were recorded from 510 nm-750 nm. Each scan represents an average 
of three readings. (a) A plot showing the changes in the fluorescence emission scans with 
incremental additions of the ligand DPA 166 (b) A plot showing the binding 






Summary and Conclusions 
Our studies indicate that conjugation of Hoechst 33258 to neomycin results in the 
improved binding of Hoechst 33258 to RNA duplex. The improvement in the Hoechst 
33258 binding to the RNA duplex was determined using a variety of spectroscopic 
techniques. The Hoechst 33258 moiety of all conjugates show intercalative mode of 
binding. A clear trend that emerged out of these studies is the increased intercalation of 
the Hoechst 33258 moiety with increasing linker length. As the linker length increases 





 which is likely due to the increased flexibility allowed by the long linkers 
towards intercalative binding. DPA 169 was found to have enhanced fluorescence in the 
presence of RNA duplex as compared to Hoechst 33258 alone. Finally, association 
constants were determined by FID titration. The binding of DPA 166 to RNA duplex 





Appendix IV.  All synthesis details of compounds DPA 165-DPA173, characterization 
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TARGETING G-QUADRUPLEXES FORMED BY ONCOGENES: INSIGHTS INTO 
DUAL RECOGNITION AND EFFECTS OF LINKER LENGTH VARIATION 
Introduction 
Human genomic DNA contains contiguous stretches of repetitive guanine bases 
that may fold into higher order DNA structures such as G-quadruplex.  For example, 
many promoter sequences, as found in C-myc, VEGF, and bcl-2, C-kit have been 
observed to fold into four stranded G-quadruplex structures in solution.
1
 The formation of 
G-quadruplex has been shown to play important roles in cancer regulation and has been a 
subject of intense investigation in the recent times. Chromosomal ends (which are 
guanine rich) are often referred as telomeres and have been shown to form G-quadruplex 
structures. Understanding of G-quadruplex formation by telomeres, and its subsequent 
roles in cellular functions, is vital for developing chemotherapeutic agents for treating 
cancer. There has been substantial in vitro evidence now showing that G-quadruplex 
nucleic structures may be important in controlling the function of an enzyme called 
telomerase, which is critical to the growth of tumor cells.
2
 
The unusual properties of guanine rich nucleic acids were noticed almost a 
century ago. Five decades later, polymeric guanines were shown to adopt helical 
structures as observed in B-DNA, which are characterized by the right handed helix.
3
 It 
used four guanines to form a G-tetrad, which involved Hoogsteen base pairing. Each G-




stranded nucleic acid structure in 1960s, the biological functions of G-quadruplexes 
remained unknown until the mid 1980s. The discovery of telomerase by Blackburn
4
 was 
followed by the reports of the formation of parallel stranded G-quadruplex structures in 
the guanine rich regions,
5, 6
 as well as reports of telomerase inhibition by the formation of 
G-quadruplex
7









































Figure 6.1. The arrangement of guanine bases in a G-tetrad. The cavity in the middle is 
usually occupied by the metal cations. 
The telomeres present at the ends of chromosomes have been found to be G-rich 
and have been shown to form G-quadruplexes.
8
 In humans, the telomeric repeat unit is a 
hexamer dpp(TTAGGG)n.  A four repeat 22 mer human telomeric mimic sequence has 
been shown to adopt antiparallel quadruplex structure.
9
 Several other quadruplex 
structures resulting from the telomeric sequences of Tetrahymena
 10-12
 and Oxytricha 
nova
13-17




nucleotide tetrahymena telomeric sequence d(TGGGGT) has been shown to form a 
tetrameric quadruplex where all four DNA strands associate in the same direction, giving 
rise to a parallel quadruplex structure in the presence of both sodium  or potassium ions.
10
 
The quadruplex d(TGGGGT) results in the formation of four grooves of equal sizes, and 
is characterized by the anti orientation of the bases around the G-tetrad. On the other 
hand, a 12 mer telomeric sequence that is found in Oxytricha nova has been found to 
adopt an antiparallel structure.
14
 The antiparallel quadruplex structure formed by the 
Oxytricha nova telomere has been observed to have four grooves of unequal sizes (one 




Neidle laboratory investigated the binding of small molecules containing planar 
moieties, where the ligand binding to the quadruplex was observed to engage in the 
interaction with thymine loops.
18,19
 Recently, with the use of a combination of 
spectroscopic and modeling studies, we have reported the binding of aminoglycosides to 
the Oxytricha nova G-quadruplex.
20
 The binding of the aminoglycosides likely occurs in 
the wide groove of the quadruplex. The affinity of the ligand-quadruplex interaction was 
found to be in the micromolar range. The binding of aminoglycosides to the quadruplex 
is important not just for the discovery of the new classes of molecules, but also for the 
generation of novel G-quadruplex binding molecules, which may interact in dual fashion. 
We have recently shown that by covalently attaching neomycin to perylenediimide unit, 






ligands that bind to G-quadruplex through grooves are few, and not much is known about 
the structural requirements of the G-quadruplex grooves for the ligand binding.
22
 
A number of other G-quadruplex binding small molecules have been reported in 
the last decade. A common feature of these G-quadruplex binding molecules is the 
presence of extended aromatic ring systems that allow binding through - overlap of G-
tetrad.
23







.  In addition to this, high affinity sequence specific B-DNA 
minor groove binders have also been shown to interact with G-quadruplexes (although 
with less tight binding than the same to the B-DNA binding).
28
 In this report, we explore 
the effects of simultaneous binding of two nucleic acid binders, neomycin and Hoechst 
33258, to unimolecular G-quadruplexes formed by promoter sequences. Both of these 
nucleic acid binders have been shown to interact with G-quadruplexes with moderate to 
high affinity. We have previously demonstrated that conjugation of nucleic acid binders 
results in the higher affinity
29
 of the conjugate to a variety of nucleic acid structures. Our 
approach has included conjugation of a major groove binder ligand neomycin to a variety 







studies have shown covalent attachment of the two binding moieties result in a better 





led to the development of a series of nucleic acid binders of varying linker length and 






















































































































length of the linkers.
32
 For example, neomycin-neomycin conjugates with short linkers 
having triazole units in between have shown better binding to an RNA structure,
32
 
while the neomycin-Hoechst 33258 conjugates with a short linker has shown better 
binding to B-DNA.
30
 Below are the details of such linker effects on the G-quadruplex 
nucleic acid binding of neomycin-Hoechst 33258 conjugates. 
Materials and Methods 
General Methods.  Di-tert-butyl dicarbonate (Boc anhydride) was purchased from 
Advanced ChemTech (Louisville, KY).  Neomycin was purchased from MP Biomedicals 
(Solon, OH). All other chemicals were purchased from Aldrich (St. Louis, MO) or Acros 
Organics (Pittsburgh, PA) and used without further purification.  All solvents were 
purchased from VWR (West Chester, PA).  Silica gel (32-65 M mesh size) was 
purchased from Sorbtech (Atlanta, GA). 
1
H NMR and 
13
C NMR spectra were recorded 
on a Bruker Avance (300/500 MHz) spectrometer. Chemical shifts are given in ppm and 




C NMR).  MS (MALDI-TOF) spectra 
were collected using a Bruker Microflex mass spectrometer. Ultra Violet (UV) spectra 
were collected on a Varian (Walnut Creek CA) Cary 100 Bio UV-Vis spectrophotometer 
equipped with a thermoelectrically controlled 12-cell holder.   FID experiments were 
performed on Tecan Genois (Austria) fluorimeter equipped with a 96 well plate reader. 
Nucleic Acids. All DNA oligonucleotides were purchased from Eurofins MWG Operon 
(Huntsville, AL) and used without further purification. The nucleic acid concentrations 




solutions were prepared in buffer 10 mM Tris-HCl, 0.1 mM EDTA and 100 mM KCl at 
pH 7.5. The nucleic acid solutions were prepared by heating at 95 

C for 15 minutes, and 
then slowly allowing it cool back to room temperature. After incubation for at least two 
weeks, the quadruplex formation was checked by CD spectroscopy. The stock solution 
was stored at 4 

C and diluted to desired concentrations as required. 
Fluorescent Intercalator Displacement (FID) Experiments.  Fluorescence experiments 
were performed on Tecan Genois (Austria) equipped with a 96 well plate reader. All 
experiments were performed at room temperature (21-23 

C).  The experiments were 
performed in the 96 well plates as triplicates. The DNA solution was prepared at 1 
M/quadruplex concentration in 10 mM Tris-HCl, 0.1 mM EDTA and 100 mM KCl at 
pH 7.5. The nucleic acid was then mixed with thiazole orange (TO) at a concentration of 
2 M. The ligand was added to the DNA-TO complex solution at 1:1 ratio and followed 
by a five minute equilibration time before the fluorescence emission spectrum was 
recorded. The change in the fluorescence emission was plotted as - 
% fluorescence change = (F/IF) × 100 
where, F = Change in fluorescence upon ligand addition and IF = Initial fluorescence of 
the DNA- TO complex 
Circular Dichroism (CD) Spectroscopy. CD experiments were performed in a 3.0 mL 
quartz cell on a Jasco J-810 spectropolarimeter equipped with a thermo-electrically 
controlled cell holder. The experiments were performed at 10 M/strand concentration in 
buffer 10 mM Tris-HCl, 0.1 mM EDTA and 100 mM KCl at pH 7.5. The ligands were 




serially in small aliquots. These were  equilibrated for five minutes before the CD scan 
was taken. Each CD spectrum is an average of three scans. All experiments were 
performed at 20 

C. 
UV-Vis Absorption Studies. UV-vis absorption studies were carried on Cary 1 UV-vis 
spectropolarimeter (Walnut Creek, CA).  The absorption spectrum of the ligand samples 
(5 M) was recorded between 500-200 nm. To this, DNA sample was added to achieve 
1:1 ligand to DNA duplex ratio and absorption spectrum was recorded. The data was 
recorded every 1 nm. The experiments were performed in buffer 10 Tris-HCl, 1.0 mM 
EDTA and 100 mM KCl at pH 7.5 (T = 21-23 

C). 
Ultra Violet (UV) Thermal Denaturation Experiments.    All UV spectra were obtained 
on a 12 cell holder Cary 1E UV-Vis spectrophotometer equipped with temperature 
controller. Quartz cells with 1cm path length were used for all the experiments. 
Spectrophotometer stability and wavelength alignment were checked prior to initiation of 
each thermal denaturation experiment.   For all experiments, the samples were prepared 
by diluting a stock sample. The melting of DNA with and without the ligand was carried 
at a heating rate of 0.2 °C / min.   Samples were brought back to 20 °C after the 
experiment. All UV melting experiments were monitored at 260 nm.   For the Tm 
determination, first derivatives were used.   Data points were recorded every 1.0 °C.  The 
DNA concentration was 2 M/strand. The ligand was added to the DNA sample to 
achieve 1:1 ratio.  
Fluorescence Titration Experiments. Fluorescence titration experiments were conducted 




temperature controller. The ligand solution (0.1 M) was added with a concentrated 
DNA quadruplex solution. The ligand was excited at 350 nm and the emission spectrum 
was recorded between 400-750 nm. DNA was added successively in small aliquots until 
no more changes in the fluorescence emission spectrum of the ligand were observed. The 
resulting emission profile was then plotted to obtain binding stoichiometry and analyzed 
using non linear least square fitting method to obtain the binding constant, as described 
previously.
28
 The experiments were performed in buffer 10 Tris-HCl, 1.0 mM EDTA and 
100 mM KCl at pH 7.5. 
Results and Discussion 
Synthesis of Neomycin-Hoechst 33258 Conjugates. Neomycin-Hoechst 33258 conjugates 
were synthesized using different linking strategies. The synthesis of some of the 
conjugates was done by click chemistry which led to the preparation of conjugates DPA 
165-DPA 173 (as discussed in Chapter 5). Here, we present the synthesis of conjugates 
DPA 173-DPA 177, which gave a total of thirteen novel neomycin-Hoechst 33258 
conjugates for screening. The syntheses of DPA 174-DPA 177 (Figure 6.2) relied on 
modifications in the previously established synthetic strategies.
33
 Research in our 
laboratory has led to the development of neomycin-Hoechst 33258 conjugates using 
thiourea linkage.
31, 34
 To achieve this, Hoechst 33258 derivative terminating in an amine 
was prepared, and was then coupled with electrophilic isothiocyanate functionality, that 
can be introduced on neomycin in four synthetic steps.
35



































































































Scheme 6.1. (a) Boc2O, DMF, Et3N, H2O, 75 

C, 18 h, (55 %) (b) 2,4,6 Triisopropyl- 
benzenesulfonyl chloride, pyridine, rt, 55 %  (c) Na metal, ethanol, HSCH2CH2NH2.HCl, 
10 h, rt (80 %)  (d) NaN3, DMF:H2O  (10:1),100 

C (e) Pd-C,  H2, rt, quant. 
 
was then reacted in the presence of a catalyst 4-dimethyl aminopyridine (DMAP) giving 
the thiourea linked neomycin-Hoechst 33258 conjugates (DPA 174-DPA 177). The 
neomycin isothiocyanate preparation starts with the protection of six amino groups 
present on neomycin using tertiary butyl carbonyl (Boc) groups.
36, 37
 The protection of 
amino groups by Boc renders neomycin from being water soluble to become completely 
insoluble in water.  This also allows for much easier purification of the desired product 




(rings I, I and IV) contain amino groups on them, while ring III contains a lone primary 
















































Scheme 6.2.  (a) Dichloromethane, TCDP, rt , 60 % 
 
at 3-position in ring III (Scheme 6.1, compound 1).  The primary hydroxyl can then be 
selectively reacted with a bulky leaving group triisopropyl benzene sulfonyl chloride 
(TPS).  Conversion of the primary hydroxyl group on ring III to a good leaving group 
TPS facilitates smooth nucleophilic reactions at this position.  As a result, –NH2 
functionalities can be introduced in two ways, as depicted in Scheme 6.1, which leads to 
the formation of compounds 3 and 4.  Compound 3 is prepared by reaction compound 2 
with an aminothiolate, which is generated in situ by reaction of 2-amino ethanethiol with 
sodium metal.  Compound 4 can be prepared by nucleophilic substitution of the TPS 
group with sodium azide. The azide functionality can then be reduced to the –NH2 group 































































































































Scheme 6.3. Reagents and conditions (a) TCDP, DCM, DMAP, rt 10 h, 90 % (b) 6 or 7, 





























































Scheme 6.4. Reagents and conditions (a) dry ethanol, dry HCl, rt, 2h, qaunt. (b) Pd-C 
(10%), ethanol-ethyl acetate, H2, rt, qaunt. (c) Glacial acetic acid, ethanol, 12,  80 

C, 4h , 
40 % (d) DCM, 1,4 dioxane, PPh3,14, rt, 65 % (e) 15, Na2S2O5,H2O, ethanol, reflux, 10h, 









































































































































-NHCSNH- -(CH2)3NHCSNHO(CH2)4O(CH2)3- DPA 176
 
 
Scheme 6.5.  Reagents and conditions. (a) (i)Pyridine, DMAP, overnight, rt (ii) 4M HCl 




The lone primary amines present on neomycin in 3 or 4 can then be converted to 
their corresponding isothiocyanates in a single step, as shown in Scheme 6.2.  In addition 
to this, the amines can also be reacted with excess bisisothiocynates, which result in the 
formation of isothiocyante derivatives of neomycin with varying linker lengths.  The 
bisisothiocyanates can be prepared from commercially available diamines in a single 
step. The bisisothiocyanates (usually in at least 10 fold excess) are reacted with neomycin 
derivatives 3 or 4 containing the primary amine functionality. Scheme 6.3 shows a 
schematic for the preparation of isothiocyanate ended neomycin derivatives 9-11. The 
isothiocyanate derivatives of neomycin 9-11 were reacted with a novel Hoechst 33258 
derivative, (DPA 160) which contained a terminal –NH2 group. The synthesis of 
neomycin-Hoechst 33258 conjugates is described in Scheme 6.4. The synthesis of DPA 
160 starts with the conversion of 4-amino, 3-nitro benzonitrile into its corresponding 
benzimidate ethyl ester hydrochloride salt by bubbling dry HCl gas into a solution of 4-
amino, 3-nitro benzonitrile. 
 The synthesis of DPA 160 then proceeds in a divergent fashion where a 4-
substituted benzaldehyde derivative 15 is prepared by reacting 4-hydroxy benzaldehyde 
with 2,2,2-trifluoro-N-(3-hydroxypropyl)acetamide under Mitsunobu conditions.
38
 The 
benzaldehyde derivative 15 is then reacted with diamine derivative of the benzimidazole 
13, which was prepared in one step by catalytic reduction of 13
39
, in the presence of an 
oxidant, to afford trifluoroacetamide protected derivative of DPA 160. The 
trifluoroacetamide group is then deprotected in the presence of a mild base
38
 to afford 




Isothiocyanate ended neomycin derivatives 4/9/10/11 were reacted with DPA 160 
to afford Boc protected neomycin- Hoechst 33258 conjugates, which were then 
deprotected in the presence of a strong acid, (4M HCl in 1,4 dioxane) to obtain 
neomycin-Hoechst 33258 conjugates DPA 174-DPA 177. A generalized synthetic route 
is shown in Scheme 6.5. The prepared conjugates were characterized by TLC, 
1
H NMR 
and MALDI-TOF spectroscopy. These conjugates, however, showed aggregation, which 
led to broad proton signals. 
Preparation of G-Quadruplexes.  Transcriptional promoter sequences are G-rich and can 
potentially form G-quadruplexes. There are a growing number of literature reports that 
have suggested that promoter sequences can form stable G-quadruplexes under cellular 
conditions in vitro. One of the earliest and most studied promoter sequences has been the  
Table 6.1. A table showing the promoter sequences and their abbreviations used. 











TFO active  
against C-myc 1 
GGAAGGGGTGGGAGGGGTGGGAGGGG-3 
TFO active  














































































































































Figure 6.3.  CD spectra of various promoter quadruplexes as indicated on each graph. All 
experiments were performed in buffer 10 mM Tris-HCl, 1.0 mM EDTA and 100 mM 
KCl at pH 7.5. The DNA concentration was 10 M/strand in each experiment. Each 






one derived from the MYC gene (represented as C-myc).   Given that both neomycin and 
Hoechst 33258 have been demonstrated to bind to G-quadruplexes before, we screened 
eight promoter sequences of biological relevance for their affinity to G-quadruplexes.  
The base sequences of these promoter sequences are shown below. The G-quadruplexes 
were formed by heating the DNA oligonucleotides in a buffer containing 10 mM Tris-
HCl, 0.1 mM EDTA and 100 mM KCl at pH 7.5 for thirty minutes at 95 

C, and then 
allowing it to cool back to room temperature. The oligonucleotide samples were then 
incubated for several weeks before experiments were performed with them. The heating 
at 95 

C was done to ensure all folded structures to unfold into the single stranded form. 
Slow cooling and further incubation was done for the formation of thermodynamically 
stable G-quadruplex, as the kinetics of formation of certain types of quadruplexes, such 
as tetramolecular quadruplexes, has been found to be quite slow.
40
 The quadruplex 
formation was checked by circular dichroism. As shown in Figure 6.3, all promoter 
sequences showed similar features in their CD spectra.  In all cases, a positive CD band at 
260 nm and a negative CD band centered at 240 nm were observed, which indicated the 
formation of a parallel G-quadruplex.  These intramolecular quadruplexes were then 
screened for their affinity to neomycin-Hoechst 33258 conjugates. 
Fluorescent Intercalator Displacement (FID) Assay. FID assay allows rapid screening of 
nucleic acid binding agents in a simple assay in which a large number of nucleic acid 
binders can be identified for their structure /sequence specificity.
41,42
  This assay, 
developed by Boger, relies on the fluorescence response of an intercalator ligand (usually 





























Figure 6.4. Fluorescence titration of thiazole orange with C-myc quadruplex in buffer 10 
mM Tris-HCl, 1.0 mM EDTA and 100 mM KCl at pH 7.5. Thiazole orange (78 nmol) 
was titrated with C-myc DNA quadruplex. A concentrated DNA solution was added in 
small aliquots followed by mixing with a magnetic stirrer and three minute equilibration 
before a scan was taken. Each scan represents an average of three readings. Thiazole 
orange (TO) was excited at 502 nm and the emission spectrum was recorded between 
510-700 nm. 
 
appropriate ratio (which can be determined from a titration experiment), which results in 
a large increase in the fluorescence emission of the intercalator due to its binding to the 
nucleic acid.  The intercalator can then be displaced by the addition of the ligand of 
interest. The fluorescence emission changes corresponding to the ligand addition can be 
utilized to construct a binding isotherm. The binding isotherm can also be used to obtain 
information about the binding stoichiometry and association constant. In addition to this, 






















well. We have applied this technique to our studies. The FID assay has helped us to 
identify duplex, triplex and quadruplex nucleic acid binders previously.
43-45
 In a similar 
strategy as shown by Boger, Monchaud and coworkers have shown that this assay can 
also be utilized to identify G-quadruplex binders.
46
  Therefore, we applied this method to 
screen neomycin-Hoechst 33258 conjugates DPA 165-177 for their binding to 
unimolecular DNA quadruplexes used in this study.  
We performed a direct fluorescence titration experiment to determine the ratio of 
thiazole orange to C-myc quadruplex. As shown in Figure 6.4a, addition of increasing 
amounts of DNA to TO led to the enhancement in the fluorescence emission of thiazole 
orange. After the addition of saturating amounts of DNA, the fluorescence emission 
intensity was plotted against the ratio of TO to the C-myc quadruplex (Figure 6.4b). The 
linear regions of this plot resulted in the intersection of lines at approximately two TO 
molecules per C-myc quadruplex. This ratio was used for the remainder of the DNA 
quadruplexes in our FID experiments as small changes in the DNA:quadruplex ratio does 
not lead to any alteration in rank of the binding affinity.
46
 
Figure 6.5 shows the FID displacement plots of various G-quadruplexes formed 
by the promoter sequences as indicated on each graph.  Few trends worthy of notice can 
be immediately discerned. First of all, in all cases, addition of neomycin-Hoechst 33258 
conjugates DPA 165-DPA 177 results in much better displacement of the bound 

































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.5 (continued) 
DNA -thiazole orange (TO) complex.  [DNA] = 1 M/quadruplex, [TO] = 2 M, 
[Ligand] = 1 M. All experiments were performed in buffer 10 mM Tris-HCl, 0.1 mM 
EDTA and 100 mM KCl at pH 7.5.  Thiazole orange was excited at 501 nm and the 
emission was recorded at 534 nm. Each entry represents an average of three experiments. 
 
conjugation of neomycin and Hoechst 33258 that leads to conjugates DPA 165-DPA 177, 
results in a better binding ligand to these promoter quadruplexes. The better binding of 
conjugates DPA 165-DPA 177 could likely arise from the dual binding of neomycin and 
Hoechst 33258 moieties at independent sites.  Secondly, there is a dependence of ligand 
(DPA 165-DPA 177) binding to the amount of thiazole orange displaced from each 
nucleic acid target. The dependence of conjugate DPA 165-DPA 177 binding to the 
nucleic acid is linked to the length of the linker between neomycin and Hoechst 33258 
binding moieties of the conjugates. As seen in Figure 6.5, the C-myc quadruplex 
neomycin-Hoechst 33258 conjugates that have larger atom spacing between neomycin 
and Hoechst 33258 units (typically higher than 15 atoms) were best displacers, ( DPA 
173 and DPA 176) while the ones with the short atom spacing showed the least 
displacement. While in the case of Ki-RAS quadruplex, conjugates with small 
linkerspacing (around 10 atoms) showed the highest displacement of thiazole orange, 
while the ones with longer atom spacing between the neomycin and Hoechst 33258 units 




displacement of the intercalator probe (thiazole orange) than neomycin or Hoechst 33258 
alone. Neomycin-Hoechst 33258 conjugates with short linker spacing seemed to be better 
displacers of the bound intercalators in the cases of intramolecular quadruplexes formed 
by HER Neu, TFO C-myc 1, TFO C-myc 2 and bcl 2 quadruplexes, while quadruplexes 
formed from the promoter sequences of VEGF and Retinoblastoma did not show much 
differentiation between the displacement afforded by small or long linkers. Few possible 
factors could likely be the cause of this. First of all, the differences lie in the differences 
of nucleic acid structures itself. While all of these quadruplexes form intramolecular 
parallel quadruplexes, their loop arrangements may be very different. Some of these 
sequences have been studied by solution NMR. For example, C-myc and BCL2 have 
significant differences in their loop arrangement.
47, 48
 G-quadruplexes are highly 
polymorphic structures. Differences in the loop arrangement lead to entirely new 
molecular geometry particularly in the grooves. G-quadruplexes can lead to all different 
types of DNA grooves reaching the extremes that are not found in a typical B or A-DNA 
grooves. For example, G-quadruplex, formed by the Oxytricha nova telomeric DNA, 
results in the formation of an antiparallel quadruplex that has two medium grooves 
(similar in groove width to those found in B-DNA major groove), a narrow groove 
(similar to groove width found in A-DNA major groove) and a wide groove (where the 
groove width far exceeds the width found in the A or B-DNA major grooves).  Similar 
grooves are also found in the antiparallel G-quadruplex formed by human telomeric 
quadruplex.
9
 We have shown previously that wide groove is the likely binding site of the 




However, binding affinity of neomycin to Oxytricha nova and human telomeric DNA 
differs nearly by an order of magnitude.
20
 Given the differences in the possible loop 
forming regions of these quadruplexes, it is reasonable to think of differences in the 
grooves of these quadruplex structures formed by the promoter sequences leading to 
varied binding. Moreover, the differences in the loops can also be the reason for 
differences in the binding, as loops could also possibly interact with the two binding 
moieties of the conjugates DPA 165-DPA 177. Secondly, the differences in the linker 
structure itself can likely be the cause of differential binding, as some of linkers with 
large atom spacing (DPA 173, DPA 175, DPA 176) have possible binding sites on 
themselves either in the form of hydrogen bond acceptors (multiple oxygen atoms case of 
DPA 173) or hydrogen bond donors (through thiourea linkages present in the case of 
DPA 175-DPA 177).  The bulky linkers of some of the neomycin-Hoechst 33258 
conjugates can also create molecular crowding that could go either in a favorable or 
unfavorable way depending on the quadruplex structure. One determination that emerges 
out of this study is a definite role played by the linkers of the conjugates DPA 165-DPA 
177. We then, turned our focus to studying further the biophysical properties of the ligand 




Comparison of C-myc Binding by Neomycin-Hoechst 33258 Conjugates to Biologically 
Relevant C-myc Duplex Structures. To compare the binding of the conjugates DPA 165-
DPA 177 between C-myc quadruplex and duplex DNA structures, we performed FID 




DNA sequences to the sequences represented by TFO C-myc1 and TFO C-myc2. As 
shown in Figure 6.6a, the circular dichroism spectrum of the duplex TFO C-myc1 shows 
features of A-DNA, which is characterized by the maximum of positive CD band around 
265-270 nm. The CD spectrum of TFO C-myc2 duplex shows a broad positive CD signal 
in the region of 270-280 nm, which probably suggests the presence of both A-form and 
B-form features in this duplex (Figure 6.6b). The presence of more than one nucleic acid 
structure is ruled out given to sharpness of the unfolding transition of the duplex TFO C-
myc2 (Figure 6.6d).  TFO C-myc1 duplex showed the melting transition at 70 

C (Figure 
6.6c) while TFO C-myc2 duplex showed the same at 63 

C. 
We then turned our attention to see the differences in the duplex DNA binding of 
the conjugates DPA 165-DPA 177 and to compare them to the C-myc quadruplex 
binding. As shown in Figure 6.7, the FID displacement plots for the conjugates DPA 
165-DPA 177 are significantly different than the FID displacement profile of the 
quadruplex. While the quadruplex showed preference of conjugates with large atom 
spacing, the duplex DNAs showed higher binding affinity of neomycin-Hoechst 33258 
conjugates with short atom spacing. These results show the duplex versus quadruplex 
selectivity for different linkers of the neomycin-Hoechst 33258 conjugates. Additionally, 
one can also see that there is not much difference in the percent fluorescence emission 























































































Figure 6.6. (a) CD spectrum of TFO C-myc1 duplex (b) TFO C-myc2 duplex (c) UV-
thermal denaturation profile of TFO C-myc1 duplex (d) UV-thermal denaturation profile 
of TFO C-myc2 duplex. All experiments were performed in buffer 10 mM Tris-HCl, 0.1 
mM EDTA and 100 mM KCl at pH 7.5.  For CD experiments, the concentrations of the 
nucleic acids were 10 M/duplex, while the same for UV thermal denaturation 
experiments were 2 M/duplex. Each CD scan is an average of two scans. The CD 





In fact for TFO C-myc duplexes, Hoechst 33258 proved to cause the largest change in the 
fluorescence. We then decided to study the interaction of DPA 173 (which afforded the 
highest displacement of thiazole orange) C-myc quadruplex binding for further 
biophysical studies. The quadruplex versus duplex selectivity of DPA 173 was checked 
using fluorescent intercalator displacement titration. As shown in Figure 6.8, serial 
addition of DPA 173 to duplex DNA (TFO C-myc 1 and TFO C-myc 2)-TO complex led 
to quenching of the fluorescence emission of thiazole orange. After complete 



































































































































































































































































TFO cmyc 2 duplex
(b)
 
Figure 6.7.  FID plots showing the percent change in the fluorescence emission upon 
ligand binding in DNA -thiazole orange (TO) complexes. (a) TFO C-myc1 duplex (b) 
TFO C-myc1 duplex.  [DNA] = 1 M/duplex, [TO] = 2 M, [Ligand] = 1 M. All 
experiments were performed in buffer 10 mM Tris-HCl, 0.1 mM EDTA and 100 mM 
KCl at pH 7.5.  Thiazole orange was excited at 485 nm and the emission was recorded at 




fluorescence emission intensity of thiazole orange), DC50 values can be determined (DC50 
refers to amount of ligand required to displace 50 % of the bound intercalator). A detailed 
description of DC50 determination is outlined in chapter two. The DC50 values obtained 
from FID titrations are listed in Table 6.2. As reflected from the DC50 values, there is a 
distinct preference of DPA 173 for C-myc quadruplex in comparison to duplex structures. 
The DC50 value for C-myc quadruplex was 0.31 M while the same for TFO C-myc 1 and 
TFO C-myc 2 duplexes were 1.22 and 1.07 M respectively. The lesser value of DC50 for 





Figure 6.8. FID titration profile of DPA 173 being titrated into (a) C-myc quadruplex (b) 
TFO C-myc 1 duplex and (c) TFO C-myc 2 duplex. The DNA (0.25 M) was mixed with 
thiazole orange (0.50 M) followed by successive addition of DPA 173 at different ratios 
as indicated on the graph. Each spectrum is an average of two scans. Thiazole orange was 
excited at 501 nm and the emission was recorded between 510-750 nm. The experiment 






Table 6.2.  DC50 values obtained by titration of various nucleic acids using DPA 173. 
 







0.31 + 0.02 
C-myc duplex 1 DPA 173 1.22 + 0.17 
C-myc duplex 2 DPA 173 1.07 + 0.09 
 
 
DPA 173 Binds to the C-myc Quadruplex in a 1:1 Stoichiometry. The FID experiment 
shown in Figure 6.8c can also be used to determine the binding stoichiometry of C-myc 
quadruplex– DPA 173 interactions. As shown in Figure 6.9, the changes in the 
fluorescence emission were plotted with respect to the ligand-quadruplex stoichiometry. 
The linear sections of the plot intersect at nearly 1:1 ratio indicating that one molecule of 
the ligand binds per quadruplex. Similar binding stoichiometry has also been observed by 
Maiti and coworkers.28 This binding stoichiometry was then used to derive equation for 
determination of the association constant from a direct titration experiment. 
Circular Dichroism Studies of DPA 173 and Hoechst 33258 Binding to C-myc G-
Quadruplex. We utilized circular dichroism to further characterize the binding of DPA 
173-C-myc quadruplex interaction. As shown in Figure 6.10, the CD spectrum of C-myc 
shows a positive band at 260 nm, which is a characteristic of the formation of a parallel 
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Figure 6.9. A plot showing the binding stoichiometry of DPA 173 and C-myc quadruplex 
interaction.  
 
respectively. As shown in Figure 6.10a, incremental addition of Hoechst 33258 to the 
quadruplex resulted in the small changes in the positive band at 260 nm. However, an 
induced CD was observed at 339 nm, which is the chromophore absorption wavelength. 
The induction of induced CD as well as the changes in the positive intensity at 260 nm 
suggests the binding of Hoechst 33258 to this quadruplex. Previous studies have also 
characterized the binding of Hoechst 33258 to the C-myc quadruplex by spectroscopic 
methods.
28
 An observation to be noticed is the discernible induced CD only at ratios 
above two. This shows the requirement of a minimum ligand concentration for induced 
CD to be observed.  In contrast to the Hoechst 33258 binding, the binding of DPA 173 
resulted in much larger changes at the positive induced CD at 260 nm. However, we did 
not observe any induced CD in the Hoechst 33258 absorption region of the conjugate 
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Figure 6.10. Circular dichroism studies of C-myc quadruplex with (a) Hoechst 33258 and  
(b) DPA 173 as indicated on each graph. The DNA sample (10 M/quadruplex) was 
mixed with increasing amounts of ligands and equilibrated for five minutes before the 
scan was taken. Each spectrum is an average of three scans. All experiments were 
conducted in 10 Tris-HCl, 1.0 mM EDTA and 100 mM KCl buffer at pH 7.5. 
 
previously discussed that the induced CD spectrum was observed only above the 
ligand:quadruplex ratios of two. In the case of DPA 173, we could not study the 
DPA173-C-myc interaction at ratio over two, as as precipitation was observed when the 
ligand:quadruplex ratio was 1.8. This could possibly explain the non observable induced 
CD in the case of DPA 173. Yet the CD experiment does show the complexation of the 
conjugate to the quadruplex. 
Fluorescence Titration Experiment of DPA 173 with C-myc. To determine the association 
constant of DPA 173 binding to C-myc quadruplex, we performed a direct titration 
























































Figure 6.11.  (a)  Fluorescence emission spectrum of C-myc quadruplex-DPA 173 
complex. DPA 173 (500 nM) was mixed with increasing amounts of a concentrated C-
myc DNA quadruplex solution until saturation of the fluorescence intensity was achieved. 
Each spectrum is an average of two scans.  The excitation wavelength was 373 nm and 
the emission was recorded between 400-650 nm. The experiment was performed in 
buffer 10 mM tris-HCl, 1.0 mM EDTA and 100 mM KCl at pH 7.5 at 20 

C.  (b) A plot 
showing the non linear curve fitting of the binding isotherm obtained from the titration.  
 
quadruplex. As depicted in Figure 6.11a, the addition of incremental DNA to the DPA 
173 sample resulted in the continuous increase in the fluorescence emission intensity of 
chromophore absorption maximum at 479 nm. The increase in the intensity of the 
fluorescence emission of DPA 173 eventually reached the saturation upon addition of 
large amounts of DNA. The resulting binding isotherm is shown in Figure 6.11b. Using 
a 1:1 binding site model,
28
 the binding isotherm was fitted using the non linear least 









which shows that the binding of the conjugate is predominantly dictated by the Hoechst 
33258 moiety.
28
 The binding constant for another quadruplex TFO C-myc 1 with its best 





appendix V, Figure S1). 
Summary and Conclusions 
Our studies show that neomycin-Hoechst 33258 conjugates DPA 165-DPA 177 
show a higher displacement of the intercalator probe than Hoechst 33258 or neomycin 
alone for all G-quadruplexes derived from the promoter sequences. Comparison of the 
FID profiles of C-myc quadruplex to GC-rich duplexes show that the conjugates were 
able to better displace the thiazole orange bound to the quadruplex than the duplexes. The 
data suggests dependence of the amount of thiazole orange displaced with the linker 
spacing present on the novel neomycin-Hoechst 33258 conjugates DPA 165-DPA 177 for 
various quadruplexes. For some quadruplexes, thiazole orange was displaced the most by 
conjugates with short spacing, while some others displaced better with conjugates with 
longer spacing, or did not have much effect on the binding. Further biophysical studies of 
DPA 173 binding with C-myc suggests that the ligand binds to the quadruplex with 1:1 
binding stoichiometry and has micromolar affinities. Circular dichroism studies showed 
much larger complexation at even lower ratios, in comparison to Hoechst 33258 alone, 
which suggests a possible dual binding mode. These studies could help in the future 








C NMR, IR and MS plot of novel 




















1. Kumar, N.; Maiti, S. A thermodynamic overview of naturally occurring intramolecular 
DNA quadruplexes. Nucleic Acids Research 2008, 36, 5610-5622.  
2. Autexier, C.; Lue, N. F. The Structure and Function of Telomerase Reverse 
Transcriptase. Annu. Rev. Biochem. 2006, 75, 493-517.  
3. Gellert, M.; Lipsett, M. N.; Davies, D. R. Helix Formation by Guanylic Acid. Proc. 
Natl. Acad. Sci. U. S. A. 1962, 48, 2013-2018.  
4. Greider, C. W.; Blackburn, E. H. Identification of a specific telomere terminal 
transferase activity in tetrahymena extracts. Cell 1985, 43, 405-413.  
5. Sen, D.; Gilbert, W. Formation of parallel four-stranded complexes by guanine-rich 
motifs in DNA and its implications for meiosis. Nature (London, United Kingdom) 1988, 
334, 364-366.  
6. Sen, D.; Gilbert, W. A sodium-potassium switch in the formation of four-stranded G4-
DNA. Nature (London, United Kingdom) 1990, 344, 410-414.  
7. Zahler, A. M.; Williamson, J. R.; Cech, T. R.; Prescott, D. M. Inhibition of telomerase 
by G-quartet DNA structures. Nature 1991, 350, 718-720.  
8. Burge, S.; Parkinson, G. N.; Hazel, P.; Todd, A. K.; Neidle, S. Quadruplex DNA: 
sequence, topology and structure. Nucleic Acids Res. 2006, 34, 5402-5415.  
9. Wang, Y.; Patel, D. J. Solution structure of the human telomeric repeat 
d[AG3(T2AG3)3] G-tetraplex. Structure 1993, 1, 263-282.  
10. Aboul-ela, F.; Murchie, A. I. H.; Norman, D. G.; Lilley, D. M. J. Solution structure of 
a parallel-stranded tetraplex formed by d(TG4T) in the presence of sodium ions by 
nuclear magnetic resonance spectroscopy. J. Mol. Biol. 1994, 243, 458-471.  
11. Laughlan, G.; Murchie, A. I.; Norman, D. G.; Moore, M. H.; Moody, P. C.; Lilley, D. 
M.; Luisi, B. The high-resolution crystal structure of a parallel-stranded guanine 
tetraplex. Science 1994, 265, 520-524.  
12. Phillips, K.; Dauter, Z.; Murchie, A. I.; Lilley, D. M.; Luisi, B. The crystal structure 





13. Smith, F. W.; Feigon J. Quadruplex structure of Oxytricha telomeric DNA 
oligonucleotides. Nature 1992, 356, 164-168.  
14. Smith, F. W.; Feigon, J. Strand orientation in the DNA quadruplex formed from the 
Oxytricha telomere repeat oligonucleotide d(G4T4G4) in solution. Biochemistry (N. Y. ) 
1993, 32, 8682-8692.  
15. Schultze, P.; Smith, F. W.; Feigon, J. Refined solution structure of the dimeric 
quadruplex formed from the Oxytricha telomeric oligonucleotide d(GGGGTTTTGGGG). 
Structure 1994, 2, 221-233.  
16. Schultze, P.; Hud, N.; Smith, F.; Feigon, J. The effect of sodium, potassium and 
ammonium ions on the conformation of the dimeric quadruplex formed by the Oxytricha 
nova telomere repeat oligonucleotide d(G(4)T(4)G(4)). Nucl. Acids Res. 1999, 27, 3018-
3028.  
17. Haider, S.; Parkinson, G. N.; Neidle, S. Crystal Structure of the Potassium Form of an 
Oxytricha nova G-quadruplex. J. Mol. Biol. 2002, 320, 189-200.  
18. Haider, S. M.; Parkinson, G. N.; Neidle, S. Structure of a G-quadruplex–Ligand 
Complex. J. Mol. Biol. 2003, 326, 117-125.  
19. Campbell, N. H.; Patel, M.; Tofa, A. B.; Ghosh, R.; Parkinson, G. N.; Neidle, S. 
Selectivity in Ligand Recognition of G-Quadruplex Loops. Biochemistry (N. Y. ) 2009, 
48, 1675-1680.  
20. Ranjan, N.; Andreasen, K. F.; Kumar, S.; Hyde-Volpe, D.; Arya, D. P. 
Aminoglycoside Binding to Oxytricha nova Telomeric DNA. Biochemistry 2010, 49, 
9891-9903.  
21. Xue, L.; Ranjan, N.; Arya, D. P. Synthesis and spectroscopic studies of the 
aminoglycoside (Neomycin)-perylene conjugate binding to human telomeric DNA. 
Biochemistry 2011, 50, 2838-2849.  
22. Cosconati, S.; Marinelli, L.; Trotta, R.; Virno, A.; Mayol, L.; Novellino, E.; Olson, A. 
J.; Randazzo, A. Tandem Application of Virtual Screening and NMR Experiments in the 
Discovery of Brand New DNA Quadruplex Groove Binders. J. Am. Chem. Soc. 2009, 
131, 16336-16337.  
23. Monchaud, D.; Teulade Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. 




24. Haq, I.; Trent, J. O.; Chowdhry, B. Z.; Jenkins, T. C. Intercalative G-Tetraplex 
Stabilization of Telomeric DNA by a Cationic Porphyrin. J. Am. Chem. Soc. 1999, 121, 
1768-1779.  
25. Jantos, K.; Rodriguez, R.; Ladame, S.; Shirude, P. S.; Balasubramanian, S. Oxazole-
Based Peptide Macrocycles: A New Class of G-Quadruplex Binding Ligands. J. Am. 
Chem. Soc. 2006, 128, 13662-13663.  
26. Kerwin, S. M.; Chen, G.; Kern, J. T.; Thomas, P. W. Perylene Diimide G-Quadruplex 
DNA Binding Selectivity is Mediated by Ligand Aggregation. Bioorg. Med. Chem. Lett. 
2002, 12, 447-450.  
27. Rossetti, L.; Franceschin, M.; Bianco, A.; Ortaggi, G.; Savino, M. Perylene diimides 
with different side chains are selective in inducing different G-Quadruplex DNA 
structures and in inhibiting telomerase. Bioorg. Med. Chem. Lett. 2002, 12, 2527-2533.  
28. Maiti, S.; Chaudhury, N. K.; Chowdhury, S. Hoechst 33258 binds to G-quadruplex in 
the promoter region of human c-myc. Biochem. Biophys. Res. Commun. 2003, 310, 505-
512.  
29. Shaw, N. N.; Xi, H.; Arya, D. P. Molecular recognition of a DNA:RNA hybrid: sub-
nanomolar binding by a neomycin-methidium conjugate. Bioorg. Med. Chem. Lett. 2008, 
18, 4142-4145.  
30. Kumar, S.; Xue, L.; Arya, D. P. Neomycin-Neomycin Dimer: An All-Carbohydrate 
Scaffold with High Affinity for AT-Rich DNA Duplexes. J. Am. Chem. Soc. 2011, 133, 
7361-7375.  
31. Willis, B.; Arya, D. P. Recognition of B-DNA by Neomycin-Hoechst 33258 
Conjugates. Biochemistry 2006, 45, 10217-10232.  
32. Kumar, S.; Arya, D. P. Recognition of HIV TAR RNA by triazole linked neomycin 
dimers. Bioorg. Med. Chem. Lett. 2011, 21, 4788-4792.  
33. Kelly, D. P.; Bateman, S. A.; Martin, R. F.; Reum, M. E.; Rose, M.; Whittaker, A. R. 
D. DNA binding compounds. V. Synthesis and characterization of boron-containing 
bibenzimidazoles related to the DNA minor groove binder, Hoechst 33258. Aust. J. 
Chem. 1994, 47, 247-262.  
34. Arya, D. P.; Willis, B. Reaching into the major groove of B-DNA: synthesis and 
nucleic acid binding of a neomycin-hoechst 33258 conjugate. J. Am. Chem. Soc. 2003, 




35. Charles, I.; Xue, L.; Arya, D. P. Synthesis of aminoglycoside-DNA conjugates. 
Bioorg. Med. Chem. Lett. 2002, 12, 1259-1262.  
36. Wang, H. Design and synthesis of RNA binding aminoglycoside antibiotics, 
University of Californina, San Diego, Californina, San Diego, 1998.  
37. Michael, K.; Wang, H.; Tor, Y. Enhanced RNA binding of dimerized 
aminoglycosides. Bioorg. Med. Chem. 1999, 7, 1361-1371.  
38. Willis, B.; Arya, D. P. Recognition of B-DNA by Neomycin-Hoechst 33258 
Conjugates. Biochemistry 2006, 45, 10217-10232.  
39. Kelly, D. P.; Bateman, S. A.; Hook, R. J.; Martin, R. F.; Reum, M. E.; Rose, M.; 
Whittaker, A. R. D. DNA binding compounds. VI. Synthesis and characterization of 2,5'-
disubstituted bibenzimidazoles related to the DNA minor groove binder Hoechst 33258. 
Aust. J. Chem. 1994, 47, 1751-1769.  
40. Mergny, J. L.; Cian, A. D.; Ghelab, A.; Sacca, B.; Lacroix, L. Kinetics of 
tetramolecular quadruplexes. Nucleic Acids Res. 2005, 33, 81-94.  
41. Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C.; Hedrick, M. P. A Simple, 
High-Resolution Method for Establishing DNA Binding Affinity and Sequence 
Selectivity. J. Am. Chem. Soc. 2001, 123, 5878-5891.  
42. Boger, D. L.; Fink, B. E.; Hedrick, M. P. Total Synthesis of Distamycin A and 2640 
Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, 
Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen 
for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity. 
J. Am. Chem. Soc. 2000, 122, 6382-6394.  
43. Xi, H.; Davis, E.; Ranjan, N.; Xue, L.; Hyde-Volpe, D.; Arya, D. P. Thermodynamics 
of nucleic Acid "shape readout" by an aminosugar. Biochemistry 2011, 50, 9088-9113.  
44. Xi, H.; Kumar, S.; Dosen-Micovic, L.; Arya, D. P. Calorimetric and spectroscopic 
studies of aminoglycoside binding to AT-rich DNA triple helices. Biochimie 2010, 92, 
514-529.  
45. Kumar, S.; Xue, L.; Arya, D. P. Neomycin-Neomycin Dimer: An All-Carbohydrate 
Scaffold with High Affinity for AT-Rich DNA Duplexes. J. Am. Chem. Soc. 2011, 133, 
7361-7375.  
46. Monchaud, D.; Allain, C.; Teulade-Fichou, M. Development of a fluorescent 
intercalator displacement assay (G4-FID) for establishing quadruplex-DNA affinity and 




47. Dai, J.; Chen, D.; Jones, R. A.; Hurley, L. H.; Yang, D. NMR solution structure of the 
major G-quadruplex structure formed in the human BCL2 promoter region. Nucleic Acids 
Research 2006, 34, 5133-5144.  
48. Mathad, R. I.; Hatzakis, E.; Dai, J.; Yang, D. c-MYC promoter G-quadruplex formed 
at the 5′-end of NHE III1 element: insights into biological relevance and parallel-stranded 
G-quadruplex stability. Nucleic Acids Research 2011, .  
49. Ambrus, A.; Chen, D.; Dai, J.; Jones, R. A.; Yang, D. Solution Structure of the 
Biologically Relevant G-Quadruplex Element in the Human c-MYC Promoter. 

























































 Aminoglycoside Binding to G-Quadruplex Nucleic Acids 
 
 
Figure S1. ITC titration of Oxytricha nova quadruplex (GGGGTTTTGGGG)2 with  
paromomycin   in buffer  10 mM sodium cacodylate, 0.5 mM EDTA and 90 mM KCl  at 
pH 7.0.     The heat burst curves (top panel in the figures) is the result of 10L injections 
of a concentrated ligand solution into the DNA solution in buffer conditions as described 
earlier. The data points (lower panel in the figures) reflect the corrected injection heats, 
which were obtained by subtracting the dilution heats obtained from separate control 
experiments in which ligand was titrated with buffer only. The red line represents the 
calculated fits of the data using one binding site model. The data fitting was carried out 


































































Figure S2.   Determination of fluorescence quenching of (a) titration of thiazole orange 
with neomycin in buffer 10 mM Sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl 
at pH 7.0. (T = 20 

C) (b) FID experiment of thiazole orange bound to Oxytricha nova 
telomeric quadruplex using spermine in buffer 10 mM Sodium cacodylate, 0.5 mM 










Figure S3.  UV thermal denaturation profile of Oxytricha nova G-quadruplex DNA in 
the absence and presence of neomycin. The oligonucleotide concentration was 10 M/ str 
while the ligand concentration was 5 M in buffer 10 mM sodium cacoldylate, 0.5 mM 
EDTA and 100 mM NaCl at pH 7.0.The nucleic acid samples were heated at the rate of 







Figure S4. ITC titration of Oxytricha Nova quadruplex d(GGGGTTTTGGGG)2 buffer 
10 mM sodium cacodylate, 0.5 mM EDTA and 30 mM KCl at pH 7.0  (a) 30 














Figure S5.  (a) A plot showing 
1
H NMR titration of neomycin into Oxytricha nova G-
quadruplex DNA. (b) Bar graph plots of chemical shifts observed in the imino and 
aromatic region. The shifts were calculated at ligand: DNA ratio of 1:1 (at this ratio the 








Figure S6.   ITC titration of neomycin into Oxytricha nova telomeric DNA in buffer 10 
mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at  (a) pH 5.5 (b) pH 6.8  The 

























































Figure S7.   ITC titration of neomycin into human telomeric DNA in buffer 10 mM 
sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at (a) pH 5.5 (b) pH 6.8 The heat 
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Figure S8. (a) FID titration profile of d(TG4T) with neomycin. [DNA] = 8 M/strand, [TO] = 4 
M. The  experiment was performed in  buffer 10 mM sodium cacodylate, 0.5 mM EDTA, 60 
mM KCl at pH 7.0 at  20 


















Figure S9.  ITC titration profile of neomycin being titrated into a tetramolecular 
quadruplex d(T4G4T4) having extended thymines in buffer  containing 10 mM sodium 
cacodylate, 0.5 mM EDTA and 90 mM KCl at pH 7.0. The experiment was performed at 
20 

C.  Each heat burst curve is an outcome of 10 L injection of 300 M neomycin into 
















Figure S10.  Temperature dependent NMR studies of d(TG4T) (0.37 mM/quadruplex)
 
quadruplex showing destacking  exhibited by the resolving and sharpening of the 
1
H 
NMR signals. The experiments were performed at the indicated temperatures in buffer 10 
mM sodium cacodylate, 0.5 mM EDTA, 30 mM KCl at pH 7.0 in (a) 100 % D2O (b) 90 








Figure S11.  
1
H NMR studies of d(TG4T) (0.37 mM/quadruplex)
 
quadruplex in the 
absence and presence of neomycin  at 1:1 ratio (quadruplex:ligand). The experiments 
were performed at the indicated temperatures in buffer 10 mM sodium cacodylate, 0.5 






Figure S12. ITC titration of d(TG4T) with neomycin in 10 mM sodium cacodylate, 0.5 
mM EDTA and 60 mM KCl at pH 7.0. The DNA concentration was 60 M/strand. 
Neomycin (300 M) was added serially (10 L injection) to the DNA solution at (a) 50 















































































































































































Figure S13.  UV thermal denaturation profiles of various aminoglycosides (a-e) with 
d(TG4T). Each ligand was mixed with the DNA quadruplex (5 M/strand) in 1:1 ratio.  
The heating was carried at a rate of 0.3 

C/min. The experiments were performed in 




Table S1.  ITC titration of  Oxytricha nova telomeric quadruplex with neomycin at 
various temperatures in buffer 10 mM sodium cacodylate, 0.5 mM EDTA and 100 
mM NaCl at pH 7.0. 
[Salt] 













1.34 + 0.02 
 















Table S2. Association constant and binding stoichiometry obtained from the ITC 
titration of neomycin into human telomeric quadruplex DNA in buffer 10 mM 




















Table S3.  PDB ID of nucleic acid used in the docking studies. 
Nucleic acid 
 





Triplex DNA 1D3R 
Oxytricha DNA 156D 






Table S4. ITC derived binding stoichiometry and association constants for the A-site 
rRNA-neomycin interaction. 
 










60 mM KCl 
 
0.81 + 0.02 
 
(8.11 + 3.22) 
 
2.23 + 0.02 
 


















Determination of number of ion pairs formed during ligand-nucleic acid interaction. The 
number of ion pairs formed during the interaction of neomycin with the Oxytricha Nova 




log (Ka) = log(K)-Zψ log([K
+
])          (1)   
where Ka is the association constant for the ligand-nucleic acid interaction at 20 
°
C, K is 
the equilibrium constant for the bimolecular reaction between the ligand and the nucleic 
acid, Z is the number of ion pairs formed between the ligand and the nucleic acid while ψ 
is the thermodynamic counterion binding parameter for the nucleic acid used in the study. 
Since, the quadruplex formed by Oxytricha nova gives rise to four grooves that 
have some characteristics of either A-form or B-form nucleic acids (groove width is 
closer to A-form major groove width in the narrow groove of the quadruplex while it is 
closer to B-DNA major groove widths in the case of medium grooves) we assume the ψ 
value in the present case to be intermediate between the values deduced for A-form and 
B-form nucleic acids. The ψ value described for polymeric RNA duplex (poly rA.rU) is 
0.89
2, 3
 while the same for helical duplex DNA is 0.88 for monovalent cations.
2, 3
 The ψ 
value for denatured (unstructured) DNA has been assigned as 0.70.
2
 However ψ values 
for oligomers are smaller in comparison to polymers due to reduced net association with 
counterions
4
. Wilson and coworkers have determined a ψ value of 0.68 + 0.02 for a 20 
mer hairpin oligonucleotide at AATT drug binding site.
5
 Record and Lohman have 




by the following relationship
4
 – 
ψ (duplex DNA) = 0.88- (2.53/N)    (2) 
where N is the number of phosphates in the oligomers. Though the validity of this 
relationship was not tested for small N values and it was suggested that the ψ values 
determined from this method may have systematic error,
4
 considering this method to be 
valid the ψ value for a 12 mer oligomer duplex is 0.67. 
     Using these extremes, the Z value obtained in the present case is supposed to 
be intermediate between 1.34-1.79 which suggests formation of at least one ion pair in 
the present case (but not more than two). 
Procedure for determination of thermodynamic parameters using Van’t Hoff analysis. 
The raw data from the thermal melting curves were first plotted in Kaleidagraph (version 
4.0) and the upper and lower baselines were linearly fit. The resulting equations were 
then used to convert the raw data to fraction folded using the equation 
  
                
                       
………………………………… (3).  
Where, = fraction folded, m(U) = slope of upper baseline, A(U) = intercept of 
the upper baseline,  m(L) = slope of the lower baseline, A(L) = intercept of the lower 
baseline, A (T)= Absorbance of at the corresponding temperature (T). 
This represents the data between 1 (fully folded state) to 0 (fully unfolded state).  The 




   
 
         
…………………………………………………………………… (4). 
Where, Ka = association constant,  = fraction Folded, C0 = initial strand 
concentration of the quadruplex. 
Following this, ln(Ka) was plotted versus 1/T to afford a linear relationship which 
gave –H/R as slope and S/R as intercept where,  
H = molar enthalpy (van’t Hoff), S = molar entropy (van’t Hoff), R = gas constant 
The data in the range of = 0.87 to = 0.13 was used for van’t Hoff analysis. 
Procedue for fluorescence intercalator displacement (FID) titration of d(TG4T) with 
neomycin. FID titration was performed on a Photon Technology International instrument 
(Lawrenceville, NJ). The experiment was performed in a 3.0 mL quartz cell in buffer 10 
mM sodium cacodylate, and 0.5 mM EDTA, 60 mM KCl buffer at pH 7.0 at  ( T = 20 

C). The quadruplex solution was prepared at 8 M/strand concentration in buffer 10 mM 
sodium cacodylate, and 0.5 mM EDTA, 60 mM KCl buffer at pH 7.0. It was mixed with 
thiazole orange (TO) at a concentration of 4 M. The ligand was serially added to the 
DNA/TO complex solution and followed by a 4 minute equilibration time before the 
fluorescence spectrum was recorded. The TO excitation was performed at 501 nm and the 
emission was recorded between 510-700 nm. 
 
Procedure for NMR experiments of neomycin-d(TG4T) interaction. All NMR experiments 




and a temperature controller (Department of Chemistry, Clemson University NMR 
facility). The DNA concentration used in 
1
H MNR titrations was 0.37 mM per 
quadruplex and a final volume of 250 L. The low temperature experiments were 
performed after two hours of equilibration at the desired temperature and they have + 0.1 

C deviations to the reported temperatures. All the experiments were performed in a 
Shimegi microvolume NMR tube matched with D2O. All NMR samples contained 10 
mM sodium cacodylate, 0.5 mM EDTA, 30 mM KCl buffer, pH 7.0. Samples were 
prepared either as (90 % H2O + 10 % D2O) or 100 % D2O. For 1D water suppression, a 
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(Figure S1 continued) 
Figure S1. UV thermal denaturation profiles of dA60.dT60 (1M/strand) in the presence 
of various ligands (10 M) as indicated on each graph. The heating was performed at rate  
of  0.2 

C/min. All experiments were carried in buffer 10 mM sodium cacodylate, 0.5 




























































































































































































































































































































































Figure S2. UV thermal denaturation profiles of d(CGCAAATTTGCG)2 (1M/strand) in  
the presence of various ligands (1 M) as indicated on each graph. The heating was 
carried at rate of 0.2 

C/min. All experiments were carried in buffer 10 mM sodium 







Figure S3. DSC melting profile of d(CGCAAATTTGCG)2 (50 mM/duplex) in the buffer 
10 mM sodium cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. The heating was 














































   
   


























































































































































































































































































































































































(Figure S4 continued) 
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(Figure S4 continued) 
 
Figure S4.  Excess site ITC titration graphs of interactions of DPA 151, DPA 157 and 
DPA 159 with d(CGCAAATTTGCG)2. The experiments were carried at 10 mM/ duplex 
concentration.  50 mM ligand solutions were injected to the DNA at indicated 
temperatures. 




Synthesis of 4-(hex-5-ynyloxy)benzaldehyde (DPA 152-a). To a solution of p-hydroxy 
benzaldehyde (1.00 g, 8.18 mmol) in dry dichloromethane (15.0 mL) and dioxane (5.0 
mL), 5-Hexyn-1-ol (0.80 g, 8.18 mmol) and triphenyl phosphine (3.17 g, 12.1 mmol) 
were added under argon . This reaction mixture was ice cooled. To this DIAD (2.40 mL, 
12.1 mmol) was added dropwise. The reaction mixture was stirred at 0 

C for 1h followed 
by stirring at room temperature was 6 h. TLC on silica gel showed completion of 
reaction. Volatiles were evaporated and the crude mixture was redissolved in ethyl 
acetate-hexanes (80.0 mL, 1:1 v/v). The mixture was allowed to stand in the refrigerator 
for a day and the precipitated solid was vacuum filtered and concentrated.  The crude 
mixture was loaded on a silica gel column and eluted with hexanes- ethyl acetate (0-25% 
ethyl acetate in hexanes) to yield the desired compound as colorless oil ( 1.4 g, 85 %): Rf  
=  0.7 (hexanes-ethyl acetate 7:3);  
1
H NMR (300 MHz, CDCl3)  9.81(s, 1H), 7.82 (dd,  




6.25 Hz, 2H, -OCH2CCH),  2.32-2.27 (m, 2H), 2.00-1.91 (m, 3H), 1.79-1.69 (m, 2H); 
13











carboxamide (DPA 152-b). To solution of   N- Methoxy, N-methyl 3, 4 dinitrobenzamide 
(1.00 g, 3.91 mmol) in ethanol (30.0 mL), 10% Pd-C (0.10 g) was added. Hydrogenation 
for 5 h at atmospheric pressure yielded corresponding diamine which was (after filtration 
of the catalyst) used without further characterization. 4-(hex-5-ynyloxy)benzaldehyde 
(0.82 g, 4.10 mmol) and   sodium metabisulfite (0.39  g, 2.05 mmol ) in  water ( 0.50 mL) 
was added into it. The reaction mixture was refluxed for 8h. Volatiles were evaporated 
under reduced pressure. Column chromatography on silica gel using dichloromethane-
methanol (0-8 % methanol in dichloromethane) as eluent afforded the desired product as 
pale brown oil (1.1 g, 74 %): Rf  = 0.75 (in dichloromethane-isopropanol 9:1 v/v); IR 
(neat, cm
-1
) 3297 (alkyne C-H stretch), 2938 (aromatic C-H stretch), 2869, 2116 (alkyne 
C-C stretch), 1723, 1591, 1379, 1109, 835; 
1
H NMR (300 MHz, DMSO-d6) 8.13 (d, br, 
J = 13.78Hz, 2H), 7.93-7.80 (1H), 7.67 (dd, J1 = 8.27 Hz, J2 = 8.36 Hz, 1H), 7.48 (d, J = 
8.62 Hz, 1H), 7.11 (d, br, J = 8.87 Hz, 2H), 4.07 (t, J = 4.64 Hz, 2H, -OCH2CCH), 3.57 




(m, 2H), 1.67-1.57 (m, 2H) (Imino proton was not observed because of exchange with the 
NMR solvent); 
13
C NMR (75 MHz, DMSO-d6)  170.2, 160.7, 153.8, 146.0, 143.4, 
137.0, 128.7, 123.0, 119.0, 115.3, 111.8, 84.7, 71.8, 67.6, 60.9, 34.1, 28.2, 25.0, 21.1, 
17.9; MS (MALDI-TOF) m/z calcd. for C22H23N3O3 [M]
+ 









Synthesis of 2-(4-(hex-5-ynyloxy)phenyl)-3H-benzimidazole-5-carbaldehyde (DPA 152-
c). To a stirred suspension of 2-(4-(hex-5-ynyloxy)phenyl)-N-methoxy-N-methyl-3H-
benzoimidazole-5-carboxamide (0.77 g, 2.04 mmol) in  dry THF (40.0 mL), lithium 
aluminum hydride (0.31 g, 8.17 mmol) was added in small portions at -70 

C under argon 
and the stirring was continued for 12h at  0 

C .TLC was used to monitor the progress of 
the reaction. The reaction mixture was quenched by the addition of saturated ammonium 
chloride solution (100 mL). The resulting grey precipitate was filtered off. The filtrate 
was extracted by ethyl acetate (3 × 100 mL). Organic layers were combined and dried 
over sodium sulfate. Volatiles were removed under reduced pressure. Column 
chromatography on silica gel using hexanes-ethyl acetate (1:1-2:1) as eluent afforded the 
desired compound as light yellow liquid (0.47 g, 72 %): Rf  =  0.66 (ethyl acetate:hexanes 
6:4 v/v); mp 156-158 ºC; IR (neat, cm
-1
) 3289 (alkyne C-H stretch), 2915 (aromatic C-H 





H NMR (300 MHz, methanol-d4) (br, 1H), 9.89 (s, 1H), 7.96 (br, 1H) 7.87 (dd, 
J1 = 8.89 Hz, J2 = 2.01 Hz, 2H,), 7.69 (dd, J1 = 9.8 Hz, J2 = 1.44 Hz, 1H,), 7.56 (d, J = 
8.32 Hz, 1H), 6.91 (dd, , J1 = 8.92 Hz, J2 = 2.02 Hz, 2H), 3.93-3.89 (t, J = 5.91 Hz, 2H, -
OCH2CCH), 2.25-2.20 (m, 3H), 1.88-1.79 (m, 2H), 1.69-1.59 (m, 2H); 
13
C NMR 
(75MHz , DMSO-d6) 192.4, 171.5, 161.5, 155.2, 131.7, 128.3, 123.7, 121.0, 114.6, 
83.3, 68.5, 67.4, 60.1, 27.9, 24.8, 19.9, 17.4, 16.5; MS (MALDI-TOF) m/z calcd. for 
C20H18N2O2 [M]
+ 














bibenzo[d]imidazole (DPA 152). To a solution of 5-(4-methylpiperazin-1-yl)-2-
nitroaniline (0.28 g, 1.00 mmol) in ethanol (40.0 mL), Pd-C (0.10 g) was added which 
was followed by hydrogenation at atmospheric pressure for 5h. TLC on silica gel showed 
complete reduction of the starting material. Charcoal was filtered off over a bed of celite. 
To this, 2-(4-(hex-5-ynyloxy)phenyl)-3H-benzimidazole-5-carbaldehyde (0.35 g, 1.10 
mmol) and a solution of Na2S2O5 (0.10 g, 0.55 mmol) in water (0.20 mL) were added and 
the mixture was refluxed for 23 h . The reaction mixture was allowed to come to room 
temperature. The filtrate was evaporated under reduced pressure. Column 
chromatography on silica gel using  dichloromethane-methanol as eluent (0-15 % 
methanol in dichloromethane) afforded the desired product as yellow solid (0.36 g, 72%): 






) 3293 (alkyne C-H stretch), 2938 (aromatic C-H stretch), 2811, 2116 
(alkyne C-C stretch), 1618, 1449, 1248, 1171, 970, 839;  
1
H NMR (500 MHz, methanol-
d4) 8.21 (s, 1H), 8.00 (dd , J1 = 8.60Hz, J2 = 2.06 Hz, 2H), 7.92 (dd, J1 = 8.64 Hz, J2  = 
2.02 Hz¸1H) 7.66 (d, J = 8.30 Hz, 1H), 7.51 (d,  J = 9.00 Hz, 1H) , 7.12 (d, J = 8.80 Hz, 
1H), 7.04 (d, J = 8.54 Hz, 1H), 7.02 (dd, J1 = 8.84 Hz, J2 = 2.06 Hz, 2H), 4.01 (t, J = 2.26 
Hz, 2H, -OCH2CCH), 3.24 (t, J = 4.62 Hz, 4H), 2.75 (t, J = 4.66 Hz, 4H), 2.53 (s, br, 
1H), 2.44 (s, 3H), 2.28-2.24 (m , br, 2H), 1.93-1.86 (m, br, 2H), 1.70-1.77 (m, br, 2H) 
(Imino protons were not observed because of exchange with the NMR solvent) ;  MS 
(MALDI-TOF) m/z calcd. for C31H32N6O [M]
+ 







Synthesis of 4-(undec-10-ynyloxy)benzaldehyde (DPA153-a). To an ice cold solution of 
p-hydroxybenzaldehyde (0.50 g, 4.09 mmol) in dry dichloromethane-dioxane mixture 
(15.0 mL 2:1 v/v), triphenyl phosphine (1.60 g, 6.05 mmol) and 10-undecyn-1-ol (0.70 g, 
6.05 mmol) were dissolved and kept at 0 

C. To this, diisopropyl azodicarboxylate (1.22 
g, 6.05 mmol) was added dropwise over a period of 15 min.  The contents were initially 
stirred at 0 

C for 30 min and then allowed to warm up to room temperature and stirred 
overnight.  Progress of the reaction was monitored by thin layer chromatography on silica 
gel. The crude mixture was concentrated and redissolved in ethyl acetate-hexanes mixture 




off and the filtrate was concentrated under reduced pressure.  Column chromatography on 
silica gel using  hexanes-ethyl acetate as eluent (0-50 % ethyl acetate in hexanes) 
afforded the desired compound as white solid (0.58 mg,  52 % ): Rf  = 0.54  (hexanes-
ethyl acetate 7:3 v/v); mp 65-68 ºC; IR (neat, cm
-1
) 3421 (alkyne C-H stretch), 2927 
(aromatic C-H stretch), 2849, 2097 (alkyne C-C stretch), 1684, 1599, 1263, 1163, 1101, 
1020; 
 1
H NMR (300 MHz, CDCl3)  9.90 (s, 1H), 7.84 (dd, J1 = 7.1 Hz, J2 = 1.9 Hz, 2H), 
7.00 (dd,  J1 = 7.1 Hz, J2 = 1.9 Hz, 2H), 4.06 (t, J = 6.50 Hz, 2H, -OCH2CCH), 2.23-2.18 
( m, 2H), 1.96 (t, J = 2.71 Hz, 1H, -OCH2CCH), 1.88-1.79 (m ,2H), 1.58-1.27 (12H); 
13
C 
NMR (125 MHz, CDCl3) 190.8, 164.2, 131.9, 129.7, 114.7, 84.7, 74.3 68.4, 68.1, 29.3, 











benzo[d]imidazole-6-carboxamide (DPA 153-b). To solution of   N- Methoxy, N-methyl 
3, 4 dinitrobenzamide (0.40 g, 1.37 mmol) in ethanol-ethyl acetate mixture (15.0 mL), 10 
% Pd-C (0.09 g) was added. Hydrogenation at atmospheric pressure for 5h afforded 




4-(undec-10-ynyloxy)benzaldehyde (0.49 g, 1.78 mmol) and   sodium metabisulfite (0.26 
g, 1.37 mmol ) in  water ( 1.00 mL) were added into it and the reaction mixture was 
refluxed overnight. Volatiles were evaporated under reduced pressure.  The crude product 
was purified on a silica gel column using  dichlromethane-methanol (0-10 %  methanol in 
dichloromethane) as eluent to afford the desired product as slightly yellow  gummy solid 
(0.60 g, 85 % ): Rf = 0.67 (dichloromethane-isopropanol 9:1 v/v); IR (neat, cm
-1
)  3305 
(alkyne C-H stretch) , 2927 (aromatic C-H stretch), 2857, 2112 (alkyne C-C stretch), 
1896, 1614, 1499, 1248, 1175, 1012, 835, 742; 
1
H NMR (300 MHz, acetone-d6)   8.17 
(d, J = 8.4 Hz, 2H),  8.03-7.87 (br, 1H),  7.68-7.50 (m, 2H), 7.11 (d, J = 8.7 Hz, 2H), 4.14 
(t, J = 6.2 Hz, 2H, -OCH2CCH), 3.62 (s, 3H), 3.34 (s, 3H), 2.32 (t, J =  2.5 Hz, 1H, -
OCH2CCH), 2.21-2.16 (m, 2H), 1.88-1.78 (m, 2H), 1.57-1.30 (m, 12H) (Imino proton 
was not observed because of exchange with the NMR solvent); 
13
C NMR (75 MHz, 
acetone-d6)  170.1, 160.9, 153.4, 138.9, 137.2, 128.3, 128.2, 122.7, 122.4, 118.2, 117.5, 
114.7, 113.8, 101.2, 84.1, 68.9, 67.9, 60.2, 33.3, 29.7-28.2 (peaks masked with the 
acetone-d6 peak), 25.8, 27.8; MS (MALDI-TOF) m/z calcd. for C27H33N3O3  447.57, 















Synthesis of 2-(4-(undec-10-ynyloxy)phenyl)-1H-benzo[d]imidazole-6-carbaldehyde 
(DPA 153-c). To a solution of N-methoxy-N-methyl-2-(4-(undec-10-ynyloxy)phenyl)-
1H-benzo[d]imidazole-6-carboxamide (0.80 g, 1.78 mmol) in THF-ether (80.0 mL, 3:1), 
lithium aluminum hydride (0.20 g, 5.28 mmol) was added  at -78 

C under argon and then 
allowed to  stir  at 0 

C  for 8h . The reaction mixture was quenched by the addition of 
saturated ammonium chloride solution (75.0 mL). The resulting grey precipitate was 
filtered off. The filtrate was extracted with ethyl acetate (3 × 100 mL). Organic layers 
were combined and dried over sodium sulfate. Volatiles were removed under reduced 
pressure. Column chromatography on silica gel  using  hexanes-ethyl acetate as eluent 
afforded the desired compound as a light yellow solid (0.42 g, 60 % ):  Rf = 0.78 (ethyl 
acetate-hexanes 6:4); mp 126-128 ºC; IR (neat, cm
-1
) 3305 (alkyne C-H stretch), 2930 
(aromatic C-H stretch), 2857, 2108 (alkyne C-H stretch), 1726, 1503, 1375, 1263, 1178, 
1117, 1043;   
1
H NMR (300 MHz,  acetone-d6) 10.08 (s, 1H), 8.20 (d, J = 8.8 Hz, 2H), 
8.14 (1H), 7.80 (dd, J1 = 8.3 Hz, J2 = 1.3 Hz, 1H), 7.72 (d, J =  8.3 Hz, 1H), 7.11 (d, J = 
8.9 Hz, 2H), 4.10 (t, J = 6.5 Hz, 2H, -OCH2CCH), 2.32 (t, J = 2.7 Hz, 1H, -OCH2CCH), 




observed because of exchange with the NMR solvent); 
13
C NMR (125 MHz, acetone-d6) 
 191.5, 161.3, 155.3, 154.0, 149.3, 144.5, 139.7, 138.9, 135.3, 131.8, 128.4, 127.9, 
123.3, 122.1, 119.0, 114.9, 113.7, 112.9, 111.3, 84.0, 68.8, 67.9,  33.5, 28.1; MS 
(MALDI-TOF) m/z  calcd. for C25H28N2O2 
 














bibenzo[d]imidazole (DPA 153). To a solution of 5-(4-methylpiperazin-1-yl)-2-
nitroaniline (0.24 g, 1.02 mmol) in ethanol- ethyl acetate mixture (30.0 mL), Pd-C (0.10 
g) was added followed by hydrogenation at atmospheric pressure for 5h. TLC on silica 
gel showed complete reduction of the starting material. Charcoal was filtered over a bed 
of celite. To the filtrate, 2-(4-(undec-10-ynyloxy)phenyl)-1H-benzo[d]imidazole-6-
carbaldehyde (0.40 g, 1.02 mmol) and a solution of Na2S2O5 (0.19 g, 1.02 mmol) in water 
(1.0 mL) was added and the mixture was refluxed for 14h. Volatiles were removed under 
reduced pressure. Column chromatography on silica gel in dichloromethane-methanol (0-
15 % methanol in dichlromethane)  afforded the pure product as yellow solid (0.29 g,  50 
%): Rf = 0.32 ( dichlromethane-methanol 8:2); mp 170-175 ºC; IR (neat, cm
-1
) 2919 
(aromatic C-H stretch), 2853, 1614, 1445, 1256, 1178, 1005, 835; 
1
H NMR (300 MHz, 
methanol-d4)  8.20 (br, 1H), 7.95-7.89 (br, 3H), 7.63 (d, J = 8.5Hz, 1H), 7.50 (d, J = 8.7 
Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 7.01 (dd, J1 = 8.8 Hz, J2 = 2.2 Hz, 1H), 6.93 (d, J = 8.5 




(s, 3H), 2.19-2.11( m ,br, 3H), 1.73-1.63 ( m, 2H), 1.52-1.22( br, 12H) (Imino protons 
were not observed because of exchange with the NMR solvent); 
13
C NMR (75 MHz, 
DMSO-d6)  160.7, 153.1, 148.0, 145.4, 144.6, 139.3, 136.5, 135.7, 128.6, 124.7, 122.6, 
120.7, 119.0, 115.3, 115.1, 111.8, 85.02, 71.5, 71.5, 68.1, 61.5, 55.2, 46.0, 33.6, 29.3, 
29.2, 29.1, 28.9, 28.5, 28.4, 25.9, 18.1; MS (MALDI-TOF) m/z calcd. for C36H42N6O 






Synthesis of 4-(prop-2-ynyloxy) butan-1-ol.
1
 To a solution of 1, 4 butanediol (10.0 mL, 
0.11 mol) in dry THF, sodium hydride (2.40 g, 0.10 mol) was added at 0 

C. The mixture 
was stirred for 30 min at 0 

C. To this, propargyl bromide (11.9 g, 0.10 mol) was added 
slowly and stirred at 0 

C. The mixture was allowed to warm up to room temperature and 
then stirred for 20h. The reaction was quenched by pouring the mixture into water. It was 
then extracted with diethyl ether (3 ×100 mL). The organic layers were combined and 
dried with sodium sulfate. The volatiles were evaporated. The crude product was purified 
on a silica gel column using hexane-diethyl ether as eluent to afford the desired product 
as brown oil (7.50 g, 45 %): Rf = 0.47 (ethyl acetate: hexane 1:1 v/v); IR (neat, cm
-1
) 
3402 (O-H, H-bonded), 3292 (alkyne C-H stretch), 2945 (aromatic C-H stretch), 2863, 
2115 (alkyne C-C stretch), 1711, 1441, 1355, 1241, 1102, 677; 
1
H NMR (500 MHz, 
CDCl3) 4.13 (d, J = 2.7 Hz, 2H, -CH2OCH2CCH), 3.62 (t, J = 5.5 Hz, 2H, -OCH2CH2-




1.69-1.61 (m, 4H); 
13






Synthesis 4-(4-(prop-2-ynyloxy)butoxy)benzaldehyde (DPA 154-a). To a solution of p-
hydroxybenzaldehyde (4.00 g, 32.7 mmol) in dry dichloromethane-dioxane (40.0 mL, 3:1 
v/v), triphenyl phosphine (12.6 g, 48.0 mmol) and 4-(prop-2-ynyloxy) butan-1-ol (4.20 g, 
32.7 mmol) were dissolved and the solution was ice cooled. To this, diisopropyl 
azodicarboxylate (9.70 g, 48.0 mmol) was added drop wise over a period of 15 min at 0 

C.  The contents were initially stirred at 0 

C for 30 min and then at room temperature 
overnight. The solvents were removed under reduced pressure and the mixture was 
redissolved in ethyl acetate-hexanes (100 mL, 1:1 v/v) and allowed to stand in the 
refrigerator overnight. The precipitated solid was filtered off and the filtrate was 
concentrated under reduced pressure. Column chromatography on silica gel using 
hexanes-ethyl acetate as eluent, afforded the desired compound as pale yellow oil (6.2 g, 
82 %): Rf = 0.55 (hexanes-ethyl acetate 7:3 v/v); IR (neat, cm
-1
) 3289 (alkyne C-H 
stretch), 2950 (aromatic C-H stretch), 2869, 2116 (alkyne C-C stretch), 2009, 1904, 1688, 
1595, 1503, 1310, 1101, 831;
 1
H NMR (500 MHz, CDCl3)  9.84 (s, 1H), 7.79 (dd, J1 = 
1.79 Hz, J2 = 8.81 Hz, 2H), 6.96 (d,  J = 8.81 Hz, 2H),  4.13 (d,  J = 2.39 Hz, 2H), 4.04 (t, 




1.79-1.74 (m, 2H); 
13
C NMR (125 MHz, CDCl3)  190.7, 164.1, 131.9, 129.8, 114.7, 79.9, 











benzo[d]imidazole-6-carboxamide (DPA 154-b). To solution of   N- Methoxy, N-methyl 
3, 4 dinitrobenzamide (0.73 g, 2.86 mmol) in ethanol-ethyl acetate mixture (40.0 mL, 3:1 
v/v), 10 % Pd-C (0.30 g) was added. Hydrogenation at the atmospheric pressure for 5h 
yielded corresponding diamine which was (after filtration of the catalyst) used without 
further characterization (Rf = 0.46 in dichloromethane:methanol 9:1, v/v). 4-(4-(prop-2-
ynyloxy)butoxy)benzaldehyde (0.70 g, 2.86 mmol) and   sodium metabisulfite (0.54 g, 
2.86 mmol ) in  water ( 1.00 mL) was added into it and the reaction mixture was refluxed 
for 6h.  Volatiles were evaporated under reduced pressure. The crude product was 
purified by column chromatography on a silica gel using  dichloromethane-methanol as 
eluent to afford the desired product as pale yellow gummy solid (0.70 g, 61 %): Rf = 0.50 
(in dichloromethane-methanol 9:1 v/v); IR (neat, cm
-1
)  3231 (alkyne C-H stretch) , 2941 
(aromatic C-H stretch), 2867, 2230 (alkyne C-C stretch), 2060,  1608, 1416, 1257, 1171, 
1098, 1104, 836, 738, 632;  
1
H NMR (500 MHz, methanol-d4) 7.98 (dd, J1 = 8.90 Hz, 
J2 = 2.00 Hz,  2H), 7.93 (br, 1H), 7.59-7.55 (m, 2H),  6.99 (dd, J1 = 8.65, J2 = 2.00,  2H), 




(s, 3H), 3.55 (t, J = 6.40 Hz, 2H),  3.39 (s, 3H), 2.85 (t, J = 2.26 Hz, 1H, -
CH2OCH2CCH), 1.84-1.78 (m, 2H), 1.74-1.68 (m, 2H) (Imino proton was not observed 
because of exchange with the NMR solvent) ; 
13
C NMR (75 MHz, methanol-d4)  170.5, 
161.1, 154.1, 140.5, 138.4, 128.1, 127.6, 122.7, 121.2, 114.6, 113.6,  79.5, 74.3, 69.4, 

















carbaldehyde (DPA 154-c).To a solution of N-methoxy-N-methyl-2-(4-(4-(prop-2-
ynyloxy)butoxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide (0.70 g, 1.71 mmol) in 
THF-ether (80.0 mL, 3:1), lithium aluminum hydride (0.26 g, 6.58 mmol) was added  at -
78 

C  and then allowed to  warm up and stir  at 0 

C  for 6 h . The reaction mixture was 
quenched by the addition of saturated ammonium chloride solution (100 mL). The grey 
solid that precipitated out was filtered off. The filtrate was extracted with ethyl acetate (3 
× 75 mL). Organic layers were combined and dried over sodium sulfate. Volatiles were 
removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel using hexanes-ethyl acetate (0-80 % ethyl acetate in 
hexanes) yielded the desired compound as a light yellow liquid (0.33 g, 55 %);  Rf = 0.65 
(ethyl acetate-hexane 8:2  v/v); IR (neat, cm
-1




(alkyne C-C stretch),  1686, 1604,  1498, 1424,  1249,  1089, 1008, 836, 7 660; 
1
H NMR 
(500 MHz, methanol-d4)  9.99 (s, 1H), 8.08 (s, br, 1H),  8.00 (dd, J1 = 8.82 Hz, J2 = 1.95 
Hz, 2H), 7.80 (dd, J1 = 8.28 Hz, J2 = 1.46 Hz, 1H), 7.67 (s, br, 1H), 7.05 (dd, J1 = 9.06 
Hz, J2 = 2.01 Hz, 2H) , 4.18 (d, J = 2.32 Hz, 2H, -CH2OCH2CCH), 4.05 (t, J = 6.32 Hz, 
2H, -OCH2CH2-), 3.61 (t, J = 6.27 Hz, 2H),  2.87 (t, J = 2.56 Hz, 1H, -CH2OCH2CCH), 
1.91-1.85 ( m, 2H),  1.80-1.75 (m, 2H) (Imino proton was not observed because of 
exchange with the NMR solvent); 
13
C NMR (75 MHz, methanol-d4) 192.4, 161.4, 
131.7, 128.3, 123.7, 120.0, 114.7, 79.4, 74.2, 69.1, 67.5, 57.3, 29.13, 25.73, 25.70 (Four 
aromatic carbon peaks were not observed likely  because of aggregation of the molecule) 
; MS (MALDI-TOF) m/z for C21H20N2O3 [M]
+ 















2,5'-bibenzo[d]imidazole (DPA 154). To a solution of 5-(4-methylpiperazin-1-yl)-2-
nitroaniline (0.21 g, 0.91 mmol) in ethanol- ethyl acetate mixture (20.0 mL), Pd-C (0.15 
g) was added and the mixture was hydrogenated for 5h at the atmospheric pressure. TLC 
on silica gel showed complete reduction of the starting material. Charcoal was filtered 
off. To this, 2-(4-(4-(prop-2-ynyloxy)butoxy)phenyl)-1H-benzo[d]imidazole-6-
carbaldehyde (0.32 g, 0.91 mmol) and a solution of Na2S2O5 (0.17 g, 0.91 mmol) in water 
(1.00 mL) was added. The mixture was refluxed for 12h following which it was allowed 




mixture was purified by column chromatography  on a silica gel column using  
dichloromethane-methanol as eluent ( 0-15 % methanol in dichloromethane) which 
afforded the desired product as yellow solid (0.29 g, 60 %): Rf = 0.40 (dichloromethane-
methanol 8:2 v/v); mp 150-155 ºC; IR (neat, cm
-1
) 3409 (N-H wagging), 2934 (aromatic 
C-H stretch), 2857, 2236 (alkyne C-C stretch), 2062, 1970, 1630, 1433, 1252, 1205, 
1009, 796; 
1
H NMR (300 MHz, methanol-d4) 8.21 (d, J = 1.11 Hz, 1H) 7.98 (dd,  J1 = 
8.86 Hz, J2 = 2.00 Hz, 2H), 7.91 (dd, J1 = 8.46 Hz, J2 = 1.75 Hz, 1H), 7.65 (d, J = 8.46 
Hz, 1H), 7.50 (d, J = 8.86 Hz, 1H), 7.14 (d, J = 2.00 Hz, 1H), 7.04-7.00 (m, 3H), 4.17 (d, 
J = 2.47 Hz, 2H), 4.01 (t, J = 6.15 Hz, 2H), 3.59 (t, J = 6.14 Hz, 2H), 3.34-3.30 (Some 
peaks masked with NMR solvent signal) 3.03 (t, J = 4.63 Hz, 4H),  2.86 (t, J = 2.32 Hz, 
1H), 2.66 (s, 3H), 1.88-1.72 (m, 4H) (Imino protons were not observed because of 
exchange with the NMR solvent); 
13
C NMR (75 MHz, methanol-d4)  161.1, 153.9, 
152.4, 147.4, 138.9, 134.5, 129.9, 128.1 (two peaks), 124.2, 121.3, 121.0, 115. 1,115.0, 
114.5, 112.1, 101.3, 79.4, 74.2, 71.2, 69.1, 67.5, 63.5, 57.3, 54.2, 49.3, 43.5, 25.7; MS 






Synthesis of 6-(prop-2-ynyloxy) hexan-1-ol.
1
 To a solution of 1, 6 hexanediol (7.00 g, 
59.2 mmol) in dry THF (60.0 mL), sodium hydride (1.08 g, 45.0 mmol) was added under 
argon at 0 

C and stirred for 30 min. To this, propargyl bromide (5.00 g, 42.0 mmol) was 
added and stirred at 0 

C for another 30 minutes. The mixture was allowed to warm to 




on silica gel. The reaction was quenched by pouring the reaction mixture into water. The 
mixture was extracted with diethyl ether (3 × 100 mL). The organic layers were 
combined and dried with sodium sulfate. The volatiles were evaporated and the crude 
product was purified by column chromatography on a silica gel column using hexanes–
ethyl acetate as eluent to afford the desired product pale yellow oil (2.80 g, 42 %): Rf = 
0.31 (hexanes-ethyl acetate 7:3 v/v); IR (neat, cm
-1
) 3399 (-OH H-bonded), 3297 (alkyne 
C-H stretch), 2937 (aromatic C-H stretch), 2868, 2120 (alkyne C-C stretch), 1711,  1462, 
1360, 1241, 1090, 669; 
1
H NMR (300 MHz, CDCl3)  4.07 (d, J = 2.3 Hz, 2H, -
CH2OCH2CCH), 3.54 (t, J = 6.7 Hz, 2H, -OCH2CH2-), 3.46 (t, J = 6.6 Hz, 2H), 2.56 (br, 
1H), 2.41 (t, J = 2.3 Hz, 1H, -CH2OCH2CCH), 1.58-1.48 (m, 4H), 1.35-1.28(br, m, 4H); 
13





Synthesis of 4-(6-(prop-2-ynyloxy)hexyloxy)benzaldehyde (DPA 155-a). To a solution of 
p-hydroxybenzaldehyde (1.50 g, 12.2 mmol) in dry dichloromethane-dioxane (30.0 mL, 
dichloromethane: dioxane 4:1, v/v), triphenyl phosphine (4.75 g, 18.2 mmol) and 6-
(prop-2-ynyloxy) hexan-1-ol (1.87 g, 12.2 mmol) were added and the solution was ice 
cooled. To this, diisopropyl azodicarboxylate (DIAD) (3.66 g, 18.2 mmol) was added at 0 

C slowly over 15 min.  The contents were initially stirred at 0 

C for 30 min and then at 
room temperature overnight. Progress of the reaction was monitored by thin layer 




gummy residue was dissolved in 100 mL (1:1 v/v) ethyl acetate:hexanes and was allowed 
to stand in the refrigerator for a day. The precipitated solid was filtered off and the filtrate 
was concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using hexanes-ethyl acetate as eluent  which afforded the 
desired compound as pale yellow liquid (1.10 g, 32 %): Rf = 0.73 (hexane:ethyl acetate 
6.5:3.5, v/v); IR (neat, cm
-1
)  3288 (alkyne C-H stretch), 2945 (aromatic C-H stretch), 
2859, 2160 (alkyne C-C stretch), 2060,  1683, 1593, 1503, 1315, 1254, 1164, 1106, 1025,  
841, 661, 620; 
1
H NMR (500 MHz, CDCl3)  9.88 (s, 1H), 7.83 (d, J = 8.77 Hz, 2H), 
6.99 (d, J = 8.77 Hz, 2H), 4.15 (d, J = 2.29 Hz, 2H, -CH2OCH2CCH), 4.05 (t, J = 6.30 
Hz, 2H, -OCH2CH2-), 3.54 (t, J = 6.67 Hz, 2H), 2.44 (t, J = 2.48 Hz, 1H, -
CH2OCH2CCH), 1.86-1.81 (m, 2H), 1.68-1.62 (m, 2H), 1.54-1.43 (m, 4H); 
13
C NMR 
(125 MHz, CDCl3)  190.7, 164.2, 131.9, 129.8, 114.7, 80.0, 74.1, 70.0, 68.2, 58.0, 29.4, 
29.9, 25.8, 25.7; MS MALDI-TOF  m/z  calcd for C16H20O3 260.32, found 261.87 
[M+H]
+















3, 4 dinitrobenzamide (0.93 g, 3.65 mmol) in ethanol-ethyl acetate mixture (40.0 mL, 3:1 
v/v), 10% Pd-C (0.30 g) was added. Hydrogenation for 5h at the atmospheric pressure 
yielded corresponding diamine which was (after filtration of the catalyst) used without 
further characterization (Rf = 0.46 in dichloromethane:methanol 9:1, v/v). 4-(6-(prop-2-
ynyloxy) hexyloxy) benzaldehyde (0.95 g, 3.65 mmol) and   sodium metabisulfite (0.69 
g, 3.65 mmol) in water (1.00 mL) was added into it and the reaction mixture was refluxed 
for 6h.  Volatiles were evaporated under reduced pressure. The crude product was 
purified on a silica gel column using  dichloromethane-methanol (0-10 % methanol in 
dichloromethane) as eluent to afford the desired product as thick brown liquid (1.15 g, 73 
%): Rf  = 0.56 (in dichloromethane-methanol 9:1 v/v); IR (neat, cm
-1
)  3327 (alkyne C-H 
stretch), 2933 (aromatic C-H stretch), 2859, 2180 (alkyne C-H stretch),1617, 1491, 1254, 
1172, 1094, 1021, 849, 743, 661; 
1
H NMR (500 MHz, acetone-d6) 12.23 (br, 1H), 8.18 
(dd, J1 = 8.98 Hz, J2 = 2.05 Hz,  2H), 7.97 (br, 1H), 7.59 (br, 2H),  7.07 (d, J1 = 8.84, J2 = 
1.83,  2H), 4.14 (d, J = 2.15 Hz, 2H, -CH2OCH2CCH), 4.06 (t, J = 6.47 Hz, 2H, -
OCH2CH2-),  3.61 (s, 3H), 3.52 (t, J = 6.68 Hz, 2H),  3.35 (s, 3H), 2.95 (t, J = 2.37 Hz, 
1H, -CH2OCH2CCH), 1.83-1.77 (m, 2H), 1.64-1.58 (m, 2H), 1.54-1.41 (m, 4H) ; 
13
C 
NMR (125 MHz, acetone-d6)  170.1, 161.0, 153.4, 131.6, 128.3, 128.2, 122.7, 122.5,  
114.8, 114.1,  80.3, 74.6, 71.1, 69.4, 67.9, 67.8,  60.2, 57.4, 33.3, 29.4, 25.7, 25.6; MS 
(MALDI-TOF) m/z calcd for C25H29N3O4 [M]
+ 















carbaldehyde (DPA 155-c). To a solution of  N-methoxy-N-methyl-2-(4-(6-(prop-2-
ynyloxy)hexyloxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide (1.00 g, 2.37 mmol) in 
THF-ether (80.0 mL, 3:1), lithium aluminum hydride (0.26 g, 6.93 mmol) was added  at -
78 

C under argon and then allowed to  stir  at 0 

C  for 8h . The reaction mixture was 
quenched by the addition of saturated ammonium chloride solution (50.0 mL). The 
resulting grey precipitate was filtered off. The filtrate was extracted with ethyl acetate (3 
× 50 mL). Organic layers were combined and dried over sodium sulfate. Volatiles were 
removed under reduced pressure. The crude product was purified by column 
chromatography using hexanes-ethyl acetate  (0-80 % ethyl acetate in hexanes) as eluent 
to give the desired compound  as sticky light yellow solid (0.36 g, 42 %): Rf = 0.51 (ethyl 
acetate-hexanes 8:2 v/v); IR (neat, cm
-1
)  2929 (aromatic C-H stretch), 2855, 1687 (C=O 
stretch), 1605, 1262, 1184, 1094, 1012, 824, 743; 
1
H NMR (500 MHz, methanol-d4)   
10.04 (s, 1H), 8.13 (s, br, 1H),  8.06 (dd, J1 = 8.83 Hz, J2 = 1.99 Hz), 2H), 7.84 (dd, J1 = 
8.35 Hz, J2 = 1.29 Hz, 1H), 7.72 (s, br, 1H), 7.10 (dd, J1 = 8.81 Hz, J2 = 2.01 Hz, 2H) , 




(t, J = 6.46 Hz,  2H) 2.85 (t, J = 2.26 Hz, 1H, -CH2OCH2CCH),  1.85-1.81 (m, 2H),  
1.67-1.62 (m, 2H), 1.58-1.45(m, 4H) ( Imino proton was not observed because of 
exchange with the NMR solvent); 
13
C NMR (75 MHz, methanol-d4) 192.4, 171.5, 
161.5, 155.2, 139.5, 131.7, 128.3, 127.9, 123.7, 120.9, 115.9, 114.6, 79.4, 74.2, 69.5, 
67.7, 57.3, 29.0, 28.8, 25.5, 25.4; MS (MALDI-TOF) m/z for calcd for C23H24N2O3 














Synthesis of 6-(4-methylpiperazin-1-yl)-2'-(4-(6-(prop-2-ynyloxy) hexyloxy) phenyl)-1H, 
3’H-2, 5’-bibenzo[d]imidazole (DPA 155). To a solution of 5-(4-methylpiperazin-1-yl)-
2-nitroaniline (0.20 g, 0.87 mmol) in ethanol- ethyl acetate mixture (20.0 mL, 3:1 v/v), 
Pd-C (0.10 g) was added followed by hydrogenation for  5 h at the atmospheric pressure. 
Catalyst was filtered off. To this, 2-(4-(6-(prop-2-ynyloxy) hexyloxy) phenyl)-1H-
benzo[d]imidazole-6-carbaldehyde (0.33 g, 0.87 mmol) and a solution of Na2S2O5 (0.16 
g, 0.87 mmol) in water (1.00 mL) was added and the mixture was refluxed overnight. The 
reaction mixture was brought to room temperature. Volatiles were removed reduced 
pressure.  The crude mixture was purified by column chromatography on a silica gel 
column using dichloromethane-methanol as eluent to  afford the desired product as 
yellow solid (0.27 g, 56 % ): Rf = 0.44 (dichlormethane-methanol 8:2 v/v); mp 178-180 
ºC; IR (neat, cm
-1
) 3390 (alkyne C-H stretch), 2942 (aromatic C-H stretch), 2853, 2259 
(alkyne C-C stretch), 2128, 1611, 1452, 1256, 1175, 1020, 989, 816; 
1




methanol-d4) 8.21 (br, 1H) 7.99-7.91 (m, 3H), 7.65 (d, J = 8.56 Hz, 1H), 7.50 (d, J = 
8.65 Hz, 1H ), 7.12 (d, J = 1.79 Hz, 1H)  7.05-6.99 (m, 3H),  4.13 (d, J = 2.31 Hz , 2H), 
3.94 (t, J = 6.48 Hz, 2H), 3.52 (t, J = 6.33 Hz, 2H),  3.22 (t, J = 4.64 Hz, 4H), 2.84 (t,  J = 
2.42 Hz, 1H), 2.71 (t, J = 4.71 Hz, 4H),  2.41 (s, 3H), 1.77-1.70 (m, 2H), 1.64-1.55 (m, 
2H), 1.54-1.36 (m, 4H) (Imino protons were not observed due to exchange with the NMR 
solvent); 
13
C NMR (75 MHz, DMSO-d6)  160.7, 153.2, 147.9, 135.9, 132.5, 132.0, 
129.3, 129.1, 128.7, 124.9, 122.7, 121.5, 120.8, 116.5, 115.3, 114.1, 109.2, 81.6, 77.3, 
69.5, 68.1, 57.7, 55.1, 50.1, 45.8, 31.1, 29.3, 29.0, 25.8, 25.7;  MS (MALDI-TOF) m/z 
cald for C34H38N6O2 562.30, found 562.52 [M]
+






 To a solution of 1, 8 octanediol (8.00 g, 54.7 
mmol) in dry THF (60.0 mL), sodium hydride (1.08 g, 45.0 mmol) was added under 
argon at 0 

C. The mixture was stirred for 30 min at 0 

C. To this, propargyl bromide 
(4.00 g, 35.0 mmol) was added and stirred at 0 

C for another 30 min. The reaction 
mixture was allowed to warm to room temperature and stirred overnight. The progress of 
reaction was monitored using TLC on silica gel. The reaction was quenched by pouring 
the mixture in water followed by extraction with diethyl ether (3 × 100 mL). The organic 
layers were combined and dried with sodium sulfate. The volatiles were evaporated under 
reduced pressure and the remaining liquid residue was purified by column 
chromatography on silica gel using hexanes–ethyl acetate (0-50 % ethyl acetate in 




= 0.41 (hexanes:ethyl acetate 7:3  v/v); IR (neat, cm
-1
)  3382 (O-H H-bonded), 3288 
(alkyne C-H stretch), 2953 (aromatic C-H stretch), 2872,  2128 (alkyne C-C stretch), 
1709, 1462, 1364, 1102,  669; 
1
H NMR (500 MHz, CDCl3) 4.12 (d, J = 2.74 Hz, 2H, 
CH2OCH2CCH), 3.60 (t, J = 6.62 Hz, 2H, -OCH2CH2-), 3.49 (t, J = 6.62 Hz, 2H), 2.42 
(t, J = 2.28 Hz, 1H, -CH2OCH2CCH), 1.96 (br, s, 1H), 1.60-1.51 (m, 4H), 1.36-1.30 (m, 
8H); 
13







Synthesis of 4-(8-(prop-2-ynyloxy)octyloxy)benzaldehyde (DPA 156-a). To a solution of 
p-hydroxybenzaldehyde (0.82 g, 6.73 mmol) in dry dichloromethane-dioxane (30.0 mL, 
dichloromethane: dioxane 2:1, v/v), triphenyl phosphine (2.64 g, 10.1 mmol) and 8-(prop-
2-ynyloxy) octan-1-ol (1.24 g, 6.73 mmol) were added and the solution was ice cooled. 
To this, diisopropyl azodicarboxylate (DIAD) (2.03 g, 10.1 mmol) was added at 0 

C 
slowly over 15 min.  The contents were initially stirred at 0 

C for 30 min and then at 
room temperature overnight. Progress of the reaction was monitored by thin layer 
chromatography on silica gel. The solvents were removed under reduced pressure. The 
gummy residue was dissolved in 40.0 mL ethyl acetate:hexane (1:1 v/v)  and left in the 
refrigerator for a day. The precipitated solid was filtered off and the filtrate was 
concentrated under reduced pressure. The crude product was purified by  column 




compound as white solid (1.18 g, 40 %): Rf = 0.67 (hexanes:ethyl acetate 7:3 v/v); mp 50-
52 ºC; IR (neat, cm
-1
) 3293 (alkyne C-H stretch), 2993 (aromatic C-H stretch), 2855, 
1695 (C=O stretch), 1601, 1580, 1511,  1319, 1249, 1155, 1094, 1008, 829,  641; 
1
H 
NMR (500 MHz, CDCl3)  9.91 (s, 1H), 7.85 (d, J = 8.60 Hz, 2H), 7.01 (d, J = 8.60 Hz, 
2H), 4.16 (d, J = 2.20 Hz, 2H, -CH2OCH2CCH), 4.06 (t, J = 5.96 Hz, 2H, -OCH2CH2-), 
3.54 (t, J = 6.39 Hz, 2H), 2.44 (t, J = 1.99 Hz, 1H, -CH2OCH2CCH), 1.86-1.81 (m, 2H), 
1.64-1.60 (m, 2H), 1.53-1.47 (m, 2H), 1.43-1.36 (m, 6H); 
13
C NMR (125 MHz, CDCl3)  











benzo[d]imidazole-6-carboxamide (DPA 156-b). To solution of   N- Methoxy, N-methyl 
3, 4 dinitrobenzamide (0.88 g, 3.47 mmol) in ethanol-ethyl acetate mixture (40.0 mL, 3:1 
v/v), Pd-C (10%) (0.30 g) was added. Hydrogenation for 5h at the atmospheric pressure 
yielded corresponding diamine which was (after filtration of catalyst) used without 
further characterization (Rf = 0.46 in dichloromethane:methanol 9:1, v/v). 4-(8-(prop-2-
ynyloxy) octyloxy) benzaldehyde (1.00 g, 3.47 mmol) and   sodium metabisulfite (0.66 g, 




for 6h.  Volatiles were evaporated under reduced pressure. The crude product was 
purified by column chromatography on  silica gel using  dichloromethane-methanol as 
eluent to afford the desired product as sticky pale yellow sticky solid (1.35 g, 87 %): Rf = 
0.75 (in dichloromethane-methanol 9:1 v/v); IR (neat, cm
-1
) 3432 (N-H wagging), 2946 
(aromatic C-H stretch), 2853, 2112 (alkyne C-H stretch), 1630 (C=O stretch), 1256, 
1175, 1101; 
1
H NMR (500 MHz, acetone-d6) 12.27 (br, 1H), 8.19 (dd, J1 = 8.83 Hz, J2 
= 2.05 Hz,  2H), 7.97 (br, 1H), 7.60 (2H),  7.06 (d, J1 = 8.77, J2 = 2.53,  2H), 4.13 (d, J = 
2.14 Hz, 2H, -CH2OCH2CCH), 4.05 (t, J = 6.43 Hz, 2H, -OCH2CH2-),  3.61 (s, 3H), 3.49 
(t, J = 6.43 Hz, 2H),  3.35 (s, 3H), 2.94 (t, J = 2.14 Hz, 1H, -CH2OCH2CCH), 1.82-1.78 
(m, 2H), 1.60-1.55 (m, 2H), 1.51-1.45 (m, 2H), 1.41-1.32 (m, 6H) ; 
13
C NMR (125 MHz, 
acetone-d6) 170.1, 161.0, 153.4, 135.7, 128.3, 128.2, 122.7, 122.5,  114.8, 80.3, 74.5, 
71.1, 69.9, 69.5, 67.9, 60.2, 57.4,  33.3, 29.3, 29.2, 29.0;  MS (MALDI-TOF) m/z calcd. 
for C27H33N3O4 [M]
+ 









carbaldehyde (DPA 156-c). To a solution of  N-methoxy-N-methyl-2-(4-(8-(prop-2-
ynyloxy)octyloxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide (1.21 g, 2.61 mmol) in 






C under argon and then allowed to  stir  at 0 

C  for 8h . The reaction mixture was 
quenched by the addition of saturated ammonium chloride solution (100 mL). The 
resulting grey precipitate was filtered off. The filtrate was extracted with ethyl acetate (3 
× 50 mL). Organic layers were combined and then dried over sodium sulfate. Volatiles 
were removed under reduced pressure. The crude product was purified by column 
chromatography using ethyl acetate-hexane (0-80 % ethyl acetate in hexanes) as eluent to 
give the desired compound as  light yellow liquid (0.85 g, 81 %): Rf = 0.73 (ethyl acetate-
hexane 8:2 v/v); mp 84-86 ºC; IR (neat, cm
-1
) 3411 (N-H wagging), 3304 (alkyne C-H 
stretch), 2928 (aromatic C-H stretch), 2839, 2107 (alkyne C-C stretch), 1719 (C=O 
stretch), 1637, 1469, 1339, 1106, 938, 717,  628; 
1
H NMR (500 MHz, methanol-d4)   
9.94 (s, 1H), 8.02 (s, br, 1H),  7.93 (dd, J1 = 8.76 Hz, J2 = 1.89 Hz), 2H), 7.74 (dd, J1 = 
8.08 Hz, J2 = 1.25 Hz, 1H), 7.62 (s, br, 1H), 6.95 (dd, J1 = 8.84 Hz, J2 = 1.82 Hz, 2H) , 
4.11 (d, J = 2.38 Hz, 2H, -CH2OCH2CCH), 3.88 (t, J = 6.57 Hz, 2H, -OCH2CH2-), 3.48 
(t, J = 6.34 Hz,  2H) 2.83 (t, J = 2.38 Hz, 1H, -CH2OCH2CCH),  1.72-1.67 ( m, 2H),  
1.56-1.51 (m, 2H), 1.41-1.26 (m, 8H) (Imino proton was not observed due to exchange 
with the NMR solvent); 
13
C NMR (75 MHz, methanol-d4) 192.3, 161.4, 131.6, 128.2, 
123.7, 120.8, 114.6, 79.5, 74.2, 69.6, 67.8, 57.3, 29.13, 29. 07, 29.05, 28.9, 25.7, 25.6; 




















Synthesis of 6-(4-methylpiperazin-1-yl)-2'-(4-(8-(prop-2-ynyloxy) octyloxy) phenyl)-1H, 
3’H-2, 5’-bibenzo[d]imidazole (DPA 156). To a solution of 5-(4-methylpiperazin-1-yl)-
2-nitroaniline (0.35 g, 1.50 mmol) in ethanol- ethyl acetate mixture (40.0 mL, 3:1 v/v), 
Pd-C (0.10 g) was added and then it was hydrogenated for  5h at the atmospheric 
pressure. Catalyst was filtered off. To this, 2-(4-(8-(prop-2-ynyloxy) octyloxy) phenyl)-
1H-benzo[d]imidazole-6-carbaldehyde (0.61 g, 1.50 mmol) and a solution of Na2S2O5 
(0.28 g, 1.50 mmol) in water (1.00 mL) was added. The mixture was refluxed overnight. 
The reaction mixture was brought to room temperature. Volatiles were removed reduced 
pressure.  The crude mixture was purified by column chromatography on a silica gel 
column using dichloromethane-methanol (0-15 % methanol in dichloromethane) as 
eluent to  afford the desired product as yellow solid (0.62 g, 71% ): Rf = 0.35 
(dichlormethane-methanol 8:2 v/v); mp 174-176 ºC; IR (neat, cm
-1
) 3405 (N-H wagging), 
2927 (aromatic C-H stretch), 2846, 1634 (C=O stretch), 1437, 1256, 1178, 1086; 
1
H 
NMR (500 MHz, methanol-d4) 8.18 (br, 1H) 7.91-7.89 (m, 3H), 7.63 (d, J = 7.65 Hz, 
1H), 7.48 (d, J = 8.20 Hz, 1H ), 7.09 (s, br, 1H), 7.00 (dd, J1 = 8.47 Hz, J2 = 1.91 Hz, 
1H),  6.89 (d, J = 8.46 Hz, 2H), 4.11 (d, J = 2.19 Hz , 2H, -CH2OCH2CCH), 3.80 (t, J = 
6.48 Hz, 2H, -OCH2CH2-), 3.47 (t, J = 6.28 Hz, 2H), 3.19 (t, J = 3.55 Hz, 4H), 2.84 (t,  J 
= 2.45 Hz, 1H, -CH2OCH2CCH), 2.65 (t, J = 4.10 Hz, 4H),  2.37 (s, 3H), 1.66-1.61 (m, 
2H), 1.55-1.50 (m, 2H), 1.35-1.22 (m, 8H); 
13




153.8, 152.3, 146.1, 134.8, 133.1, 120.8, 124.1, 121.2, 120.9, 115.6, 114.8, 114.4, 100.5, 
79.5, 74.1, 71.4, 70.3, 69.6, 67.7, 67.4, 57.3, 54.7, 50.3, 48.4, 44.6, 29.1, 29.06, 29.03, 
28.8, 25.7, 25.6; MS (MALDI-TOF) m/z cald for C36H42N6O2 590.33, found 590.60 [M]
+




Synthesis of 10-(prop-2-ynyloxy) decan-1-ol. To a solution of 1, 10 decanediol (4.00 g, 
22.9 mmol)  in dry THF, sodium hydride (0.48 g, 20.0 mmol) was added under argon at 0 

C. The mixture was stirred for 30 min at 0 

C. To this, propargyl bromide (2.37 g, 20.0 
mmol) was added and stirred at 0 

C for another 30 min and then at room temperature for 
24h. The progress of reaction was monitored using TLC on silica gel. The reaction 
mixture was quenched by pouring the mixture into water. The mixture was extracted with 
diethyl ether (3 × 100 mL). The organic layers were combined at dried with sodium 
sulfate. The volatiles were evaporated under reduced pressure. The crude product was 
purified by column chromatography on  silica gel using hexanes-ethyl acetate (0-50 % 
ethyl acetate in hexanes) as eluent to afford the desired product (2.40 g, 50 %): Rf = 0.74 
(hexanes-ethyl acetate 60:40 v/v); IR (neat, cm
-1
) 3411 (O-H H-bonded), 3304 (alkyne C-
H stretch), 2928 (aromatic C-H stretch), 2107 (alkyne C-C stretch), 1719, 1637, 1469, 
1339, 1106, 938, 717, 628;  
1
H NMR (500 MHz, CDCl3)  4.14 (d, J = 2.4 Hz, 2H, -
CH2OCH2CCH), 3.63 (t, J = 6.2 Hz¸ 2H, -OCH2CH2-), 3.51 (t, J = 6.5 Hz, 2H), 2.43 (t, J 
= 2.3 Hz, 1H, -CH2OCH2CCH), 1.64-1.52 (m, 4H), 1.40-1.30 (br, 12H) (The hydroxyl 













Synthesis of 4-(10-(prop-2-ynyloxy)decyloxy)benzaldehyde (DPA 158-a). To a solution of 
p-hydroxybenzaldehyde (1.00 g, 8.18 mmol) in dry dichloromethane-dioxane mixture 
(40.0 mL 3:1 v/v), triphenyl phosphine (3.20 g, 12.1 mmol) and 10-(prop-2-
ynyloxy)decan-1-ol (1.73 g, 8.18 mmol) were added and the solution was ice cooled. To 
this, diisopropyl azodicarboxylate (2.44 g, 12.1 mmol) was added at 0 

C slowly over 15 
min.  The contents were initially stirred at 0 

C for 30 minutes and then at room 
temperature overnight. Progress of the reaction was monitored by thin layer 
chromatography on silica gel. The crude mixture was concentrated and redissolved in 
ethyl acetate-hexanes mixture {80.0 mL, 1:1 (v/v)} and kept in the refrigerator for a day. 
The solid crashed out was filtered off and the filtrate was concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel 
(hexanes-ethyl acetate (0-50 % ethyl acetate in hexanes) afforded the desired compound 
as white solid (0.93 g, 36 %): Rf = 0.73 (hexanes-ethyl acetate 7:3); mp 52-53 ºC; IR 
(neat) cm
-1 
3251 (alkyne C-H stretch), 2942 (aromatic C-H stretch), 2853, 2116 (alkyne 
C-C stretch), 1692 (C=O stretch), 1599, 1499, 1252, 1159, 1093, 1001. 835;
  1
H NMR 
(300 MHz, CDCl3)  9.88 (s, 1H), 7.83 (dd, J1 = 8.8 Hz, J2 = 1.9 Hz, 2H), 6.99 (d, J = 8.7 




3.51 (t, J = 6.6 Hz, 2H), 2.43 (t, J = 2.30 Hz, 1H, -CH2OCH2CCH),  1.86-1.77 ( m, 2H), 
1.65-1.56 (m, 2H), 1.46-1.32 (br, 12H); 
13
C NMR (75 MHz, CDCl3)   190.7, 164.2, 
131.9, 129.7, 114.7, 80.0, 76.6, 74.0, 70.2, 68.4, 58.0, 30.9, 29.5, 29.4, 29.3, 29.2, 29.0, 









benzo[d]imidazole-6-carboxamide (DPA 158-b). To solution of   N- Methoxy, N-methyl 
3, 4 dinitrobenzamide (0.64 g, 2.84 mmol) in ethanol-ethyl acetate mixture (20.0 mL 3:1 
v/v), 0.20 g of 10 % Pd-C was added. It was then hydrogenated for 5h at the atmospheric 
pressure to afford corresponding diamine which was used without purification after 
filtration of the catalyst.  4-(10-(prop-2-ynyloxy)decyloxy)benzaldehyde (0.90 g, 2.84 
mmol) and   sodium pyrosulfite (0.54 g, 2.84 mmol ) in  water ( 1.00 mL) were added 
into it and the reaction mixture was refluxed for 10h. Volatiles were evaporated under 
educed pressure. The crude product was purified on a silica gel column using  
dichlromethane-methanol (0-8 % methanol in dichloromethane) as eluent to afford the 
desired product as slightly yellow solid (0.86 g, 70 %):  Rf = 0.85  {dichloromethane-
isopropanol  9:1 (v/v)}; IR (neat cm
-1
) 2930 (aromatic C-H stretch), 2849, 2116 (alkyne 
C-C stretch), 1611, 1425, 1252, 1178, 1093, 1016, 819, 731;  
1




acetone-d6)   8.17 (d, J1 =  8.8 Hz, J2 = 1.9 Hz¸ 2H), 8.04-7.88(br,1H), 7.66- 7.53 (br, 
3H), 7.09 (d, J1 = 8.8 Hz, J2 = 1.9 Hz¸ 2H), 4.13 (d, J = 2.30 Hz, 2H, -CH2OCH2CCH), 
4.08 (t, J = 6.5 Hz, 2H, -OCH2CH2-), 3.61 (s, 3H), 3.49 (t, J = 6.4 Hz¸ 2H), 3.34 (s, 3H), 
2.92 (t, J = 2.4 Hz¸ 1H, -CH2OCH2CCH), 1.85-1.76 ( m, 2H), 1.59-1.30 (m, 14H) (Imino 
proton was not observed likely because of exchange with the NMR solvent); 
13
C NMR 
(75 MHz, acetone-d6)  170.0, 160.9, 153.6, 153.1, 146.2, 136.7, 134.3, 128.2, 122.9, 
122.5, 119.3, 117.9, 114.7, 111.5, 110.2, 80.3, 74.5, 69.5, 67.9, 60.2, 57.4, 33.2, 25.8 
(some carbon peaks are merged with the NMR solvent peak); MS (MALDI-TOF) m/z 











158-c). To a solution of N-methoxy, N-methyl-2-(4-(10-(prop-2-
ynyloxy)decyloxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide (0.80 g, 1.62 mmol) in 
THF-ether (80.0 mL, 3:1 v/v), lithium aluminum hydride (0.18 g, 4.8 mmol) was added  
at -78 

C under argon and then allowed to  stir  at 0 

C overnight . The reaction mixture 
was quenched by the addition of saturated ammonium chloride solution (75.0 mL). The 
resulting grey precipitate was filtered off. The filtrate was extracted with ethyl acetate (3 




were removed under reduced pressure. Column Chromatography on silica gel using  
hexanes-ethyl acetate (0- 80 % ethyl acetate in hexanes)  as eluent yielded the desired 
compound as a light yellow solid (0.43 g, 61 %):  Rf = 0.68 { ethyl acetate-hexanes 7:3 
(v/v)}; mp 124-126 ºC; IR (neat, cm
-1
) 3228 (alkyne C-H stretch), 2923 (aromatic C-H 
stretch), 2846, 1688 (C=O stretch), 1618, 1456, 1290, 1244, 1070, 850; 
1
H NMR (300 
MHz, acetone-d6)  10.09 (s, 1H), 8.22-8.05 (br, 3H),7.82-7.62 (2H), 7.13 (d,  J = 8.0 Hz, 
2H), 4.12 (br, 4H), 3.49 (t,  J = 6.4 Hz, 2H), 1.88-1.76 ( m, 2H), 1.57-1.25 (m, 14H) 
(Terminal alkyne proton is water peak coming from the NMR solvent  at  2.90. Imino 
proton was not observed likely because of the exchange with the NMR solvent); 
13
C 
NMR (75 MHz, DMSO-d6)  192.9, 161.1, 154.9, 131.4, 128.9, 123.4, 122.1, 115.3, 
81.0, 77.2, 69.5, 68.2, 60.2, 57.7, 29.4, 29.3, 29.2 (two peaks), 26.0, 25.9; MS (MALDI-















1H,3'H-2,5'-bibenzo[d]imidazole (DPA 158). To a solution of 5-(4-methylpiperazin-1-
yl)-2-nitroaniline (0.16 g, 0.78 mmol) in ethanol- ethyl acetate mixture (20.0 mL), 10 % 
Pd-C (80 mg) was added followed by hydrogenation for 5h at the atmospheric pressure. 
TLC on silica gel showed complete reduction of the starting material. Charcoal was 
filtered over a bed of celite. To the filtrate, 2-(4-(10-(prop-2-ynyloxy)decyloxy)phenyl)-




(0.15 g, 0.78 mmol) in water (1.00 mL) was added and the mixture was refluxed for 14h. 
Volatiles were removed under reduced pressure. The crude product was purified by 
column chromatography on silica gel using dichloromethane-methanol ( 0-15 % 
methanol in dichloromethane) as eluent to afford the pure product as yellow solid (0.24 g,  
55 %): Rf = 0.38 ( dichloromethane - methanol 8:2 v/v); mp 162-164 ºC; IR (neat, cm
-1
) 
3397 (N-H wagging), 2930 (aromatic C-H stretch), 2846, 2112 (alkyne C-C stretch), 
1630 (C=O stretch), 1452, 1252, 1182, 1097, 1009; 
1
H NMR (300 MHz, methanol-d4) 
8.25 (br, 1H) 8.03-7.94 (br, 3H), 7.68 (d, br, 1H), 7.52 (d, br, 1H), 7.14 (br, 1H), 7.06-
7.03 (m, 3H), 4.12 (t, J = 4.6Hz , 2H), 3.99 (br, 2H), 3.52-3.48 (2H), 3.24 (br, 4H), 2.83-
2.81 (t, J = 2.18 Hz, 1H), 2.73 (br, 4H),  2.42 (s, 3H), 1.77-1.68 (m, 2H), 1.57-1.33 (14H) 
(Imino protons were not observed because of exchange with solvent); 13C NMR (125 
MHz, DMSO-d6)  160.7, 153.4, 147.9, 145.5, 144.6, 136.0, 128.7, 125.0, 122.7, 121.5, 
120.8, 119.0, 116.4, 115.3, 111.8, 109.3, 81.0, 77.2, 69.6, 68.2, 61.6, 57.7, 55.2, 50.2, 
49.0, 45.9, 29.6, 29.4, 29.2(2), 29.1, 26.0, 25.9, 15.6  ; MS (MALDI-TOF) m/z calcd. for 






Synthesis of 12-(prop-2-ynyloxy) dodecan-1-ol.
1
 To a solution of 1, 12 dodecanediol 
(6.00 g, 29.6 mmol) in dry THF, sodium hydride (0.64 g, 27.0 mmol) was added under 
argon at 0 

C. The mixture was stirred for 30 min at 0 

C. To this, propargyl bromide 
(3.21 g, 27.0 mmol) was added and stirred at 0 

C for another 30 min and then at room 




extracted with diethyl ether (3 × 100 mL). The organic layers were combined and dried 
with sodium sulfate. The volatiles were evaporated under reduced pressure. The crude 
mixture was purified  on a silica gel column using petroleum ether-ethyl acetate as eluent 
to afford the desired product as brown oil (3.20 g, 49 %): Rf = 0.55 (hexanes-ethyl acetate 
60:40 v/v);  IR (neat, cm
-1
) 3411 (O-H H-bonded), 3308 (alkyne C-H stretch), 2924 
(aromatic C-H stretch), 2851, 2111 (alkyne C-C stretch), 1698, 1469, 1355, 1224, 1102, 
664; 
1
H NMR (300 MHz, CDCl3)  4.07 (d, J = 2.3 Hz, 2H), 3.54 (t, J = 6.5 Hz, 2H), 
3.45 (t, J = 6.5 Hz, 2H), 2.39 (t, J = 2.4 Hz, 1H), 1.58-1.44 (m, 4H), 1.24-1.17(br, 16H); 
13
C NMR (75 MHz, CDCl3) 79.9, 76.7, 74.1, 70.1, 62.6, 57.8, 32.6, 30.8, 29.55, 29.51, 






Synthesis of 4-(12-(prop-2-ynyloxy)dodecyloxy)benzaldehyde (DPA 157-a). To a solution 
of p-hydroxybenzaldehyde (1.00 g, 8.18 mmol) in dry dichloromethane-1,4 dioxane (40.0 
mL, 3:1 v/v), triphenyl phosphine (3.17 g, 12.1 mmol)  were added under argon and the 
solution was ice cooled. 12-(prop-2-ynyloxy)dodecan-1-ol (1.96 g, 8.18 mmol) was 
added into it. To this, diisopropyl azodicarboxylate (DIAD) (2.44 g, 12.1 mmol) was 
added at 0 

C slowly over 15 min.  The contents were initially stirred at 0 

C for 30 min 
and then at room temperature overnight. Volatiles were removed under reduced pressure. 
The mixture was redissolved in ethyl acetate-hexanes (80.0 mL, 1:1 v/v). The crude 
mixture was then allowed to stand in the refrigerator for a day. The solid crashed out was 




was purified by column chromatography on silica gel using petroleum ether-ethyl acetate 
(0-80 % ethyl acetate in petroleum ether) as eluent to afford the desired compound as 
white solid (0.82 g, 30 %): Rf = 0.75 (petroleum ether-ethyl acetate 8:2 v/v); 
 1
H NMR 
(300 MHz, CDCl3) δ 9.89 (s, 1H), 7.83 (dd, J1 = 8.8 Hz, J2 = 2.5 Hz, 2H,), 7.00 (d, J = 
8.7 Hz, 2H), 4.15 (d, J = 2.4 Hz¸ 2H), 4.05 (t, J = 6.5 Hz, 2H), 3.52 (t, J = 6.6 Hz, 2H), 
2.43 (t, J = 2.30 Hz, 1H),  1.86-1.78 ( m, 2H), 1.65-1.56 (m, 2H), 1.46-1.20 (br, 16H); 
13
C NMR (75 MHz, CDCl3)    190.8, 164.2, 131.9, 129.7, 114.7, 80.0, 74.0, 70.3, 68.4, 









benzo[d]imidazole-6-carboxamide (DPA 157-b). To solution of   N-Methoxy, N-methyl 
3, 4 dinitrobenzamide (0.59 g, 2.31 mmol) in ethanol-ethyl acetate mixture (20.0 mL, 1:1 
v/v), 10% Pd-C (0.20 g) was added. Hydrogenation for 5h at the atmospheric pressure 
afforded corresponding diamine which was (after filtration of the catalyst) used without 
purification. 4-(12-(prop-2-ynyloxy)dodecyloxy)benzaldehyde (0.97 g, 2.31 mmol) and 
sodium metabisulfite (0.43 g, 2.31 mmol ) in  water (1.00 mL) were added into it and the 
reaction mixture was refluxed overnight. Volatiles were evaporated under reduced 




dichloromethane-isopropanol (0-10 % isopropanol in dichloromethane)  as eluent to 
afford the desired product as sticky yellow solid (0.32 g, 27 %): Rf = 0.64 
(dichloromethane-isopropanol 9:1 v/v);  
1
H NMR (500 MHz, acetone-d6)  12.0 (s, br, 
1H), 8.18 (d, J = 8.8 Hz, 2H), 8.05-7.87(br, 1H), 7.67- 7.53 (br, 2H), 7.10 (d, J1 = 8.8 Hz, 
J2 = 2.0 Hz, 2H), 4.13-4.08 (m, 4H), 3.62 (s, 3H), 3.49 (t, J = 6.6 Hz, 2H), 3.35 (s, 3H), 
2.92 (t, J = 2.4 Hz, 1H),  1.85-1.79 ( m, 2H), 1.59-1.48 (m, 4H), 1.42-1.28 (14H); 
13
C 
NMR (125 MHz, acetone-d6)  170.0, 160.9, 131.8, 128.7, 128.6, 128.2, 122.9, 122.5, 
114.8 (two peaks), 111.5, 110.1, 80.3, 74.5, 69.5, 67.9, 60.1, 57.4, 33.2, 28.5, 21.3 (seven 
carbon peaks merged with the NMR solvent peak); MS (MALDI-TOF)  m/z calcd for 










Synthesis of compound 2-(4-(12-(prop-2-ynyloxy)dodecyloxy)phenyl)-1H-
benzo[d]imidazole-6-carbaldehyde (DPA 157-c). To a solution of N-methoxy-N-methyl-
2-(4-(12-(prop-2-ynyloxy)dodecyloxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide 
(0.30 g, 0.57 mmol) in THF-ether (20.0 mL, 2:1 v/v), lithium aluminum hydride (0.06 g, 
1.70 mmol) was added  at -78 

C under argon and then allowed to  stir  at 0 

C  for 24 h . 
TLC on silica gel was used to monitor the progress of the reaction. The reaction mixture 




resulting grey precipitate was filtered off. The aqueous mixture was extracted with ethyl 
acetate (3 × 75 mL). Organic layers were combined and then dried over sodium sulfate. 
Volatiles were removed under reduced pressure.  The crude product was purified by 
column chromatography using  hexanes:ethyl acetate (0-80 % ethyl acetate in hexanes) as 
eluent to afford the desired compound as a light yellow solid (0.24 g, 91 %): Rf = 0.63 
(hexanes-ethyl acetate 4:6 v/v); 
1
H NMR (500 MHz, acetone-d6)  10.08 (s, 1H), 8.22-
8.06 (br, 3H),7.81-7.79 (2H), 7.11 (d, J = 8.9 Hz, 2H), 4.13-4.08 (m, 4H), 3.48 (t, J = 6.5 
Hz, 2H) 2.92 (t, J = 2.4 Hz, 1H),  1.86-1.77 ( m, 2H), 1.58-1.45 (m, 2H), 1.41-1.26 (m, 
16H) (Imino proton was not observed likely because of the exchange with the NMR 
solvent); 
13
C NMR (125 MHz, acetone-d6)  191.4, 161.3, 144.5, 132.5, 131.8, 131.1, 
128.7, 128.4, 123.0, 122.0, 119.0, 114.8, 113.3, 80.2, 74.5, 69.5, 67.9, 67.4, 57.3, 38.7, 
30.2, 26.0, 25.8, 23.6, 22.7, 21.3, 13.4;    MS (MALDI-TOF)  m/z calcd for C29H36N2O3 












Synthesis of Compound 6-(4-methylpiperazin-1-yl)-2'-(4-(12-(prop-2-
ynyloxy)dodecyloxy)phenyl)-1H,3'H-2,5'-bibenzo[d]imidazole (DPA 157). To a solution 
of 5-(4-methylpiperazin-1-yl)-2-nitroaniline (0.12 g, 0.50 mmol) in ethanol- ethyl acetate 
mixture (20 mL 1:1 v/v), Pd-C (75 mg) was added and then it was hydrogenated for 5h at 




corresponding diamine. After filtering the catalyst, 2-(4-(12-(prop-2-
ynyloxy)dodecyloxy)phenyl)-1H-benzo[d]imidazole-6-carbaldehyde (0.24 g, 0.52 mmol) 
and a solution of Na2S2O5 (0.09 g, 0.50 mmol) in water (0.50 mL) were added. The 
mixture was refluxed for 20h. It was then allowed to come to the room temperature. 
Volatiles were removed under reduced pressure. The crude mixture was purified on a 
silica gel column using dichloromethane-methanol (0-15 % methanol in 
dichloromethane) to afford the desired product as yellow solid (0.13 g, 40 %): Rf = 0.37 
(dichloromethane-methanol 8:2 v/v); mp 135-140 ºC; IR (neat, cm
-1
) 3382 (alkyne C-H 
stretch), 2969 (aromatic C-H stretch), 1649, 1576, 1468, 1240, 1005; 
1
H NMR (300 
MHz, methanol-d4) 8.23 (br, 1H) 8.02-7.99 (br, 2H), 7.92 (d, J = 7.5 Hz, 1H), 7.68-
7.65 (d, J = 7.9 Hz, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.13-7.02 (4H), 4.09-3.98 (4H), 3.48 
(2H), 3.20 (t, J = 4.3Hz, 4H), 2.90-2.79 (5H) 2.14 (s, 3H), 1.84-1.66 (m, 2H),1.60-
1.20(m, 18H) (Imino protons were not observed likely because of the exchange with the 
NMR solvent); 
13
C NMR (125 MHz, methanol-d4)  161.8, 148.0, 128.1, 124.2, 121.4, 
115.0, 114.6, 79.4, 74.0, 69.6, 67.8, 57.2, 54.6, 50.1, 29.2, 25.6 (all carbon atoms were 
not observed because of aggregation effects); MS (MALDI-TOF) m/z calcd for 












 To a solution of hexaethylene 
glycol in dry THF (10.0 g, 35.4 mmol) at 0 

C, sodium hydride (0.77 g, 32 mmol) was 
added and the mixture was stirred for 30 min. To this, propargyl bromide (3.8 g, 32 




stirring was continued for 20 h. Water (200 mL) was added to this mixture and then 
extracted with ethyl acetate (3 × 200 mL). Organic layers were combined and dried with 
sodium sulfate. Volatiles were evaporated under reduced pressure. and the crude product 
was purified using ethyl acetate-acetone as eluent to afford the desired compound as light 
brown oil (4.8 g, 46 %): Rf = 0.39 (ethyl acetate: acetone 7:3 v/v); 
1
H NMR (500 MHz, 
CDCl3)  4.16 (d, J = 2.00 Hz, 2H), 3.69-3.55 (m, 24H), 2.85 (t, J = 5.75 Hz, 1H), 2.43 
(t, J = 2.25 Hz, 1H); 
13
C NMR (125 MHz, CDCl3)  79.6, 74.5, 72.5, 70.5, 70.3, 70.3, 











Synthesis of 4-(3,6,9,12,15,18-hexaoxahenicos-20-ynyloxy)benzaldehyde (DPA 159-a). 
To a solution of p-hydroxybenzaldehyde (1.50 g, 12.5 mmol) in dry dichloromethane-
dioxane (50.0 mL, 4:1 v/v), triphenyl phosphine (4.70 g, 18.0 mmol) and 3,6,9,12,15,18-
hexaoxahenicos-20-yn-1-ol (4.00 g, 12.5 mmol) were dissolved and the solution was ice 
cooled. To this, diisopropyl azodicarboxylate (3.60 g, 18.0 mmol) was added drop wise 
over a period of 15 min at 0 

C.  The contents were initially stirred at 0 

C for 30 min and 
then at room temperature overnight. The volatiles were removed under reduced pressure 
and the mixture was redissolved in ethyl acetate-hexane (60.0 mL, 1:1 v/v) and allowed to 
sit in the refrigerator overnight. The precipitated solid was filtered and the filtrate was 
concentrated under reduced pressure. The crude product was purified by column 




hexane ) and then ethyl acetate-acetone (0-10% v/v acetone in ethyl acetate) as eluent, 
afforded the desired compound as pale yellow oil (4.80 g, 90 %): Rf = 0.63 (ethyl acetate-
acetone 7:3 v/v); IR (neat cm
-1
) 3247 (alkyne C-H stretch) , 2871 (aromatic C-H stretch), 
2111 (alkyne C-C stretch), 1694 (C=O stretch), 1600, 1502, 1437, 1347, 1261, 1110, 832, 
726, 542;  
 1
H NMR (500 MHz, CDCl3)  9.85(s, 1H), 7.80 (dd, J1 = 1.82 Hz, J2 = 8.80 
Hz, 2H), 7.00 (dd, J1 = 1.73 Hz, J2 = 8.62 Hz, 2H), 4.18 (m, 4H), 3.86 (t, J = 4.88 Hz, 
2H), 3.72-3.62 (m, 20H), 2.44 (t, J = 2.59 Hz, 1H); 
13
C NMR ( 125 MHz, CDCl3)  















methyl-1H-benzo[d]imidazole-6-carboxamide (DPA 159-b). To a solution of   N- 
Methoxy, N-methyl 3, 4 dinitrobenzamide (0.90 g, 3.53 mmol) in ethanol-ethyl acetate 
mixture (50.0 mL, 3:1 v/v), Pd-C (10%) (400 mg) was added. Hydrogenation for 5h at the 
atmospheric pressure yielded corresponding diamine which was used without further 
characterization after filtration of the catalyst over a bed of celite (Rf = 0.46 in 
dichloromethane:methanol 9:1, v/v). 4-(3,6,9,12,15,18-hexaoxahenicos-20-




) in  water ( 1.00 mL) was added into it and the reaction mixture was refluxed for 6h.  
The reaction mixture was allowed to come to room temperature. The volatiles were 
evaporated under reduced pressure. The crude product was purified on a silica gel column 
using  dichloromethane-methanol (0-10% methanol in dichloromethane) as eluent to 
afford the desired product as pale yellow solid (0.85 g, 41 %): Rf = 0.48 (in 
dichloromethane:methanol 9:1 v/v); IR (neat, cm
-1
) 3247 (alkyne C-H stretch), 2876 
(aromatic C-H stretch), 2116 (alkyne C-C stretch), 1614, 1449, 1259, 1101, 843;  
1
H 
NMR (500 MHz, methanol-d4)  8.06 (dd, J1 = 8.79 Hz, J2 = 2.04 Hz,  2H), 7.96 (br, 
1H), 7.64 (d, J = 8.18 Hz, 1H), 7.59 (dd, J1 = 8.38 Hz, J2 = 1.53 Hz, 1H),  7.12 (dd, J1 = 
8.79, J2 = 1.84,  2H), 4.21 (t, J = 4.30 Hz, 2H),  4.17 (d, J = 2.35 Hz, 2H), 3.87 (m, 2H),  
3.72-3.60 (m, 23H), 3.42 (s, 3H), 2.86 (t, J = 2.25 Hz, 1H) (Imino proton was not 
observed likely because of the exchange with the NMR solvent); 
13
C NMR (75 MHz, 
methanol-d4)  170.5, 161.0, 154.0, 134.6, 131.3, 128.2, 127.7, 122.7, 121.6, 115.8, 
114.8, 113.7, 79.2, 74.5, 70.40, 70.21, 70.15, 70.12, 69.93, 69.32, 69.15, 68.69, 67.46,  
60.1, 57.6, 33.3 (some carbon peaks are overlapped on each other); MS (MALDI-TOF) 
m/z calcd. for C31H41N3O9 [M]
+ 



















carbaldehyde (DPA 159-c). To a solution of  2-(4-(3,6,9,12,15,18-hexaoxahenicos-20-
ynyloxy)phenyl)-N-methoxy-N-methyl-1H-benzo[d]imidazole-6-carboxamide (0.85 g, 
1.41 mmol) in THF-ether (100 mL, 3:1 v/v), lithium aluminum hydride (0.32 g, 8.40 
mmol) was added  at -78 

C under argon and then allowed to  stir  at 0 

C  overnight . 
The reaction mixture was quenched by addition of saturated ammonium chloride solution 
(50.0 mL). The resulting grey precipitate was filtered off. The filtrate was extracted with 
ethyl acetate (3 × 100 mL). Organic layers were combined and then dried over sodium 
sulfate. Volatiles were removed under reduced pressure. The crude product was purified 
by column chromatography using dichloromethane-isopropanol as eluent to give the 
desired compound yielded the  as a light yellow liquid (0.42 g, 56 %): Rf = 0.72 
(dichloromethane-isopropanol 9:1 v/v); IR (neat, cm
-1
)  2871 (aromatic C-H stretch), 
1972, 1690 (C=O stretch), 1604, 1498, 1441, 1290, 1249,  1106, 954, 852; 
1
H NMR (500 
MHz, methanol-d4)   10.03 (s, 1H), 8.13 (s, br, 1H),  8.07 (dd, J1 = 8.82 Hz, J2 = 1.93 
Hz, 2H), 7.84 (dd, J1 = 8.32 Hz, J2 = 1.33 Hz, 1H), 7.72 (s, br, 1H), 7.14 (dd, J1 = 8.74 
Hz, J2 = 1.96 Hz, 2H) , 4.23 (t, J = 4.26 Hz, 2H),  4.18 (d, J = 2.19 Hz, 2H), 3.89 (m, 2H), 
3.74-3.60 (m, 20H) 2.86-2.82 (t, J = 2.41 Hz, 1H); 
13
C NMR (75 MHz, methanol-d4) 
192.4, 161.2, 155.3, 134.6, 131.7, 128.3 (two peaks), 123.7, 121.3, 115.8, 115.8, 114.8, 
79.2, 74.5, 71.6, 70.40, 70.21, 70.15, 69.93, 69.30, 69.14, 68.6, 67.4, 57.6 (some carbon 
peaks are masked with the NMR solvent peak) ; MS (MALDI-TOF) m/z  calcd for 
C29H36N2O8 540.24, found 541.08 ([M+H]
+






















methylpiperazin-1-yl)-1H,3'H-2,5'-bibenzo[d]imidazole (DPA 159). To a solution of 5-
(4-methylpiperazin-1-yl)-2-nitroaniline (0.18 g, 0.78 mmol) in ethanol- ethyl acetate 
mixture (40.0 mL, 3:1 v/v), Pd-C (0.10 g) was added and then it was hydrogenated for  5h 
at the atmospheric pressure. Catalyst was filtered off. To this, 2-(4-(3,6,9,12,15,18-
hexaoxahenicos-20-ynyloxy)phenyl)-1H-benzo[d]imidazole-6-carbaldehyde (0.42 g, 0.78 
mmol) and a solution of Na2S2O5 (0.15 g, 0.78 mmol) in water (1.00 mL) was added and 
the mixture was refluxed overnight. The reaction mixture was brought to room 
temperature. Volatiles were removed under reduced pressure.  The crude mixture was 
purified by column chromatography on a silica gel and eluted with dichloromethane-
methanol (0-20 % methanol in dichloromethane) to  afford the desired product as yellow 
solid (0.38 g, 66% ): Rf = 0.44 (dichlormethane-methanol 8:2 v/v); mp 134-138 ºC; IR 
(neat, cm
-1
) 3402 (N-H wagging), 3186 (alkyne C-H stretch), 2871 (aromatic C-H 




H NMR (500 MHz, 
methanol-d4) 8.23 (br, 1H) 8.00 (d, J = 8.82 Hz, 2H), 7.93 (dd, J1 = 8.58 Hz, J2 = 1.45 
Hz, 1H),  7.66 (d, J = 8.38 Hz, 1H), 7.50 (d, J = 8.71 Hz, 1H ), 7.12 (d, J = 1.78 Hz, 1H),  
7.02 (m, 3H), 4.16 (d, J = 2.51 Hz, 2H), 4.11 (t, J = 4.16 Hz, 2H), 3.80 (t, J = 4.36 Hz, 




4.56 Hz, 4H),  2.41 (s, 3H) (Imino protons were not observed likely because of the 
exchange with the NMR solvent); 
13
C NMR (75 MHz, methanol-d4)  159.3, 152.2, 
150.7, 146.5, 146.3, 137.5, 133.0, 126.6, 122.6, 120.1, 119.5, 114.3, 113.6, 113.5, 113.3, 
113.1, 111.0, 99.3, 77.6, 73.0, 71.1, 70.0, 68.79, 68.59, 68.53, 68.48, 68.32, 67.73, 67.53, 
67.08, 65.7, 62.0, 56.0, 53.1, 48.6, 42.9, 27.3 ;  MS (MALDI-TOF) m/z cald for 
C40H50N6O7 726.37, found 726.17 [M]
+







































C NMR  spectrum of DPA151-b. 
 





















C NMR spectrum of DPA151-c. 
 
 










































C NMR spectrum of DPA 152-a. 
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C NMR spectrum of DPA 152-b. 
 
















C NMR spectrum of DPA 152-c. 
 





IR spectrum  of DPA 152-c. 
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MALDI-TOF spectrum of DPA 152. 
 
 








H NMR spectrum of DPA 153-a. 
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C NMR spectrum of DPA 153-b. 
 















C NMR spectrum of DPA 153-c. 
 
 





IR spectrum  of DPA 153-c. 
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C NMR spectrum  of  DPA 153. 
 









































































































































































































































































































































































































































































































































IR spectrum of DPA 155-c. 
 
 
























































































































































































































































































































H NMR spectrum of DPA 158-c 
 

















C NMR spectrum of DPA 158. 
 















































C NMR spectrum of DPA 157-b. 
 





























C NMR spectrum  of DPA 157. 
 
















C NMR spectrum of 3,6,9,12,15,18-hexaoxahenicos-20-yn-1-ol  
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MALDI-TOF spectrum of DPA 159-b. 
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Evaluation of Nucleic Acid Binding and Biological Activity of  








































































































































































































































































































































































































































Figure S1.  UV thermal denaturation profiles of all ligands studied with dA60.dT60 
duplex.  The DNA duplex (1 M / duplex) was mixed with various ligands (as indicated 




C ( at a rate of 0.2 

C / min) in buffer 10 mM sodium cacodylate, 0.1 mM EDTA and 





 Figure S2a.  
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Figure S2c. IR spectrum of DPA 101. 
 







Figure S3a.  
1
H NMR spectrum of DPA 102 in acetone-d6. 
 
Figure S3b.  
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Figure S3c.  IR spectrum of DPA 102. 
 

















Figure S4c. IR spectrum of DPA 103. 
 







H NMR of DPA 105 in methanol-d4. 
 






Figure S5c.  MALDI-TOF spectrum of DPA 105. 
 
 
 Figure S6a. 
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C NMR spectrum of DPA 108. 
 





Figure S6d. IR spectrum of DPA 108. 
 
Figure S7a.  
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Figure S7b.  
13
C NMR spectrum of DPA 112 in methanol-d4. 
 

















C NMR spectrum of DPA 851 in DMSO-d6. 
 
















C NMR spectrum of DPA 852 in DMSO-d6 
 
















Figure S10b. IR spectrum of DPA 854. 
 





Figure S11a.  
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Figure S11c. IR spectrum of DPA 855. 
 
















Figure S12c. IR spectrum of DPA 856. 
 





Figure S13a.  
1
H NMR spectrum of DPA 857 in D2O. 
 















Figure S14b. IR spectrum of DPA 858. 
 






Topoisomerase I inhibition results. 
 
 
Figure S15. Inhibitory activities of compounds (a) DPA152 and (b) DPA153 against E. 
coli DNA topoisomerase I. The E. coli DNA topoisomerase I inhibition assays were 
performed as described in materials and methods. The plasmid DNA molecules were 
isolated and subjected to 1% agarose gel electrophoresis in the absence of chloroquine. 
(a) Lanes 1 to 11 contain 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0 µM of DPA152, 
respectively. The bottom panel shows the The quantification analysis of the inhibitory 
activities of DPA152 (b) Lanes 1 to 11 contain 0, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0 6.0, 7.0, 8.0, 
10 µM of DPA153, respectively. Lane 12 is the supercoiled plasmid DNA pBAD-GFPuv. 








Figure S16. Inhibitory activities of compounds (a) DPA154 and (b) DPA157 against E. 
coli DNA topoisomerase I. The E. coli DNA topoisomerase I inhibition assays were 
performed as described in materials and methods. The plasmid DNA molecules were 
isolated and subjected to 1% agarose gel electrophoresis in the absence of chloroquine. 
(a) Lanes 1 to 11 contain 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0 µM of DPA154, 
respectively. Lane 12 is the supercoiled plasmid DNA pBAD-GFPuv. The bottom panel 
shows the The quantification analysis of the inhibitory activities of DPA154 (b) Lanes 1 
to 11 contain 0, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0 6.0, 7.0, 8.0, 10 µM of DPA157, respectively. 







Figure S17. Inhibitory activities of compounds (a) Hoechst 33342 and (b) Hoechst 33258  
against E. coli DNA topoisomerase I. The E. coli DNA topoisomerase I inhibition assays 
were performed as described in materials and methods. The plasmid DNA molecules 
were isolated and subjected to 1% agarose gel electrophoresis in the absence of 
chloroquine. (a) Lanes 1 to 11 contain 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 10.0 µM 
of Hoechst 33342, respectively. Lane 12 is the supercoiled plasmid DNA pBAD-GFPuv. 
The bottom panel shows the The quantification analysis of the inhibitory activities of 
Hoechst 33342. (b) Lanes 1 to 11 contain 0, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0 6.0, 7.0, 8.0, 10 
µM of Hoechst 33258, respectively. The bottom panel shows the quantification analysis 





Intercalative Binding of Bisbenzimidazole Unit of 












Synthesis of  DPA 151-d. 
  To a solution of DPA 151 (40.0 mg, 86.3 mol) in dry THF (20.0 mL), NaH was added 
(50.0 mg, 2.00 mmol) at 0 

C. After 15 min stirring, (Boc)2O (100 mg, excess)  was 
added to the mixture and it was allowed to  slowly warm to room temperature . After 5h, 
the reaction mixture was concentrated under the stream of nitrogen. The crude product 
was purified by column chromatography on silica gel (5 micron mesh size) using 
dichloromethane-methanol (0-20 % methanol in dichloromethane) as eluent to obtain the 
desired product which eluted as two rotamers which moved distinctly during the TLC 
analysis.  The rotamer I (Rf = 0.68 in dichloromethane:methanol 8.5:1.5 v/v) was obtained 
in 32 % yield and rotamer II (Rf = 0.59 in dichloromethane:methanol 8.5:1.5 v/v) was 
obtained in 19 % yield: 
1
H NMR (500 MHz, methanol-d4)(Rotamer I) 8.38 (d, J = 1.65 
Hz ,1H), 7.84 (d, J = 8.38 Hz, 1H), 7.70-7.64 (5H), 7.21-7.18 (m, 3H), 4.88 (d, J = 2.24 




4.78 Hz 4H),  2.45 (s, 3H), 1.47-1.40 (18H); MS (MALDI–TOF) m/z  calcd for 
C38H42N6O, 662.32, found 662.48 [M
+
]; (Rotamer II) 8.40 (d, J = 1.32 Hz, 1H), 7.99 (d, 
J = 9.04 Hz ,1H), 7.84 (d, J = 8.60 Hz, 1H) , 7.72 (dd, J1 = 8.2 Hz, J2 = 2.13 Hz , 1H), 
7.70-7.67 (m, 2H),  7.29- 7.18 (m, 4H), 4.88 (d, J = 2.39 Hz, 2H),  3.33 (peak masked by 
residual MeOH), 3.04 (t, J = 2.39 Hz, 1H), 2.78 (t, J = 4.51 Hz, 4H), 2.46 (s, 3H), 1.47-
































Synthesis of DPA 165 
 To a solution of diBoc protected DPA 151 (rotamer I, Rf = 0.65 in dichloromethane-
methanol v/v, 14.3 mg, 21.6 mol) in ethanol (1.00 mL), a solution of Boc protected 
neomycin-azide (26.8 mg, 21.6 mol) in ethanol (1.00 mL) was added followed by 
addition of a freshly made copper(I) catalyst made by adding aqueous solutions of CuSO4 
(1.40 mg, 9.00 mol) and sodium ascorbate (3.40 mg, 18.0 mol). The reaction mixture 
was stirred for 10h at room temperature under the darkness. TLC on silica gel indicated 




product was purified using column chromatography on silica gel using dichloromethane-
methanol (0-10 % methanol in dichloromethane) as eluent. This yielded Boc protected 
DPA 165 (26.3 mg, Rf  = 0.59 in dichloromethane: methanol 8.5:1.5, v/v). 
1
H NMR (500 
MHz, methanol-d4) 8.36 (br, 1H), 7.83 (d, J = 8.98 Hz, 1H), 7.71-7.56 (m, 5H), 7.29 (d, 
J = 8.88 Hz, 2H), 7.21 (d, J = 8.98 Hz, 1H), 7.12 (s, 1H), 6.68-6.58 (br, 2H), 5.45-5.36 
(m, 2H), 5.17 (s, br, 1H), 4.98 (2H), 4.74-4.29 (m, 3H), 4.20-3.88 (m, 2H), 3.79-3.37 (m, 
15H), some proton signals are masked with residual MeOH from NMR solvent, 2.89 (m, 
5H), 2.54 (s, 3H), 2.45-2.41 (m, 1H), 2.07-2.01 (m, 1H), 1.49-1.28 (m, 72H); 
MS(MALDI-TOF) m/z calcd. for C91H135N15NaO29 1924.94, found 1925.33 [M+H]
+
. 
 Boc protected DPA 165 (8.7 mg, 4.57 mol) was dissolved in dichloromethane (2.0 mL) 
followed by addition of trifluoroacetic acid (0.1 mL). The mixture was stirred for 4h at 
room temperature.  Water (2.0 mL) was added to it. The mixture was washed with 
dichloromethane (3 × 1 mL). The aqueous layer was lyophilized to afford the desired 
compound as pale yellow solid (5.9 mg, 38 % cumulative yield for two steps): UV max = 
338 nm in water; 
1
H NMR (500 MHz, D2O)  8.24 (s, 1H), 8.19 (s, 1H), 8.02-7.96 (m, 
3H), 7.88 (d, J = 8.55 Hz, 1H), 7.65 (d, J = 8.54 Hz. 1H), 7.29-7.11 (m, 4H), 6.02 (d, J = 
3.83 Hz, 1H), 5.35-5.34 (d, J = 3.34 Hz, 1H), 5.29 (s, br, 2H), 5.21 (s, br, 1H),  4.83-4.79 
(dd, J1 = 3.19Hz, J2 = 2.71 Hz, 1H), 4.50 (m, 1H), 4.38 (t, J = 4.63 Hz, 1H), 4.21 (t, J = 
4.63 Hz, 1H), 4.12 (t, J = 5.79 Hz, 1H), 4.02 (t, J = 8.68 Hz, 1H), 3.94 (t, J = 9.24 Hz, 
1H), 3.90-3.77 (m, 5H), 3.74 (s, br, 1H), 3.62-3.42 (m ,7H), 3.39-3.08 (m, 10H), 2.88 (s, 


















Synthesis of DPA 152-d 
To a solution of DPA 152 (60.0 mg, 0.12 mmol) in dry THF (20 mL) NaH was added 
(97.0 mg, 3.88 mmol) at 0 

C. After 30 min stirring, (Boc)2O (0.1 g, 0.45 mmol)  was 
added to the solution and the mixture  was allowed to  slowly warm to room temperature . 
After overnight stirring, the reaction mixture was concentrated under the stream of 
nitrogen and mixed with some silica powder (5 micron mesh size). The reaction mixture 
was purified using column chromatography on silica gel (5 micron mesh size) using 
dichloromethane-methanol (0-10 % methanol in dichloromethane) as eluent to obtain the 
desired product which eluted as two different rotamers (rotamer I 35.6 mg, 43 %; rotamer 
II 27.1 mg, 32 %) and a mixture of rotamer I and rotamer II (10 mg, 12 %): Rf  = (0.53 for 
rotamer I and 0.46 for rotamer II respectively in dichloromethane:methanol 9:1 v/v); 
1
H 
NMR (500 MHz, methanol-d4) (rotamer I) 8.37-8.20 (two sets of doublets, 8.37 (d, J = 
1.41 Hz) and 8.21 (d, J = 8.59 Hz), 1H), 7.97-7.82 (two sets of doublets, 7.97 (d, J = 1.46 
Hz) and 7.83 (d, J =  8.34 Hz), 1H),   7.72-7.61 (m, 5H), 7.20 (dd, J1 = 2.10 Hz , J2 = 
8.59 Hz, 1H), 7.11 (dd, J1 = 3.07 Hz, J2 = 8.59 Hz, 2H), 4.13 (t, J = 6.3 Hz,  2H), 3.34 




2.32-2.27 (m, 3H),  2.00- 1.94 (m, 2H), 1.78-1.72 (m, 2H), 1.48-1.40 (18H); 
13
C NMR 
(75 MHz, methanol-d4)160.8, 155.7, 152.5, 150.0, 148.5, 142.5, 135.7, 134.7, 133.2, 
130.7, 128.7, 125.8, 123.4, 119.8, 119.0, 118.3, 115.6, 113.5, 101.4, 86.0. 85.4, 83.2, 
68.4, 67.3, 54.6, 49.4, 44.6, 29.6, 27.9, 26.3, 24.8, 17.4 ;  MS (MALDI-TOF) m/z calcd 
for C41H48N6O5 704.36 found 704.31 [M]
+
. (rotamer II) 8.39-8.21 (two sets of doublets, 
8.39 (d, J = 1.40 Hz) and 8.22 (d, J = 8.54 Hz), 1H)  7.99 (d, J = 8.89 Hz, 1H),  7.84 (d, J 
= 8.20 Hz, 1H) ,  7.72 (dd, J1 = 1.47 Hz, Hz, J2 = 8.29 Hz, 1H), 7.68-7.65 (m, 2H), 7.14-
7.11 (m, 2H),   7.29- 7.22 (m, 2H),  4.14 (d, J = 6.30 Hz, 2H), 3.33 (peak masked by 
residual MeOH), 2.73 (t, J = 4.58 Hz, 4H), 2.42 (s, 3H), 2.33-2.27 (m, 3H), 2.01-1.95 (m 
, 2H), 1.79-1.72 (m, 2H), 1.49-1.43 (18H); MS (MALDI-TOF) m/z calcd for C41H48N6O5 





























Synthesis of DPA 166 
To a solution of Boc protected DPA152 (rotamer I, Rf = 0.53 in 




of Boc protected neomycin-azide (47.0 mg, 37.7 mol)  in ethanol (1.00 mL) was added 
followed by by addition of a freshly made copper(I) catalyst made by adding aqueous 
solutions of CuSO4 (1.6 mg, 10.0 mol) and sodium ascorbate (4.0 mg, 20.0 mol). The 
reaction mixture was stirred for 12h at room temperature. TLC on silica gel indicated 
formation of the product.  Solvents were evaporated under reduced pressure. The crude 
mixture was purified by column chromatography on silica gel (5 micron, mesh size) 
using dichloromethane-methanol (0-12 % methanol in dichloromethane) as eluent. This 
yielded diBoc protected DPA 166 (35.4 mg, Rf = 0.40 in dichloromethane: methanol 9:1 
v/v): 
1
H NMR (500 MHz, methanol-d4) 8.36 (br, 1H), 8.02-7.81 (m, 2H), 7.70-7.57 (m, 
4H), 7.20-7.11 (m, 4H), 6.72-6.58 (br, 2H), 5.44 (s, br, 1H), 5.19 (s, br, 1H), 5.17 (s, br, 
1H), 4.63-4.16 (m, 6H), 4.10-3.47 (m, 14H), 3.34 (some proton signals are masked with 
residual MeOH from NMR solvent), 3.29-3.19 (m, 3H), 2.87 (t, J = 6.19 Hz, 2H), 2.76 (s, 
br, 4H), 2.45 (s, 3H), 1.96-1.90 (m, br, 4H), 1.49-1.30 (m, 72H); MS(MALDI-TOF) m/z 
calcd. for C94H141N15NaO29 1968.94, found 1973.85 [M+5H]
+
. 
 The diboc protected neomycin-Hoechst 33258 conjugate was then dissolved in 
dichloromethane (3.0 mL) followed by addition of trifluoroacetic acid (0.4 mL). The 
mixture was stirred for 6h at room temperature.  Water (2.0 mL) was added to it. It was 
washed with dichloromethane (3 × 1 mL). The aqueous layer was lyophilized to afford 
the desired compound as pale yellow solid (32.3 mg, 40 % for two steps): UV max = 338 
nm in water; 
1
H NMR (500 MHz, D2O)   8.23 (s, br,  1H),  8.01-7.89 (m, 4H), 7.83 (s, 
br, 1H),  7.65 (d, J = 9.21 Hz, 1H), 7.28 (d,  J =  9.21  Hz, 1H), 7.25 (s, br, 1H),  7.12 (d, 




4.64-4.60 (peaks overlapping with HDO signal),  4.51-4.46 (m, 1H),  4.35 (t, J = 4.41 Hz, 
1H), 4.22 (t, J = 4.21 Hz, 1H), 4.13 (t, J = 2.37 Hz, 1H), 4.09- 4.03 (m, 2H),  4.01- 3.91 
(m, 2H), 3.88-3.78 (m, 4H), 3.74 (s, br, 1H), 3.68 (t, J  = 3.27 Hz, 1H), 3.60-3.56 (3H),  
3.52-3.05 (m ,14H), 2.89 (s, 3H), 2.42-2.36 (m, 1H), 1.83-1.72(m, 5H); MS (MALDI-













Synthesis of DPA 153-d 
To a solution of DPA 153 (0.10 g, 0.17 mmol) in dry THF (40.0 mL) NaH was added 
(0.10 g, 4.16 mmol) at 0 

C. After 30 min stirring, (Boc)2O (0.20 g, 0.91 mmol) was 
added to the solution and the mixture  was allowed to  slowly warm to room temperature . 
After overnight stirring, the reaction mixture was concentrated under the stream of 
nitrogen and mixed with small amount of silica powder (5 micron mesh size). The crude 
product was purified by column chromatography on silica gel (5 micron mesh size) using 
dichloromethane-ethanol (0-15 % methanol in dichloromethane) as eluent to obtain the 
desired product which eluted as two different rotamers  (rotamer I 33.7 mg, 25% and 
rotamer II 42.0 mg, 31 %) and a mixture of rotamer I and rotamer II (41.4 mg, 31%) : Rf 
= (0.38 for rotamer I and 0.23 for rotamer II respectively in dichloromethane:ethanol 9:1 
v/v); 
1
H NMR (300 MHz, methanol-d4) (rotamer I) 8.36-8.19 (two sets of doublets, 8.36 




= 1.1 Hz) and 7.81 (d, J =  8.28 Hz), 1H),   7.72-7.60 (m, 5H), 7.20 (dd, J1 = 2.30 Hz , J2 
= 8.90 Hz, 1H), 7.11 (dd, J1 = 2.01 Hz, J2 = 8.79 Hz, 2H), 4.10 (t, J = 6.26 Hz,  2H), 3.34 
(some peaks masked by residual MeOH peak from the NMR solvent), 2.72 (t, J = 4.71 
Hz, 4H), 2.42 (s, 3H) , 2.21-2.16 (m, 2H),  1.89- 1.79 (m, 2H), 1.58-1.37 (m, 30H); 
13
C 
NMR (75 MHz, methanol-d4) 160.9, 155.7, 152.6, 150.0, 148.5, 142.5, 141.2,  138.7 
135.7, 134.7, 130.7, 128.7, 125.8, 123.6, 119.0, 118.2, 115.7, 113.8, 101.4, 86.0. 85.4, 
83.7, 67.9, 67.8, 54.6, 49.5, 44.6, 33.4,  29.2, 29.1, 29.0, 28.8, 28.7 (two peaks),  28.3 
(two peaks), 26.4, 25.7; MS (MALDI-TOF) m/z calcd for C46H58N6O5 774.44 found 
774.03 [M]
+
. (rotamer II)  
1
H NMR (300 MHz, methanol-d4) 8.38-8.19 (two sets of 
doublets, 8.38 (d, J = 1.1 Hz) and 8.21 (d, J = 8.47 Hz), 1H)  7.99-7.82 (m, 2H),  7.73-
7.63 (m, 3H),  7.28-7.20 (m, 2H),   7.09 (dd, J1 = 1.92 Hz , J2 =  8.68, 2H),  4.09 (t, J = 
6.20 Hz, 2H), 3.33 (peak masked by residual MeOH), 2.72 (t, J = 4.74 Hz, 4H), 2.41 (s, 
3H), 2.20-2.15 (m, 2H), 1.88-1.79 (m , 2H), 1.55-1.30 (30H); 
13
C NMR (75 MHz, 
methanol-d4) 161.0, 155.5, 154.0. 149.4, 142.7, 141.2, 138.7, 134.6, 133.2, 130.7, 
128.4, 125.9, 123.3, 120.0, 118.2, 116.3, 114.8, 113.3, 105.4, 86.0, 85.5, 83.6, 67.9, 67.8, 
54.6, 49.5, 44.6, 33.4, 29.2, 29.1, 29.0, 28.8, 28.7, 28.3, 26.4, 26.3, 25.7,17.6;  MS 

































Synthesis of DPA 167. 
To a solution of diBoc protected DPA153 (rotamer I 28.7 mg, 37.0 mol) in ethanol 
(3.50 mL), a solution of Boc protected neomycin-azide (46.0 mg, 37.0 mol)  in ethanol 
(1.00 mL) was added followed by addition of a freshly made copper(I) catalyst made by 
adding aqueous solutions of CuSO4 (1.60 mg, 10.0 mol) and sodium ascorbate (3.96 
mg, 20.0 mol). The reaction mixture was stirred for 42h at room temperature. TLC on 
silica gel indicated formation of the product.  Solvents were evaporated under reduced 
pressure. The crude mixture was purified by column chromatography on silica gel (5 
micron, mesh size) using dichloromethane-ethanol (0-12 % ethanol in dichloromethane) 
as eluent. This yielded Boc protected DPA 166 (35.2 mg, Rf = 0.45 in dichloromethane: 
ethanol 9:1 v/v). The starting material alkyne was also recovered (11.2 mg).  The Boc 
protected neomycin-Hoechst 33258 conjugate was then dissolved in dichloromethane 
(3.0 mL) followed by addition of trifluoroacetic acid (0.6 mL). The mixture was stirred 




dichloromethane (3 × 1 mL). The aqueous layer was lyophilized to afford the desired 
compound as pale yellow solid (24 mg, 30 %  cumulative yield for two steps): UV max = 
339 nm in water; 
1
H NMR (500 MHz, D2O)   8.14 (br, 1H),  7.98-7.77 (m, 6H), 7.61 (d, 
J = 8.83 Hz, 1H),  7.24-7.06 (br, 3H), 5.94 (d,  J = 3.08 Hz, 1H), 5.34-5.33 (br, 2H), 5.20 
(s, br, 1H), 4.66 (peaks overlapping with HDO signal),  4.50-4.46 (m, 2H),  4.36 (t, J = 
5.23 Hz, 2H), 4.21 (t, J = 5.23 Hz, 2H), 4.12 (t, J = 3.35 Hz, 1H), 4.04- 3.94 (m, 4H), 
3.87-3.66 (m, 6H), , 3.61-3.55 (3H),  3.50 (br , 2H), 3.45- 3.08 (m, 16H), 2.88 (s, 3H), 
2.86 (br, 1H), 2.62-2.58 (m, 2H), 2.40-2.34 (m, 1H), 1.87-1.79 (m, 1H), 1.68-1.16(m, 














Synthesis of DPA154-d 
To a solution of DPA 154 (0.11 g, 0.20 mmol) in dry THF (60.0 mL), NaH was added 
(0.05 g, 2.08 mmol) at 0 

C. After stirring for 30 min on ice, (Boc)2O (0.20 g, 0.90 mmol)  
was added to the solution and the mixture  was allowed to  slowly warm to room 
temperature . The stirring was continued overnight following which the reaction mixture 
was concentrated under the stream of nitrogen. The reaction mixture was mixed with 
small amount of silica (5 micron mesh size). The crude product was purified by column 




12 % methanol in dichloromethane) as eluent to obtain the desired product which eluted 
as two rotamers (rotamer I, 25.2 mg, 17 % and rotamer II, 18.1 mg, 19 %) and a mixture 
of rotamer I and rotamer II (64.8 mg, 42%)} : Rf = (0.61 for rotamer I and 0.54 for 
rotamer II respectively in dichloromethane:ethanol 8.5:1.5 v/v); 
1
H NMR (500 MHz, 
methanol-d4) (rotamer I) 8.37-8.20 (two sets of doublets, 8.37 (d, J = 1.43 Hz) and 8.20 
(d, J = 8.61 Hz), 1H), 7.97-7.83 (two sets of doublets, 7.97 (d, J = 1.46 Hz) and 7.84 (d, J 
=  8.37 Hz), 1H),   7.72-7.62 (m, 5H), 7.21 (dd, J1 = 8.86 Hz , J2 = 2.40 Hz, 1H), 7.11 
(dd, J1 = 8.85 Hz, J2 = 1.19 Hz, 2H), 4.19 (d, J = 2.39 Hz, 2H), 4.15 (t, J = 6.22 Hz,  2H),  
3.64 (t, J = 6.45 Hz, 2H), 3.34 (some peaks masked by residual MeOH peak from the 
NMR solvent), 2.87 (t, J = 2.39 Hz, 1H), 2.80 (br, 4H) 2.47 (s, 3H) , 1.95- 1.91 (m, 2H), 
1.84-1.79 (m, 2H) 1.48-1.36 (18H); MS (MALDI-TOF) m/z calcd for C42H50N6O6 
734.37, found 734.20 [M]
+
; (rotamer II) 
1
H NMR (500 MHz, methanol-d4) 8.39-8.20 
(two sets of doublets, 8.39 (d, J = 1.42 Hz) and 8.21 (d, J = 8.52 Hz), 1H)  7.99-7.83 (two 
sets of doublets 7.98 (d,  J = 8.98 Hz),  7.84 (d, J = 8.15 Hz) 2H) ,  7.72 (dd, J1 = 8.39 Hz, 
Hz, J2 = 1.53 Hz, 1H), 7.66-7.64 (m, 2H), 7.28-7.20 (m, 2H), 7.12-7.10 (dd, J1 = 8.75 Hz, 
J2 = 1.78 Hz, 2H),  4.19 (d, J = 2.25 Hz, 2H),  4.13 (d, J = 6.27 Hz, 2H), 3.65-3.62 (t, J = 
6.27 Hz, 2H), 3.29 (br, 4H),  2.87 (t, J = 2.24 Hz, 1H), 2.69 (t, J = 4.73 Hz, 4H), 2.39 (s, 
3H), 1.95-1.90 (m, 2H), 1.84-1.98 (m, 2H), 1.48-1.40 (18H); MS (MALDI-TOF) m/z 



































Synthesis of DPA 168 
To a solution of diBoc protected DPA154 (rotamer I, 25.2 mg, 34.0 mol) in ethanol 
(3.00 mL), a solution of Boc protected neomycin-azide (42.1 mg, 34.1 mol) in ethanol 
(1.00 mL) was added followed by addition of a freshly made copper(I) catalyst made by 
adding aqueous solutions of CuSO4 (1.60 mg, 10.0 mol) and sodium ascorbate (3.90 
mg, 20.0 mol) in water (1.00 mL). The reaction mixture was stirred for 24h at room 
temperature. TLC on silica gel indicated formation of the product.  Solvents were 
evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel (5 micron, mesh size) using dichloromethane-ethanol (0-12 
% ethanol in dichloromethane) as eluent. This yielded Boc protected DPA 168 (39.5 mg, 
Rf = 0.46 in dichloromethane: methanol 9:1 v/v).  This product (34.5 mg) was then 
dissolved in dichloromethane (3.00 mL) followed by addition of trifluoroacetic acid (0.60 
mL). The mixture was stirred overnight at room temperature. Water (3.00 mL) was added 




layer was lyophilized to afford the desired compound as  yellow solid (25.2 mg, 39 % for 
two steps): UV max = 337 nm in water; 
1
H NMR (500 MHz, D2O)   8.11 (s, br,   1H), 
8.04 (s, 1H), 7.94-7.83 (m, 4H), 7.58 (d, J = 9.00 Hz, 1H), 7.22 (dd,  J1 = 9.15 Hz, J2 = 
1.60 Hz,  1H), 7.16 (br, 1H), 7.05 (d, J = 8.5 Hz,  2H), 5.94 (d,  J = 3.78 Hz, 1H), 5.32 (d, 
J = 3.19 Hz, 1H), 5.21 (d, J = 1.30 Hz, 1H), 4.58 (s, br, 2H), 4.47-4.44 (m, 1H), 4.35 (t, J 
= 4.94 Hz, 1H), 4.21 (t, J = 5.08 Hz, 1H), 4.12 (t, J = 2.90 Hz, 1H), 4.00-3.90 (m, 4H), 
3.87-3.73 (m, 6H), 3.58-3.05 (m , 18H), 2.86 (s, 3H), 2.40-2.36 (m, 1H), 1.75-1.62 (m, 
4H) (some  protons signals are masked by the residual HDO peak from the NMR 














Synthesis of DPA 155-d 
To a solution of DPA 155 (0.10 g, 0.18 mmol) in dry THF (50.0 mL), NaH was added 
(12.0 mg, 0.50 mmol) at 0 

C. After stirring for 15 min, (Boc)2O (0.23 g, 1.08 mmol)  
was added to the solution and the mixture  was allowed to  slowly warm to room 
temperature . After overnight stirring, the reaction mixture was concentrated under 
stream of nitrogen. A small amount of silica powder (5 micron mesh size) was added into 
it. The crude product was purified by column chromatography on silica gel using 




desired product which eluted as two different rotamers (rotamer I 38 mg, 28%  and 
rotamer II 46.6 mg, 34%) : Rf = (0.71 for rotamer I and 0.50 for rotamer II respectively in 
dichloromethane:ethanol 8:2 v/v); 
1
H NMR (500 MHz, methanol-d4) (rotamer I) 8.37-
8.20 (set of two doublets 8.36 (d, J = 1.03 Hz), 8.21(d, J = 8.54 Hz), 1H), 7.98-7.83 (two 
sets of doublets 7.97 (d, J = 1.38 Hz), 7.84 (d, J = 8.10 Hz), 1H}, 7.71-7.61 (m, 5H), 7.19 
(dd, J1 = 8.89 Hz , J2 = 2.12 Hz, 1H), 7.10 (dd, J1 = 8.73 Hz, J2 = 2.28 Hz, 2H), 4.16 (d, J 
= 2.28 Hz,  2H), 4.11 ( t, J = 6.30 Hz, 2H),  3.56 (t, J = 6.45 Hz, 2H),  2.85 (t, J = 2.21 
Hz, 1H), 2.71 (t, J = 4.72 Hz, 4H), 2.41 (s, 3H) , 1.88- 1.83 (m, 2H), 1.68-1.62 (m, 2H), 
1.59-1.53 (m, 2H), 1.51-1.39 (m, 20H) (some proton signals are masked by the NMR 
solvent peak); 
13
C NMR (75 MHz, methanol-d4) 160.9, 155.7, 152.5, 150.1, 148.4, 
148.2, 142.5, 135.7, 134.7, 133.2, 130.7, 128.7, 125.8, 123.3, 119.0, 118.3, 115.6, 113.9, 
101.4, 86.0, 85.4, 79.4, 74.1, 69.5, 67.8, 57.3, 54.6, 49.5, 44.6, 29.0, 28.8, 26.4, 26.3, 25.5 
(two peaks), 25.4;  MS (MALDI-TOF) m/z calcd for C44H54N6O6 762.41.09 found 762.23 
[M]
+
. (rotamer II) 
1
H NMR (500 MHz, methanol-d4) 8.39-8.21 (two sets of doublets, 
8.39 (d, J = 1.1 Hz ) and 8.21 (d, J = 8.94 Hz), 1H), (two sets of doublets  7.98 (d, J = 
8.72 Hz, 1H) and   7.84 (d,  J = 8.04 Hz) , 2H),   7.72 (dd, J1 = 1.56 Hz, Hz, J2 = 8.05 Hz, 
1H), 7.65 (m, 2H),  7.28-7.20 (m, 2H), 7.10 (m, 2H),  4.16 (d, J = 1.75 Hz, 2H), 4.10 (t, J 
= 6.26 Hz, 2H), 3.56 (t, J = 6.26 Hz, 2H), 3.29 (br, 4H), 2.85 (t, J = 2.46 Hz, 1H), 2.70 (t, 
J = 4.47 Hz, 4H),  2.40 (s, 3H), 1.88-1.82 (m, 2H),  1.68-1.62 (m , 2H), 1.59-1.53 (m, 
2H), 1.51-1.39 (m, 20H); 
13
C NMR (125 MHz, methanol-d4)  160.9, 155.8, 154.0, 
149.5, 148.2, 142.7, 141.2, 134.6, 130.6, 128.4, 127.9, 126.0, 123.4, 120.4, 118.3, 115.8, 





































Synthesis of DPA 169 
To a solution of Boc protected DPA155 (rotamer I, 27.9 mg, 36.5 mol) in ethanol (3.00 
mL), a solution of Boc protected neomycin-azide (45.3 mg, 36.5 mol) in ethanol (1.00 
mL) was added followed by addition of a freshly made copper(I) catalyst made by adding 
aqueous solutions of CuSO4 (1.6 mg, 10.0 mol) and sodium ascorbate (3.9 mg, 20.0 
mol). The reaction mixture was stirred for 24h at room temperature. TLC on silica gel 
indicated formation of the product.  Volatiles were evaporated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (5 micron, mesh 
size) using dichloromethane-ethanol as eluent. This yielded Boc protected DPA 170 (49.1 
mg, Rf = 0.33 in dichloromethane: methanol 9:1 v/v).  This product (46.5 mg) was then 
dissolved in dichloromethane (2.00 mL) followed by addition of trifluoroacetic acid (0.60 
mL). The mixture was stirred overnight at room temperature.  Water (3.0 mL) was added 




aqueous layer was lyophilized to afford the desired compound as  yellow solid (32 mg, 40 
% cumulative yield for two steps): UV max = 338 nm in water; 
1
H NMR (500 MHz, 
D2O)   8.17 (s, br, 1H), 8.03 (s, 1H), 7.96-7.85 (m, 4H), 7.62 (d, J = 9.06 Hz, 1H), 7.27 
(d,  J = 9.54, 1H), 7.23 (s, br, 1H), 7.07 (d, J = 7.6 Hz,  2H), 5.94 (d,  J = 3.82 Hz, 1H), 
5.32 (d, J = 2.86 Hz, 1H), 5.21 (s, br, 1H), 4.56 (s, br, 2H), 4.49-4.44 (m, 1H), 4.34 (t, J = 
3.34 Hz, 1H), 4.21 (t, J = 3.81 Hz, 1H), 4.12 (t, J = 3.10 Hz,1H), 4.00-3.90 (m, 4H), 3.88-
3.72 (m, 6H), 3.63-3.07 (m, 18H) 2.88 (s, 3H), 2.40-2.37 (m, 1H), 1.82-1.64 (m, 3H),  
1.57-1.52 (m, 2H), 1.41-1.27 (m, 4H) (some proton signals are masked by the NMR 












Synthesis of DPA 156-d 
To a solution of DPA 156 (0.10 g, 0.16 mmol) in dry THF (50.0 mL), NaH was added 
(12.0 mg, 0.50 mmol) at 0 

C. After 15 min stirring, (Boc)2O (0.11 g, 0.50)  was added to 
the solution and the mixture  was allowed to  slowly warm to room temperature . After 
5h, the reaction mixture was concentrated under the stream of nitrogen gas. Small amount 
of silica powder (5 micron mesh size ) was added to it. The crude product was purified by 
column chromatography using dichloromethane-methanol (0-15% ethanol in 
dichloromethane) as eluent to obtain the desired product which eluted as two different 




(0.73 for rotamer I and 0.47 for rotamer II respectively in dichloromethane:ethanol 8:2 
v/v); 
1
H NMR (500 MHz, methanol-d4) (rotamer I) 8.37-8.21 {set of two doublets 8.37 
(d, J = 1.27 Hz), 8.21(d, J = 8.62 Hz), 1H}, 7.98-7.83 {two sets of doublets 7.97 (d, J = 
1.42 Hz), 7.84 (d, J = 8.37 Hz), 1H}, 7.72-7.61 (m, 5H), 7.20 (dd, J1 = 8.49 Hz , J2 = 
2.21 Hz, 1H), 7.11 (dd, J1 = 8.96 Hz, J2 = 1.98 Hz, 2H), 4.15 (d, J = 2.21 Hz,  2H), 4.10 ( 
t, J = 6.17 Hz, 2H),  3.54 (t, J = 6.51 Hz, 2H),  2.85 (t, J = 2.21 Hz, 1H), 2.72-2.70 (t, J = 
4.65 Hz, 4H), 2.41 (s, 3H) , 1.88- 1.82 (m, 2H), 1.64-1.59 (m, 2H), 1.57-1.51 (m, 

































Synthesis of DPA 170 
To a solution of Boc protected DPA156 (rotamer I, 27.0 mg, 34.1 mol) in ethanol (3.00 
mL), a solution of Boc protected neomycin-azide (42.3 mg, 34.1 mol) in ethanol (1.00 
mL) was added followed by addition of a freshly made copper(I) catalyst made by adding 




mol). The reaction mixture was stirred for 24h at room temperature. TLC on silica gel 
indicated formation of the product.  Volatiles were evaporated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (5 micron, mesh 
size) using dichloromethane-ethanol (0-12 % ethanol in dichloromethane) as eluent. This 
yielded Boc protected DPA 170 (49.1 mg, Rf = 0.33 in dichloromethane: methanol 9:1 
v/v).  This product (46.5 mg) was then dissolved in dichloromethane (2.00 mL) followed 
by addition of trifluoroacetic acid (0.60 mL). The mixture was stirred overnight at room 
temperature.  Water (3.0 mL) was added to it which was followed by washing with 
dichloromethane (3 × 1 mL). The aqueous layer was lyophilized to afford the desired 
compound as  yellow solid (35 mg, 48 % for two steps): UV max = 338 nm in water; 
1
H 
NMR (500 MHz, D2O)   8.18 (s, br,  1H), 8.03 (s, 1H), 7.97-7.86 (m, 4H), 7.64 (d, J = 
9.15 Hz, 1H), 7.28 (d,  J = 9.15, 1H), 7.24 (s, br, 1H), 7.07 (d, J = 7.8 Hz,  2H), 5.94 (d,  
J = 4.20 Hz, 1H), 5.32 (d, J = 2.94 Hz, 1H), 5.21 (d, J = 1.20 Hz, 1H), 4.55 (s, br, 2H), 
4.48 (m, 1H), 4.35-4.34 (t, J = 4.86 Hz, 1H), 4.22-4.20 (t, J = 4.86 Hz, 1H), 4.13-4.11 (t, 
J = 3.10 Hz,1H), 4.00-3.88 (m, 4H), 3.88-3.77 (m, 4H), 3.74 (s, br, 2H),  3.60-3.42 (m, 
9H), 3.38-3.09 (m, 9H) 2.88 (s, 3H), 2.40-2.37 (m, 1H), 1.82-1.74 (m, 1H),  1.71-1.63 
(m, 2H), 1.53-1.48 (m, 2H), 1.36-1.20 (m, 8H) (some proton signals are masked by the 



















Synthesis of DPA158-d 
To a solution of DPA 158 (0.10 g, 0.16 mmol) in dry THF (40.0 mL), NaH was added 
(0.10 g, 4.16 mmol) at 0 

C. After 15 min stirring, (Boc)2O (0.20 g, 0.91 mmol)  was 
added to the solution and the mixture was allowed to slowly warm to room temperature . 
After 5h, the reaction mixture was concentrated under the stream of nitrogen gas and 
mixed with small amount of silica powder (5 micron mesh size). The crude mixture was 
purified by column chromatography on silica gel (5 micron mesh size) using 
dichloromethane-ethanol (0-15% ethanol in dichloromethane) as eluent to obtain the 
desired product which eluted as two different rotamers (rotamer I, 49.3 mg, 37 % and 
rotamer II 41 mg, 31 % ) and a mixture of rotamer I and rotamer II (33 mg, 25%): Rf = 
(0.28 for rotamer I and 0.14 for rotamer II respectively in dichloromethane:ethanol 9:1 
v/v); 
1
H NMR (300 MHz, methanol-d4) (rotamer I) 8.36-8.18 (two sets of doublets, 8.36 
(d, J = 1.0 Hz) and 8.21 (d, J = 8.95 Hz), 1H), 7.96-7.81 (two sets of doublets, 7.86 (d, J 
= 1.0 Hz) and 7.81 (d, J =  8.30 Hz), 1H),   7.71-7.59 (m, 5H), 7.18 (dd, J1 = 2.16 Hz , J2 
= 8.79 Hz, 1H), 7.09 (dd, J1 = 1.99 Hz, J2 = 8.80 Hz, 2H), 4.13 (d, 2.49 Hz, 2H),  4.09 (t, 
J = 6.31 Hz,  2H), 3.52 (5, J = 6.64 Hz, 2H), 3.34 (some peaks masked by residual 




2.40 (s, 3H) , 1.86-1.79 (m, 2H),  1.60- 1.30 (m, 32H); 
13
C NMR (125 MHz, methanol-
d4) 160.9, 155.4,  152.4, 150.0, 148.5, 148.1, 142.5, 135.7,  134.7, 133.3, 130.7, 128.7, 
126.0, 123.4, 119.8, 119.1, 118.3, 115.7, 114.0, 101.6, 86.0. 85.5, 79.4, 74.0, 69.6,  67.9, 
57.3, 54.6, 49.5, 44.6,  29.2, 29.0 (two peaks), 28.8, 26.4(two peaks),  25.8 (two peaks),  
25.7, 17.6; MS (MALDI-TOF) m/z calcd for C48H62N6O6 818.47 found 818.16 [M]
+
. 
(rotamer II)  
1
H NMR (300 MHz, methanol-d4) 8.38-8.19 (two sets of doublets, 8.38 (d, 
J = 1.2 Hz, 1H) and 8.20 (d, J = 8.84 Hz), 1H)  7.99-7.82 (m, 2H),  7.73-7.62 (m, 3H),  
7.28-7.19 (m, 2H),   7.09 (dd, J1 = 2.05 Hz , J2 =  8.81, 2H), 4.14 (d, J = 2.47 Hz, 2H) 
4.09 (t, J = 6.26 Hz, 2H), 3.52 (t, J = 6.51 Hz, 2H),  3.29(t, J = 4.35 Hz, 4H),  2.82 (t, J = 
2.47 Hz, 1H),  2.69 (t, J = 4.85 Hz, 4H), 2.39 (s, 3H), 1.86-1.78 (m , 2H), 1.61-1.33 
(32H); 
13
C NMR (125 MHz, methanol-d4) 161.0, 155.8, 153.9, 149.5, 148.2, 142.6, 
141.2,  134.6, 133.3, 130.7, 128.4, 126.0, 123.4, 120.0, 118.3, 116.3, 115.8,  114.8, 114.0, 
105.4, 86.0, 85.5,  83.6, 79.4, 74.0, 69.6,  67.9, 57.3,  54.6, 49.6, 44.6, 29.3, 29.2, 29.1, 
29.0 (two peaks), 28.8, 26.4 (two peaks), 25.7 two peaks); MS (MALDI-TOF) m/z 




































Synthesis of DPA 171. 
To a solution of Boc protected DPA158 (rotamer I, 39.2 mg, 47.9 mol) in ethanol (3.00 
mL), a solution of Boc protected neomycin-azide (60.0 mg, 47.9 mol) in ethanol (1.00 
mL) was added followed by addition of a freshly made copper(I) catalyst made by adding 
aqueous solutions of CuSO4 (1.75 mg, 11.0 mol) and sodium ascorbate (4.35 mg, 22.0 
mol) in water (0.50 mL). The reaction mixture was stirred for 24h at room temperature. 
TLC on silica gel indicated formation of the product.  Solvents were evaporated under 
reduced pressure. The crude mixture was purified using column chromatography on silica 
gel (5 micron, mesh size) using dichloromethane-ethanol as eluent. This yielded Boc 
protected DPA 171 (41.1 mg, Rf   = 0.36 in dichloromethane: ethanol 9:1 v/v).  The 
product was dissolved in dichloromethane (3.00 mL) followed by addition of 
trifluoroacetic acid (0.60 mL). The mixture was stirred for 2h at room temperature. Water 
(3.00 mL) was added to it which was followed by washing it with dichloromethane (3×1 




solid (32 mg, 29 % for two steps): UV max = 338 nm in water; 
1
H NMR (500 MHz, D2O)  
 8.16 (s, br,  1H), 8.03 (s, br, 1H), 7.93-7.85 (m, 4H), 7.65 (d, J = 9.55 Hz, 1H), 7.28-
7.24 (m, 2H), 7.05 (s, br,  2H), 5.95 (s, br, 1H), 5.33 (s,b r, 2H), 5.21 (s, br, 1H), 4.54 (s, 
br, 2H), 4.47 (s, br, 1H), 4.35 (s, br, 1H), 4.22 (s, br, 1H), 4.12 (s, br, 1H), 3.99-3.74 (m, 
10H), 3.61-3.09 (m, 20H), 2.88 (s, 3H), 2.40-2.37 (m, 1H), 1.80-1.77 (m, 1H),  1.66 (s, 
br, 2H), 1.50 (s, br, 2H), 1.37-1.29 (m, 4H),  1.23-1.21 (m, 14H); MS (MALDI-TOF) m/z 













Synthesis of DPA 157-d 
To a solution of DPA 157 (53.0 mg, 82.0 mol) in dry THF (20.0 mL), NaH was added 
(50 mg, 2 mmol) at 0 

C. After 15 min stirring, (Boc)2O (80.0 mg, excess)  was added 
into the solution and the mixture  was allowed to  slowly warm to room temperature . 
After stirring for 5h, the reaction mixture was concentrated under the stream of nitrogen. 
Small amount of silica powder (5 micron mesh size ) was added to it. The crude product 
was purified by column chromatography using dichloromethane-methanol (0-15% 
ethanol in dichloromethane)  as eluent to obtain the desired product which eluted as two 
different rotamers (rotamer I 26 mg,  37 %) and a mixture of rotamer I and rotamer II (33 
mg, 47 %): Rf = (0.58 for rotamer I and 0.51 for rotamer II respectively in 
dichloromethane:methanol 8.5:1.5 v/v); 
1




(set of two doublets 8.37 (d, J = 1.31 Hz), 8.21(d, J = 8.48 Hz), 1H), 7.97-
7.83 (two sets of doublets 7.97 (d, J = 1.48 Hz), 7.84 (d, J = 8.15 Hz), 1H), 7.72-7.61 (m, 
5H), 7.21 (dd, J1 = 8.44 Hz , J2 = 2.47 Hz, 1H), 7.11 (dd, J1 = 3.49 Hz, J2 = 7.13 Hz, 2H), 
4.14-4.10 (m, 4H), 3.68 (s, 1H), 3.57-3.51 (m, 6H),  2.72 (t, J = 4.37 Hz, 4H), 2.42 (s, 
3H) , 1.88- 1.82 (m, 2H), 1.61-1.51 (m, 16H), 1.48-1.41 (20H); 
13
C NMR (125 MHz, 
methanol-d4) 155.7, 154.1, 150.0, 148.2, 142.5, 135.7, 133.3, 130.6, 128.7, 125.8, 
119.0, 118.3, 115.6, 113.9, 101.4, 86,0, 65.5, 79.4, 74.0, 69.6 , 67.9, 65.4, 61.6, 57.2, 
54.6, 49.5, 49.6, 32.2, 29.2, 26.4, 14.0; MS (MALDI-TOF) m/z calcd for C50H66N6O6 
































Synthesis of DPA 172 
To a solution of Boc protected DPA157 (rotamer I, 19.0 mg, 22.4 mol) in ethanol (3.00 
mL), a solution of Boc protected neomycin-azide (37.0 mg, 30.0 mol)  in ethanol (1.00 




aqueous solutions of CuSO4 (1.4 mg, 9.0 mol) and sodium ascorbate (3.4 mg, 18.0 
mol) in water (1.0 mL). The reaction mixture was stirred for 12h at room temperature. 
TLC on silica gel indicated formation of the product.  Volatiles were evaporated under 
reduced pressure. The crude mixture was purified using column chromatography on silica 
gel (5 micron, mesh size) using dichloromethane-methanol (0-12 % methanol in 
dichloromethane) as eluent. This yielded Boc protected DPA 172 (18.1 mg, Rf = 0.41 in 
dichloromethane: methanol 9:1 v/v).  The product was then dissolved in dichloromethane 
(2.0 mL) followed by addition of trifluoroacetic acid (0.6 mL). The mixture was stirred 
overnight at room temperature.  Water (3.0 mL) was added to it which was followed by 
washing with dichloromethane (3 × 1 mL). The aqueous layer was lyophilized to afford 
the desired compound as pale yellow solid (9.1 mg, 13 % for two steps): UV max = 339 
nm in water; 
1
H NMR (500 MHz, D2O)   8.25 (s, br,  1H), 8.03 (s, 1H), 8.00-7.89 (m, 
4H), 7.67 (d, J = 8.47 Hz, 1H), 7.30 (dd,  J1 = 2.35, J2 = 9.4  Hz, 2H), 7.12 (d, J = 8.9 Hz,  
2H), 5.95 (d,  J = 3.77 Hz, 1H), 5.33 (d, J = 3.77 Hz, 1H), 5.21 (d, J = 1.41 Hz, 1H), 4.55 
(s, br, 2H), 4.48-4.46 (m, 1H), 4.35 (t, J = 4.71 Hz, 1H), 4.22 (t, J = 4.24 Hz, 1H), 4.13 (t, 
J = 2.36 Hz, 1H), 4.04-3.91 (m, 4H), 3.88-3.73 (m, 5H), 3.68-3.10 (m, 17H), 2.89 (s, 
3H), 2.41-2.36 (m, 1H), 1.72-166 (m, 2H), 1.51-1.46 (m, 2H), 1.38-1.30 (m, 2H),  1.29-




















Synthesis of DPA159-d 
To a solution of DPA 159 (0.10 g, 0.13 mmol) in dry THF (60.0 mL), NaH was added 
(50.0 mg, 2.08 mmol) at 0 

C. After 30 min stirring, (Boc)2O (0.20 g, 0.90 mmol)  was 
added to the solution and the mixture  was allowed to  slowly warm to room temperature . 
After overnight stirring, the reaction mixture was concentrated under the stream of 
nitrogen gas.  The crude mixture was mixed with small amount of silica powder (5 
micron mesh size). The crude product was purified by column chromatography on silica 
gel (5 micron mesh size) using dichloromethane-methanol (0-20 % methanol in 
dichloromethane) as eluent to obtain the desired product which eluted as two rotamers 
(rotamer I 26.8 mg, 21 % and a mixture of rotamer I and rotamer II (40.8 mg, 31 %): Rf  = 
(0.69 for rotamer I and 0.52 for rotamer II respectively in dichloromethane:methanol 
8.5:1.5 v/v); 
1
H NMR (500 MHz, methanol-d4) (rotamer I) 8.37-8.20 (two sets of 
doublets, 8.37 (d, J = 1.59 Hz) and 8.22-8.20 (d, J = 8.32 Hz), 1H), 7.97-7.83 (two sets of 
doublets, 7.97 (d, J = 1.43 Hz) and 7.85-7.83 (d, J =  8.32 Hz), 1H),   7.72-7.61 (m, 5H), 
7.22-7.14 (m, 3H), 4.27 (t, J = 3.30 Hz,  2H), 4.20-4.19 (m, 2H), 3.92 (t, J = 4.24 Hz, 
2H), 3.72-3.62 (m, 20H),   2.77- 2.75 (br, 5H), 2.45 (s, 3H) , 1.48-1.41 (18H) (some 
proton signals are masked by the NMR solvent peak); MS (MALDI-TOF) m/z calcd for 
C50H66N6O11 926.47, found 926.13 [M]
+
. (rotamer II)  
1




8.39-8.19 (two sets of doublets, 8.39 (d, J = 1.87 Hz, 1H) and 8.20 (d, J = 8.60 Hz), 
1H)  7.99-7.66 (m, 5H),  7.28-7.12 (m, 4H), 4.25-4.19 (m, 3H) 3.92-3.64 (m, 22H), 3.34-
3.29 (m, 2H),  3.29 (br, 4H),  2.72 (br, 4H), 2.42 (s, 3H), 1.48-1.40 (m, 18H); 
13
C NMR 
125 MHz, methanol-d4)  160.7, 155.6, 153.9, 149.4, 148.2, 142.7, 134.7, 133.2, 130.7, 
128.4, 127.8, 126.1, 120.1, 118.3, 116.3, 115.8, 114.9, 114.0, 105.5, 86.1, 85.5, 79.2, 
75.4, 71.6, 70.2, 70.1 (overlapped peaks), 69.9, 69.3, 68.7, 67.5, 57.6, 54.6, 49.5, 44.5, 




































Synthesis of DPA 173 
To a solution of diBoc protected DPA159 (rotamer I, 26.8 mg, 28.0 mol) in ethanol 
(3.00 mL), a solution of Boc protected neomycin-azide (34.7 mg, 34.1 mol) in ethanol 
(1.0 mL) was added followed by addition of a freshly made copper(I) catalyst made by 
adding aqueous solutions of CuSO4 (1.60 mg, 10.0 mol) and sodium ascorbate (3.90 
mg, 20.0 mol) in water (1.00 mL). The reaction mixture was stirred for 24h at room 




evaporated under reduced pressure. The crude product was purified by column 
chromatography on silica gel (5 micron mesh size) using dichloromethane-ethanol (0-15 
% ethanol in dichloromethane) as eluent. This yielded Boc protected DPA 173 (26.8 mg, 
Rf = 0.38 in dichloromethane: methanol 9:1 v/v).  This product (20.4 mg) was then 
dissolved in dichloromethane (3.00 mL) followed by addition of trifluoroacetic acid (0.60 
mL). The mixture was stirred overnight at room temperature.  Water (3.00 mL) was 
added to it which was followed by washing it with dichloromethane (3 × 1 mL). The 
aqueous layer was lyophilized to afford the desired compound as  yellow solid (18.1 mg, 
24 % for two steps): UV max = 335 nm in water; 
1
H NMR (500 MHz, D2O)  8.24 (s, br,  
1H), 8.04-7.84 (m, 4H), 7.64 (d, J = 8.95 Hz, 1H), 7.34-7.26 (m, 2H), 7.17-7.13 (m, 3H), 
5.93 (d,  J = 4.01 Hz, 1H), 5.32 (d, J = 3.65 Hz, 1H), 5.20 (d, J = 1.42 Hz, 1H), 4.70 
(some peaks masked by residual H2O signal), 4.59 (s, br, 2H), 4.48-4.45 (m, 1H), 4.32 (t, 
J = 5.07 Hz, 1H), 4.21 (br, 2H), 4.13 (t, J = 2.95 Hz, 1H), 4.00-3.80 (m, 5H), 3.75-3.73 
(m, 2H), 3.63-3.09 (m, 23H),  2.88 (s, 3H), 2.40-2.36 (m, 1H), 1.82-1.75 (m, 1H), 1.08 











H NMR spectrum of DPA 151-d (rotamer I) 
 






H NMR spectrum of DPA 151-d (rotamer II) 
 






H NMR spectrum of diBoc protected DPA 165. 
 

















TOCSY spectrum of DPA 165.  
 
 








H NMR spectrum of DPA 152-d (rotamer I) 
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MALDI-TOF spectrum of DPA 166. 
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C NMR of DPA 153-d (rotamer I). 
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C NMR spectrum of DPA 153-d (rotamer II). 
 







H NMR spectrum of DPA 167. 
 






H NMR spectrum of DPA 154-d (rotamer I). 
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H NMR spectrum of diBoc DPA 154-d (rotamer II). 
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H NMR spectrum of DPA 155-d (rotamer II). 
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MALDI-TOF spectrum of DPA 155-d (rotamer I). 
 
 






H NMR spectrum of DPA 169. 
 






H NMR of DPA 156-d (rotamer I). 
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H NMR spectrum of DPA 156-d (rotamer II). 
 
 






H NMR spectrum of DPA 170. 
 






H NMR sprectrum of DPA 158-d (rotamer I) 
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H NMR spectrum of DPA 158-d (rotamer II). 
 




































H NMR sprectrum of DPA 171. 
 






H NMR spectrum of DPA 157-d (rotamer I). 
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MALDI-TOF spectrum of DPA 157-d (rotamer I). 
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H NMR spectrum of DPA 159 (rotamer II) 
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H NMR spectrum of DPA 173. 
 












































































































Figure S1.  LD spectra of Poly r(A).r(U)  in the absence and presence of neomycin-
Hoechst 33258 conjugates (DPA 165-DPA 173) as indicated on each graph. [Poly 
r(A).r(U)] = 1000 M, [ligand] = 100 M (rbd 10). All experiments were performed in 
buffer 10 mM sodium, cacodylate, 0.5 mM EDTA and 100 mM NaCl at pH 7.0. The 
nucleic acid was flow oriented in a microvolume couette cell at 3000 rpm.   Each 
spectrum represents an average of three scans. All experiments were conducted at 22 

C. 




(Figure S1 continued) 
assumed base tilt of  77
 
in the uncomplexed RNA. The reduced linear dichroism (LDr) of 
the RNA bases was found to be 0.0225 at 260 nm and the corresponding S value was 
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Targeting G-Quadruplexes Formeed by Oncogenes: Insightsinto Dual Recognition and 
Effects of Linker Variation 
General scheme of synthesis of compounds 9-11. To a solution of compound 4 or 5 
(~40.0 mol) in pyridine (2.00 mL), catalytic amount of dimethyl amino pyridine 
(DMAP) was added in dichloromethane (0.5 mL) was added followed by addition of 
appropriate bisisothicynate (6-8 fold excess). The mixture was stirred at room 
temperature for 24h. TLC on silica gel indicated completion of reaction. Pyridine was 
removed under reduced pressure and the resulting crude mixture was purified on a silica 
gel column using DCM-MeOH as eluent in 80-85% yield. 
Synthesis of compound 9. 
1
HNMR (300 MHz, acetone-d6) 7.48 (1H), 7.34 (1H), 6.38 
(1H), 6.23-5.94 (5H), 6.10 (2H), 5.25-5.19 (2H), 5.01 (1H), 4.76 (1H), 4.56 (1H), 4.42 
(2H), 4.30-4.19 (4H),  4.06 (1H), 3.93-3.42 (19H), 3.27 (2H), 1.45 (54H), 1.30(8H); MS 
(MALDI-TOF) m/z calcd for C60H105N9O24S3 1432.71, found 1455.23 [M+Na]
+
. 
 Synthesis of compound 10. 
1
H NMR (500 MHz, acetone-d6) 7.32 (1H), 7.15 (1H), 6.58 
(1H), 6.38 (1H), 6.09-5.92 (4H), 5.28 (1H), 5.13 (1H), 4.98 (2H), 4.73 (1H), 4.55 -4.43 
(4H), 4.25-4.05 (6H), 3.94 (1H), 3.84-3.45 (25H), 1.97 (2H), 1.84 (2H), 1.63 (4H), 1.46 







 Synthesis of compound 11.  
1
H NMR (500 MHz, acetone-d6) 7.34 (1H), 7.19 (1H), 6.40 
(1H), 6.19-6.17 (1H), 6.10(2H), 5.93 (1H), 5.24-5.19 (2H), 5.02 (1H), 4.75 (1H), 4.49-
4.38 (3H), 4.26-4.22 (4H), 4.07 (1H), 3.93 (1H), 3.85-3.76 (7H), 3.63 (26H), 3.26 (2H), 
1.98 (2H), 1.86 (2H), 1.45 (54H), 1.31(8H); MS (MALDI-TOF) m/z calcd for 











Synthesis of 2,2,2 trifluro-N-(3-(4-formylphenoxy)propyl)acetamide (15). To an ice cold 
solution of p-hydroxybenzaldehyde (1.00 g, 8.18 mmol) in dry dichloromethane (25.0 
mL) and 1, 4 dioxane (5.00 mL),  triphenylphosphane  (3.17 g, 12.1 mmol) and 3- 
hydroxyl propyltrifluoroacetamide (1.39 g, 16.3 mmol) were added. To this, diisopropyl 
azodicarboxylate (DIAD) (2.44 gm, 12.2 mmol) was added slowly at 0 

C over 15 min.  
The contents were initially stirred at 0 

C for 30 min and then at room temperature 
overnight. The solvents were removed under reduced pressure. To this, ethyl acetate-
hexanes mixture (80 mL, 1:1 v/v) was added and then allowed to stand overnight in the 
refrigerator. The precipitated solid was filtered out and the filtrate was concentrated. The 
crude mixture was purified by column chromatograpahy on a silica gel using hexanes- 
ethyl acetate as eluent to isolate the desired product as white solid (480 mg, 22 %): Rf = 
0.55 (hexanes-ethyl acetate 7:3); 
1
H NMR (500 MHz, CDCl3)  9.88 (s, 1H), 7.84 (d, J = 




3.61(m, 2H), 2.18-2.13 (m, 2H); 
13
C NMR (500 MHz, CDCl3)  190.7, 163.2, 157.5, 
132.1, 130.3, 114.7, 66.5, 37.9, 21.9 (one carbon peak is likely to be masked by the NMR 
solvent peak); 
19

















bibenzimidazol-2'-yl)phenoxy)propyl)acetamide(trifluoroacetamide protected DPA 160). 
To a solution of  2-(4-amino, 3-nitrophenyl)-6-(4-methylpiperazin-1-yl)-1H-
benzoimidazole (0.38 g, 1.09 mmol) in a mixture of  ethanol-ethyl acetate (50.0 mL), Pd-
C (0.10 g) was added and the mixture was hydrogenated at room temperature at the 
atmospheric pressure. TLC indicated completion of the reduction. Charcoal was filtered 
off and the filtrate was added with 2,2,2 trifluro-N-(3-(4-
formylphenoxy)propyl)acetamide (0.30 g, 1.09 mmol). To this an aqueous solution of 
Na2S2O5 (0.20 g, 1.09 mmol in 1.0 mL water) was added and the mixture was refluxed 
for 10h. The reaction mixture was concentrated under reduced pressure. The crude 
product was purified by column chromatography on a silica gel column using 
dichloromethane-methanol (0- 20 % methanol in dichloromethane) as eluent. The desired 
product was obtained as orange-red solid (0.20 g, 48 %): Rf = (0.37 in dichloromethane-
methanol 6.5:3.5 v/v);  
1
H NMR (500 MHz, DMSO-d6)  13.02 (s, 1H), 12.64 (br ,1H), 




3.4 Hz, 1H), 7.74-7.61(br, 1H), 7.47 (br, 1H), 7.13 (d, J = 8.2 Hz, 2H), 6.96-6.94 (br, 
2H), 4.13-4.11 (t, J = 5.8 Hz, 2H), 3.19 (br, 4H), 2.67(br, 4H), 2.57(br, 4H), 2.35 (s, 3H), 
2.02-1.99 (m, 2H); MS (MALDI-TOF) m/z calcd for C30H30F3N7O2 577.24,  found 
576.91. 
Synthesis of DPA 160. To a solution 2,2,2-trifluoro-N-(3-(4-(6-(4-methylpiperazin-1-yl)-
1H,3'H-2,5'-bibenzimidazol-2'-yl)phenoxy)propyl)acetamide (0.18 g, 0.31 mmol) in a 
mixture of methanol-water (14.0 mL, 5:2 v/v) was added K2CO3 (0.21 g, 1.55 mmol) and 
the mixture was stirred at room temperature for 18h. Volatiles were removed under 
reduced pressure. The crude product was then purified on a silica gel column using 
dichlromethane-methanol-triethyl amine as eluent. The desired product was obtained as 
yellow solid (80 mg, 53 %): Rf = 0.1 (dichloromethane-methanol 8:2 v/v); 
1
H NMR (500 
MHz, D2O with trace trifluoroacetic acid -d)  7.10-7.09 (br, 2H), 7.00 (br, 2H), 6.96-
6.94 (1H), 6.82 (br, 1H), 6.60 (br,1H), 6.52-6.50 (d, br, 1H), 6.38-6.36 (s, br, 2H), 3.41 
(2H), 2.90 (t, J = 7.2 Hz, 2H), 2.72 (br, 4H), 2.12 (s,3H), 1.75(m,2H) ); MS (MALDI-








Synthesis of DPA 174.  To a solution of DPA 160 (10.8 mg, 22.4 mol) in dry pyridine 
(2.0 mL), catalytic amount of dimethyl amino pyridine (DMAP) in dichloromethane (0.5 
mL) was added. In a separate vial, Boc protected neomycin-isothiocynate (17.1 mg, 12.9 
mol) was taken in 1.0 mL dry pyridine and ice cooled. To an ice cold solution of DPA 
160, the Boc protected neomycin-isothiocynate was added at 0 

C under argon. The 
reaction mixture was then brought up to room temperature and stirred overnight. TLC 
indicated formation of product (Rf = 0.50 in dichloromethane-methanol 8.5-1.5 v/v). 
Pyridine was evaporated under reduced pressure and the reaction mixture was further 
purified by column chromatography on silica gel using dichloromethane-methanol as 
eluent to afford the desired compound as yellowish white solid. The Boc protected 
conjugate was then taken up in dichloromethane (2.0 mL) 4M HCl in 1, 4 dioxane (0.5 
mL) was added to it and stirred for 30 min. Diethyl ether (2 × 1 mL) was  added to induce 
precipitation of the desired compound. The precipitated product was centrifuged and 
washed with dichloromethane (2 × 1 mL). The solid was then dried under vacuum to 
afford the title compound as yellow solid (9 mg, 50 % cumulative yield for two steps):  
1
H NMR (D2O, 300 MHz)  8.26-8.10 (br, 2H), 7.91 (br, 2H), 7.52 (br, 2H), 7.44-7.27 
(2H), 7.04-7.01 (d, J = 7.9 Hz, 2H), 6.10 (s, br, 1H), 5.48 (br, 2H), 4.15-3.15 (52H), 2.66 
(2H), 2.11-2.00 (6H), 1.86 (4H),  1.43 (2H) (some peaks are masked in solvent 








Synthesis of DPA 175.  To a solution of DPA 160 (8.40 mg, 22.4 mol) in dry pyridine 
(2.0 mL), catalytic amount of dimethyl amino pyridine (DMAP) in dichloromethane (0.5 
mL) was added. In a separate vial, Boc protected neomycin-isothiocynate 9 (25.0 mg, 
17.4 mol) was taken in 1.0 mL dry pyridine and ice cooled. To an ice cold solution of 
DPA 160, the Boc protected neomycin-isothiocynate was added at 0 

C under argon. The 
reaction mixture was then brought up to room temperature and stirred overnight. TLC 
indicated formation of product (Rf = 0.45 in dichloromethane-methanol 8.5-1.5 v/v). 
Pyridine was evaporated under reduced pressure and the reaction mixture was further 
purified by column chromatography on silica gel using dichloromethane-methanol (0-20 
% methanol in dichloromethane) as eluent to afford the desired compound as yellowish 
solid (14.5 mg). The Boc protected conjugate was then taken up in dichloromethane (2.0 
mL) 4M HCl in 1, 4 dioxane (0.5 mL) was added to it and stirred for 30 min. Diethyl 
ether (2 × 1 mL) was  added to induce precipitation of the desired compound. The 
precipitated product was centrifuged and washed with dichloromethane (2 × 1 mL). The 
solid was then dried under vacuum to afford the title compound as yellow solid (8.5 mg, 
32 % cumulative yield for two steps): (Boc protected DPA 175)  
1
H NMR (300 MHz, 
Methanol-d4)  8.30 (s, 1H), 8.11-8.09 (br, 2H), 7.73 (d, J = 7.4 Hz, 1H), 7.65-7.54 (1H), 
7.22-7.07 (3H), 6.97 (d, J = 6.5 Hz, 2H), 5.40 (1H), 5.18 (1H), 4.96 (2H), 4.32-4.05 (4H), 
3.93 (1H), 3.80-3.50 (14H), 3.25 (7H), 3.04 (s, 3H), 2.91-2.85 (2H), 2.65 (2H), 2.14-1.94 
(2H), 1.46 (54H), 0.93 (10H) (some proton signals are  masked by  the NMR solvent  




Synthesis of DPA 176.  To a solution of DPA 160 (10.0 mg, 20.8 mol) in dry pyridine 
(2.0 mL), catalytic amount of dimethyl amino pyridine (DMAP) in dichloromethane (0.5 
mL) was added. In a separate vial, Boc protected neomycin-isothiocynate 10 (25.0 mg, 
16.4 mol) was taken in 1.0 mL dry pyridine and ice cooled. To an ice cold solution of 
DPA 160, the Boc protected neomycin-isothiocynate was added at 0 

C under argon. The 
reaction mixture was then brought up to room temperature and stirred overnight. TLC 
indicated formation of product (Rf = 0.52 in dichloromethane-methanol 8.5-1.5 v/v). 
Pyridine was evaporated under reduced pressure and the reaction mixture was further 
purified by column chromatography on silica gel using dichloromethane-methanol (0-20 
% methanol in dichloromethane) as eluent to afford the desired compound as yellowish 
solid (14 mg). The Boc protected conjugate was then taken up in dichloromethane (2.0 
mL) 4M HCl in 1, 4 dioxane (0.5 mL) was added to it and stirred for 30 min. Diethyl 
ether (2 × 1 mL) was  added to induce precipitation of the desired compound. The 
precipitated product was centrifuged and washed with dichloromethane (2 × 1 mL). The 
solid was then dried under vacuum to afford the title compound as yellow solid (9.1 mg, 
26 % cumulative yield for two steps): (Boc protected DPA 176)
 1
H NMR (300 MHz) 
8.31 (s, 1H), 8.11-8.09 (br, 2H), 7.90 (s, 1H), 7.74 (br, 1H), 7.66 (d, J = 8.4 Hz, 1H), 
7.23-7.08 (4H), 6.98 (d, J = 6.9Hz, 1H), 6.60-6.48 (1H), 5.44-5.36 (1H), 5.11 (1H), 4.94 
(2H), 4.41-4.10 (3H), 4.04-3.93 (2H), 3.25-3.18 (8H),  2.79 (2H), 2.31-2.10 (3H),  2.07-
1.77 (5H), 1.45 (54H), 0.91 (9H) (some proton signals are masked by the NMR solvent 




Synthesis of DPA 177.  To a solution of DPA 160 (10.0 mg, 20.8 mol) in dry pyridine 
(2.0 mL), catalytic amount of dimethyl amino pyridine (DMAP) in dichloromethane (0.5 
mL) was added. In a separate vial, Boc protected neomycin-isothiocynate 11 (25.0 mg, 
15.8) mol) was taken in 1.0 mL dry pyridine and ice cooled. To an ice cold solution of 
DPA 160, the Boc protected neomycin-isothiocynate was added at 0 

C under argon. The 
reaction mixture was then brought up to room temperature and stirred overnight. TLC 
indicated formation of product (Rf = 0.25 in dichloromethane-methanol 8.5-1.5 v/v). 
Pyridine was evaporated under reduced pressure and the reaction mixture was further 
purified by column chromatography on silica gel using dichloromethane-methanol (0-20 
% methanol in dichloromethane) as eluent to afford the desired compound as yellowish 
solid (14 mg). The Boc protected conjugate was then taken up in dichloromethane (2.0 
mL) 4M HCl in 1, 4 dioxane (0.5 mL) was added to it and stirred for 30 min. Diethyl 
ether (2 × 1 mL) was  added to induce precipitation of the desired compound. The 
precipitated product was centrifuged and washed with dichloromethane (2 × 1 mL). The 
solid was then dried under vacuum to afford the title compound as yellow solid (9.1 mg, 
28 % cumulative yield for two steps): 
1
H NMR (300 MHz, D2O) 8.54-7.04 (m, 10H), 
6.10 (s, br, 1H), 5.46 (s, br, 1H), 4.65-4.20 (m, 3H), 4.15-2.90 (m, 61H), 2.66 (br, 1H), 
2.33-1.50 (m 8H), 1.49-1.41 (m, 2H) (some proton signals are masked by the NMR 












H NMR spectrum of 9. 
 






H NMR spectrum of 10. 
 







H NMR spectrum of 11. 
 






H NMR spectrum of compound 15. 
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F NMR spectrum of compound 15. 
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MALDI-TOF spectrum of trifluoroacetamide protected DPA 160. 
 
1





MALDI-TOF spectrum of DPA 160. 
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MALDI-TOF spectrum of DPA 174. 
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MALDI-TOF spectrum of  Boc protected DPA 175. 
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MALDI-TOF spectrum of DPA 175. 
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MALDI-TOF spectrum of Boc protected DPA 176. 
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MALDI-TOF spectrum of DPA 176.
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Figure S1. Fluorescence titration of DPA 166 with TFO C-myc 1 quadruplex (a) raw 
emission profile of DPA 166 being titrated with TFO C-myc 1 (b) fluorescence emission 
at 468 nm showing the changes with respect to the concentration of ligand added (c) 
binding stoichiometry plot. [DPA 166] = 100 nM. The buffer used in the experiment was 
10 mM tris-HCl, 1.0 mM EDTA and 100 mM KCl at pH 7.5. The experiment was 
performed at 20 

C. 
 
 
 
 
 
 
 
 
 
 
